Βιογραφικό σημείωμα - med.uth.gr · Βιογραφικό σημείωμα Γεώργιος Ντάιος MD, MSc (ESO Stroke Medicine), PhD, FESO Ιατρός ²

Βιογραφικό σημείωμα Γεώργιος Ντάιος MD, MSc (ESO Stroke Medicine), PhD, FESO

Ιατρός – Παθολόγος

Επίκουρος Καθηγητής Παθολογίας

Παθολογική Κλινική & Ομώνυμο Ερευνητικό Εργαστήριο

Ιατρική Σχολή Πανεπιστημίου Θεσσαλίας

Λάρισα, 23 Φεβρουαρίου 2016

Γεώργιος Ντάιος

2

ΠΙΝΑΚΑΣ ΠΕΡΙΕΧΟΜΕΝΩΝ 23 Φεβρουαρίου 2016

ΠΙΝΑΚΑΣ ΠΕΡΙΕΧΟΜΕΝΩΝ

ΠΙΝΑΚΑΣ ΠΕΡΙΕΧΟΜΕΝΩΝ ......................................................................................................................................... 2

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ .............................................................................................................................................. 3 SHORT CURRICULUM VITAE ....................................................................................................................................................... 4 ΣΥΝΤΟΜΟ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ ........................................................................................................................................ 5 ΠΡΟΣΩΠΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ ..................................................................................................................................................... 6 ΑΚΑΔΗΜΑΪΚH ΣΤΑΔΙΟΔΡΟΜΙΑ ................................................................................................................................................. 6 ΤΙΤΛΟΙ ΠΑΝΕΠΙΣΤΗΜΙΑΚΩΝ ΣΠΟΥΔΩΝ ............................................................................................................................... 6 GRANTS - ΥΠΟΤΡΟΦΙΕΣ - ΒΡΑΒΕΙΑ ............................................................................................................................................ 6 ΕΡΕΥΝΑ/ΜΕΤΕΚΠΑΙΔΕΥΣΗ/ΕΡΓΑΣΙΑ ΣΤΟ ΕΞΩΤΕΡΙΚΟ ..................................................................................................... 6 ΜΕΤΕΚΠΑΙΔΕΥΤΙΚΑ ΠΡΟΓΡΑΜΜΑΤΑ ...................................................................................................................................... 6 ΚΛΙΝΙΚΕΣ ΠΙΣΤΟΠΟΙΗΣΕΙΣ ......................................................................................................................................................... 7 ΣΥΜΜΕΤΟΧΗ ΣΕ ΕΡΕΥΝΗΤΙΚΑ ΠΡΩΤΟΚΟΛΛΑ & ΕΡΕΥΝΗΤΙΚΕΣ ΟΜΑΔΕΣ ................................................................ 7 ΔΙΔΑΚΤΙΚΟ ΕΡΓΟ ............................................................................................................................................................................. 7 ΜΕΛΟΣ ΕΠΙΤΡΟΠΩΝ ΔΙΠΛΩΜΑΤΙΚΩΝ ΕΡΓΑΣΙΩΝ Ή ΔΙΔΑΚΤΟΡΙΚΩΝ ΔΙΑΤΡΙΒΩΝ .................................................... 8 ΚΛΙΝΙΚΟ ΕΡΓΟ .................................................................................................................................................................................. 8 ΟΜΙΛΙΕΣ – ΣΥΝΕΝΤΕΥΞΕΙΣ .......................................................................................................................................................... 9

Στην Ελλάδα ............................................................................................................................................................................. 9 Στο εξωτερικό.......................................................................................................................................................................... 11

ΣΥΝΤΟΝΙΣΜΟΣ ΣΤΡΟΓΓΥΛΩΝ ΤΡΑΠΕΖΩΝ ΣΥΝΕΔΡΙΩΝ ................................................................................................... 12 ΟΡΓΑΝΩΤΙΚΗ/ΕΠΙΣΤΗΜΟΝΙΚΗ ΕΠΙΤΡΟΠΗ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΚΔΗΛΩΣΕΩΝ ...................................................... 12 ΣΥΜΜΕΤΟΧΗ ΣΤΗΝ ΣΥΓΓΡΑΦΗ ΙΑΤΡΙΚΩΝ ΒΙΒΛΙΩΝ ......................................................................................................... 12 ΣΥΝΕΝΤΕΥΞΕΙΣ/ΑΡΘΡΟΓΡΑΦΙΑ ΣΤΑ ΜΕΣΑ ΜΑΖΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ ....................................................................... 13 ΛΟΙΠΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ ΣΤΟ ΧΩΡΟ ΤΗΣ ΥΓΕΙΑΣ .............................................................................................................. 13 ΜΕΛΟΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΤΑΙΡΕΙΩΝ ΚΑΙ ΔΡΑΣΤΗΡΙΟΤΗΤΑ ΣΤΟ ΠΛΑΙΣΙΟ ΑΥΤΩΝ ............................................ 14 ΣΥΣΤΑΤΙΚΕΣ ΕΠΙΣΤΟΛΕΣ ........................................................................................................................................................... 14

ΑΝΑΛΥΤΙΚΟ ΥΠΟΜΝΗΜΑ ΔΗΜΟΣΙΕΥΜΑΤΩΝ ................................................................................................... 15

ΚΑΤΑΤΑΞΗ ΕΡΓΑΣΙΩΝ & ΒΙΒΛΙΟΓΡΑΦΙΚΕΣ ΑΝΑΦΟΡΕΣ ................................................................................. 71 ΠΛΗΡΕΙΣ ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΞΕΝΑ ΠΕΡΙΟΔΙΚΑ ................................................................................................................. 72

Κατευθυντήριες Οδηγίες ....................................................................................................................................................... 72 Πρωτότυπες εργασίες ............................................................................................................................................................ 73 Άρθρα ανασκόπησης ........................................................................................................................................................... 102 Μεταναλύσεις ....................................................................................................................................................................... 109 Ενδιαφέρουσες περιπτώσεις ............................................................................................................................................... 113 Debates .................................................................................................................................................................................. 116 Προσκεκλημένα Editorials .................................................................................................................................................. 117 Απαντήσεις σε Επιστολές .................................................................................................................................................... 118 Επιστολές ............................................................................................................................................................................... 120

ΠΛΗΡΕΙΣ ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΑΓΓΛΟΦΩΝΑ ΕΛΛΗΝΙΚΑ ΠΕΡΙΟΔΙΚΑ ......................................................................... 125 ΠΛΗΡΕΙΣ ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΕΛΛΗΝΙΚΑ ΠΕΡΙΟΔΙΚΑ .................................................................................................... 126 ΑΝΑΚΟΙΝΩΣΕΙΣ ΣΕ ΞΕΝΑ ΣΥΝΕΔΡΙΑ ................................................................................................................................... 128 ΑΝΑΚΟΙΝΩΣΕΙΣ ΣΕ ΕΛΛΗΝΙΚΑ ΣΥΝΕΔΡΙΑ ........................................................................................................................ 134 ΠΕΡΙΛΗΨΕΙΣ ΕΡΓΑΣΙΩΝ ΔΗΜΟΣΙΕΥΜΕΝΕΣ ΣΕ ΕΛΛΗΝΙΚΑ ΠΕΡΙΟΔΙΚΑ .................................................................. 140

ΑΞΙΟΛΟΓΗΤΗΣ ............................................................................................................................................................. 142 ΑΡΘΡΩΝ ΣΕ ΔΙΕΘΝΗ ΙΑΤΡΙΚΑ ΠΕΡΙΟΔΙΚΑ.......................................................................................................................... 143 ΑΙΤΗΣΕΩΝ ΧΡΗΜΑΤΟΔΟΤΗΣΗΣ ............................................................................................................................................ 149 ΕΡΓΑΣΙΩΝ ΣΕ ΔΙΕΘΝΗ ΣΥΝΕΔΡΙΑ .......................................................................................................................................... 149

ΣΥΝΕΧΙΖΟΜΕΝΗ ΙΑΤΡΙΚΗ ΕΚΠΑΙΔΕΥΣΗ ............................................................................................................ 150

ΣΥΓΚΕΝΤΡΩΤΙΚΟΣ ΠΙΝΑΚΑΣ................................................................................................................................... 155


3

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ 23 Φεβρουαρίου 2016

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ


4


SHORT CURRICULUM VITAE

George Ntaios serves as an Assistant Professor of Internal Medicine in the University of Thessaly. He is a board-

certified Internist with academic training and certification in Stroke Medicine, and practices in the Department of

Medicine in Larissa University Hospital.

After graduating from the Medical Faculty of Charles University in 2000, he continued his postgraduate studies in

Thessaloniki where he completed his MSc and PhD courses in 2003 and 2008 respectively in the Aristoteles

University of Thessaloniki. In 2011, he completed successfully the European Master in Stroke Medicine in Danube

University (Krems, Austria) supported by scholarships from the European Stroke Organization (ESO) and the

Hellenic Society of Atherosclerosis. He attended the ESO Stroke Summer Schools in Barcelona (2007) and Lausanne

(2008). He worked for one year as a stroke research fellow in the Acute Stroke Unit of the Lausanne University

Hospital.

He co-chairs the ESO Guidelines Committee since May 2014 and is the leading author of the Standard Operating

Procedure for the development of the ESO Guidelines. Also, he chaired the working group which developed the ESO

guidelines for the temperature management in acute ischaemic stroke and a member of the working group preparing

the ESO guidelines for glycemia management in acute ischaemic stroke. He is a member of the Editorial Board of the

Virtual Stroke University, the Scientific Committee of the European Stroke Organization Conference (ESOC) and the

European Stroke Journal. Also, he serves as the Secretary General of the Hellenic Stroke Organization.

His main research interest focuses on secondary stroke prevention and stroke prognosis. He participates in

observational studies and randomized controlled trials of acute stroke management and stroke prevention as

National Co-ordinator or Principal Investigator.

He is author of >110 articles in peer-reviewed journals like the Lancet, Stroke and Neurology, invited speaker in >60

international and local conferences, and invited reviewer in >60 journals.

He is blessed with a wonderful wife and three lovely children. He prefers enjoying his free time with family at home.


5


ΣΥΝΤΟΜΟ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

Ο Γεώργιος Ντάιος υπηρετεί ως Επίκουρος Καθηγητής Παθολογίας στο Πανεπιστήμιο Θεσσαλίας. Έχει την

ειδικότητα της Παθολογίας και εξειδίκευση στα Αγγειακά Εγκεφαλικά Επεισόδια, και ασκεί πλήρη κλινικά

καθήκοντα στην Παθολογική Κλινική του Πανεπιστημιακού Νοσοκομείου Λάρισας.

Μετά την αποφοίτησή του από την Ιατρική Σχολή του Πανεπιστημίου του Καρόλου (Πράγα, Τσεχική Δημοκρατία)

το 2000, συνέχισε τις σπουδές στη Θεσσαλονίκη, όπου ολοκλήρωσε τις μεταπτυχιακές σπουδές (MSc) και τη

διδακτορική διατριβή του (PhD) το 2003 και το 2008 αντίστοιχα, στο Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης. Το

2011, ολοκλήρωσε με επιτυχία το European Master in Stroke Medicine στο Πανεπιστήμιο του Δούναβη (Krems,

Αυστρία) το οποίο υποστηρίχθηκε από υποτροφίες από τον European Stroke Organization και την Ελληνική

Εταιρεία Αθηροσκλήρωση. Παρακολούθησε το Θερινά Σχολεία Εγκεφαλικών Επεισοδίων του ESO στη Βαρκελώνη

(2007) και τη Λωζάνη (2008). Εργάστηκε ως κλινικός ερευνητής και μετεκπαιδεύτηκε επί ένα χρόνο στην Μονάδα

Εγκεφαλικών Επεισοδίων του Πανεπιστημιακού Νοσοκομείου της Λωζάνης (CHUV) ερευνητής. Επίσης, από το 2015

υπηρετεί τον Ελληνικό Οργανισμό Εγκεφαλικών ως γενικός γραμματέας.

Είναι επικεφαλής της Επιτροπής Κατευθυντήριων Οδηγιών του ESO (ESO Guidelines Committee) από τoν Μάιο

2014. Επίσης, είναι επικεφαλής της Ομάδας Εργασίας που ετοιμάζει τις Κατευθυντήριες Οδηγίες του ESO για τη

διαχείριση της θερμοκρασίας κατά το οξύ ισχαιμικό ΑΕΕ, και συμμετέχει στην ομάδα εργασίας που ετοιμάζει τις

Κατευθυντήριες Οδηγίες του ESO για τη αντιμετώπιση της υπεργλυκαιμίας κατά το οξύ ισχαιμικό ΑΕΕ. Επιπλέον,

είναι μέλος της Επιστημονικής Επιτροπής του European Stroke Organization Conference, είναι μέλος του editorial

board του European Stroke Journal, ενώ συμμετείχε στην Επιτροπή Εκπαίδευσης του ESO (ESO Education

Committee) και στην Ομάδα Εργασίας του ESO για τις stroke registries (ESO Stroke Registry Task Force). Επίσης,

από το 2015 υπηρετεί τον Ελληνικό Οργανισμό Εγκεφαλικών ως γενικός γραμματέας.

Το ερευνητικό του ενδιαφέρον επικεντρώνεται στην πρόγνωση, πρωτογενή και δευτερογενή πρόληψη, και την οξεία

αντιμετώπιση του ισχαιμικού εγκεφαλικού επεισοδίου. Συμμετέχει σε μελέτες παρατήρησης και τυχαιοποιημένες

κλινικές μελέτες στο ερευνητικό πεδίο του ισχαιμικού εγκεφαλικού επεισοδίου ως Εθνικός Συντονιστής ή κύριος

ερευνητής.

Έχει συγγράψει πάνω από 110 άρθρα σε περιοδικά όπως το Lancet, Stroke, Neurology, Atherosclerosis, και υπήρξε

προσκεκλημένος ομιλητής σε περισσότερα από 60 διεθνή και Ελληνικά επιστημονικά συνέδρια. Έχει προσκληθεί ως

κριτής σε περισσότερα από 60 διεθνή περιοδικά.

Είναι ευλογημένος με μια θαυμάσια σύζυγο και τρία υπέροχα παιδιά, και προτιμά να απολαμβάνει τον ελεύθερο

χρόνο του με την οικογένεια στο σπίτι.


6


ΠΡΟΣΩΠΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ

Ονοματεπώνυμο Γεώργιος Ντάιος του Κωνσταντίνου Ημερομηνία γεννήσεως 06 Νοεμβρίου 1975 Υπηκοότητα Ελληνική Οικογενειακή κατάσταση Έγγαμος, 3 παιδιά Επαγγελματική διεύθυνση Παθολογική Κλινική, Πανεπιστημιακό Νοσοκομείο

Λάρισας, Βιόπολις 41110, Λάρισα Στοιχεία επικοινωνίας T: +30 241 3502888

M: +30 697 2770288 F: +30 241 3501557 E-mail: [email protected]

ΑΚΑΔΗΜΑΪΚH ΣΤΑΔΙΟΔΡΟΜΙΑ

06/02/2014 Εκλογή στη θέση Επίκουρου Καθηγητή Παθολογίας, Ιατρική Σχολή, Πανεπιστήμιο Θεσσαλίας 10/01/2012 Διορισμός στη θέση Λέκτορα Παθολογίας, Ιατρική Σχολή, Πανεπιστήμιο Θεσσαλίας 2011 Διδάσκων ΠΔ407 στην Ιατρική Σχολή Πανεπιστημίου Θεσσαλίας κατά το εαρινό εξάμηνο 23/03/2010 Εκλογή στη θέση Λέκτορα Παθολογίας, Ιατρική Σχολή, Πανεπιστήμιο Θεσσαλίας

ΤΙΤΛΟΙ ΠΑΝΕΠΙΣΤΗΜΙΑΚΩΝ ΣΠΟΥΔΩΝ

2011 MSc (Stroke Medicine), Πανεπιστήμιο του Δούναβη, Αυστρία 2008 PhD, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης 2003 MSc, Ιατρική Ερευνητική Τεχνολογία, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης 2000 MD, Πανεπιστήμιο Καρόλου, Τσεχία

GRANTS - ΥΠΟΤΡΟΦΙΕΣ - ΒΡΑΒΕΙΑ

2015-2020 PRECIOUS: PREvention of Compliations to Improve Outcome in elderly patients with acute Stroke. Funded with 6,000,000€ by the European Union/Horizons 2020 (http://www.precious-trial.eu)

28/02/2015 1ο Βραβείο προφορικής ανακοίνωσης: «Μεταβλητότητα της αρτηριακής πίεσης στο οξύ αγγειακό εγκεφαλικό επεισόδιο: προκαταρκτικά αποτελέσματα της μελέτης PREVISE». 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία με Διεθνή συμμετοχή, Θεσσαλονίκη

09/02/2012 Best poster presentation: “Derivation and double external validation of an integer-based prognostic score (ASTRAL score) to predict functional outcome in acute ischemic stroke: a collaborative analysis of the ASTRAL, Athens and Vienna stroke registries”, Swiss Stroke Trialists Meeting, Ζυρίχη, Ελβετία, 250CHF

2009 European Stroke Organisation, 6,000€

2009 Ελληνική Εταιρεία Αθηροσκλήρωσης, 4,000€

ΕΡΕΥΝΑ/ΜΕΤΕΚΠΑΙΔΕΥΣΗ/ΕΡΓΑΣΙΑ ΣΤΟ ΕΞΩΤΕΡΙΚΟ

2009 - 2011 MSc (Stroke Medicine), Πανεπιστήμιο του Δούναβη, Αυστρία Αύγουστος - Οκτώβριος 2011 Έμμισθος κλινικός ερευνητής.

Μονάδα Αγγειακών Εγκεφαλικών Επεισοδίων, St. George’s Hospital, Λονδίνο, Ηνωμένο Βασίλειο

Ιούλιος-Δεκέμβριος 2010 Έμμισθος κλινικός ερευνητής, Μονάδα Αγγειακών Εγκεφαλικών Επεισοδίων, CHUV, Λωζάννη, Ελβετία

Ιανουάριος-Ιούνιος 2009 Έμμισθος κλινικός ερευνητής, Μονάδα Αγγειακών Εγκεφαλικών Επεισοδίων, CHUV, Λωζάννη, Ελβετία

ΜΕΤΕΚΠΑΙΔΕΥΤΙΚΑ ΠΡΟΓΡΑΜΜΑΤΑ

2013 5ο Ετήσιο Μετεκπαιδευτικό Πρόγραμμα Παθολογικής Κλινικής και Ομώνυμου Ερευνητικού Εργαστηρίου Πανεπιστημίου Θεσσαλίας

2012 4ο Ετήσιο Μετεκπαιδευτικό Πρόγραμμα Παθολογικής Κλινικής και Ομώνυμου Ερευνητικού

http://www.precious-trial.eu/

http://www.precious-trial.eu/


7


Εργαστηρίου Πανεπιστημίου Θεσσαλίας 2008 12th European Stroke Initiative (EUSI) Stroke Summer School, Λωζάννη, Ελβετία 2008 Ετήσιο Μετεκπαιδευτικό Πρόγραμμα Επείγουσας Προνοσοκομειακής Ιατρικής του ΕΚΑΒ 2007 11th European Stroke Initiative (EUSI) Stroke Summer School, Βαρκελώνη, Ισπανία 2007 Ετήσιο Πρόγραμμα Μετεκπαιδευτικών Μαθημάτων, Διαβητολογική Εταιρεία Βόρειας Ελλάδος 2007 Εξαμηνιαίο Πρόγραμμα Εκπαίδευσης Εκπαιδευτών μελών ΔΕΠ Ιατρικής ΑΠΘ 2006 Ετήσιο Πανελλαδικό Εκπαιδευτικό Πρόγραμμα στις Λοιμώξεις, Ελληνική Εταιρεία Λοιμώξεων ΚΛΙΝΙΚΕΣ ΠΙΣΤΟΠΟΙΗΣΕΙΣ

2014 Good Clinical Practice (GCP) certification 2009 National Institute of Health Stroke Scale (NIHSS) training certification, National Stroke Organization 2009 Modified Rankin Scale training certification, University of Glasgow 2008 Επείγουσα Προνοσοκομειακή Ιατρική, Εθνικό Κέντρο Άμεσης Βοήθειας & Υπουργείο Υγείας και

Κοινωνικής Αλληλεγγύης 2007 Δίπλωμα Επάρκειας στη Διαχείριση του Αεραγωγού, Ελληνική Εταιρεία Διαχείρισης Αεραγωγού 2007 Advanced Pediatric Life Support APLS, Εθνική Επιτροπή Καρδιοαναπνευστικής Αναζωογόνησης του

ΚΕΣΥ & Advanced Life Support Group, UK 2007 Advanced Life Support (ALS) Provider, European Resuscitation Council

ΣΥΜΜΕΤΟΧΗ ΣΕ ΕΡΕΥΝΗΤΙΚΑ ΠΡΩΤΟΚΟΛΛΑ & ΕΡΕΥΝΗΤΙΚΕΣ ΟΜΑΔΕΣ

2015 NAVIGATE-ESUS, https://clinicaltrials.gov/ct2/show/NCT02313909, (Steering Committee member, National Leader in Greece, Principal Investigator in Larissa)

2015 PRECIOUS, (Member of the Executive Committee, National Leader in Greece, Principal Investigator in Larissa)

2014 BIOSIGNAL, https://clinicaltrials.gov/ct2/show/NCT02274727, (Principal investigator in Larissa) 2014 SORCAN (Stroke Outcome Research Canada), www.sorcan.ca (International collaborator) 2014 EBBINGHAUS, www.clinicaltrials.gov/show/NCT02207634, (Principal investigator in Larissa) 2014 GLORIA_AF, www.clinicaltrials.gov/show/NCT01468701 (Sub-investigator in Larissa) 2013 LASTRO (Larissa Stroke Outcome Registry), (Principal Investigator) 2013 PREVISE, www.clinicaltrials.gov/ct2/show/NCT01915862 (Sub-investigator in Larissa) 2013 FOURIER, www.clinicaltrials.gov/ct2/show/NCT01764633, (Principal investigator in Larissa) 2011 ENOS, www.clinicaltrials.gov/ct2/show/NCT00989716, (National Co-ordinator for Greece)

ΔΙΔΑΚΤΙΚΟ ΕΡΓΟ

Μετά την εκλογή στη θέση Λέκτορα 2011-2013 Συμμετοχή στην από έδρας διδασκαλία του μαθήματος Προπαιδευτική Παθολογία Ι

της Ιατρικής Σχολής Πανεπιστημίου Θεσσαλίας και στα εβδομαδιαία κλινικά φροντιστήρια παρά τη κλίνη του ασθενούς (Υπεύθυνος: Καθηγητής κ. Κ. Π. Μακαρίτσης)

2011-2013 Συμμετοχή στην από έδρας διδασκαλία του μαθήματος Παθολογία Ι της Ιατρικής Σχολής Πανεπιστημίου Θεσσαλίας και στα εβδομαδιαία κλινικά φροντιστήρια παρά τη κλίνη του ασθενούς (Υπεύθυνος: Καθηγητής κ. Γ. Ν. Νταλέκος)

2011-2013 Συμμετοχή στην από έδρας διδασκαλία του μαθήματος Παθολογία ΙΙ της Ιατρικής Σχολής Πανεπιστημίου Θεσσαλίας και στα εβδομαδιαία κλινικά φροντιστήρια παρά τη κλίνη του ασθενούς (Υπεύθυνος: Καθηγητής κ. Λ. Σακκάς)

2011-2013 Συμμετοχή στην από έδρας διδασκαλία των εκτοετών φοιτητών της Ιατρικής Σχολής Πανεπιστημίου Θεσσαλίας κατά την άσκησή τους στο τρίμηνο της Παθολογίας (Υπεύθυνος: Καθηγητής κ. Γ. Ν. Νταλέκος)

2011 Συμμετοχή στην από έδρας διδασκαλία του μαθήματος Παθολογία Ι της Ιατρικής Σχολής Πανεπιστημίου Θεσσαλίας και στα εβδομαδιαία κλινικά φροντιστήρια παρά τη κλίνη του ασθενούς με βάση το ΠΔ407 (Υπεύθυνος: Καθηγητής κ. Γ. Ν. Νταλέκος)

Πριν την εκλογή στη θέση Λέκτορα 2009 Συμμετοχή στην από έδρας διδασκαλία του επιλεγόμενου μαθήματος της Ιατρικής

Σχολής ΑΠΘ ‘Θρομβοεμβολικές Παθήσεις’.

https://clinicaltrials.gov/ct2/show/NCT02313909

https://clinicaltrials.gov/ct2/show/NCT02274727

http://www.sorcan.ca/

http://www.clinicaltrials.gov/show/NCT02207634

http://www.clinicaltrials.gov/show/NCT01468701

http://www.clinicaltrials.gov/ct2/show/NCT01915862




8


2008 Εκπαιδευτής στο επιλεγόμενο μάθημα της Ιατρικής Σχολής ΑΠΘ ‘Κλινικές Δεξιότητες’ 2008 Εκπαιδευτής στο ΙΕΚ ΕΚΑΒ Θεσσαλονίκης στις παρακάτω θεματικές ενότητες: α)

Τοπογραφική ανατομία θώρακος και β) Φυσιολογία νεφρών, 2007 Εκπαιδευτής στο ΙΕΚ ΕΚΑΒ Κατερίνης στο Β’ Ταχύρρυθμο Εαρινό Εξάμηνο, στην

ειδικότητα ‘Διασώστης-Πλήρωμα ασθενοφόρου’ στις παρακάτω θεματικές ενότητες: α) Εφαρμογές πρωτοκόλλων επί διαφόρων νοσημάτων και συνδρόμων, β) Μαζικές καταστροφές.

2004-2008 Εκπαίδευση ασκούμενων φοιτητών Οδοντιατρικής (ΣΤ’ εξαμήνου) στην Α΄ Προπαιδευτική Παθολογική Κλινική ΑΠΘ Νοσοκομείου ΑΧΕΠΑ,

2004-2008 Εκπαίδευση ασκούμενων φοιτητών Ιατρικής (ΣΤ’ εξαμήνου) στην Α΄ Προπαιδευτική Παθολογική Κλινική ΑΠΘ Νοσοκομείου ΑΧΕΠΑ,

2003, 2004 & 2007 Εκπαιδευτής στο Εκπαιδευτικό Τμήμα των Κυριών Εθελοντριών Νοσηλευτικής του Ελληνικού Ερυθρού Σταυρού Κατερίνης στις παρακάτω θεματικές ενότητες: α) Ανατομία, β) Παθολογία.

ΜΕΛΟΣ ΕΠΙΤΡΟΠΩΝ ΔΙΠΛΩΜΑΤΙΚΩΝ ΕΡΓΑΣΙΩΝ Ή ΔΙΔΑΚΤΟΡΙΚΩΝ ΔΙΑΤΡΙΒΩΝ

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή 30/06/2015 Μέλος τριμελούς επιτροπής για την διπλωματική εργασία του κ. Α. Μπασδάνη με τίτλο

«Ασθενείς και επιβάρυνση φροντιστών μετά το Αγγειακό Εγκεφαλικό Επεισόδιο», ΠΜΣ «Πρωτοβάθμια φροντίδα υγείας», Πανεπιστήμιο Θεσσαλίας

5/11/2014 Επιβλέπων Διδακτορικής Διατριβής της Ιατρού κ. Αναστασίας Καραγιαννάκη, , η οποία εκπονείται στο Πανεπιστήμιο Θεσσαλίας με τίτλο «Μελέτη της επίδρασης της προηγούμενης λήψης αντιυπερτασικών φαρμάκων στους δείκτες μεταβλητότητας της αρτηριακής πίεσης και της αρτηριακής σκληρίας σε ασθενείς με οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο», σε συνεργασία με τους κ.κ. Αναπληρωτή Καθηγητή Χρήστο Σαββόπουλο (Ιατρική ΑΠΘ) και Αναπληρωτή Καθηγητή Χαράλαμπο Μηλιώνη (Ιατρική Πανεπιστημίου Ιωαννίνων).

8/10/2014 Μέλος τριμελούς επιτροπής για την διπλωματική εργασία του κ. Θ. Σίμου με τίτλο «Παρακολούθηση των ασθενών με ΑΕΕ στην κοινότητα», ΠΜΣ «Πρωτοβάθμια φροντίδα υγείας», Πανεπιστήμιο Θεσσαλίας

8/10/2014 Μέλος τριμελούς επιτροπής για την διπλωματική εργασία της κ. Στυλιανής Γιάτσιου με τίτλο «Η αποπληξία από την αρχαιότητα έως τους σύγχρονους χρόνους», ΠΜΣ «Πρωτοβάθμια φροντίδα υγείας», Πανεπιστήμιο Θεσσαλίας

Μετά την εκλογή στη θέση Λέκτορα 10/10/2013 Μέλος τριμελούς επιτροπής για την διπλωματική εργασία του κ. Λ. Μπούζα με τίτλο

«Μελέτη της επιβάρυνσης των άτυπων φροντιστών ασθενών με Αγγειακό Εγκεφαλικό Επεισόδιο», ΠΜΣ «Πρωτοβάθμια φροντίδα υγείας», Πανεπιστήμιο Θεσσαλίας

26/04/2013 Μέλος τριμελούς συμβουλευτικής επιτροπής για την Διδακτορική Διατριβή του ιατρού κ. Νικολάου Κακαλέτση, η οποία εκπονείται στο Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ) με τίτλο «Σύγκριση δεικτών μεταβλητότητας της αρτηριακής πίεσης και της αρτηριακής σκληρίας στην πρόγνωση της μεσοπρόθεσμης έκβασης του οξέος ισχαιμικού αγγειακού εγκεφαλικού επεισοδίου», σε συνεργασία με τους κ.κ. Καθηγητή Απόστολο Χατζητόλιο (Επιβλέπων, Ιατρική ΑΠΘ) και Αναπληρωτή Καθηγητή Χαράλαμπο Μηλιώνη (Ιατρική Πανεπιστημίου Ιωαννίνων).

13/11/2012 Μέλος τριμελούς επιτροπής για την διπλωματική εργασία της κ. Ειρήνης Πουλακίδα με τίτλο «Η επίδραση της υδροξυχλωροκίνης στην αθηροσκλήρυνση»», ΠΜΣ «Κλινικές Εφαρμογές Μοριακής Ιατρικής», Πανεπιστήμιο Θεσσαλίας

ΚΛΙΝΙΚΟ ΕΡΓΟ

Μετά την εκλογή στη θέση Λέκτορα Από τις 09/2012 Υπεύθυνος Εξωτερικού Ιατρείου Παρακολούθησης και Αποκατάστασης Αγγειακών


9


Συμβαμάτων του Πανεπιστημιακού Γενικού Νοσοκομείου Λάρισας

Από τον 02/2012 Παθολογική Κλινική Πανεπιστημίου Θεσσαλίας, Πανεπιστημιακό Νοσοκομείο Λάρισας

08/2011 - 09/2011 Μονάδα Αγγειακών Εγκεφαλικών, St. George’s Hospital, Λονδίνο, Ηνωμένο Βασίλειο

07/2010 – 12/2010 Μονάδα Αγγειακών Εγκεφαλικών, CHUV, Λωζάνη, Ελβετία

Πριν την εκλογή στη θέση Λέκτορα 07/2009 – 07/2010 Επικουρικός Επιμελητής ΕΣΥ, Α’ Προπαιδευτική Παθολογική Κλινική, ΑΧΕΠΑ

01/2009 – 06/2009 Μονάδα Αγγειακών Εγκεφαλικών, CHUV, Λωζάνη, Ελβετία

07/2008 – 10/2008 Τρίμηνη άσκηση στη διάρκεια της ειδικότητας στη Μονάδα Εντατικής Θεραπείας, ΑΧΕΠΑ

04/2008 – 07/2008 Τρίμηνη άσκηση στη διάρκεια της ειδικότητας στην Α’ Καρδιολογική Κλινική, ΑΧΕΠΑ

04/2004 – 11/2008 Ειδίκευση στην Παθολογία, Α’ Προπαιδευτική Παθολογική Κλινική, ΑΧΕΠΑ

02/2003 – 02/2004 Οπλίτης Ιατρός

07/2001 – 11/2002 Υποχρεωτική υπηρεσία υπαίθρου, Κέντρο Υγείας Λιτοχώρου

ΟΜΙΛΙΕΣ – ΣΥΝΕΝΤΕΥΞΕΙΣ

Στην Ελλάδα

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή 25/01/2016 “Preventing & managing intracranial hemorrhage while in antithrombotics”. Heart Vessels &

Stroke, Athens 19/12/2015 «Κρυπτογενή εγκεφαλικά έμφρακτα», Εκπαιδευτικές Ημερίδες Εγκεφαλικών επεισοδίων 2015-

2016 του Ελληνικού Οργανισμού Εγκεφαλικών, 1η Ημερίδα με τίτλο «Παθοφυσιολογία και κατάταξη των ισχαιμικών εγκεφαλικών επεισοδίων», ΑΘήνα

19/12/2015 «Εγκεφαλικά λόγω νόσου των μικρών αγγείων», Εκπαιδευτικές Ημερίδες Εγκεφαλικών επεισοδίων 2015-2016 του Ελληνικού Οργανισμού Εγκεφαλικών, 1η Ημερίδα με τίτλο «Παθοφυσιολογία και κατάταξη των ισχαιμικών εγκεφαλικών επεισοδίων», ΑΘήνα

6/12/2015 «Η δίαιτα στην πρόληψη του ΑΕΕ», Πρόγραμμα Μεταπτυχιακών Σπουδών «Η διατροφή στην υγεία και στη νόσο» του Πανεπιστημίου Θεσσαλίας, Λάρισα

5/12/2015 «Ασθενής με κρυπτογενές ισχαιμικό έμφρακτο», 6o συμπόσιο των Ομάδων Εργασίας της Ελληνικής Εταιρείας Αθηροσκλήρωσης, Αθήνα

10/10/2015 «Ischaemic stroke in diabetes: is it really a macrovascular complication?». FENS Featured Regional Meeting 2015, Θεσσαλονίκη

3/10/2015 «Pradaxa: 5 χρόνια μετά τη RELY. Από τη θεωρεία στην πράξη: Συνήθη κλινικά σενάρια». 7ο Πανελλήνιο Εκπαιδευτικό Σεμινάριο του Ινστιτούτου Μελέτης Έρευνας & Εκπαίδευσης για το Σακχαρώδη Διαβήτη και τα Μεταβολικά Νοσήματα με θέμα «Οι Σύγχρονες εξελίξεις στη διάγνωση και αντιμετώπιση μεταβολικών νοσημάτων και συνοδών παθολογικών καταστάσεων», Αγριά Βόλου

14/06/2015 «Εμβολικά Εγκεφαλικά Απροσδιόριστης Αιτολογίας». Pulse & Cardioelectrics, Ηράκλειο Κρήτης 05/05/2015 «Ρύθμιση της αντιπηκτικής αγωγής κατά τη διάρκεια προγραμματισμένων επεμβατικών

πράξεων». Μετεκπαιδευτικά Μαθήματα της Κλινικής Ενδοκρινολογίας και Μεταβολικών Νόσων του Πανεπιστημίου Θεσσαλίας, Λάρισα

24/04/2015 «Ασθενής με κρυπτογενές ισχαιμικό έμφρακτο», 3ο Πανελλήνιο Συνέδριο Θρόμβωσης - Αντιθρομβωτικής Αγωγής, Αθήνα

28/03/2015 «Παθοφυσιολογία και δευτερογενής αντιθρομβωτική θεραπεία των ισχαιμικών αγγειακών εγκεφαλικών επεισοδίων», Ημερίδα Χρονίων Νοσημάτων, Αράχωβα

21/03/2015 “New anticoagulants in clinical practice”, 7o Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα

19/03/2015 «Antiplatelet treatment in secondary stroke prevention: the role of Triflusal», 7o Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα

19/03/2015 «Management of anticoagulation during elective interventional procedures», 7o Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα

8/03/2015 «Κρυπτογενή εγκεφαλικά εμφρακτα: εξελίξεις στη διάγνωση και θεραπεία», Heart Vessels Stroke, Αθήνα


10


26/02/2015 «Αντιαιμοπεταλιακή αγωγή στην δευτερογενή πρόληψη των ισχαιμικών εγκεφαλικών επεισοδίων: ο ρόλος της τριφλουζάλης», 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη

27/11/2014 «Ο ρόλος της τριφλουζάλης στην δευτερογενή αντιμετώπιση του ισχαιμικού εγκεφαλικού», Εκδήλωση υπό την αιγίδα του Ινστιτούτου Εσωτερικής Παθολογίας και Ηπατολογίας, Λάρισα

13/11/2014 «Σακχαρώδης διαβήτης και αγγειακή νόσος: Ιδιαιτερότητες στην πρόληψη και αντιμετώπιση: Καρωτιδική νόσος», 28ο Πανελλήνιο Ετήσιο Συνέδριο Διαβητολογικής Εταιρείας Βόρειας Ελλάδας, Θεσσαλονίκη

11/04/2014 «Ασθενής με κενοχωριώδες (lacunar) ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο, 2ο Πανελλήνιο Συνέδριο Θρόμβωσης – αντιθρομβωτικής αγωγής, Αθήνα

27/03/2014 “Carotid disease: how confident are we for the benefit of endarterectomy?”, 6ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα

27/03/2014 «Πρόληψη Θρομβοεμβολικών επεισοδίων με Dabigatran: Υπάρχουν νεότερα δεδομένα;», 6ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα

09/03/2014 «Ισχαιμικό ΑΕΕ σε διαβητικούς: πρόκειται πράγματι για μάκροαγγειακή επιπλοκή;», 2η Πανθεσσαλική Εκπαιδευτική Συνάντηση, Λάρισα

08/03/2014 «Meet the Experts: Antithrombotics in stroke management». ALPIC, Μέτσοβο 19/02/2014 «Πρόληψη Θρομβοεμβολικών επεισοδίων με Dabigatran: Υπάρχουν νεότερα δεδομένα;»,

Εκπαιδευτικές Ημερίδες Πρωτοβάθμιας Φροντίδας Υγείας «Γ. Παπαδάκης», Αθήνα Μετά την εκλογή στη θέση Λέκτορα 24/01/2014 «CHANCE», Συνέδριο ‘Heart Vessels and Stroke’, Hellenic Cardiovascular Research Society &

Hellenic Cardiological Society, Αθήνα 23/01/2014 «Κλινική εικόνα και παθοφυσιολογία του συνδρόμου Cushing», 6ο Ετήσιο Μετεκπαιδευτικό

Πρόγραμμα Παθολογικής Κλινικής Πανεπιστημίου Θεσσαλίας, Λάρισα 30/11/2013 «Πόσο σίγουροι είμαστε για το όφελος της ενδαρτηρεκτομής;», 5ο Συμπόσιο των Ομάδων

Εργασίας της Ελληνικής Εταιρείας Αθηροσκλήρωσης, Αθήνα 05/11/2013 «Δευτερογενής πρόληψη ισχαιμικών αγγειακών εγκεφαλικών επεισοδίων» στο πλαίσιο των

Εκπαιδευτικών Μαθημάτων της Καρδιολογικής Κλινικής ΠΘ, Λάρισα 28/09/2013 «Κλινικές περιπτώσεις αντιθρομβωτικής αγωγής σε ασθενείς με εγκεφαλικό επεισόδιο», Ημερίδα

Ι.Μ.Ε.Θ.Α., Καβάλα 21/09/2013 «Αγγειακά Εγκεφαλικά Επεισόδια», 2ο Επιστημονικό Συμπόσιο ΕΠΒΕ, Αγριά Βόλου 11/05/2013 “Αντιαιμοπεταλιακή αγωγή σε ασθενείς με ΑΕΕ: Ποια, σε ποιους ασθενείς και για πόσο χρονικό

διάστημα;”, Εαρινό Σεμινάριο Πρωτοβάθμιας Φροντίδας Υγείας, Ελληνική Εταιρεία Έρευνας & Εκπαίδευσης στην Πρωτοβάθμια Φροντίδα Υγείας, Βόλος

12/04/2013 “Εγκεφαλικά επεισόδια και αντιθρομβωτική αγωγή στην κλινική ιατρική πρακτική μετά το νοσοκομείο: Νεώτερα αντιπηκτικά”, 1ο Πανελλήνιο Συνέδριο Θρόμβωσης – Αντιθρομβωτικής Αγωγής, Αθήνα

05/04/2013 “Carotid disease: how confident are we for the benefit of endarterectomy?” Advances in diagnosis and management of intracranial vascular lesions, Larissa

09/03/2013 «Σακχαρώδης διαβήτης και Αγγειακά Εγκεφαλικά Επεισόδια», 1η Πανθεσσαλική Εκπαιδευτική Συνάντηση, Λάρισα

27/01/2013 “Θρομβόλυση μετά το παράθυρο των 4.5 ωρών με βάση τις απεικονιστικές τεχνικές, Συνέδριο ‘Heart Vessels and Stroke’, Hellenic Cardiovascular Research Society & Hellenic Cardiological Society, Αθήνα

27/01/2013 «Πόσο σίγουροι είμαστε για το όφελος της ενδαρτηρεκτομής;», Συνέδριο ‘Heart Vessels and Stroke’, Hellenic Cardiovascular Research Society & Hellenic Cardiological Society, Αθήνα

20/11/2012 «Βασικές αρχές αντιμετώπισης του αγγειακού εγκεφαλικού επεισοδίου», Μετεκπαιδευτικά Μαθήματα Ενδοκρινολογικής Κλινικής ΠΘ, Λάρισα

18/10/2012 «Οξεία αντιμετώπιση του αγγειακού εγκεφαλικού επεισοδίου», 5ο Ετήσιο Μετεκπαιδευτικό Πρόγραμμα Παθολογικής Κλινικής Πανεπιστημίου Θεσσαλίας, Λάρισα

19/05/2012 «Ενδαρτηρεκτομή και αγγειοπλαστική στην αντιμετώπιση του ισχαιμικού ΑΕΕ», 38ο Πανελλήνιο Ιατρικό Συνέδριο, Αθήνα

03/05/2012 «Πνευμονική εμβολή: επιδημιολογία, αιτιοπαθογένεια, κλινική εικόνα», 4ο Ετήσιο Μετεκπαιδευτικό Πρόγραμμα Παθολογικής Κλινικής Πανεπιστημίου Θεσσαλίας, Λάρισα

29/03/2012 «Αντιθρομβωτική αγωγή σε ασθενείς με μη καρδιοεμβολικό αγγειακό εγκεφαλικό επεισόδιο», 4ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα

21/01/2012 “Παροδικά Ισχαιμικά Αγγειακά Εγκεφαλικά Επεισόδια: Ορισμός και Επιδημιολογικά δεδομένα: κίνδυνος ισχαιμικού εγκεφαλικού και εμφράγματος μυοκαρδίου”. Συνέδριο ‘Heart Vessels and Stroke’, Hellenic Cardiovascular Research Society & Hellenic Cardiological Society, Αθήνα

20/01/2012 “SAMMPRIS”, Συνέδριο ‘Heart Vessels and Stroke’, Hellenic Cardiovascular Research Society &


11


Hellenic Cardiological Society, Αθήνα 03/12/2011 «Παράγοντες Κινδύνου για την εμφάνιση ΑΕΕ αθηροθρομβωτικής αιτιολογίας», 4ο Συμπόσιο

Ομάδων Εργασίας της Ελληνικής Εταιρίας Αθηροσκλήρωσης, Αθήνα 23/09/2011 «Βασικές αρχές παθοφυσιολογίας αγγειακών εγκεφαλικών επεισοδίων», Φθινοπωρινές Ημέρες

Παθολογίας με κεντρικό θέμα «Αγγειακό Εγκεφαλικό Επεισόδιο: και μετά τί;», Λίμνη Πλαστήρα 12/03/2011 «Θεραπευτική αντιμετώπιση ασθενών με αθηροθρομβωτικό ισχαιμικό ΑΕΕ», Συνέδριο

Παθολογίας Κεντρικής Ελλάδας, Λάρισα 23/01/2011 «Διατατική μυοκαρδιοπάθεια ισχαιμικής ή μη ισχαιμικής αρχής και εμβολική νόσος» Συνέδριο

‘Heart Vessels and Stroke’, Hellenic Cardiovascular Research Society & Hellenic Cardiological Society, Αθήνα

19/06/2010 Συμμετοχή σε στρογγυλή τράπεζα του 15ου σεμιναρίου του Ελληνικού Κολεγίου Νεφρολογίας και Υπέρτασης με θέμα «Επείγοντα καρδιαγγειακά συμβάματα στη χρόνια νεφρική νόσο», Ξάνθη

Πριν την εκλογή στη θέση Λέκτορα 23/01/2010 «Γενικά Μέτρα Θεραπευτικής Αντιμετώπισης στο Οξύ Ισχαιμικό ΑΕΕ», Συνέδριο ‘Κολπική

Μαρμαρυγή και Αγγειακά Εγκεφαλικά Επεισόδια’, Hellenic Cardiovascular Research Society & Hellenic Cardiological Society, Αθήνα

30/10/2009 «Η ρύθμιση της αρτηριακής πίεσης κατά το οξύ ΑΕΕ», Πανελλήνιο Συνέδριο Αγγειακών Εγκεφαλικών Νόσων, Αλεξανδρούπολη

18/05/2007 «Συνταγογραφία στον Σακχαρώδη Διαβήτη και το Μεταβολικό Σύνδρομο», Σεμινάριο ‘Συνταγογραφία’, International Society of Quality of Life and Medical Practice, Θεσσαλονίκη

18/05/2007 «Xor;hghsh farm;akvn se asuene;iw me nefrik;h anep;arkeia», Semin;ario ‘Syntagograf;ia’, International Society of Quality of Life and Medical Practice, Uessalon;ikh

Στο εξωτερικό

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή 5/02/2016 “Stroke prevention in non-valvular atrial fibrillation”. 10th Portuguese Stroke Conference. Porto,

Portugal 11/12/2015 “Stroke in the era of NOACs”, MIDI anticoagulation Academy: “Innovations in anticoagulation:

Challenges in emergency and individual patient management”, Oslo, Norway 21/11/2015 GRADE methodology. 3rd ESO GRADE workshop, Garmisch-Partenkirchen, Germany 16/10/2015 "Embolic Strokes of Undetermined Source: not so cryptogenic any more?”, European PFO

summit, Zurich, Switzerland 10/09/2015 "Embolic Strokes of Undetermined Source: not so cryptogenic any more?”, XV Congresso

Nazionale della Società Italiana per lo Studio dello Stroke & 10th Regional Meeting of the Meditarranean Stroke Society, Ragusa, Italy

18/04/2015 “Monitoring: what, when and how long?”, 1st European Stroke Organisation Conference, Glasgow, UK

17/04/2015 “Prime time for acute prevention with double anti-agreggation – moderator”, 1st European Stroke Organisation Conference, Glasgow, UK

12/01/2015 GRADE methodology. 2nd ESO GRADE workshop, Frankfurt, Germany 18/11/2014 “Summary and Next steps? Targets for 2016 - where do we need to update guidelines?”, ESO

Karolinska Stroke Update, Stockholm, Sweden 18/11/2014 “ESO Guidelines: temperature management in acute ischaemic stroke”, ESO Karolinska Stroke

Update, Stockholm, Sweden 08/05/2014 “ESO Guidelines: temperature management in acute ischaemic stroke”, European Stroke

Conference, Nice, France 08/05/2014 “ A short introduction on GRADE”, European Stroke Conference, Nice, France Μετά την εκλογή στη θέση Λέκτορα 23/11/2013 “New oral anticoagulants: are we ready for wide use after stroke: yes”, 2013 Joint Meeting of te

Belgian Neurological Society and the Belgian Stroke Council – Controversies in Stroke, Leuven, Belgium

06/09/2012 “Cerebrovascular prevention in cardiac failure”, State of the Art, CHUV, Lausanne, Switzerland 29/09/2012 “The ASTRAL score to predict outcome in acute ischemic stroke”, XII Congresso Nazionale Della

Societa’ Italiana Per Lo Studio Dello Stroke. “Ictus: Quale futuro?” L” Aquila, Italy


12


ΣΥΝΤΟΝΙΣΜΟΣ ΣΤΡΟΓΓΥΛΩΝ ΤΡΑΠΕΖΩΝ ΣΥΝΕΔΡΙΩΝ

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή 19/12/2015 Εκπαιδευτικές Ημερίδες Εγκεφαλικών επεισοδίων 2015-2016 του Ελληνικού Οργανισμού

Εγκεφαλικών, 1η Ημερίδα με τίτλο «Παθοφυσιολογία και κατάταξη των ισχαιμικών εγκεφαλικών επεισοδίων», ΑΘήνα

19/03/2015 Oral presentations session: cardiovascular diseases, 7ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα

09/03/2014 «Διαβήτης και Καρδιαγγειακή νόσος», 2η Πανθεσσαλική Εκπαιδευτική Διημερίδα, Λάρισα Μετά την εκλογή στη θέση Λέκτορα 19/05/2012 «Βρογχικό άσθμα», Φθινοπωρινές ημέρες Παθολογίας: Παθήσεις αναπνευστικού. Καλαμπάκα

ΟΡΓΑΝΩΤΙΚΗ/ΕΠΙΣΤΗΜΟΝΙΚΗ ΕΠΙΤΡΟΠΗ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΚΔΗΛΩΣΕΩΝ

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή

19/12/2015 Εκπαιδευτικές Ημερίδες Εγκεφαλικών επεισοδίων 2015-2016 του Ελληνικού Οργανισμού

Εγκεφαλικών, 1η Ημερίδα με τίτλο «Παθοφυσιολογία και κατάταξη των ισχαιμικών εγκεφαλικών επεισοδίων», ΑΘήνα

21-22/11/2015 3rd GRADE methodology. ESO GRADE workshop, Garmisch-Partemkirchen, Germany 10-12/05/2016 2nd European Stroke Organisation Conference, Barcelona, Spain 11-12/09/2015 Φθινοπωρινές ημέρες Παθολογίας: ενδοκρινικά και μεταβολικά νοσήματα. Αγριά Βόλου

24/04/2015 3ο Πανελλήνιο Συνέδριο Θρόμβωσης - Αντιθρομβωτικής Αγωγής, Αθήνα 17-19/04/2015 European Stroke Organisation Conference, Glasgow, UK 19-21/03/2015 7ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα

12/01/2015 GRADE methodology. ESO GRADE workshop, Frankfurt, Germany 16-18/11/2014 ESO Karolinska Stroke Update, Stockholm, Sweden 26-27/09/2014 Φθινοπωρινές ημέρες Παθολογίας: λοιμώξεις. Λουτρά Αριδαίας, Πόζαρ 27-29/03/2014 6ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα

Μετά την εκλογή στη θέση Λέκτορα

20-22/09/2013 2ο Επιστημονικό Συμπόσιο ΕΠΒΕ με θέμα “Οδηγίες αντιμετώπισης καρδιαγγειακού κινδύνου

στην καθ’ ημέρα πράξη», Αγριά Βόλου 2013-2014 6ο Ετήσιο Μετεκπαιδευτικό Πρόγραμμα της Παθολογικής Κλινικής Πανεπιστημίου Θεσσαλίας

13-14/09/2013 Φθινοπωρινές ημέρες Παθολογίας: Παθήσεις του γαστρεντερικού σωλήνα και του παγκρέατος, Συρράκο Ιωαννίνων

12-13/04/2013 1o Πανελλήνιο Συνέδριο Θρόμβωσης - Αντιθρομβωτικής Αγωγής, Αθήνα 28-30/03/2013 5ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα 14-15/09/2012 Φθινοπωρινές ημέρες Παθολογίας: Παθήσεις αναπνευστικού. Καλαμπάκα

2012-2013 5ο Ετήσιο Μετεκπαιδευτικό Πρόγραμμα της Παθολογικής Κλινικής Πανεπιστημίου Θεσσαλίας 29-31/03/2012 4ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα 23-24/09/2011 Φθινοπωρινές Ημέρες Παθολογίας με κεντρικό θέμα «Αγγειακό Εγκεφαλικό Επεισόδιο: και μετά

τί;», Λίμνη Πλαστήρα

18-20/06/2010 15ο Σεμινάριο του Ελληνικού Κολλεγίου Νεφρολογίας και Υπέρτασης, «Επείγουσες καταστάσεις στη Νεφρολογία», Ξάνθη

ΣΥΜΜΕΤΟΧΗ ΣΤΗΝ ΣΥΓΓΡΑΦΗ ΙΑΤΡΙΚΩΝ ΒΙΒΛΙΩΝ


13


Μετά την εκλογή στη θέση Επίκουρου Καθηγητή 2014 Liontos A, Milionis H, Ntaios G. Medical and behavioral intervention for carotid atherosclerotic disease.

In: Carotid Artery Disease: risk factors, prognosis and management. Nova Biomedical Eds, New Yorkpp. 1-33

2014 Ntaios G, Polychronopoulou E, Makaritsis K. Asymptomatic carotid disease: how confident are we about the benefit of endarterectomy?. In: Carotid Artery Disease: risk factors, prognosis and management. Nova Biomedical Eds, New York, pp. 97-115

Μετά την εκλογή στη θέση Λέκτορα 2010 Επιμέλεια έκδοσης του βιβλίου Χατζητόλιος Α. «Θρομβοεμβολικές Παθήσεις», εκδόσεις Mendor Πριν την εκλογή στη θέση Λέκτορα 2010 Κεφάλαιο με τίτλο «Αντιαιμοπεταλιακή αγωγή» στο Χατζητόλιος Α. «Θρομβοεμβολικές Παθήσεις», εκδόσεις

Mendor 2009 Επιμέλεια μετάφρασης του βιβλίου ECG made easy, 3rd edition, εκδόσεις Ροτόντα, ISBN: 960-98037-9-2 2008 Επιμέλεια ελληνικής μετάφρασης του βιβλίου ‘Lipids and Atherosclerosis’, εκδόσεις Mendor

ΣΥΝΕΝΤΕΥΞΕΙΣ/ΑΡΘΡΟΓΡΑΦΙΑ ΣΤΑ ΜΕΣΑ ΜΑΖΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ

Μετά την εκλογή στη θέση Λέκτορα 04/03/2011 Συνέντευξη στο ραδιοφωνικό σταθμό «Ράδιο Ενημέρωση» 92.2FM σε σχέση με τα Αγγειακά

Εγκεφαλικά Επεισόδια 14/02/2011 Άρθρο στο Ένθετο “Health” της εφημερίδας «Ελεύθερος Τύπος» με τίτλο «Καρωτιδική νόσος και

ισχαιμικά επεισόδια» 17/04/2010 Συνέντευξη στην εκπομπή «Υγεία για όλους» του Μιχάλη Κεφαλογιάννη, Νέα Ελληνική Τηλεόραση

(ΝΕΤ), Αθήνα

ΛΟΙΠΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ ΣΤΟ ΧΩΡΟ ΤΗΣ ΥΓΕΙΑΣ

Μετά την εκλογή στη θέση Λέκτορα - Αναπληρωματικό μέλος της Επιτροπής Αξιολόγησης Προσωπικού στο πλαίσιο Δράσης «Διμερής Συνεργασία

Ελλάδας-Γαλλίας 2013» με τίτλο “CampyRisk: Το Campylobacter spp. στην τροφική αλυσίδα των Ορνιθίων Κρεατοπαραγωής: εκτίμηση και διαχείριση των κινδύνων για τη δημόσια υγεία» (κωδικός 4743 Επιτροπής Ερευνών Πανεπιστημίου Θεσσαλίας) (09 Ιανουαρίου 2014).

- Αναπληρωματικό μέλος της επιτροπής αξιολόγησης των αποτελεσμάτων των διαγωνισμών και των διαδικασιών διαπραγμάτευσης του τακτικού διαγωνισμού μέσω ΕΣΠΑ έτους 2013 με αριθμό διακήρυξης 23/2013 για την προμήθεια και εγκατάσταση εξοπλισμού για την Πανεπιστημιακή Παθολογική, την Ενδοκρινολογική, την Αγγειοχειρουργική κα το τμήμα Αιμοδοσίας του Πανεπιστημιακού Γενικού Νοσοκομείου Λάρισας (ΑΔΑ: ΒΛΩ3469060-ΤΑΚ)

- Τακτικό μέλος της τριμελούς επιτροπής διενέργειας και αξιολόγησης των αποτελεσμάτων του πρόχειρου μειοδοτικού διαγωνισμού για την προμήθεια συστήματος παρακολούθησης ζωτικών παραμέτρων των ασθενών και την προμήθεια ιατρικών αναπνευστικών συσκευών για τις ανάγκες της Πανεπιστημιακής Παθολογικής Κλινικής του Π.Γ.Ν.Λ., συνολικής προϋπολογιζόμενης δαπάνης € 28.509,26 με το Φ.Π.Α., με αριθμό διακήρυξης 58/2012 (ΑΔΑ: Β4ΜΡ469060-41Ρ).

Πριν την εκλογή στη θέση Λέκτορα - Ταμίας Ιατρικού Συλλόγου Πιερίας, 07/2002 – 04/2004 - Εθελοντική συμμετοχή στο ‘Πρόγραμμα Προληπτικής Ιατρικής και Ενημέρωσης’ της Νομαρχιακής Αυτοδιοίκησης

Πιερίας σε συνεργασία με την Τοπική Αυτοδιοίκηση, τη Διεύθυνση Πρωτοβάθμιας Εκπαίδευσης Πιερίας και το σύλλογο ‘Χαμόγελο του Παιδιού’ στα σχολεία των Δήμων Πέτρας, Πιερίων, Ελαφίνας, Πύδνας και Δίου του νομού Πιερίας, 2002


14


ΜΕΛΟΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΤΑΙΡΕΙΩΝ ΚΑΙ ΔΡΑΣΤΗΡΙΟΤΗΤΑ ΣΤΟ ΠΛΑΙΣΙΟ ΑΥΤΩΝ

2015- Ελληνικός Οργανισμός Εγκεφαλικών (Ιδρυτικό μέλος & Γενικός Γραμματέας) 2013 - Ινστιτούτο Μελέτης και Εκπαίδευσης στη Θρόμβωση και την Αντιθρομβωτική Αγωγή 2012 - Ινστιτούτο Εσωτερικής Παθολογίας και Ηπατολογίας (μέλος ΔΣ - ταμίας) 2011 - Ελληνική Εταιρεία Καρδιοαγγειακής Έρευνας 2009 - Fellow of the European Stroke Organisation (FESO)

- Επικεφαλής (chair) της ESO Guidelines Committee, (ης επιτροπής η οποία είναι υπεύθυνη για την προετοιμασία των κατευθυντήριων οδηγιών του ESO) (2014)

- Μέλος της ESO Education Committee (2011-2015) - Μέλος της ESO Stroke Registry Task Force (2013) - Επικεφαλής (chair) της ομάδας εργασίας για τις ESO guidelines σχετικά με: “Temperature

management in acute ischemic stroke” (2013) - Μέλος της ομάδας εργασίας για τις ESO guidelines σχετικά με: “Hyperglycemia management in

acute ischemic stroke” (2015) 2009 - Ελληνική Εταιρεία Αθηροσκλήρωσης

- Μέλος της Ομάδας Εργασίας για τα Αγγειακά Εγκεφαλικά Επεισόδια 2009 European Atherosclerosis Society 2009 - Εταιρεία Παθολογίας Βορείου Ελλάδος

- Επικεφαλής ομάδας εργασίας για τα Αγγειακά Εγκεφαλικά Επεισόδια 2008 - Διαβητολογική Εταιρεία Βορείου Ελλάδος 2008 Ελληνική Εταιρεία Λοιμώξεων

ΣΥΣΤΑΤΙΚΕΣ ΕΠΙΣΤΟΛΕΣ

Michael Brainin (2013) Patrik Michel, University of Lausanne (2013)


15

ΑΝΑΛΥΤΙΚΟ ΥΠΟΜΝΗΜΑ ΔΗΜΟΣΙΕΥΜΑΤΩΝ 23 Φεβρουαρίου 2016

ΑΝΑΛΥΤΙΚΟ ΥΠΟΜΝΗΜΑ ΔΗΜΟΣΙΕΥΜΑΤΩΝ


16


Μετά την εκλογή στη θέση Επίκουρου Καθηγητή Continuing versus Stopping Prestroke Antihypertensive Therapy in Acute Intracerebral Hemorrhage: A Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke Trial

Kailash Krishnan, Polly Scutt, Lisa Woodhouse, Alessandro Adami, Jennifer L. Becker, Lesley A. Cala, Ana M. Casado, Christopher Chen, Robert A. Dineen, John Gommans, Panos Koumellis, Hanna Christensen, Ronan Collins, Anna Czlonkowska, Kennedy R. Lees, George Ntaios, Serefnur Ozturk, Stephen J. Phillips, Nikola Sprigg, Szabolcs Szatmari, Joanna M. Wardlaw, Philip M. Bath, DSc, FRCP* for the ENOS Investigators

Journal of Stroke and Cerebrovascular Diseases 2016, online early

Background and purpose: More than 50% of patients with acute intracerebral hemorrhage (ICH) are taking antihypertensive drugs before ictus. Although antihypertensive therapy should be given long term for secondary prevention, whether to continue or stop such treatment during the acute phase of ICH remains unclear, a question that was addressed in the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Methods: ENOS was an international multicenter, prospective, randomized, blinded endpoint trial. Among 629 patients with ICH and systolic blood pressure between 140 and 220 mmHg, 246 patients who were taking antihypertensive drugs were assigned to continue (n = 119) or to stop (n = 127) taking drugs temporarily for 7 days. The primary outcome was the modified Rankin Score at 90 days. Secondary outcomes included death, length of stay in hospital, discharge destination, activities of daily living, mood, cognition, and quality of life. Results: Blood pressure level (baseline 171/92 mmHg) fell in both groups but was significantly lower at 7 days in those patients assigned to continue antihypertensive drugs (difference 9.4/3.5 mmHg, P < .01). At 90 days, the primary outcome did not differ between the groups; the adjusted common odds ratio (OR) for worse outcome with continue versus stop drugs was .92 (95% confidence interval, 0.45-1.89; P = .83). There was no difference between the treatment groups for any secondary outcome measure, or rates of death or serious adverse events. Conclusions: Among patients with acute ICH, immediate continuation of antihypertensive drugs during the first week did not reduce death or major disability in comparison to stopping treatment temporarily.

Συμφωνία (Consensus) ειδικών για την ορθολογική χορήγηση των αναστολέων της PCSK9

Β. Άθυρος, Θ. Αλεξανδρίδης, Δ. Αλεξόπουλος, Α. Αχείμαστος, Π. Βάρδας, Δ. Βλαχάκος, Χ. Βλαχόπουλος, Ε. Γανωτάκης, Ι. Γουδέβενος, Ευ. Δρογκάρη, Μ. Ελισάφ, Ι. Ιωαννίδης, Γ. Κολοβού, Β. Κώτσης, Ι. Λεκάκης, Ευ. Λυμπερόπουλος, Α. Μελιδώνης, Α. Μπαργιώτα, Ε. Μπιλιανού, Β. Νικολάου, Γ. Ντάιος, Ν. Παπάνας, Στ. Παππάς, Χ. Πίτσαβος, Λ. Ραλλίδης, Δ. Ρίχτερ, Ι. Σκούμας, Ν. Τεντολούρης, Δ. Τζιακάς, Κ. Τζιόμαλος, Δ. Τούσουλης, Α. Τσελέπης, Κ. Τσιούφης, Χ. Χρυσοχόου Ελληνική Επιθεώρηση Αθηροσκλήρωσης 6(Συμπλήρωμα):3–8 Hormones 2016, in press

Μέχρι την ανακοίνωση-δημοσίευση των προοπτικών τυχαιοποιημένων μελετών που θα πιστοποιήσουν την επίδραση αυτών των φαρμάκων στην καρδιαγγειακή νοσηρότητα και θνητότητα, προτείνεται η συνταγογράφησή τους να περιορίζεται σε ειδικές ομάδες ατόμων πολύ υψηλού κινδύνου που αναμένεται να ωφεληθούν από τη θεραπεία.

Οι ακόλουθες οδηγίες βρίσκονται σε συμφωνία με τις πρόσφατες συστάσεις της Εθνικής Επιτροπής Λιπιδίων (NLA) των ΗΠΑ και συνοψίζονται στον πίνακα 1. Σημειώνεται ότι πρέπει πάντα πρώτα να ελέγχεται η συμμόρφωση του ασθενή στη ήδη χορηγούμενη υπολιπιδαιμική θεραπεία. Οι ομάδες που αναμένεται να ωφεληθούν από τη θεραπεία είναι: (1) οι ασθενείς με οικογενή υπερχοληστερολαιμία, (2) οι ασθενείς με εγκατεστημένη αγγειακή νόσο και οι διαβητικοί ασθενείς πολύ υψηλού κινδύνου που δεν επιτυγχάνουν τους στόχους της υπολιπιδαιμικής αγωγής με τη μέγιστη διαθέσιμη υπολιπιδαιμική αγωγή (υψηλές δόσεις αποτελεσματικών στατινών + εζετιμίμπη) και 3. οι ασθενείς με δυσανεξία στις στατίνες. Οι ασθενείς με οικογενή υπερχοληστερολαιμία είναι άτομα υψηλού καρδιαγγειακού κινδύνου με ιδιαίτερα υψηλά επίπεδα LDL χοληστερόλης που δεν επιτυγχάνουν τους στόχους της υπολιπιδαιμικής αγωγής στην καθημέρα κλινική πράξη.

Εμβολικά εγκεφαλικά απροσδιόριστης προέλευσης. Μια νέα κατηγορία ασθενών με ισχαιμικό εγκεφαλικό επεισόδιο

Γ. Ντάιος

Heart Vessels & Brain 2015, online early Ειδικό άρθρο ανασκόπησης σχετικά με τα εμβολικά εγκεφαλικά απροσδιόριστης προέλευσης, όπου συζητείται η επιδημιολογία, χαρακτηριστικά και η έκβασή τους. Prediction of Large Vessel Occlusions in Acute Stroke: NIHSS is hard to beat Peter Vanacker, Mirjam Heldner, Michael Amiguet, Mohamed Faouzi, Patrick Cras, George Ntaios, Marcel Arnold, Heinrich P. Mattle, Jan Gralla, Urs Fischer, Patrik Michel Critical Care Medicine 2016, online early

Objective: Endovascular treatment (EVT) for acute ischemic stroke (AIS) with a large vessel occlusion (LVO) was recently shown to be effective. We aimed to develop a score capable of predicting LVO eligible for EVT in the early hospital management.


17


Design: Retrospective, cohort study

Setting: Two tertiary, Swiss stroke centers

Patients: Consecutive AIS patients (1’645 patients, ASTRAL registry), who had a CT-angiography within 6 and 12 hours of symptom onset, were categorized according to occlusion site. Demographic and clinical information were used in logistic regression analysis to derive predictors of LVO (defined as intracranial carotid, basilar and M1-segment of middle cerebral artery occlusions). Based on logistic regression coefficients, an integer score was created and validated internally and externally (848 patients, Bern).

Interventions: none

Measurement & main results: LVO were present in 316 (21%) patients in the derivation and 566 (28%) in the external validation cohort. Five predictors added significantly to the score: NIHSS and hemineglect at admission, female sex, atrial fibrillation, no history of stroke, nor pre-stroke handicap (mRS<2). Diagnostic accuracy in internal and external validation cohort was excellent (AUC 0.84 both). The score performed slightly better than NIHSS-alone regarding prediction error (Wilcoxon signedrank test, p< 0.001), and regarding discriminatory power in derivation and pooled cohorts(AUC 0.81 vs. 0.80; p=0.02 DeLong’s test).

Conclusion: Our score accurately predicts presence of emergent large vessel occlusions which are eligible for endovascular treatment. However, incorporation of additional demographic and historical information available on hospital arrival provides minimal incremental predictive compared a NIHSS-alone prediction.

Difficult situations in anticoagulation after stroke: between Scylla and Charybdis George Ntaios, Gregory Lip Current Opinion in Neurology 2016, online early

Purpose of review: A significant proportion of stroke patients are treated with anticoagulants for secondary stroke prevention. Often, in such patients, stroke physicians are required to make difficult clinical decisions when confronted with the dilemma to choose between the risk of thromboembolism and the risk of bleeding. This article focuses on three common anticoagulant-related situations where the stroke physician needs to find the delicate balance between the two risks.

Recent findings: Three typical case vignettes are presented and the associated dilemmas are discussed: a) a patient with an anticoagulant-related intracranial haemorrhage: would you restart anticoagulation?, b) an anticoagulated patient with a previous stroke due to atrial fibrillation is scheduled for an elective polyp removal: how would you handle anticoagulation perioperatively?, and c) a patient presents with an ischemic stroke due to atrial fibrillation: how soon would you start anticoagulation for secondary stroke prevention? The article summarizes the related literature and discusses the pros and cons of each choice. Summary: The available evidence is limited; we need to individualize our approach according to the specific characteristics of our patients, and share the decision process with our patients and their proxies taking strongly into consideration their values and preferences. Glyceryl trinitrate for acute intracerebral haemorrhage: results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial, a subgroup analysis

Kailash Krishnan, Polly Scutt, Lisa Woodhouse, Alessandro Adami, Jennifer L Becker, Eivind Berge, Lesley A Cala, Ana M Casado, Valeria Caso, Christopher Chen, Hanna Christensen, Ronan Collins, Anna Czlonkowska, Robert A Dineen, John Gommans, Panos Koumellis, Ken Lees, George Ntaios, Serefnur Ozturk, Stephen J Phillips, Stuart J Pocock, Asita de Silva, Nikola Sprigg, Szabolcs Szatmari, Joanna M Wardlaw, Philip M Bath Stroke 2015, online early IF:

Background and purpose: The Efficacy of Nitric oxide in Stroke (ENOS) trial found that transdermal glyceryl trinitrate (GTN, a nitric oxide donor) lowered blood pressure but did not improve functional outcome in patients with acute stroke. However, GTN was associated with improved outcome if patients were randomised within 6 hours of stroke onset.

Methods: In this pre-specified subgroup analysis, the effect of GTN (5 mg/day for 7 days) versus no GTN was studied in 629 patients with intracerebral haemorrhage presenting within 48 hours and with systolic blood pressure >140 mmHg. The primary outcome was the modified Rankin Scale (mRS) at 90 days.

Results: Mean blood pressure at baseline was 172/93 mmHg and significantly lower (difference -7.5/-4.2 mmHg; both p< 0.05) on day 1 in 310 patients allocated to GTN as compared with 319 randomised to no GTN. No difference in the mRS was observed between those receiving GTN versus no GTN (adjusted odds ratio, OR for worse outcome with GTN 1.04, 95% confidence interval (CI) 0.78-1.37; p=0.84). In the subgroup of 61 patients randomised within 6 hours, GTN improved functional outcome with a shift in the modified Rankin Scale (OR 0.22, 95% CI 0.07-0.69, p=0.001). There was no significant difference in the rates of serious adverse events between GTN and no GTN. Conclusions: In patients with intracerebral haemorrhage within 48 hours of onset, GTN lowered blood pressure, was safe but did not improve functional outcome. Very early treatment might be beneficial but needs assessment in further studies. Effect of hyperacute (within 6 hours) transdermal glyceryl trinitrate, a nitric oxide donor, on outcome after stroke Lisa Woodhouse, Polly Scutt, Kailash Krishnan, Eivind Berge, John Gommans, George Ntaios, Joanna Wardlaw, Nikola


18


Sprigg, Philip M Bath Stroke 2015, online early IF:

Background and Purpose - Nitric oxide donors are candidate treatments for acute stroke, potentially through haemodynamic, reperfusion and neuroprotectant effects, especially if given early. Although the large ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial of transdermal glyceryl trinitrate (GTN) was neutral, a pre-specified subgroup suggested that GTN improved functional outcome if administered early after stroke onset.

Methods – Prospective analysis of subgroup of patients randomised into the ENOS trial within 6 hours of stroke onset. Safety and efficacy of GTN versus no GTN were assessed using data on early and late outcomes.

Results - 273 patients were randomised with 6 hours of ictus: mean (SD) age 69.9 (12.7) years, male 154 (56.4%), ischaemic stroke 208 (76.2%), Scandinavian Stroke Scale 32.1 (11.9), and total anterior circulation syndrome 86 (31.5%). As compared with no GTN, the first dose of GTN lowered blood pressure by 9.4/3.3 mmHg (p=<0.01, p=0.064), and shifted the modified Rankin Scale to a better outcome by day 90, adjusted common odds ratio 0.51 (95% CI 0.32-0.80). Significant beneficial effects were also seen with GTN for disability (Barthel Index), quality of life (EQ-Visual Analogue Scale), cognition (telephone Mini-Mental State Examination) and mood (Zung depression scale). GTN was safe to administer with less SAEs by day 90 (GTN 18.8% vs no GTN 34.1%) and death (hazard ratio 0.44, 95% CI 0.20-0.99; p=0.047).

Conclusions – In a sub-group analysis of the large ENOS trial, transdermal glyceryl trinitrate was safe to administer and associated with improved functional outcome and less deaths when administered within 6 hours of stroke onset.

External validation of the ISAN score for predicting stroke-associated pneumonia in the Athens Stroke Registry Vasileios Papavasileiou, Haralampos Milionis, Craig J. Smith, Konstantinos Makaritsis, Benjamin D. Bray, Patrik Michel, Jane Molloy, Efstathios Manios, Konstantinos Vemmos, George Ntaios


Background and purpose: The ISAN (Independence pre-stroke, Sex, Age, National Institutes of Health Stroke Scale) score was developed recently for predicting stroke associated pneumonia (SAP), one of the most common complications after stroke. The aim of this study was to externally validate the ISAN score.

Methods: Data included in the Athens Stroke Registry between 06/1992 and 12/2011 were used for this analysis. Inclusion criteria were the availability of all ISAN score variables (pre-stroke independence, sex, age, NIHSS). Receiver operating characteristics curve and linear regression analyses were used to determine the discriminatory power of the score and to assess the correlation between actual and predicted pneumonia in the study population. Separate analyses were performed

for acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) patients.

Results: The analysis included 3204 patients (AIS:2732, ICH:472). The ISAN score demonstrated excellent discrimination in patients with AIS [area under the curve AUC:0.83 (95%CI:0.81-0.85)]. In the ICH group, the score was less effective [AUC:0.69 (95%CI:0.63-0.74)]. Higher risk-groups of ISAN score were associated with an increased relative risk (RR) of SAP; risk increase was more prominent in the AIS population. Predicted pneumonia correlated very well with actual pneumonia (R2: 0.885; β-coefficient: 0.941, p<0.001 and R2: 0.880, β-coefficient: 0.938, p<0.001 for AIS and ICH groups, respectively).

Conclusions: In our external validation in the Athens Stroke Registry cohort, the ISAN score predicted SAP very accurately in AIS patients and demonstrated good discriminatory power in the ICH group. Further validation and assessment of clinical usefulness would strengthen the score’s utility further.

The European Stroke Organisation Guidelines: a standard operating procedure George Ntaios, Natan M. Bornstein, Valeria Caso, Hanne Christensen, Jacques De Keyser, Hans-Christoph Diener, Exuperio Diez-Tejedor, Jose M. Ferro, Gary A. Ford, Armin Grau1, Emanuella Keller, Didier Leys, David Russell, Danilo Toni, Guillaume Turc, Bart Van der Worp, Nils Wahlgren, Thorsten Steiner, for the European Stroke Organisation International Journal of Stroke, 2015, online early

In 2008, the recently founded European Stroke Organisation (ESO) published its guidelines for the management of ischaemic stroke and transient ischaemic attack1. This highly cited document was translated in several languages and was updated in 2009. Since then, the ESO has published guidelines for the management of intracranial aneurysms and subarachnoidal haemorrhage, for the establishment of stroke units and stroke centers3, and recently for the management of intracerebral haemorrhage.

In recent years, the methodology for the development of guidelines has evolved significantly. To keep pace with this progress and driven by the strong determination of the ESO to further promote stroke management, education and research, the ESO decided to delineate a detailed standard operating procedure (SOP) for its guidelines. There are two important cornerstones in this SOP: the first is the implementation of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology for the development of its Guideline Documents. The second one is the decision of the ESO is to move from the classical model of a single Guideline Document about a major topic – e.g. management of ischaemic stroke – to focused modules, i.e. subdivisions of a major topic. This will enable the ESO to react faster when new developments in a specific stroke field occur and update its recommendations on the related module rather swiftly; with the previous approach of a single large Guideline Document, its entire revision had to be completed before an updated publication, delaying the


19


production of up-to-date guidelines. After discussion within the ESO Guidelines Committee (GC) and significant input from ESO members as well as methodologists and analysts, this document presents the official SOP for the development of the Guideline Documents of the ESO. Prognostic value of 24-h ABPM in acute ischemic stroke for short, medium and long-term outcome: A systematic review and meta-analysis N. Kakaletsis, G. Ntaios, H. Milionis, A. Haidich, K. Makaritsis, C. Savopoulos, E. Berge, A. Hatzitolios International Journal of Stroke, 2015, online early

Background and Purpose - The association of blood pressure (BP) levels during the acute phase of ischemic stroke with outcome remains controversial. The objective of this systematic review is to assess the predictive value of systolic (SBP) and diastolic BP (DBP), measured by ambulatory blood pressure monitoring (ABPM) methods during the acute phase of ischemic stroke, compared to the values of causally derived BP measurement.

Methods - We searched for studies with patients admitted within 24 hours of stroke onset, and who had ABPM during the first 24 hours of admission. We identified studies that reported BP in those with good outcome and in those with poor outcome at end of follow-up, and performed a meta-analysis of the effect of mean BP and BP variability on outcome.

Results - High SBP and DBP levels derived with ABPM were associated with poor short, medium and long-term outcome, but the same was not found for casual BP measurements. An increase in SBP of 9.1 mmHg (95%CI: 6.6-11.6, p<0.001; I2=9%) and an increase in DBP of 2.3 mmHg (95%CI: 0.8-3.7, p<0.001; I2=0%) was associated with poor outcome. A decrease of BP during night was associated with good outcome. BP variability was not significantly associated with outcome after stroke. Conclusions - Higher SBP and DBP levels derived with ABPM were associated with poor outcome. The same was not found for higher casual BP measurements on admission, and it is possible that ABPM conveys better prognostic information. European Stroke Organisation (ESO) guidelines for the management of temperature in patients with acute ischaemic stroke G. Ntaios, T. Dziedzic, P. Michel, V. Papavasileiou, J. Petersson, D. Staykov, B. Thomas, T. Steiner, for the European Stroke Organisation International Journal of Stroke, 2015, online early

Background: Hyperthermia is a frequent complication in patients with acute ischaemic stroke. On the other hand, therapeutically induced hypothermia has shown promising potential in animal-models of focal cerebral ischaemia. This Guideline Document presents the European Stroke Organisation (ESO) guidelines for the management of temperature in patients with acute ischaemic stroke.

Methods: A multidisciplinary group identified related questions and created its recommendations based on evidence from randomized controlled trials (RCTs) elaborating the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. This Guideline Document was reviewed within the ESO and externally, and was approved by the ESO Guidelines Committee and the ESO Executive Committee.

Results: We found low-quality evidence and therefore, we cannot make any recommendation for treating hyperthermia as a means to improve functional outcome and/or survival in patients with acute ischaemic stroke and hyperthermia; moderate evidence to suggest against routine prevention of hyperthermia with antipyretics as a means to improve functional outcome and/or survival in patients with acute ischaemic stroke and normothermia; very low quality evidence to suggest against routine induction of hypothermia as a means to improve functional outcome and/or survival in patients with acute ischaemic stroke. Conclusions: The currently available data about the management of temperature in patients with acute ischaemic stroke are limited and the strengths of the recommendations are therefore weak. We call for new RCTs as well as recruitment of eligible patients to ongoing RCTs to allow for better-informed recommendations in the future. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis George Ntaios, Vasileios Papavasileiou, Haralampos Milionis, Konstantinos Makaritsis, Anastasia Vemmou, Eleni Koroboki, Efstathios Manios, Konstantinos Spengos, Patrik Michel, Konstantinos Vemmos Stroke 2015, online early Προφορική ανακοίνωση στο 1st European Stroke Organisation Conference, Glasgow, UK, 18/04/2015

Background and purpose: Information about outcomes in Embolic Stroke of Undetermined Source (ESUS) patients is unavailable. This study provides a detailed analysis of outcomes of a large ESUS population.

Methods: Dataset was derived from the Athens Stroke Registry. ESUS was defined according to the Cryptogenic Stroke/ESUS International Working Group criteria. Endpoints were mortality, stroke recurrence, functional outcome and a composite cardiovascular endpoint (CCE) comprising recurrent stroke, myocardial infarction, aortic aneurysm rupture or sudden cardiac death. We performed Kaplan–Meier analyses to estimate cumulative probabilities of outcomes by stroke type, and Cox-regression to investigate if stroke type was outcome predictor.

Results: 2731 patients were followed-up for a mean of 30.5±24.1months. There were 73 (26.5%) deaths, 60 (21.8%) recurrences


20


and 78 (28.4%) CCEs in the 275 ESUS patients. The cumulative probability of survival in ESUS was 65.6% (95% confidence intervals, CI:58.9-72.2%), significantly higher compared to cardioembolic stroke (38.8%, 95%CI:34.9-42.7%).. The cumulative probability of stroke recurrence in ESUS was 29.0% (95%CI:22.3-35.7%), similar to cardioembolic strokes (26.8%, 95%CI:22.1-31.5%), but significantly higher compared to all types of non-cardioembolic stroke. 172 (62.5%) ESUS patients had favorable functional outcome compared to 280 (32.2%) in cardioembolic and 303 (60.9%) in large-artery atherosclerotic. ESUS patients had similar risk of CCE as all other stroke types, with the exception of lacunar strokes which had significantly lower risk [adjusted HR:0.70 (95%CI:0.52-0.94)] Conclusions: Long-term mortality risk in ESUS is lower compared to cardioembolic strokes despite similar rates of recurrence and CCE. Recurrent stroke risk is higher in ESUS than in non-cardioembolic strokes. Δευτερογενής πρόληψη σε ασθενείς με ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο Γ. Ντάιος Ελληνική Ιατρική Επιθεώρηση 2014: 103:139-44

Στις 20-22 Σεπτεμβρίου 2013 η Εταιρεία Παθολογίας Βορείου Ελλάδος διοργάνωσε το 2ο Επιστημονικό Συμπόσιο αφιερωμένο στις Οδηγίες Αντιμετώπισης Καρδιαγγειακού Κινδύνου στην καθ’ ημέρα πράξη στην Αγριά Βόλου. Το παρόν άρθρο αποτελεί μία σύνοψη της εισήγησης του κ. Γ. Ντάιου με θέμα τη δευτερογενή πρόληψη σε ασθενείς με ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο (ΑΕΕ). Τα θέματα που αναπτύσσονται είναι η αντιαιμοπεταλιακή αγωγή σε μη καρδιοεμβολικό ΑΕΕ, ο ρόλος των στατινών, οι επεμβάσεις επαναγγείωσης σε αθηροσκληρωτικά ΑΕΕ και η αντιπηκτική αγωγή σε καρδιοεμβολικά ΑΕΕ. Η δευτερογενής πρόληψη στα ισχαιμικά αγγειακά εγκεφαλικά επεισόδια (ΑΕΕ) καθορίζεται σε σημαντικό βαθμό από τον παθοφυσιολογικό τύπο του επεισοδίου. Στα μη καρδιοεμβολικά ΑΕΕ, τα αντιθρομβωτικά εκλογής είναι τα αντιαιμοπεταλιακά, ενώ αντίθετα στα καρδιοεμβολικά ΑΕΕ είναι τα αντιπηκτικά. Οι στατίνες έχουν σημαντικό ρόλο στα αθηροσκληρωτικά ΑΕΕ, όπως επίσης και οι επεμβάσεις επαναγγείωσης (κυρίως η ενδαρτηρεκτομή) σε ασθενείς με σημαντικού βαθμού στένωση της καρωτίδας. Association of circadian blood pressure and heart rate patterns with severity of acute ischemic stroke: preliminary results

N. Kakaletsis, H. Milionis, G. Ntaios, C. Savopoulos, K. Makaritsis, K. Tziomalos, G.N. Dalekos, M. Elisaf, A.I. Hatzitolios

E-poster στο 7o Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας 19-21/03/2015, Λάρισα

Βaseline characteristics and outcomes of patients with acute ischemic stroke treated with intravenous thrombolysis in the department of medicine of the University of Thessaly

G. Ntaios, A. Karagiannaki, K. Makaritsis, G. N. Dalekos, on behalf of the medical personnel of the Department of Medicine of the University of Thessaly

Προφορική ανακοίνωση στο 7o Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας 19-21/03/2015, Λάρισα

Background: In February 2014, the Department of Medicine of University of Thessaly was equipped with the necessary infrastructure to allow for intravenous thrombolysis in patients with acute ischemic stroke.

Objectives: The present study summarizes the baseline characteristics and outcomes of patients thrombolyzed until 31/12/2014.

Methods: Patient data were derived from the Larissa Stroke Outcome Registry (LASTRO).

Results: Among 146 patients admitted during this period, 8 (5.5%) patients (mean age: 71±6 years old, 37.5% females) were treated with intravenous alteplase. The mean values of NIHSS, arterial pressure and serum glucose were 13, 140/76mmHg and 121mg/dl respectively. The presenting symptoms/signs included paresis (75%), aphasia (75%), dysarthria (37.5%), hypesthesia (37.5%), reduced vigilance (25%), optic field defects (25%), balance disturbance (12.5%) and gaze palsy (12.5%). The etiology of the event was cardioembolism in 62.5% of patients, large-artery atherosclerosis in 12.5% and undetermined in 25%. The onset-to-admission, admission-to-CT, CT-to-thrombolysis and onset-to-thrombolysis intervals were 58 minutes, 26 minutes, 17 minutes and 132 minutes respectively. One (12.5%) patient was complicated by intracerebral haemorrhage and another patient (12.5%) was intubated due to cardiopulmonary insufficiency and transferred to the intensive care unit due to severe brainstem infarction. All patients were alive during the most recent follow-up; functional outcome is favorable (i.e. mRS: 0-2) in 4 (50%) patients.

Conclusions: Intravenous thrombolysis of patients with acute ischemic stroke was successfully implemented in the routine clinical practice of our department and is now a standard-of-care for such patients. The characteristics and outcomes of our thrombolyzed patients do not differ from other published reports of stroke thrombolysis registries.

Predictive value of the ASTRAL score, the Charlson and the Elixhauser indexes in acute ischemic stroke Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P. Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015


Προφορική ανακοίνωση στο 1st European Stroke Organisation Conference, Glasgow, UK, 18/04/2015

Background: There is limited information on the impact of comorbidities on outcome of stroke patients. The aim was to


21


evaluate the prognostic value of the Charlson/Deyo and Elixhauser comorbidity indexes (CI) on functional outcome and mortality in patients with acute ischemic stroke (AIS) in short-, medium- and long-term and to test whether they can add further predictive value in addition to the existing clinical predictive model (ASTRAL-score).

Methods: We assessed 3,099 consecutive AIS patients from the ASTRAL-registry regarding unfavorable functional outcome, (mRS>2) and mortality at 7 days, 3 and 12 months. The discriminatory power of the indexes was expressed with the area-under-the-curve (AUC).

Results: Comparing AUC, the ASTRAL-score was a more accurate predictor of outcomes than Charlson/Deyo and Elixhauser CIs in the short-, medium- and long-term. The Elixhauser CI was always more accurate than the Charlson/ Deyo CI, especially in the short-term. However the combination of the ASTRAL-score with the Charlson/Deyo CI has the highest AUC. Conclusion: The ASTRAL-score is better predictor of AIS outcome (functional outcome or death) than Charlson/Deyo and Elixhauser CIs in short-, medium- and long-term. It may be statistically improved with the addition of the Charlson/ Deyo CI, but this addition is of limited clinically use because of its complex calculation. Comorbidity analysis and 3-months functional outcome in acute ischemic stroke: data from the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) Kakaletsis N., Papavasileiou V., Lambrou D., Ntaios G., Michel P. Ανηρτημένη ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015



Aim: The aim was to evaluate the prevalence of comorbid diseases and their impact on handicap prediction in patients with acute ischemic stroke (AIS) in medium-term and to test whether they can add further predictive value in addition to already existing clinical predictive models.

Methods: We assessed 2,590 consecutive AIS patients from the ASTRAL-registry regarding 3 months unfavorable outcome, defined as a modified Rankin score of >2. We constructed multivariable logistic regression models by including 45 comorbidities plus age or NIHSS or age&NIHSS or the ASTRAL-score as independent variables. The β-coefficient of each covariate was used to generate an integer-based point scoring system. We assessed the discriminatory power of the indexes and compared them by calculating the area-under-the-curve (AUC).

Results: 6 variables were positively and 2 negatively associated with 3 months handicap (Table1). The AUC of the derived comorbidity index (Figure1) differed slightly but statistically significantly from the pure ASTRAL-score’s AUC (0.857vs.0.846, p<0.001).

Conclusions: Adding an ASTRAL-derived comorbidities index to the existing ASTRAL-score slightly improves prediction of 3 months handicap slightly. This improvement is of limited clinical use because it more than doubles the number of variables needed for its calculation.

Temperature change, short and long-term mortality in acute ischemic stroke Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P. Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015


Ανηρτημένη ανακοίνωση στο 1st European Stroke Organisation Conference, 17-19/04/2015, Glasgow

Aim: The aim of the study is to explore the association between baseline temperature (T) levels, T change during the first 24 hours, and mortality in a representative acute ischemic stroke (AIS) population.

Methods: All patients registered in the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) between 2003 and 2013 were analyzed (n=2,555). The outcome was mortality at 7 days, 3 and 12 months. A local polynomial surface algorithm was used to assess the effect of T values on the three outcomes.

Results: Hypo- and hyperthermic admission T values were associated with more unfavorable outcomes in the short and long-term. This association disappeared with subacute hypothermia but strengthened with hyperthermia. T<37°C that increased over 24 hours was associated with a higher, and T>37°C that decreased with a lower mortality. Conclusions: Both hypo-and hyperthermia on admission are associated with increased short- and long-term mortality after AIS. A T decrease of initially elevated body temperatures over 24 hours reduced mortality. We found little evidence that spontaneous hypothermia in the acute stage of stroke was associated with short- or long-term benefits. Temperature change, short and long-term handicap in acute ischemic stroke Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P. Ανηρτημένη ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015




22


Aim: The aim of the study is to explore the association between baseline temperature (T) levels, T change during the first 24 hours, and functional outcome in a representative acute ischemic stroke (AIS) population.

Methods: All patients registered in the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) between 2003 and 2013 were analyzed (n=2,555). Unfavorable outcomes at 7 days, 3 and 6 months were defined as modified Rankin scores>2. A local polynomial surface algorithm was used to assess the effect of T values on the three outcomes.

Results: Acute and sub-acute normothermia, but not hypothermia, was associated with less unfavorable short- and long-term outcome. Low or normal admission temperatures followed by a T increase over 24 hours were associated with a worse prognosis, whereas a mild baseline T increase followed by a decrease was associated with better outcome at 7 days. These dynamic associations with handicap disappeared after 3 and 12 months. Conclusions: Elevated body temperature in AIS is associated with a worse functional outcome, but initial hypothermia does not seem to be protective. These insights may help to adapt individual treatment decisions and to plan future therapeutic studies. Comorbidity analysis and long-term mortality in acute ischemic stroke: data from the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P. Ανηρτημένη ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015



Aim: The aim was to evaluate the prevalence of comorbid diseases and their impact on mortality prediction in patients with acute ischemic stroke (AIS) in the long-term and to test whether they can add further predictive value in addition to already existing clinical predictive models.

Methods: We assessed 2,693 consecutive AIS patients from the ASTRAL-registry regarding 12 months mortality. We constructed multivariable logistic regression models by including 45 comorbidities plus age, or NIHSS, or age&NIHSS, or the prognostic ASTRAL-score as independent variables. The β-coefficient of each covariate was used to generate an integer-based point scoring system. We assessed the discriminatory power of the indexes and compared them by calculating the area-under-the-curve (AUC).

Results: 9 variables were positively and 2 negatively associated with long-term mortality (Table 1). The AUC of the derived comorbidity index (Figure 1) was somewhat better compared to pure ASTRAL-score’s AUC (0.853 vs 0.805, p<0.001). Conclusion: Taking account comorbid diseases for the prediction of long-term mortality in stroke in addition to already existing models may add more predictive information which could be used as stratification tools in cohort longitudinal studies. Προγνωστική ισχύς της 24ωρης καταγραφής της αρτηριακής πίεσης στο οξύ ισχαιμικό ΑΕΕ: μετα-ανάλυση Κακαλέτσης Ν., Ντάιος Γ., Μηλιώνης Χ., Χάιδιτς Α.-Μ., Μακαρίτσης Κ., Σαββόπουλος Χ., Berge E., Χατζητόλιος Ι. Α. Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015


Εισαγωγή: Η σχέση των επιπέδων της αρτηριακής πίεσης (ΑΠ) κατά την οξεία φάση του ισχαιμικού εγκεφαλικού επεισοδίου (ΑΕΕ) με την έκβαση, δεν έχει ακόμα διευκρινιστεί πλήρως. Σκοπός: Η αξιολόγηση της προγνωστικής αξίας της συστολικής (ΣΑΠ) και διαστολικής ΑΠ (ΔΑΠ) που καταγράφονται με τη μέθοδο της 24ωρης καταγραφής (ABPM), κατά την οξεία φάση του ΑΕΕ σε σύγκριση με τις τιμές της ΑΠ που μετρήθηκαν κατά την εισαγωγή. Υλικό-Μέθοδος: Έγινε αναζήτηση μελετών με ασθενείς που εισήχθησαν εντός 24 ωρών από την έναρξη του ΑΕΕ, και οι οποίοι υποβλήθηκαν σε ABPM κατά το πρώτο 24ωρο της νοσηλείας τους. Οι μελέτες ανέφεραν τις τιμές της ΑΠ ξεχωριστά σε ασθενείς με καλή και πτωχή λειτουργική έκβαση στο τέλος της παρακολούθησης. Πραγματοποιήσαμε μετα-ανάλυση της επίδρασης της μέσης ΑΠ και της μεταβλητότητας της ΑΠ στην έκβαση. Αποτελέσματα: Τα υψηλά επίπεδα της ΣΑΠ και ΔΑΠ όπως μετρούνται με ABPM σχετίστηκαν με πτωχή βραχυ-, μεσο- και μακροπρόθεσμη έκβαση χωρίς να ισχύει το ίδιο για τις μετρήσεις κατά την εισαγωγή. Υψηλότερη ΣΑΠ κατά 9,1mmHg (95%CI: 6,6-11,6, p<0,001; I2=9%) και ΔΑΠ κατά 2,3 mmHg (95%CI: 0,8-3,7, p=0,002; I2=0%) συσχετίστηκε με πτωχή έκβαση. Η μείωση της ΑΠ κατά τη διάρκεια της νύχτας σχετίστηκε με καλή έκβαση. Δεν βρέθηκε συσχέτιση της μεταβλητότητας της ΑΠ με την έκβαση μετά το ΑΕΕ. Συμπεράσματα: Υψηλότερες τιμές της ΣΑΠ και ΔΑΠ, όπως μετρούνται με ABPM σχετίστηκαν με πτωχή έκβαση. Το ίδιο δεν βρέθηκε για την ΑΠ κατά την εισαγωγή, και είναι πιθανό ότι η μέθοδος ABPM εμπεριέχει καλύτερή προγνωστική πληροφορία. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. The ENOS Trial Investigators


23


Lancet 2015; 385:617-28

Background: High blood pressure is associated with poor outcome after stroke. Whether blood pressure should be lowered early after stroke, and whether to continue or temporarily withdraw existing antihypertensive drugs, is not known. We assessed outcomes after stroke in patients given drugs to lower their blood pressure.

Methods: In our multicentre, partial-factorial trial, we randomly assigned patients admitted to hospital with an acute ischaemic or haemorrhagic stroke and raised systolic blood pressure (systolic 140-220 mm Hg) to 7 days of transdermal glyceryl trinitrate (5 mg per day), started within 48 h of stroke onset, or to no glyceryl trinitrate (control group). A subset of patients who were taking antihypertensive drugs before their stroke were also randomly assigned to continue or stop taking these drugs. The primary outcome was function, assessed with the modified Rankin Scale at 90 days by observers masked to treatment assignment. This study is registered, number ISRCTN99414122.

Findings: Between July 20, 2001, and Oct 14, 2013, we enrolled 4011 patients. Mean blood pressure was 167 (SD 19) mm Hg/90 (13) mm Hg at baseline (median 26 h [16-37] after stroke onset), and was significantly reduced on day 1 in 2000 patients allocated to glyceryl trinitrate compared with 2011 controls (difference -7·0 [95% CI -8·5 to -5·6] mm Hg/-3·5 [-4·4 to -2·6] mm Hg; both p<0·0001), and on day 7 in 1053 patients allocated to continue antihypertensive drugs compared with 1044 patients randomised to stop them (difference -9·5 [95% CI -11·8 to -7·2] mm Hg/-5·0 [-6·4 to -3·7] mm Hg; both p<0·0001). Functional outcome at day 90 did not differ in either treatment comparison-the adjusted common odds ratio (OR) for worse outcome with glyceryl trinitrate versus no glyceryl trinitrate was 1·01 (95% CI 0·91-1·13; p=0·83), and with continue versus stop antihypertensive drugs OR was 1·05 (0·90-1·22; p=0·55).

Interpretation: In patients with acute stroke and high blood pressure, transdermal glyceryl trinitrate lowered blood pressure and had acceptable safety but did not improve functional outcome. We show no evidence to support continuing prestroke antihypertensive drugs in patients in the first few days after acute stroke. Resuming anticoagulation after brain hemorrhage while on warfarin treatment: INR at the tie of bleeding should be taken into consideration: authors’ reply G. Ntaios, S. Sacco Internal and Emergency Medicine 2015, online early Balestrino et al. suggest that for patients who experienced bleeding while on supratherapeutic INR levels, warfarin may be re-started while implementing a strategy to better control INR value. To support this, they argue that, very often, bleeding during warfarin therapy occurs when INR exceeds the therapeutic range. Indeed, in nearly half of patients with a bleeding event while on oral anticoagulant, INR is at supratherapeutic levels, as shown by a recent study as well as a previous meta-analysis. However, at the same time and on the other hand, the results of these two studies may be read in the other way round: in nearly half of patients with a bleeding event while on oral anticoagulant, INR is not at supratherapeutic levels; i.e. a patient who is treated with oral anticoagulants may still bleed even if we manage to keep INR within the therapeutic window. Therefore, this suggestion (i.e. to re-initiate warfarin in a patient who suffered an intracerebral haemorrhage while on supratherapeutic INR and, at the same time, (successfully) implement strategies to control INR more adequately) may not be the answer given that this patient may still bleed, even with a therapeutic INR. Of course, this comes on top of another significant issue: how effectively do we control INR and how much can this be improved? Recent data about anticoagulation control were frustrating: among 2,683,674 INR measurements in 138,319 patients in office-based community practice in the United States, only 53.7% measurements were within the therapeutic range. Similar results were also reported in the hospital setting, where INR was in the therapeutic range in only 54.5% of 18,867 patients hospitalized for atrial fibrillation. Several methods have been proposed to improve INR control but even in cases that INR measurements and dose adjustments are frequent, several other factors (e.g. renal and hepatic metabolism, interactions with drugs taken occasionally, balance of hemostasis, patient compliance) may lead to failure of any attempt to tackle stable INR values. According to our opinion, in a patient who has already had a cerebral hemorrhage with warfarin in the presence of an elevated INR value, this event may be considered as an indicator of difficulty to keep INR within the therapeutic range even for the future, rather than a factor which can be corrected and managed without risks. The suggestion by Balestrino et al. needs to be considered with caution, as well as our own suggestions in our recent debate; strong recommendations about re-initiation of warfarin in patients with intracerebral haemorrhage are hindered by the scarcity of high-quality evidence. In this context, we are confident that Balestrino et al. agree that further research is urgently needed to provide more insight into this controversial topic. Finally, we will not restrain ourselves from repeating that the patient’s values and preferences should definitely become a part of the decision process. A Clinical Score to Predict Major Arterial Occlusions Eligible for Endovascular Recanalization in Acute Stroke based on the ASTRAL registry Peter Vanacker, Mirjam Heldner, Michael Amiguet, Mohamed Faouzi, Patrick Cras, George Ntaios, Marcel Arnold, Heinrich P Mattle, Urs Fischer, Patrik Michel Poster presentation at the International Stroke Conference 2015, Nashville, USA

Aims: Endovascular treatment (EVT) for acute ischemic stroke (AIS) has the potential to improve clinical outcome in well selected patients with a major intracranial occlusion. This study aimed to identify easily available pre-hospital predictors and


24


to develop a clinical score to detect AIS patients with such occlusions potentially eligible for acute EVT.

Methods: Consecutive AIS enrolled in the ASTRAL registry with good quality CT-angiography within 12h after onset were selected (1’645 patients, Lausanne) and categorized according to occlusion site. Easily accessible demographic and clinical information were used in a logistic regression analysis to derive predictors of major intracranial occlusions (intracranial carotid, basilar and M1-artery). The score was created developed using the beta-logistic regression coefficients of the logistic regression analysis, and was validated internally and externally (848 patients, Bern).

Results: Major intracranial occlusions were present in 316 (21%) acute stroke patients in the derivation and 566 (28%) in the internal validation cohort. From all 12 significant predictors of major intracranial occlusions, a 7- item score was developed to obtain the best diagnostic performance; it was termed ASTRAL-O score according to its constituents: Admission NIHSS (A): (NIHSS 0-4: 0 points; 5-9: 4; 10-14: 8; ≥15: 12), absence of pre-STroke handicap (mRS≤2) (ST: 2 points), absence of previous STroke (ST: 1 point), Right-sided stroke (R: 3 points), Atrial fibrillation (A: 1 point), Level of consciousness decreased (L: 1 point) and wOmen (O:2 points). Diagnostic accuracy of the score in both the internal and external validation cohort was good at different cut-off levels (AUC 0.84 and 0.76 respectively). A Wilcoxon signed rank test showed that the ASTRAL-0 score performed better than NIHSS alone in term of predicted probabilities. Conclusions: The ASTRAL-O score accurately predicts the major intracranial occlusions eligible for EVT. It improves predicted probabilities over the NIHSS alone. This tool could help to rapidly triage stroke patients in the hyper-acute phase. Predicting functional outcome and symptomatic intracranial hemorrhage in patients with acute ischemic stroke: a glimpse into the crystal ball? G. Ntaios, V. Papavasileiou, P. Michel, T. Tatlisumak, D. Strbian Stroke 2015, online early When encountering a patient with ischemic stroke, a stroke physician needs to make an outcome prediction for several reasons. First, a prediction may help patients and families have more realistic expectations about the patient's future and plan their long-term living arrangements. Second, outcome prediction may be useful in making treatment decisions. For example, avoidance or de-escalation of aggressive treatment measures in patients who would achieve an excellent outcome regardless of such therapy or in those who would experience a very poor and unacceptable outcome despite that treatment. Third, outcome prediction could aid in stroke research to control for case-mix variation in nonrandomized studies and to refine selection criteria in randomized, controlled acute stroke trials. An ideal stroke prognostic score system should include a limited number of readily available and relevant parameters, be easily and quickly applicable in the clinical setting (e.g., without need of complex mathematical formulas or nonconventional time-consuming additional investigations), be accurate with low intra- and inter-rater disagreement, be validated externally in large independent and preferably multiple populations, and be proven reliably useful in guiding treatment decisions. Extensive research has been performed during the recent years on prognostic scores for the prediction of stroke outcome and risk of symptomatic intracranial hemorrhage (sICH). This review summarizes current prognostic scores, discusses the scientific background behind the scores’ main components, acknowledges their strengths and limitations, and highlights the areas which warrant further research. Due to the space limitations, scores which were initially developed for one outcome (e.g. functional outcome) and were later validated also for other outcomes (e.g., post-thrombolytic sICH) will be discussed only for the initially validated outcome. Further, scores for strictly selected populations and scores for patients treated with endovascular procedures are not included in this review. Response to Letter Regarding Article "Embolic stroke of undetermined source in the Athens Stroke registry: a descriptive analysis.” G. Ntaios, K. Vemmos Stroke 2015, online early As it is mentioned in our article, 142 (51.6%) patients with Embolic Stroke of Undetermined Source (ESUS) had a 24-hours ambulatory Holter monitoring, whereas 195 (70.9%) ESUS patients had continuous electrocardiographic (ECG) monitoring for 1 week or until discharge from the stroke unit. For the latter patients, continuous ECG monitoring was observed by the trained nurse personnel of the acute stroke unit and intermittently analyzed by the treating physician. Mahagne et al. point to the group of our patients who had only continuous ECG monitoring (but not an ambulatory 24-hours Holter monitoring) and comment that “it is not possible to classify patients in ESUS group if these minimal cardiac investigations are not performed”. We disagree with this opinion. It was previously shown by the Heidelberg group that the use of Holter (over a period of 24 hours) does not provide any additional benefit compared to continuous monitoring with intermittent analysis by trained staff alone. In particular, among the entire population of 370 patients with ischemic stroke or transient ischemic attack, no patient with atrial fibrillation (AF) would have been overseen performing only the continuous ECG monitoring. What is even more striking in this study is that compared to the 24-hours Holter monitoring, the prolonged (i.e. during entire hospitalization, as it was also the case in our study) continuous ECG monitoring lead to significantly higher detection rate of AF. In particular, almost 85% of patients with a newly diagnosed AF detected by prolonged continuous ECG monitoring would have been overseen by performing only the 24-hours Holter monitoring. Therefore, we believe that our strategy for the detection of covert AF, as described in the methods section of our recent article,


25


is not suboptimal compared to the “minimal requirement” of a 24-hours ambulatory Holter monitoring, but rather perhaps superior. This is also supported by our data where the rate of detection of covert AF during the post-discharge follow-up was numerically higher in ESUS patients who had only prolonged continuous ECG monitoring during hospitalization compared to ESUS patients who had only an ambulatory 24-hours ambulatory Holter monitoring (27.5% vs. 30.8%, p=0.64). Delays in pre-hospital and in-hospital acute ischemic stroke management Nikolaos Kakaletsis, Haralampos Milionis, George Ntaios, Ioanna A. Panagopoulou, Anastasia Karagiannaki, Konstantinos Makaritsis, Thomas Tegos, Konstantinos Tziomalos, Christos Savopoulos, Apostolos I. Hatzitolios


Background - Stroke is one of the leading causes of morbidity and mortality worldwide. Intravenous thrombolytic therapy given within 3 hours after stroke onset, improves significantly the outcome and is now widely accepted. The “time is brain” concept express the emergency of the appropriate treatment of stroke. Delays during acute ischemic stroke (AIS) management have been identified at three different levels; failure to recognize the symptoms of stroke and contact emergency services (population level), failure to prioritize transport of stroke patients (level of the emergency services and emergency physicians) and delays in neuroimaging, which is sufficient for identification of contraindications to thrombolysis and allows its timely administration and thus inefficient in-hospital care (hospital level). The purpose of this study is to evaluate the duration of “stroke onset to hospital arrival” time and of “hospital arrival to computerized tomography (CT) initiation” time, in three University Hospitals of Northern and Central Greece. Methods – We used data derived from the multicenter observational PREVISE study (11/2013-11/2014) concerning the prognostic value of blood pressure variability in AIS. Age, gender, NIHSS on admission and the exact time of stroke onset, arrival at hospital and CT initiation were recorded. Statistical analysis for continuous data was made by ANOVA test, while for non-continuous data chi-square test was used. Results - A total of 163 AIS patients with mean NIHSS 9.9, mean age 80.6 years, male 43.8%, consisted the material of our study. In 15 of them we used as time of onset, the time that stroke has been detected by their relatives and in 9 of them, the last time that patients were seen being well without stroke. The mean “onset-to-door” time was 5 hours and 36 minutes and the mean “door-to-CT initiation” time was 2 hours and 15 minutes. Furthermore, the observed frequency of intravenous thrombolytic therapy was only 2.5%, but the potential frequency according to age, NIHSS and time was 8.6% and by excluding the delayed time of arrival the frequency of potential candidates for thrombolysis increased to 29.4% (Table). Discussion – The long duration of the “onset-to-door” time may reflect the unawareness concerning the recognition of signs and symptoms of stroke by the patients or by relatives but also the nature of first medical contact, and the means of transportation to hospital. Indeed, the interval from symptom onset to first call for medical help has been found to be the predominant part of pre-hospital delay, due to lack of awareness of stroke symptoms and recognition of their severity, the denial of the disease and the hope that symptoms would resolve. Stroke awareness depends on demographic and socio-cultural factors, and on personal medical knowledge. This suggests that educating the population to recognize stroke symptoms (e.g. Face-Arm-Speech-Test) and changing people’s attitude to acute stroke, may reduce the delay from stroke onset to emergency department (ED) involvement. Education should also be directed to paramedics and ED staff to improve the accuracy of stroke identification and speed up the transfer to the hospital. The mean “door-to-CT initiation” time of 2 hours and 15 minutes was far more than 25 minutes, which has been proposed by international stroke guidelines, constituting another barrier to timely intravenous thrombolytic therapy. In all participating hospitals there were at least one patient who underwent CT for AIS after 6 hours of his arrival. This may reflect the increased burden of EDs of the public health system with many patients suggesting the necessity of more facilities and their better organization. Finally, thrombolysis does not seem to be implemented widely (2.5%) compared to the threefold potential frequency (8.6%) of its application. In addition to this, if all patient arrived in time after stroke (within two hours of stroke onset) this percentage could be increased approximately ten times (29.4%) resulting in better outcomes. Available written care protocols for AIS and implementation of continuous quality improvement scheme have been proposed to diminish in-hospital delays. Leukoaraiosis and recurrent stroke risk in patients with and without atrial fibrillation: the Athens Stroke Registry George Ntaios, Gregory Lip, Dimitris Lambrou, Vasileios Papavasileiou, Efstathios Manios, Haralampos J. Milionis, Konstantinos Spengos, Konstantinos P. Makaritsis, and Kostas N Vemmos Neurology 2015, online early


Objective: We aimed to investigate the association between leukoaraiosis and long-term risk for stroke recurrence adjusting for clinical scores developed and validated for the prediction of stroke risk like CHADS2 and CHA2DS2-VASc. Methods: Study population was derived from the Athens Stroke Registry and was categorized in two subgroups according to the presence of atrial fibrillation (AF). Cox-proportional-hazards analysis was performed to assess the independent predictors of stroke recurrence. To investigate whether leukoaraiosis adds to the prognostic accuracy of CHADS2 and CHA2DS2-VASc scores, we used likelihood ratio test (LRT). Overall model assessment was performed with Nagelkerke R2 and Harrell’s c-statistic. Kaplan-Meier analyses were also performed. Results: Among 1892 patients, there were 320 (16.9%) with leukoaraiosis and 670 (35.4%) with AF. In the Kaplan-Meier


26


analysis, there was significant difference in cumulative probability of stroke recurrence between patients with and without leukoaraiosis in the non-AF group (p<0.01), but not in the AF-group (p=0.46). On Cox multivariate analysis, leukoaraiosis was found a significant independent predictor of stroke recurrence only in the non-AF group, in the models adjusting for CHADS2 (HR: 1.86, 95%CI: 1.35-2.56) and CHA2DS2-VASc scores (HR:1.82, 95%CI:1.32-2.51). Leukoaraiosis was not a predictor of stroke recurrence in the AF group. Leukoaraiosis did not improve the predictive accuracy of the two scores, whether in the non-AF group [Harrell’s c-statistic: 0.56 vs. 0.59 (p=0.31) for the model including CHADS2; 0.56 vs 0.59 (p=0.44) for the model including CHA2DS2-VASc] or the AF-groups [Harrell’s c-statistic: 0.63 vs. 0.62 for the model including CHADS2; 0.64 vs 0.64 for the model including CHA2DS2-VASc]. Conclusions: Leukoaraiosis is independent predictor of stroke recurrence in non-AF stroke patients. However, leukoaraiosis did not increase the predictive accuracy of the CHADS2 and CHA2DS2-VASc scores to predict stroke recurrence in AF or non-AF stroke patients. Restarting oral anticoagulants after intracerebral hemorrhage: Pros G. Ntaios Internal and Emergency Medicine 2014, in press This is the pro position in a debate about restarting oral anticoagulants after intracerebral hemorrhage. It is concluded that current data show that there is weak evidence that reinitiation of anticoagulants in patients with warfarin-associated ICH does not increase mortality and bleeding risk, and in this context, they argue in favor of restarting anticoagulants in these patients. Moreover, the substitution of warfarin by one of the new oral anticoagulants seems to further enhance the safety of this strategy for patients with AF or VTE, but not for patients with mechanical valves. Needless to say, of course, that the patient should definitely be a part of the decision process after being thoroughly informed about all potential risks and strategies. Embolic strokes of undetermined source (ESUS) in the Athens Stroke Registry: a descriptive analysis G. Ntaios, V. Papavasileiou, H. Milionis, K. Makaritsis, E. Manios, K. Spengos, P. Michel, K. Vemmos Stroke 2015;46:176-181


Background and purpose: A new clinical construct termed Embolic Stroke of Undetermined Source (ESUS) was recently introduced but no such population has been described yet. Our aim is to provide a detailed descriptive analysis of an ESUS population derived from a large prospective ischemic stroke registry using the proposed diagnostic criteria. Methods: The criteria proposed by the Cryptogenic Stroke/ESUS International Working Group were applied to the Athens Stroke Registry to identify all ESUS patients. ESUS was defined as a radiologically confirmed non-lacunar brain infarct in the absence of a) extracranial or intracranial atherosclerosis causing ≥50% luminal stenosis in arteries supplying the ischemic area, b) major-risk cardioembolic source, and c) any other specific cause of stroke. Results: Among 2735 patients admitted between 1992 and 2011, 275 (10.0%) were classified as ESUS. In the majority of ESUS (74.2%), symptoms were maximal at onset. ESUS were of moderate severity (median NIHSS: 5). The most prevalent risk factor was arterial hypertension (64.7%) and 50.9% of patients were dyslipidemic. Among potential causes of the ESUS, covert atrial fibrillation (AF) was the most prevalent: in 30 (10.9%) patients, AF was diagnosed during hospitalization for stroke recurrence, whereas in 50 (18.2%) patients AF was detected after repeated ECG monitoring during follow-up. Also, covert AF was strongly suggested in 38 patients (13.8%) but never recorded. Conclusions: About 10% of patients with first-ever ischemic stroke met criteria for ESUS; covert paroxysmal atrial fibrillation appears to be a frequent cause of ESUS. The European Stroke Organization (ESO) Guidelines T. Steiner, R.A. Salman, G. Ntaios International Journal of Stroke 2014; 9:838-9 This invited editorial discusses the recent developments in the European Stroke Organization with regards to the process of preparing its official Guidelines. Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K. Makaritsis, H. Milionis, E. Manios, P. Michel, G.Y.H. Lip, K. Vemmos International Journal of Cardiology 2014; 177:129-33



Background/objectives: The most recent ACC/AHA guidelines recommend high-intensity statin therapy in ischemic stroke patients of presumably atherosclerotic origin. On the contrary, there is no specific recommendation for the use of statin in patients with non-atherosclerotic stroke, e.g. strokes related to atrial fibrillation (AF). We investigated whether statin treatment in patients with AF-related stroke is associated with improved survival and reduced risk for stroke recurrence and future cardiovascular events.


27


Methods: All consecutive patients registered in the Athens Stroke Registry with AF-related stroke and no history of coronary artery disease nor clinically manifest peripheral artery disease were included in the analysis and categorized in two groups depending on whether statin was prescribed at discharge. The primary outcome was overall mortality; the secondary outcomes were stroke recurrence and a composite cardiovascular endpoint comprising of recurrent stroke, myocardial infarction, aortic aneurysm rupture or sudden cardiac death during the 5-year follow-up. Results: Among 1602 stroke patients, 404 (25.2%) with AF-related stroke were included in the analysis, of whom 102 (25.2%) were discharged on statin. On multivariate Cox-proportional-hazards model, statin treatment was independently associated with a lower mortality (hazard-ratio (HR): 0.49, 95%CI:0.26-0.92) and lower risk for the composite cardiovascular endpoint during the median 22 months follow-up (HR: 0.44, 95%CI:0.22-0.88), but not with stroke recurrence (HR: 0.47, 95%CI:0.22-1.01, p:0.053). Conclusions: In this long-term registry of patients with AF-related stroke, statin treatment was associated with improved survival and reduced risk for future cardiovascular events.

Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-sectional national survey in Greece G. Ntaios, V. Melikoki,, G. Perifanos, K. Perlepe, F. Gioulekas, A. Karagiannaki, I. Tsantzali, C. Lazarou, N. Beradze, E. Poulianiti, M. Poulikakou, F. Palantzas, S. Kaditi, F. Perlepe, G. Sidiropoulos, K. Papageorgiou, V. Papavasileiou, K. Vemmos, K. Makaritsis, G.N. Dalekos Journal of Stroke and Cerebrovascular Diseases 2014, online early Ανηρτημένη ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015



Background and purpose: Although stroke is the fourth cause of death in western societies, public stroke awareness remains suboptimal. The aim of this study is to estimate stroke risk perception and stroke awareness in Greece through a cross-sectional telephone survey. Methods: A trained interview team conducted this cross-sectional telephone survey between February and April 2014 using an online structured questionnaire. Participants were selected using random digit dialing of landline and mobile telephone numbers with quota sampling weighted for geographical region based on the most recent General Population Census (2011). Results: Between February and April 2014, 723 individuals [418 (58%) females, 47.4±17.8 years] agreed to respond. Among all respondents, 642 (88.8%) were able to provide at least one stroke risk factor. 673 (93.08%) respondents were able to provide correctly at least one stroke symptom or sign. When asked what would they do in case of acute onset of stroke symptoms, 497 (68.7%) responded that they would either call the ambulance or visit the closest emergency department. Only 35.3%, 18.9%, 17.2%, 20.7%, 15.0% of respondents with atrial fibrillation, arterial hypertension, dyslipidemia, diabetes mellitus and current smoking respectively considered themselves as being in high risk for stroke Conclusions: Stroke risk perception in Greece is low despite moderate public stroke awareness.

Baseline characteristics of the 4011 patients recruited into the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial The ENOS investigators International Journal of Stroke 2014, online early

Background: High blood pressure is common in acute stroke and associated with a worse functional outcome. Many patients who present with acute stroke are taking prescribed antihypertensive therapy before their stroke. Aims: ENOS tested whether lowering blood pressure and continuing pre-stroke antihypertensive therapy are each safe and effective.

Methods: This study is an international multi-centre prospective randomized single-blind blinded-endpoint parallel-group partial-factorial controlled trial of transdermal glyceryl trinitrate (a nitric oxide donor, given for seven-days) vs. no glyceryl trinitrate, and of continuing vs. stopping (temporarily for seven-days) pre-stroke antihypertensive drugs if relevant, in patients with acute ischaemic stroke or intracerebral haemorrhage and high systolic blood pressure (140–220 mmHg).

Results: Recruitment ran from July 2001 to October 2013. Four thousand eleven patients [2097 (52·3%) in the continue/stop arm] were recruited from 173 sites across 23 countries in 5 continents (Asia 14%, Continental Europe 16%, UK 64%). Baseline characteristics include: mean age 70 (standard deviation 12) years; male 57%; mean time from stroke to recruitment 26 (13) h; mean severity (Scandinavian Stroke Scale) 34 (13) of 58; mean blood pressure 167 (19)/90 (13) mmHg; ischaemic stroke 83%; and intracerebral haemorrhage 16%. The main trial results will be presented in May 2014. The results will also be presented in updated Cochrane systematic reviews and included in individual patient data meta-analyses of all relevant randomized controlled trials.

Conclusion: ENOS is a large completed international trial of blood pressure management in acute stroke and includes patients representative of many stroke services worldwide.

Blood pressure variability in acute ischemic stroke patients: : preliminary results of the PREVISE study N. Kakaletsis, G. Ntaios, H. Milionis, I. Chouvarda, A. Chytas, K. Tziomalos, D. Filos, C. Savopoulos, A.I. Hatzitolios


28


Poster at the World Stroke Congress, Istanbul, 2014 International Journal of Stroke 2014; 9 (suppl 3): 41 Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015


Introduction: There is scarcity of data about the prognostic role of blood pressure (BP) variability (BPV) during the acute phase of ischemic stroke (AIS).

Aims: Our purpose is to present the preliminary results of PREVISE study (NCT01915862) concerning the relationship between BPV in the acute phase of stroke evaluated with ambulatory 24-hour BP monitoring (ABPM) and stroke outcome.

Methods: Twenty-seven consecutive patients with AIS underwent ABPM every 20 minutes within 24 hours of admission using an automated oscillometric device (TM 2430, A&D Company Ltd) during day-time (7:00-22:59) and night-time (23:00-6:59). Mean BP parameters and several BP variability indices such as range, standard deviation, successive and coefficient of variation, sample entropy of both systolic and diastolic BP and ambulatory arterial stiffness index (AASI), were calculated. End-point was an increase in NIHSS between admission and discharge ≥2.

Results: Five patients (18.5%) whose clinical characteristics did not differ from the rest population reached the end-point (Table 1). In these patients, all BP parameters were higher but not statistically significant from stroke patients without significant decline. From BPV indices, only sample entropy was higher (2.21vs2.09, p=0.029) (Table 2).

Conclusions: Sample entropy as BPV index which describes the irregularity of a time series, could be a useful predictive factor of outcome in stroke patients but this must be confirmed in larger studies.

The impact of b-blockers on blood pressure variability in acute ischemic stroke: preliminary results of the PREVISE study N. Kakaletsis, H. Milionis, G. Ntaios, I. Chouvarda, A. Chytas, K. Tziomalos, D. Filos, C. Savopoulos, A.I. Hatzitolios Poster at the World Stroke Congress, Istanbul, 2014 International Journal of Stroke 2014; 9 (suppl 3): 42

Introduction: Reduction of blood pressure (BP) variability (BPV) has been proposed to be the next target for antihypertensive treatment in order to prevent cardiovascular events and especially stroke. Some studies suggested that calcium-channel blockers are more effective antihypertensive agents (AA) in terms of BPV reduction than beta-blockers.

Aims: The aim of the present study was to evaluate the effects of beta-blocker monotherapy compared with other AA on BPV during the acute phase of stroke in cases enrolled in the observational PREVISE study (NCT01915862).

Methods: Among 27 consecutive patients with acute ischemic stroke (AIS) who underwent ambulatory 24-hour BP monitoring (ABPM) every 20 minutes within 24 hours of admission using an automated oscillometric device (TM2430, A&D Company Ltd) during day-time (7:00-22:59) and night-time (23:00-6:59), 22 patients who were already under antihypertensive treatment were selected. BP parameters, heart rate and BPV indices, were calculated.

Results: Six patients (27.3%) received beta-blocker monotherapy during the acute phase of stroke. Clinical characteristics did not differ between the former patients and those receiving other AA (Table 1). Patients on beta-blocker monotherapy had higher range of both systolic (126.7vs85.3,p=0.027) and diastolic BP (98.3vs73.9,p=0.023), higher SD of diastolic BP (18.7vs12.3,p=0.010) and higher SV of both systolic (26.8vs16.7,p=0.005) and diastolic BP (118.8vs85.2,p=0.04) (Table 2).

Conclusions: Monotherapy with beta-blockers is associated with higher range and successive variation of BP during the acute phase of AIS and thus higher BPV. However, patients treated with beta-blockers had similar outcome compared with patients treated with other AA. These preliminary findings remain to be confirmed or refuted in larger studies.

Ιστορική μελέτη για την ανακάλυψη της ασπιρίνης και της βαρφαρίνης Γιαννοτάκη Κ., Καδδίτη Σ., Φιλιππίδου Α., Ντάιος Γ. Ανηρτημένη ανακοίνωση στο 20ο Επιστημονικό Συνέδριο Φοιτητών Ιατρικής Ελλάδας, 9-11/05/2014 Σκοπός: Η ασπιρίνη (ή αλλιώς ακετυλοσαλικυλικό οξύ) και η βαρφαρίνη, συνθετικό παράγωγο της κουμαρίνης, αποτελούν σύμφωνα με μελέτες τα σημαντικότερα αντιθρομβωτικά σκευάσματα. Η με- λέτη μας αποσκοπεί στην αναζήτηση της προέλευσης και των πιο σημαντικών ιστορικών σταθμών στην ανακάλυψη αυτών των φαρμάκων. Υλικά και Μέθοδος: Η ιστορική μελέτη διεξήχθη στο Τμήμα Ιατρικής του Πανεπιστημίου Θεσσαλίας με αναζήτηση πληροφοριών από διαδικτυακές πηγές και ιδίως απ’ την ηλεκτρονική βάση Pubmed. Στη συνέχεια έγινε έλεγχος και διαλογή των πληροφοριών με σκοπό την παράθεση των πιο σημαντικών σημείων της ιστορικής αναδρομής. Αποτελέσματα/ Συμπεράσματα: Η μελέτη κατέδειξε την ανακάλυψη της ασπιρίνης από το φλοιό της ιτιάς και φαίνεται να συνέβη από τον Ιπποκράτη(460-377πΧ). Το 1828 ανιχνεύεται από τον Γερμανό καθηγητή ΒuchnerJ. η σαλικίνη για να βρεθεί δέκα χρόνια αργότερα από το Γάλλο Piria R. Το σαλικιλικό οξύ. Το 1853 ο Καθηγητής Χημείας GerhardtC. συνέθεσε για πρώτη φορά το ακετυλοσαλικυλικό οξύ και το 1895 η ασπιρίνη κυκλοφορεί απ’ την εταιρεία Bayer με το χημικό Hoffmann. Να θεωρείται υπεύθυνος για τη σύνθεσή της. Η ανακάλυψη της βαρφαρίνης χρονολογείται το 1920 με αφορμή την θανατηφόρα γαστρεντερική αιμορραγία βοοειδών στις πολιτείες Ντακότα και Αλμπέρτα του Καναδά. Η αιτία εντοπίστηκε στο μολυσμένο τριφύλλι με το οποίο σιτίζονταν τα βοοειδή. Δέκα χρόνια μετά και ενώ οι αγρότες συνέχιζαν να χρησιμοποιούν τη χαλασμένη τροφή ο βιοχημικός Link K. και ο φοιτητής Stahmann M. του πανεπιστημίου Winsconsin απομόνωσαν την κουμαρίνη και δικουμαρόλη αντίστοιχα. Η βαρφαρίνη έλαβε το όνομά της από το Πανεπιστήμιο του Winsconsin,χρησιμοποιήθηκε αρχικά


29


ως τρωκτικοκτόνο για να καταλήξει αργότερα να χρησιμοποιείται ως αντιθρομβωτικό φάρμακο. Circadian blood pressure and heart rate patterns in acute ischaemic stroke and their relationship with short term mortality: preliminary results N. Kakaletsis, G. Ntaios, H. Milionis, C. Savopoulos, K. Makaritsis, K. Tziomalos, G.N. Dalekos, M. Elisaf, A.I. Hatzitolios E-poster at the European Stroke Conference, Nice, France, 08/05/2014 Poster at the World Stroke Congress, Istanbul, 2014 International Journal of Stroke 2014; 9 (suppl 3): 43 Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015

Introduction: Blood pressure (BP) is increased in up to 75% to 80% of patients with acute ischemic stroke (AIS) and usually decreases spontaneously over the next few days.

Aims: Our purpose is to study the relationship between BP course in the acute phase of stroke by ambulatory 24-hour BP monitoring (ABPM) and stroke severity assessed with the National Institutes of Health Stroke Scale (NIHSS).

Methods: Twenty-two consecutive patients with AIS underwent ABPM according recent guidelines, within 24 hours of onset of stroke using an automated oscillometric device (TM 2430, A&D Company Ltd) during day-time (7:00-22:59) and night-time (23:00-6:59). Known stroke risk factors and clinical findings on admission were recorded. Statistical analysis for continuous data (mean ± standard deviation) was made by Student's T-test, while for non-continuous data (numbers and percentages) chi-square test was used.

Results: Thirteen patients (59.1%) whose clinical characteristics did not differ from the rest population, except for frequency of atrial fibrillation (53.8%vs11.1%, respectively; p=0.04), had NIHSS>4 (Table 1). Furthermore, in these patients, all (mean, day and night) BP parameters derived by ABPM did not differ from stroke patients with NIHSS≤4, but all heart rate (HR) parameters were higher. The group with minor AIS had lower diastolic BP (DBP) (70.1vs75.2mmHg, p=0.009) and lower HR (60.2vs65.4bpm, p=0.009) during night compared to the day values (Table 2). Conclusions: Lower values of DBP (dipping pattern) and HR during night in AIS patients derived by ABPM are associated with minor AIS. Furthermore, higher HR values during 24h are associated with moderate/severe AIS.

Anaemia on admission predicts short and long-term outcome in patients with acute ischaemic stroke H. Milionis, V. Papavasileiou, A. Eskandari, S. D’Ambrogio-Remillard, G. Ntaios, P. Michel International Journal of Stroke 2014, online early E-poster at the European Stroke Conference, Nice, France, 08/05/2014

Background and objectives: It is still debatable whether anemia is a definite risk factor for stroke and predicts outcome. We assessed the characteristics of patients with acute ischemic stroke (AIS) and anemia and the prognostic significance of hemoglobin status on admission.

Methods: All 2439 patients of the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) between January 2003 and June 2011 were selected. Demographics, risk factors, pre-stroke treatment, clinical, radiological and metabolic variables in patients with and without anemia according to the definition of the World Health Organization were compared. Functional disability and mortality were recorded up-to 12 months from admission.

Results: Anemia patients (17.5%) were older, had lower body mass index, higher rates of coronary artery disease (CAD), atrial fibrillation, diabetes mellitus and peripheral artery disease. Anemia was associated with more severe stroke manifestations, lower systolic and diastolic blood pressure measurements, worse estimated glomerular filtration rate and elevated C-reactive protein concentrations upon admission and with increased grades in mRS during the follow-up. Patients with anemia had higher 7-day, 3-month and 12-month mortality which was explained by hemoglobin status and other factors, including age, CAD, stroke severity, and baseline C-reactive levels. Hemoglobin levels were inversely associated with recurrent stroke and mortality throughout the 12-month follow-up. Conclusion: Anemia is common among AIS patients and is associated with cardiovascular comorbidities. Low hemoglobin status independently predicts short and long-term mortality thereby warranting closer monitoring and identification of modifiable causes. Acute imaging does not improve ASTRAL score’s accuracy despite having a prognostic value G. Ntaios, V. Papavasileiou, M. Faouzi, P. Vanacker, M. Wintermark, P. Michel International Journal of Stroke 2014, in press E-poster at the European Stroke Conference, Nice, France, 08/05/2014 Background: The ASTRAL score was recently shown to reliably predict 3-month functional outcome in patients with acute ischemic stroke. Aim: to investigate whether information from multimodal imaging (MMI) increases ASTRAL score’s accuracy. Methods: All patients registered in the ASTRAL registry until 03/2011 were included. In multivariate logistic-regression analyses, we added covariates derived from parenchymal, vascular and perfusion imaging to the 6-parameter model of the


30


ASTRAL score. If a specific imaging covariate remained an independent predictor of 3-months modified Rankin score >2, the area-under-the-curve (AUC) of this new model was calculated and compared to ASTRAL score’s AUC. We also performed similar logistic regression analyses in arbitrarily chosen patient subgroups. Results: When added to the ASTRAL score, the following covariates on admission CT/MRI-based MMI were not significant predictors of outcome: any stroke-related acute lesion, any non-stroke-related lesions, chronic/subacute stroke, leukoaraiosis, significant arterial pathology in ischemic territory on CTA/MRA/Doppler, significant intracranial arterial pathology in ischemic territory, and focal hypoperfusion on perfusion-CT. The ASPECTS score on plain imaging and any significant extracranial arterial pathology on CTA/MRA/Doppler were independent predictors of outcome (odds-ratio:0.93, 95%CI:0.87-0.99 and odds-ratio:1.49, 95%CI:1.08-2.05, respectively) but did not increase ASTRAL score’s AUC (0.849 vs. 0.850, and 0.8563 vs. 0.8564, respectively). In exploratory analyses in subgroups of different prognosis, age or stroke severity, no covariate was found to increase ASTRAL score’s AUC, either. Conclusions: The addition of information derived from MMI does not increase ASTRAL score’s accuracy to predict functional outcome despite having an independent prognostic value. More selected radiological parameters applied in specific subgroups of stroke patients may add prognostic value of MMI. Association of ischemic stroke subtype with long-term cardiovascular events G. Ntaios, V. Papavasileiou, K. Makaritsis, H. Milionis, M. Patrik, K. Vemmos European Journal of Neurology 2014, in press Oral presentation at the European Stroke Conference, Nice, France, 08/05/2014 Background: There is not strong evidence whether all ischemic stroke types are associated with high cardiovascular risk. Aim was to investigate whether all ischemic stroke types are associated with high cardiovascular risk. Methods: All consecutive patients with ischemic stroke registered in Athens Stroke Registry between 1-1-1993 and 31-12-2010 were categorized according to TOAST classification and were followed-up for up to 10 years. Outcomes assessed were cardiovascular and all-cause mortality, myocardial infarction (MI), stroke recurrence, and a composite cardiovascular outcome consisting of MI, angina pectoris, acute heart failure, sudden cardiac death, stroke recurrence and aortic aneurysm rupture. The Kaplan–Meier product limit method was used to estimate the probability of each endpoint in each patient group. Cox-Proportional-hazard models were used to determine the independent covariates of each endpoint. Results: 2730 patients were followed-up for 48.1±41.9 months. The cumulative probability of 10-year cardiovascular mortality in patients with cardioembolic (46.6%, 95%CI:40.6-52.8), lacunar (22.1%, 95%CI:16.2-28.0) or undetermined (35.2%, 95%CI:27.8-42.6) stroke were either similar or higher compared to those of patients with large-artery atherosclerotic stroke (LAA) (28.7%, 95%CI:22.4-35.0). Compared to LAA, all other TOAST types had higher probability of 10-year stroke recurrence. In cox-proportional-hazard analysis, compared to patients with LAA, patients with any other stroke type were associated with similar or higher risk for the outcomes of overall mortality, cardiovascular mortality, stroke recurrence and composite cardiovascular outcome. Conclusions: LAA and cardioembolic strokes are associated with the highest risk for future cardiovascular events, with the latter carrying at least as high a risk as LAA strokes. Διεθνές Συνέδριο Εγκεφαλικών, San Diego (ΗΠΑ), 12-14 Φεβρουαρίου 2014 Β. Παπαβασιλείου, Γ. Ντάιος, Κ. Βέμμος Heart Vessels and Brain: thrombosis and antithrombosis 2012; 1:74-77 Σύνοψη των κυριότερων επιστημονικών εξελίξεων που ανακοινώθηκαν στο Διεθνές Συνέδριο Εγκεφαλικών στο San Diego, ΗΠΑ που διεξήχθη στις 12-14 Φεβρουαρίου 2014 ASTRAL-R score Predicts absence of Recanalization after Intravenous Thrombolysis in Acute Ischemic Stroke Peter Vanacker, Dimitris Lambrou, Mirjam Heldner, David Seiffge, Hubertus Mueller, Ashraf Eskandari, George Ntaios,

Pascal J Mosimann, Roman Sztajzel, Vitor Mendes Pereira, Patrick Cras, Stefan Engelter, Philippe Lyrer, Urs Fischer, Marcel Arnold, and Patrik Michel Thrombosis and haemostasis 2015, online early Προφορική ανακοίνωση στο International Stroke Conference 2014, Stroke. 2014; 45:ATP50

Background: Intravenous thrombolysis (IVT) is the best proven recanalization treatment in acute ischemic stroke (AIS), but may be insufficient in certain patients. Predicting the probability of absence of recanalization after IVT may allow for more aggressive management decisions, such as endovascular treatment. We aimed at deriving and internally validating a predictive score for non-recanalization with IVT, using readily available variables in the early stroke phase.

Methods: In prospective thrombolysis registries from four Swiss academic stroke centers, patients with a large arterial occlusion on acute imaging and with repeat arterial assessment at 24hours were selected. Based on a logistic regression analysis, an integer-based score for each covariate of the fitted multivariate model was generated. Performance of the integer-based predictive model was assessed by two internal cross validation techniques (bootstrap and delete-d multifold cross-


31


validation).

Results: In 599 thrombolyzed AIS, five variables were identified as independent predictors of absence of recanalization: Acute glucose >7mmol/L (A), significant extracranial vessel STenosis (ST), decreased Range of visual fields (R), large Arterial occlusion (A) and decreased Level of consciousness (L). All variables were weighted 1, except for (L) which obtained 2 points based on β-coefficients. ASTRAL-R scores 0, 3 and 6 corresponded to non-recanalization probabilities of 18, 44 and 74% respectively. Predictive ability showed an AUC of 0.66, with CI of 0.61-0.70 when using bootstrap and delete-d statistics.

Conclusions: The 5-item ASTRAL-R score predicts absence of recanalization at 24hours in thrombolyzed AIS patients. If confirmed by external validation, patient selection for more aggressive revascularization strategies may improve. Μετά την εκλογή στη θέση Λέκτορα Intravenous insulin treatment in acute stroke: a systematic review and meta-analysis of randomized controlled trials G. Ntaios, V. Papavasileiou, A. Bargiota, K. Makaritsis, P. Michel International Journal of Stroke 2013, in press

Introduction: Post-stroke hyperglycemia has been associated with unfavorable outcome. Several trials investigated the use of intravenous insulin to control hyperglycemia in acute stroke. This meta-analysis summarizes all available evidence from randomized controlled trials in order to assess its efficacy and safety.

Methods: We searched PubMed until 15/02/2013 for randomized clinical trials using the following search items: “intravenous insulin” or “hyperglycemia”, and “stroke”. Eligible studies had to be randomized controlled trials of intravenous insulin in hyperglycemic patients with acute stroke. Analysis was performed on intention-to-treat basis using the Peto fixed-effects method. The efficacy outcomes were mortality and favorable functional outcome. The safety outcomes were mortality, any hypoglycemia (symptomatic or asymptomatic) and symptomatic hypoglycemia.

Results: Among 462 potentially eligible articles, 9 studies with 1491 patients were included in the meta-analysis. There was no statistically significant difference in mortality between patients who were treated with intravenous insulin and controls (OR: 1.16, 95%CI: 0.89-1.49). Similarly, the rate of favorable functional outcome was not statistically different (OR: 1.01, 95%CI: 0.81-1.26). The rates of any hypoglycemia (OR: 8.19, 95%CI: 5.60-11.98) and of symptomatic hypoglycemia (OR: 6.15, 95%CI: 1.88-20.15) were higher in patients treated with intravenous insulin. There was no heterogeneity across the included trials in any of the outcomes studied.

Conclusions: This meta-analysis of randomized controlled trials does not support the use of intravenous insulin in hyperglycemic stroke patients to improve mortality or functional outcome. The risk of hypoglycemia is increased, however. PFO closure vs. medical therapy in cryptogenic stroke: a systematic review and meta-analysis G. Ntaios, V. Papavasileiou, K. Makaritsis, P. Michel International Journal of Cardiology 2013, in press

Background/Objectives: To assess whether patent foramen ovale (PFO) closure is superior to medical therapy in preventing recurrence of cryptogenic ischemic stroke or transient ischemic attack (TIA).

Methods: We searched PubMed for randomized trials which compared PFO closure with medical therapy in cryptogenic stroke/TIA using the items: “stroke or cerebrovascular accident or TIA” and “patent foramen ovale or paradoxical embolism” and “trial or study”.

Results: Among 650 potentially eligible articles, 3 were included including 2303 patients. There was no statistically significant difference between PFO-closure and medical therapy in ischemic stroke recurrence (1.91% vs. 2.94% respectively, OR:0.64, 95%CI:0.37-1.10), TIA (2.08% vs. 2.42% respectively, OR:0.87, 95%CI:0.50-1.51) and death (0.60% vs. 0.86% respectively, OR:0.71, 95%CI:0.28-1.82). In subgroup analysis, there was significant reduction of ischemic strokes in the AMPLATZER PFO Occluder arm vs. medical therapy (1.4% vs. 3.04% respectively, OR:0.46, 95%CI:0.21-0.98, relative-risk-reduction:53.2%, absolute-risk-reduction:1.6%, number-needed-to-treat:61.8) but not in the STARFlex device (2.7% vs. 2.8% with medical therapy, OR:0.93, 95%CI:0.45-2.11). Compared to medical therapy, the number of patients with new-onset atrial fibrillation (AF) was similar in the AMPLATZER PFO occluder arm (0.72% vs. 1.28% respectively, OR:1.81, 95%CI:0.60-5.42) but higher in the STARFlex device (0.64% vs. 5.14% respectively, OR:8.30, 95%CI:2.47-27.84).

Conclusions: This meta-analysis does not support PFO closure for secondary prevention with unselected devices in cryptogenic stroke/TIA. In subgroup analysis, selected closure devices may be superior to medical therapy without increasing the risk of new-onset AF, however. This observation should be confirmed in further trials using inclusion criteria for patients with high likelihood of PFO-related stroke recurrence. Improving the Prediction of Spontaneous and post-thrombolytic Recanalisation in Ischemic Stroke patients P. Vanacker, D. Lambrou, A. Eskandari, M. Cordier, G. Ntaios, P. Maeder, R. Meuli, P. Michel Journal of Stroke and Cerebrovascular Diseases 2015, online early Ανηρτημένη ανακοίνωση στο 2nd Congress of Swiss Federation of Clinical Neuro-societies, 5-7/06/2013, Montreux, Switzerland


32


Background: Endovascular treatment for acute ischemic stroke patients was recently shown to improve recanalization rates and clinical outcome in a well-defined study population. Intravenous thrombolysis alone is insufficiently effective to recanalize in certain patients or of little value in others. Accordingly, we aimed to identify predictors of recanalization in patients treated with or without intravenous thrombolysis.

Methods: In the observational ASTRAL-registry we selected those stroke patients; A) with an arterial occlusion on CTA imaging, B) who had an arterial patency assessment at 24 hours (CTA/MRA/TCD), and C) who were treated with intravenous thrombolysis or had no revascularization treatment. Based on two separate logistic regression analyses, predictors of spontaneous and post-thrombolytic recanalization were generated.

Results: Partial or complete recanalization was achieved in 121 out of 210 (58%) thrombolyzed patients. Recanalization was associated with atrial fibrillation (OR1.6, 95%CI 1.2-3.0) and absence of early ischemic changes on CT (1.1, 1.1-1.2) and inversely correlated with the presence of a significant extracranial stenosis or occlusion (0.6, 0.3-0.9). In non-thrombolyzed patients, partial or complete recanalization was significantly less frequent (37%, p<0.01). The recanalization was independently

associated with a history of hypercholesterolemia (2.6, 1.2-5.6) and the proximal site of the intracranial occlusion (2.5, 1.2-5.4), and inversely correlated with a decreased level of consciousness (0.3, 0.1-0.8), extracranial (0.3, 0.1-0.6) and basilar artery pathology (0.1, 0.0-0.6). Conclusions: Various clinical findings, cardiovascular risk factors and arterial pathology on acute CTAbased imaging are moderately associated with spontaneous and post-thrombolytic arterial recanalization at 24h. If confirmed in other studies, this information may influence patient selection towards the most appropriate revascularization strategy. Improving Prediction of Recanalization in Acute Large Vessel Occlusive Stroke P. Vanacker, D. Lambrou, A. Eskandari, P. Maeder, R. Meuli, G. Ntaios, P. Michel Journal of Thrombosis and Haemostasis 2014, in press Ανηρτημένη ανακοίνωση στο 2nd Congress of Swiss Federation of Clinical Neuro-societies, 5-7/06/2013, Montreux, Switzerland Background: Recanalization in acute ischemic stroke with large vessel occlusion is a potent indicator of good clinical outcome. Objective: to identify easily available clinical and radiological variables predicting recanalization at various occlusion sites. Methods: All consecutive, acute stroke patients from ASTRAL registry (2003-2011) who had a large vessel occlusion on CT angiography (<12hours) were included. Recanalization status was assessed at 24 (12-48) hours by CTA, MR angiography or ultrasonography. Complete and partial recanalization (corresponding to the modified Treatment In Cerebral Ischemia scale 2-3) was grouped. Patients were categorized according to occlusion site and treatment modality. Results: Among 439 patients, 51% (224) showed complete or partial recanalization. In multivariate analysis, recanalization of any occlusion site was most strongly associated with endovascular treatment including bridging therapy (OR 7.1; 95%CI:2.2-23.2), and less so with intravenous thrombolysis (OR:1.6, 95%CI:1.0-2.6) and recanalization treatments performed beyond guidelines (OR:2.6, 95%CI:1.2-5.7). Clot location (large vs. intermediate) and tandem pathology (combination of intracranial occlusion and symptomatic extracranial stenosis) were other variables discriminating between recanalizers and non-recanalizers. For patients with intracranial occlusions, the variables significantly associated with recanalization after 24 hours were: baseline NIHSS (OR:1.04 95%CI:1.02-1.1), ASPECTS scores on initial CT (OR:1.2, 95%CI:1.1-1.3) and an altered level of consciousness (OR:0.2, 95%CI:0.1-0.5). Conclusions: Acute endovascular treatment is the single most important factor promoting recanalization in acute ischemic stroke. Presence of extracranial vessel stenosis or occlusion decreases recanalization rates. In patients with intracranial occlusions, higher NIHSS and ASPECTS and normal vigilance facilitate recanalization. Integration in treatment algorithms could influence recanalization strategies in individual patients. Early major worsening in ischemic stroke: predictors and outcome G. Ntaios, D. Lambrou, D. Cuendet, P. Michel NeuroCritical Care 2013, in press Ανηρτημένη ανακοίνωση στο European Stroke Conference, London, UK, 28-31/06/2013

Introduction: We aimed to investigate the characteristics and outcome of patients suffering early major worsening (EMW) after acute ischemic stroke (AIS) and assess the parameters associated with it.

Methods: All consecutive patients with AIS in the ASTRAL registry until 10/2010 were included. EMW was defined as an NIHSS increase ≥8 points within the first 24 hours after admission. The Bootstrap version of the Kolmogorov-Smirnov test and the χ2-test were used for the comparison of continuous and categorical covariates respectively between patients with and without EMW. Multivariate logistic regression analysis was performed to identify independent predictors of EMW.

Results: Among 2155 patients, 43 (2.0%) had an EMW. EMW was independently associated with hemorrhagic transformation (OR:22.6, 95%CI:9.4-54.2), cervical artery dissection (OR:9.5, 95%CI:4.4-20.6), initial dysarthria (OR:3.7, 95%CI:1.7-8.0) and intravenous thrombolysis (OR:2.1, 95%CI:1.1-4.3), whereas a negative association was identified with initial eye deviation (OR:0.4, 95%CI:0.2-0.9). Favorable outcome at 3 and 12 months was less frequent in patients with EMW compared to patients without (11.6% vs. 55.3% and 16.3% vs. 50.7% respectively), and case fatality was higher (53.5% vs. 12.9% and 55.8% vs. 16.8%


33


respectively). Stroke recurrence within 3 months in surviving patients was similar between patients with and without EMW (9.3% vs. 9.0% respectively). Conclusions: Worsening of ≥8 points in the NIHSS score during the first 24 hours in AIS patients is related to cervical artery dissection and hemorrhagic transformation. It justifies urgent repeat parenchymal and arterial imaging. Both conditions may be influenced by targeted interventions in the acute phase of stroke. Υπάρχει όφελος από τη θρομβόλυση σε μεγαλύτερο χρονικό παράθυρο σε ασθενείς με οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο; Κριτική θεώρηση της μελέτης IST-3 (The Third International Stroke Study) Β. Παπαβασιλείου, Γ. Ντάιος, Κ. Μακαρίτσης, Κ. Βέμμος, Χ. Μηλιώνης Ελληνική Επιθεώρηση Αθηροσκλήρωσης 2013 Η ενδοφλέβια θρομβόλυση με ανασυνδυασμένο ενεργοποιητή του ιστικού πλασμινογόνου [recombinant tissue plasminogen activator (rt-PA)] στην οξεία φάση του ισχαιμικού αγγειακού εγκεφαλικού επεισοδίου (ΑΕΕ) αποτελεί εδραιωμένη και αποτελεσματική θεραπεία που βελτιώνει σημαντικά την αναπηρία των ασθενών. Η χορήγηση της θεραπείας σύμφωνα με τις ισχύουσες οδηγίες πραγματοποιείται έως και 4,5 ώρες από την εμφάνιση των συμπτωμάτων. Η IST-3 (Third International Stroke Study), η μεγαλύτερη ως τώρα μελέτη ενδοφλέβιας θρομβόλυσης, δεν κατάφερε να δείξει διαφορά στο βασικό καταληκτικό σημείο, δηλαδή στο λειτουργικό όφελος (διχοτομημένη κλίμακα Oxford Handicap Scale σε 0-2 και 3-6) από τη χορήγηση rt-PA ως και έξι ώρες από την έναρξη των συμπτωμάτων. Ωστόσο, οι ερευνητές που διεξήγαγαν τη μελέτη την παρουσιάζουν ως θετική, καθώς εστιάζουν στο οριακά θετικό αποτέλεσμα που παρουσίασε μια από τις δευτερεύουσες αναλύσεις. Επιπροσθέτως, η μελέτη παρουσιάζει σημαντικά μεθοδολογικά προβλήματα, τα οποία σε συνδυασμό με το αρνητικό αποτέλεσμα του βασικού καταληκτικού σημείου αυξάνουν τον προβληματισμό και δεν τεκμηριώνουν πιθανό όφελος από την καθυστερημένη θρομβολυτική θεραπεία. Στο παρόν άρθρο παρουσιάζεται μια κριτική θεώρηση των αποτελεσμάτων της μελέτης, ώστε να επισημανθεί το ενδεχόμενο μεταβολής της αντιμετώπισης ασθενών με οξύ ισχαιμικό ΑΕΕ στην καθημερινή κλινική πράξη.

The ASTRAL score predicts 5-year dependence and mortality in acute ischemic stroke V. Papavasileiou, H. Milionis, P. Michel, K. Makaritsis, A. Vemmou, E. Koroboki, E. Manios, K. Vemmos, G. Ntaios Stroke 2013;44:1616-1620 Ανηρτημένη ανακοίνωση στο European Stroke Conference, London, UK, 28-31/06/2013 Background and Purpose: The ASTRAL score was externally validated showing remarkable consistency on 3-month outcome prognosis in patients with acute ischemic stroke. The present study aimed to evaluate ASTRAL score’s prognostic accuracy to predict 5-year outcome. Methods: All consecutive patients with acute ischemic stroke registered in the Athens Stroke Registry between 01/01/1998 and 31/12/2010 were included. Patients were excluded if admitted >24hours after symptom onset or if any ASTRAL score component was missing. Endpoints were 5-year unfavorable functional outcome, defined as modified Rankin score 3-6, and 5-year mortality. For each outcome, the area under the receiver operating characteristics curve (AUC) was calculated; also, a multivariate Cox proportional hazards analysis was performed to investigate whether the ASTRAL score was an independent predictor of outcome. The Kaplan-Meier product limit method was used to estimate the probability of 5-year survival for each ASTRAL score quartile. Results: The AUC of the score to predict 5-year unfavorable functional was 0.89, 95%CI: 0.88-0.91. In multivariate Cox proportional hazards analysis, the ASTRAL score was independently associated with 5-year unfavorable functional outcome [hazard ratio (HR):1.09, 95%CI: 1.08-1.10]. The AUC for the ASTRAL score’s discriminatory power to predict 5-year mortality was 0.81 (95%CI: 0.78-0.83). In multivariate analysis, the ASTRAL score was independently associated with 5-year mortality (HR: 1.09, 95%CI: 1.08-1.10). During the 5-year follow-up, the probability of survival was significantly lower with increasing ASTRAL score quartiles (log-rank test <0.001). Conclusions: The ASTRAL score reliably predicts 5-year functional outcome and mortality in patients with acute ischemic stroke.

External validation of ASTRAL score to predict 3- and 12-month functional outcome in the China National Stroke Registry G. Liu, G. Ntaios, H. Zheng, Y. Wang, P. Michel, D. Zheng Wang, J. Fang, V. Papavasileiou, L. Liu, K. Dong, C. Wang, X. Zhao, Y. Wang Stroke 2013; 44:1443-5 Ανηρτημένη ανακοίνωση στο 2ο International Conference on Neurology and Epidemiology, 8-10/11/2012, Nice, France IF: Background and purpose: The ASTRAL score was recently introduced as a prognostic tool for acute ischemic stroke. It predicts 3-month outcome reliably in both the derivation and validation European cohorts. We aimed to validate the ASTRAL score in a Chinese stroke population and moreover, to explore its prognostic value to predict 12-month outcome. Methods: We applied the ASTRAL score to acute ischemic stroke patients admitted to 132 study sites of the China National Stroke Registry. Unfavorable outcome was assessed as a modified Rankin Scale score (mRS)>2 at 3 and 12 months. Areas under the curve (AUC) were calculated to quantify the prognostic value. Calibration was assessed by comparing predicted


34


and observed probability of unfavorable outcome using Pearson correlation coefficient. Results: Among 3755 patients, 1473 (39.7%) patients had 3-month unfavorable outcome. AUCs for 3 and 12 months were 0.82 and 0.81 respectively. There was high correlation between observed and expected probability of unfavorable 3- and 12-month outcome (Pearson correlation coefficient: 0.964 and 0.963 respectively). Conclusions: ASTRAL score is a reliable tool to predict unfavorable outcome at 3 and 12 months after acute ischemic stroke in the Chinese population. It is a useful tool that can be readily applied in clinical practice to risk-stratify acute stroke patients. Adipokines as mediators of endothelial function and atherosclerosis. G. Ntaios, N. Gatselis, K. Makaritsis, G. Dalekos Atherosclerosis 2013; 227:216-21 IF: For many decades, adipose tissue was considered as an inactive body compartment that was only used as an energy store. During the recent years, an increasing amount of data has revealed that adipose tissue is a major endocrine and paracrine organ producing numerous enzymes, hormones and growth factors which are collectively termed as adipokines. Several experimental and clinical studies showed that adipokines modulate insulin sensitivity and have an influence on glucose/fat metabolism and obesity. Apart from these properties, recent research revealed several direct actions of adipokines on endothelial function, vascular homeostasis and atherogenesis which are independent of their effects on glucose and fat metabolism. The present review focuses on the direct effects of adipokines on vascular/endothelial function and atherosclerosis and summarizes the experimental and clinical data which suggest a role for these molecules as potential diagnostic and prognostic cardiovascular markers as well as potential therapeutic target to reduce cardiovascular risk. Η χρήση υπολογιστικών μοντέλων (scores) στην πρόληψη, αντιμετώπιση και πρόγνωση των ισχαιμικών αγγειακών εγκεφαλικών επεισοδίων Β. Παπαβασιλείου, Χ. Μηλιώνης, Κ. Μακαρίτσης, Κ. Βέμμος, Γ. Ντάιος Ελληνική Επιθεώρηση Αθηροσκλήρωση 2013; 4:19–30 Ο σκοπός της παρούσας ανασκόπησης είναι η παρουσίαση των κυριότερων υπολογιστικών μοντέλων (scores) στο χώρο του αγγειακού εγκεφαλικού επεισοδίου (ΑΕΕ), που βοηθούν στη λήψη αποφάσεων στην καθημερινή κλινική πράξη. Παρουσιάζονται τα σημαντικότερα scores με τα εξελικτικά τους μοντέλα, τα πλεονεκτήματα και τους περιορισμούς τους στους ακόλουθους τομείς: 1. Κίνδυνος εμφάνισης ΑΑΕ σε ασθενείς με κολπική μαρμαρυγή, 2. Κίνδυνος αιμορραγίας με τη χρήση αντιπηκτικής αγωγής από του στόματος, 3. Κίνδυνος εμφάνισης εγκατεστημένου ισχαιμικού ΑΕΕ σε ασθενείς με παροδικό ΑΕΕ, 4. Κίνδυνος υποτροπής ΑΕΕ, 5. Πρόγνωση μετά από ΑΕΕ και 6. Αποτελεσματικότητα και κίνδυνος αιμορραγίας μετά από ενδοφλέβια θρομβόλυση. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease N. Gatselis, G. Ntaios, K. Makaritsis, G. Dalekos Clinical and Experimental Medicine 2013, in press Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and can progress to cirrhosis, liver failure and hepatocellular carcinoma. In the last two decades, the prevalence of NAFLD has been growing in most developed countries, mainly as a consequence of its close association with obesity and diabetes mellitus. The exact pathogenesis of NAFLD and especially the mechanisms leading to disease progression have not been completely understood. Adipocytes produce and secrete several bioactive substances known as adipocytokines which are implicated in the pathogenesis of the disease. Among them, adiponectin is an insulin-sensitizing adipocytokine possessing multiple beneficial effects on obesity-related medical complication. This review focuses on the role of adiponectin in NAFLD pathogenesis and its potential use as a diagnostic tool but also as therapeutic target for NAFLD management. Aseptic meningoencephalitis mimicking transient ischaemic attacks V. Papavasileiou, H. Milionis, M. Cordier, A. Eskandari, G. Ntaios, P. Michel Infection 2013; 41:485-91 Purpose: To highlighten meningoencephalitis as a transient ischaemic attack (TIA) mimic and suggest clinical clues for differential diagnosis. Methods: This was an observational study of consecutively admitted patients over a 9¾ year period presenting as TIAs at a stroke unit. Results: 790 patients with TIA and seven with TIA-like symptoms but a final diagnosis of viral meningoencephalitis were recognized. Most frequent presentations of meningoencephalitis patients were acute sensory hemisyndrome (six) and cognitive deficits (five). Signs of meningeal irritation were minor or absent on presentation. Predominantly lymphocytic pleocytosis, hyperproteinorachia and a normal CSF/serum glucose index (in 5 out of 6 documented patients) were present. Meningeal thickening on a brain MR was the only abnormal imaging finding. Six patients received initial vascular treatment;


35


one thrombolyzed. Finally, six patients were treated with antivirals and/or antibiotics. Although neither bacterial nor viral agents were identified on extensive testing, viral meningoencephalitis was the best explanation for all clinical and laboratory findings. Conclusions: Meningoencephalitis should always be part of the differential diagnosis in patients with a suspected TIA. The threshold for a lumbar puncture should be individually set for each patient regarding the age, the presence or not of even mild meningeal symptoms, the risk factors for vascular disease, the results of brain imaging and the basic diagnostic work-up for a stroke source. Independent Predictors of Recanalisation in Acute Ischemic Stroke P. Vanacker, D. Lambrou, A. Eskandari, G. Ntaios, P. Maeder, P. Michel Ανηρτημένη ανακοίνωση στο 17ο Swiss Trialists Stroke Meeting, St. Gallen, 31/01/2013 Ανηρτημένη ανακοίνωση στο European Stroke Conference, London, UK, 28-31/06/2013

Non-vitamin-K-antagonists oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials G. Ntaios, V. Papavasileiou, H.C. Diener, K. Makaritsis, P. Michel Stroke 2012; 43:3298-304 Ανηρτημένη ανακοίνωση στο 17ο Swiss Trialists Stroke Meeting, St. Gallen, 31/01/2013 Προφορική ανακοίνωση στο 5ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 28/03/2013

Background and purpose: To assess whether the combined analysis of all phase-III trials of non-vitamin-K-antagonists oral anticoagulants (non-VKA) in patients with atrial fibrillation (AF) and previous stroke or transient ischemic attack (TIA) shows a significant difference in efficacy or safety compared to warfarin. Methods: We searched PubMed until 31/05/2012 for randomized clinical trials using the following search items: “atrial fibrillation” AND “anticoagulation” AND “warfarin” AND “previous stroke or transient ischemic attack”. Studies had to be phase-III trials in AF patients comparing warfarin with a non-VKA currently on the market or with the intention to be brought to the market in North America or Europe. Analysis was performed on intention-to-treat basis. A fixed-effects model was used as more appropriate than a random-effects model when combining a small number of studies. Results: Among 47 potentially eligible articles, 3 were included in the meta-analysis. In 14527 patients, non-VKA were associated with a significant reduction of stroke/systemic embolism (OR:0.85, 95%CI:074-0.99, relative-risk-reduction (RRR):14%, absolute-risk-reduction (ARR):0.7%, Number-Needed-to-Treat (NNT):134 over 1.8-2.0years) compared to warfarin. Non-VKA were associated also with a significant reduction of major bleeding compared to warfarin (OR:0.86, 95%CI:075-0.99, RRR:13%, ARR:0.8%, NNT:125), mainly driven by the significant reduction of hemorrhagic stroke (OR:0.44, 95%CI:032-0.62, RRR:57.9%, ARR:0.7%, NNT:139). Conclusions: In the context of the significant limitations of combining the results of disparate trials of different agents, non-VKA appear to be associated with a significant reduction in rates of stroke or systemic embolism, hemorrhagic stroke and major bleeding when compared to warfarin in patients with prior stroke or TIA.

Blood pressure variability in subacute ischemic stroke: a neglected potential therapeutic target G. Tsivgoulis, G. Ntaios Neurology 2012; 79:2014-5 Invited editorial στο οποίο σχολιάζεται πρόσφατο άρθρο στο ίδιο περιοδικό το οποίο δείχνει ότι μεγάλες διακυμάνσεις της αρτηριακής πίεσης κατά τις πρώτες ημέρες μετά από ένα αγγειακό εγκεφαλικό επεισόδιο επιδεινώνουν την πρόγνωση και υποστηρίζει ότι θα μπορούσε να αποτελέσει ένα νεό θεραπευτικό στόχο.

CHADS2, CHA2DS2-VASc and long-term stroke outcome in patients without atrial fibrillation G. Ntaios, G.Y.H. Lip, K. Makaritsis, V. Papavasileiou, H. Milionis, A. Vemmou, E. Koroboki, P. Savvari, E. Manios, H. Milionis, K. Vemmos Neurology 2013; 80:1009-17 Ανηρτημένη ανακοίνωση στο European Stroke Conference, Λισαβώνα, 24/05/2012 Προφορική ανακοίνωση στο 5ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 28/03/2013 The CHADS2 score is used to assess the risk of stroke in patients with atrial fibrillation (AF). We investigated whether the CHADS2 score predicted mortality and cardiovascular events in stroke patients without atrial fibrillation. Methods: Consecutive non-AF patients registered in the Athens Stroke Registry between 1988 and 2011 with an acute first-ever ischemic stroke were classified into three groups according to their CHADS2 score (low: 0, intermediate: 1-2, high: >/=3) and were followed up to 5 years. The endpoints were death and major cardiovascular events. Results: Among 1757 patients (mean age 67.2±12.3, 68.2% males), there were 262 (14.9%), 1127 (64.1%) and 368 (20.9%) patients with low, intermediate and high CHADS2 score respectively. The probability of 5-years survival was significantly different between the three groups: 83.5% (95%CI: 78.2-88.8%) for the low-score, 70.5% (95%CI: 67.2-73.8%) for the intermediate-score


36


and 64.6% (95%CI: 58.9-70.3%) for the highscore group (p<0.001 by the log-rank test). In the Cox-proportional hazard analysis, mortality risk was significantly higher in the intermediate-score (HR: 2.42, 95%CI: 1.56-3.75) and high-score groups (HR: 4.06, 95%CI: 2.57-6.40) compared to the low-score group. The probability of a major cardiovascular event was significantly different between the three groups: (20.3%, 95%CI: 14.0- 26.6%) in the low-score group, (31.0%, 95%CI: 27.5-34.5%) in the intermediatescore and (40.8%, 95%CI: 33.7-47.9%) groups (p<0.001 by the log-rank test). In the Cox-proportional hazard analysis, the risk for a major cardiovascular event was significantly higher in the intermediate score (HR: 1.63, 95%CI: 1.14-2.34) and high-score groups (HR: 2.25, 95%CI: 1.38-3.65) compared to the low-score group. Conclusion: The CHADS2 score is an independent predictor of mortality and cardiovascular risk in non-AF stroke patients.

Ankle-brachial index predicts lonf-term outcome after first-ever ischemic stroke H. Milionis, A. Vemmou, G. Ntaios, K. Makaritsis, E. Koroboki, V. Papavasileiou, P. Savvari, K. Spengos, K. Vemmos European Journal of Neurology 2013, in press E-poster στο European Stroke Conference, Λισαβώνα, 24/05/2012

Background and objective: Ankle-brachial blood pressure Index (ABI) lower is a clinical tool to identify the presence of peripheral artery disease (PAD) in both symptomatic and asymptomatic patients. There is a scarcity of data associating ABI with outcome in patients with ischemic stroke. We assessed the impact of ABI on 5-year outcome in patients with first-ever acute ischemic stroke. Methods and results: ABI was assessed in a total of 653 consecutive patients with a first-ever acute ischemic stroke and follow for a period up to 6 years. One-hundred twenty nine (19.8%) stroke patients with ABI<0.9 were identified. Atheroclerotic stroke (lacunar, larger-vessel disease and cryptogenic) was the most frequent type of stroke diagnosed both in the whole cohort (64.7%) and in low ABI patients (65.1%). There was no difference in 5-year risk of stroke recurrence or composite cardiovascular events between patients with and without identified PAD. Survival was better in stroke patients with normal ABI (log rank chi2 23.35, p<0.001). The probability of 5-year survival was 49.3% (95%CI: 45.4-53.2) for low ABI patients and 56.5% (95%CI: 55.2-53.2) for normal ABI patients. On multivariate Cox-regression analysis, independent predictors of 5-year mortality included age (hazard ratio, HR 1.10, 95%CI 1.06-1.13, p<0.00.1), NIH stroke scale (HR 1.12, 95%CI 1.22-1.085, p<0.001), and low ABI (HR, 2.22, 95%CI 1.22-4.03, p=0.009). Conclusions: Five-year mortality is increased in stroke patients with low ABI. ABI does not appear to predict long-term stroke recurrence or the risk of future cardiovascular events.

Cardiovascular diseases in pregnancy Godosis D, Komaitis S, Tziomalos K, Baltatzi M, Ntaios G, Savopoulos C, Hatzitolios A. Am J Cardiovasc Dis 2012; 2:96-101

Gestation is a period of significant physiological changes that can severely affect the function of many systems, including the cardiovascular. The deviation from the standard that occurs during pregnancy may cause the deterioration of pre-existent cardiovascular diseases or the appearance of new ones. In this review we will present the most common congenital and acquired cardiovascular diseases, their clinical expression and therapeutic procedures according to the latest international guidelines.

Συμπτωματική καρωτιδική νόσος: Ενδαρτηρεκτομή ή αγγειοπλαστική; Γ. Ντάιος, Κ. Μακαρίτσης Heart Vessels and Brain: thrombosis and antithrombosis 2012; 1:74-77 Αυτό το ανασκοπικό άρθρο συνοψίζει τις κυριότερες μελέτες για την αντιμετώπιση της συμπτωματικής καρωτιδικής νόσου και παρουσιάζει τις αντίστοιχες κατευθυντήριες οδηγίες. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score G Ntaios, M Faouzi, J Ferrari, W Lang, K Vemmos, P Michel Neurology 2012; 78:1916-22 Presented in International Stroke Conference, New Orleans, USA 2012 Ανηρτημένη ανακοίνωση στο Swiss Trialists Meeting, Ζυρίχη, 09/02/2012 – Best poster award Προφορική ανακοίνωση στο 4ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 29/03/2012 Introduction: We aimed to develop and externally validate a simple, integer-based prognostic score to predict functional outcome at three months in patients with acute ischemic stroke (AIS) using variables readily available at hospital admission. Methods: Using emergently available demographic, clinical and laboratory variables of consecutive AIS patients in a single university hospital, logistic regression analysis was performed in the derivation cohort (ASTRAL registry) to identify independent predictors of unfavorable outcome, defined as modified Rankin Scale score >2. The β-coefficient of each covariate of the fitted multivariate model was used to generate an integer-based point scoring system for each one; the overall score was calculated as the sum of weighted scores of the covariates. The model was validated externally in two AIS cohorts from the


37


Athens and Vienna Stroke Registries. Two indices of accuracy were assessed: discrimination (Area Under the Curve, AUC) and calibration (Hosmer-Lemeshow test). Results: Six covariates were identified as independent predictors of unfavorable outcome in 1968 patients in ASTRAL: age (A), severity of stroke (S) measured by admission NIHSS, time from stroke onset-to-admission (T), range of visual fields on clinical exam (R), acute serum glucose (A) and level of consciousness (L). AUC in the ASTRAL cohort was 0.850. β-coefficients were multiplied by 4 and rounded to the closest integer. The score was well calibrated in the derivation (p=0.43) and validation cohorts [0.22 and 0.49 in the Athens (n=1659) and Vienna cohorts (n=653) respectively, 0.82 in their combination]. AUCs were 0.937 and 0.771 in the Athens and Vienna cohorts respectively, and 0.902 in their combination. An ASTRAL score of 28 indicates a 50% likelihood of unfavorable outcome. Conclusions: The ASTRAL score is a simple integer-based score to predict 3 months functional outcome using 6 readily available items at hospital admission. It performed well in double external validation and may be a useful tool for clinical practice and stroke research. Major Neurological Improvement is Predicted by Recanalisation and Absence of Acute Tissue Damage: An Analysis of 2'006 Consecutive Acute Ischemic Strokes D. Cuendet, G. Ntaios, D. Lambrou, P. Michel Presented in International Stroke Conference, New Orleans, USA 2012 Introduction: Major neurological improvement (MNI) in acute ischemic stroke (AIS) is related to better outcome. We aimed to evaluate predictors of MNI in a large cohort of consecutive AIS patients. Methods: In the Acute STroke Registry and Analysis of Lausanne (ASTRAL), MNI was defined as 8 point improvement of NIHSS or a NIHSS of 0-1 after 24 hours. Patients with initial NIHSS of 0-1 were excluded and missing data were imputed. For comparison of patients with and without MNI, logistic regression analysis of a large number of demographical, clinical, radiological and metabolic data was performed. The influence of MNI on length of hospital stay (LOS), favorable outcome defined as modified Rankin score 0-2 at three and 12 months, and recurrence was also assessed in univariate analysis. Results: 203 patients were excluded because of initial NIHSS of 0-1. Before imputing 50 missing NIHSS values to obtain a sample of 2’006 patients, MNI occurred in 333 (17.0%). MNI was predicted by spontaneous or therapeutic intracranial recanalization (OR= 0.49, CI 0.31-0.76, p<0.01) especially in the presence of eye deviation, absence of early ischemic lesions on neuroimaging (OR= 0.62, CI 0.47-0.82, p<0.01), earlier onset to arrival delay (OR= 0.95/60 minutes, CI 0.93 - 0.97, p<0.01) and lower systolic blood pressure at 24h (OR=0.92/10 mmHg, CI 0.86 - 0.98, p=0.01). Patients with MNI had significantly shorter LOS (median 8 vs. 10 days, p<0.01), more frequent favorable three months (73.6% vs. 47.6%, p<0.01) and 12 months outcome (66.1 vs. 43.5, p < 0.01). They also had less three (3.9% vs. 17.3%, p<0.01) and 12 months fatality (6.0% vs. 21.8% p < 0.01). Recurrence rates at three months were similar (9.0% vs. 9.2%, p=0.86). Conclusion: Absence of radiological signs of irreversible tissue damage and arterial recanalisation are strong predictors of MNI. Earlier arrival to hospital delay and lower subacute SBP also contributed to MNI. We confirm that radiological markers are strong predictors of MNI in thrombolysed and untreated patients. Stroke etiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study Vemmos K, Ntaios G, Savvari P, Vemmou AM , Koroboki E, Manios E, Kounali A, Lip GYH European Journal of Heart Failure 2012; 14:211-8 Aim: To investigate stroke etiology and assess the predictors of early and late outcome in patients with heart failure (HF) and acute stroke. Methods and results: 2904 patients, admitted between 1993 and 2010, were regularly followed up at months 1, 3 and 6, and yearly thereafter up to 10 years. There were 283 (9.7%) stroke patients with HF; atrial fibrillation (AF) was present in 144 (50.9%) of them. Stroke aetiology in patients with HF and AF was mainly cardioembolism (82%) regardless of HF aetiology. In contrast in the 139 non-AF patients with HF, stroke mechanism was associated with the aetiology of HF: valvular heart disease and dilated cardiomyopathy were related to cardioembolism in 60% and 66.7% of patients respectively, whereas HF due to coronary artery disease or hypertension was associated with atherosclerotic and lacunar stroke in 40.8% and 61.5% respectively. In the overall population, HF was independent predictor of 10-year mortality [HR=1.54 (95%CI: 1.29-1.83, p<0.001)]. Probability of 10-year survival was 19.4% (95%CI: 14.5-23.5) for HF patients and 44.1% (95%CI: 41.4-46.8) for non-HF patients (p<0.0001). 10-years mortality in HF patients was associated with functional class of HF, age, diabetes, stroke severity and inhospital aspirin use. The presence of AF in HF stroke patients did not influence 10-year survival and composite cardiovascular events (p=0.429 and p=0.406 respectively). Conclusions: In patients with heart failure, stroke etiology is influenced by the presence of AF and the underlying cause of HF. Early and late stroke outcome is associated with HF severity but not with the presence of AF. Persistent hyperglycemia at 24-48 hours in acutely hyperglycemic stroke patients is not associated with worse functional outcome G. Ntaios, C. Abatzi, M. Alexandrou, D. Lambrou , S. Chatzopoulos, M. Egli, J. Ruiz , N. Bornstein , P. Michel Cerebrovascular Diseases 2011; 32:561-6


38


Background: Recently, it was shown that the relation between admission glucose and functional outcome after ischemic stroke is described by a J-shaped curve, with a glucose range of 3.7-7.3mmol/l associated with favorable outcome. We now test the hypothesis that persistence of hyperglycemia above this threshold at 24-48 hours after stroke onset impairs 3-months functional outcome. Methods: We analyzed all patients with glucose >7.3mmol/l at admission from the Acute STroke Registry and Analysis of Lausanne (ASTRAL). Patients were divided in two groups according to their subacute glucose level at 24-48 hours after last well-being time (group I: ≤7.3mmol/l, group II: >7.3mmol/l). Favourable functional outcome was defined as modified Rankin score ≤2 at 3 months. A multiple logistic regression analysis of multiple demographic, clinical, laboratory and neuroimaging covariates was performed to assess predictors of unfavorable outcome. Results: A total of 1984 patients with ischemic stroke were admitted between 01/01/2003 and 20/10/2009 within 24 hours after last-well time. In the 421 patients (21.2%) with admission glucose >7.3mmol/l, the proportion of patients with favorable outcome was not statistically significantly different between the two groups (59.2% vs. 48.7% respectively). In multiple logistic regression analysis, unfavorable outcome was significantly associated with age (OR:1.06, 95%CI:1.03-1.08 for every 10 years increase), NIHSS score at admission (OR:1.16, 95%CI:1.11–1.21), pre-hospital Rankin score (OR:12.63, 95%CI:2.61-61.10 for patients with score >0), anti-diabetic drug usage (OR:0.36, 95%CI:0.15-0.86) and glucose at admission (OR:1.16, 95%CI:1.02-1.31 for every 1mmol/l increase). No association was found between persistent hyperglycemia at 24-28 hours and outcome in either diabetics or non-diabetics. Conclusions: In ischemic stroke patients with acute hyperglycemia, persistent hyperglycemia (>7.3mmol/l) at 24-48 hours after stroke onset is not associated with worse functional outcome at 3 months regardless whether the patient was previously diabetic or not. Perfusion-CT guided intravenous thrombolysis in patients with unknown-onset stroke: a randomized, double-blind, placebo controlled, pilot feasibility trial Michel P, Ntaios G, Reichhart M, Schindler C, Bogousslavsky J, Maeder P, Meuli R, Wintermark M Neuroradiology 2011; 54:579-88 Introduction: Patients with unknown stroke onset are generally excluded from acute recanalisation treatments. We designed a pilot study to assess feasibility of PCT-guided thrombolysis in patients with potentially salvageable ischemic tissue and unknown onset. Methods: Patients with a supratentorial stroke of unknown onset in the middle cerebral artery territory and significant volume of potentially salvageable tissue on PCT were randomized to intravenous thrombolysis with alteplase (0.9mg/kg) or placebo. Safety endpoints included intracerebral hemorrhage at 24 hours and 4 days, and mortality at 7 and 90 days. Results: At baseline, there was a trend towards older age [69.5 (57-78) vs. 49 (44-78) years] in the thrombolysis group (n=6) compared to placebo (n=6). There were two protocol violations, both regarding PCT inclusion criteria in patients randomized in the placebo group. No symptomatic hemorrhage or death occurred during the first 7 days. 3/4 (75%) and 1/5 (20%) of patients recanalized in the thrombolysis and placebo group respectively. The volume of salvaged brain tissue was 84 (44-206) cm3 in the treatment arm and 29 (8-105) cm3 in the placebo arm. Conclusions: This pilot study shows that PCT-guided thrombolysis in patients with stroke of unknown onset is feasible and calls for a larger, perfusion-imaging guided trial. Risk factors for ischaemic stroke among hypertensive patients K. Tziomalos, M. Baltatzi, M. Apostolopoulou, E. Efthymiou, K. Psianou, D. Magkou, N. Katsiki, G. Ntaios, C. Savopoulos, A. Hatzitolios European Stroke Congress, 26/05/2011, Αμβούργο 4ο Συμπόσιο Ομάδων Εργασίας της Ελληνικής Εταιρίας Αθηροσκλήρωσης, 03/12/2011, Αθήνα Isolated cerebellar infarct: imaging findings, etiopathogenesis and clinical outcome A. Vemmou, E. Koroboki, G. Ntaios, P. Savvari, A. Skafida, K. Spengos, K.N. Vemmos, European Stroke Congress, 26/05/2011, Αμβούργο Stroke in the anterior circulation: two-center comparison of combined (intravenous, intra-arterial and / or mechanical thrombectomy) with intravenous thrombolysis R.F. Sztajzel, G. Ntaios, I. Kuzmanovic, I. Momjian-Mayor, C. Bonvin, A. Viaccoz, V. Mendez-Pereira, A.P. Narata, K. Lovblad, P. Michel European Stroke Congress, 26/05/2011, Αμβούργο Association between blood pressure changes in the acute phase of stroke and outcome with respect to stroke etiology G. Ntaios, D. Lambrou, P. Michel European Stroke Congress, 26/05/2011, Αμβούργο Neurology 2012; 79:1440 - 1448 Introduction: Management of blood pressure (BP) in the acute phase of stroke remains controversial. Previous research


39


suggested that proper BP management in acute stroke may need to take into account the underlying etiology. Methods: All patients with acute ischemic stroke registered in the Acute STroke Registry and Analysis of Lausanne (ASTRAL) between 2003 and 2009 were analyzed. Unfavorable outcome was defined as modified Rankin Scale score >2. A local polynomial surface algorithm was used to assess the effect of baseline and 24-48 hours systolic (SBP) and mean arterial pressure (MAP) on outcome in patients with lacunar, atherosclerotic and cardioembolic stroke. Results: 791 patients were included in the analysis. For patients with low/normal baseline BP levels, BP elevation reduced the probability of unfavorable outcome (however slightly) in atherosclerotic stroke, but on the contrary was associated with poor outcome in lacunar and cardioembolic stroke. In all other types of stroke, BP elevation increased the probability of unfavorable outcome. For moderately high baseline BP levels, BP reduction seemed to be beneficial for all stroke types; on the contrary, it had only a minimal effect in extremely high baseline BP levels, with the optimal reduction being larger in lacunar strokes, modest in atherosclerotic and only mild in cardioembolic. Among patients with extremely elevated baseline BP, lacunar strokes were associated with better outcome compared to atherosclerotic or cardioembolic strokes. Conclusions: This study provides provide evidence to support that BP management in acute stroke may have to be tailored with respect to the underlying etiopathogenetic mechanism. An intravenous insulin protocol for strict glycemic control in acute ischaemic stroke G. Ntaios, M. Egli, A. Arsovska, D. Joye, Y. Bettex, E. Lauber, A. Eskandari, S. D’Ambrogio, B. Richoz, J. Ruiz, P. Michel, European Journal in Neurology 2012; 19:443-51 European Stroke Congress, 26/05/2011, Αμβούργο Background: There is a J-shaped association between post-stroke glycemia and outcome. We designed an intravenous insulin protocol aiming at rapid and strict glucose control in hyperglycemic ischemic stroke patients. Here, we describe the initial experience, safety and efficacy of this protocol to achieve and maintain euglycemia in the first 48 hours. Methods: The protocol is based on parallel scales for adjustment of insulin infusion rate according to current glycemia and the rate of change of glycemia, and was implemented in our stroke unit in 4/2007. Acute ischemic stroke patients with glycemia >6mmol/l were eligible for the protocol. Capillary blood glycemia was measured hourly with fingerprick test at onset of treatment and after each scale change. Target glycemia was 4.0-6.0mmol/l preprandially (5.5–8.0mmol/l postprandially). Specific algorithms were employed during meals and for patients leaving temporarily the stroke unit for diagnostic or therapeutic work-up. Results: In the 90 protocol patients, the first normoglycemia was achieved within 8hours of treatment in 91.1% of patients (median interval 4.6±2.7hours). During the median treatment duration of 29.3±10.7hours, median glucose reduction was 2.5±3.0mmol/l. The overall rate of hypoglycemias and hypokalemias was 4.5% and 18.5% respectively. There was a significant increase in the proportion of hypokalemias on the first on-treatment measurement compared to admission (24.4% vs. 8.9%, p=0.002). Conclusions: The present analysis shows that the proposed intravenous insulin protocol safely and effectively controls acute post-stroke hyperglycemia. After the addition of potassium, this protocol may be suitable for use in larger, randomized controlled trial to explore its clinical effect. The type of atrial fibrillation is associated with long- term outcome in patients with acute ischemic stroke G. Ntaios, A. Vemmou, E. Koroboki, P. Savvari, M. Saliaris, K. Spengos, K. Vemmos International Journal of Cardiology, 2013; 167:1519-23 Προφορική ανακοίνωση, European Stroke Congress, 26/05/2011, Αμβούργο Προφορική ανακοίνωση, European Congress of Internal Medicine, 7/10/2011, Αθήνα Background: There are only scarce data whether long-term outcome and mortality is different among different types of atrial fibrillation (AF). Aim of this study was to determine whether the type of atrial fibrillation is an independent predictor of long-term outcome in patients with ischemic stroke. Methods: We used data from all consecutive patients registered in the Athens Stroke Registry registered between 1993-2010. Outcome was assessed by all-cause mortality, stroke recurrence or a composite endpoint of the main cardiovascular complications. Kaplan –Meier curves of the probability to remain free of stroke recurrence, of all-cause death and of the composite event during 10-years follow up were generated. Uni- and multivariate Cox Proportional Hazard models were used to determine whether the type of AF is an independent predictor of 10-year all-cause mortality and 10-year composite CVD event. Results: 846 patients with AF were identified from a pool of 2445 patients. 366 patients (43.2%) had permanent AF, 214 (25.3%) newly diagnosed AF, 166 (19.6%) paroxysmal AF and 101 (11.9%) persistent AF. 152 (18%) of patients had a recurrent stroke during the 10 years follow up. The 10-years rate of being free of stroke recurrence was significantly less in patients with permanent AF (log-rank p=0.01). During the first 10 years after the index event, 485 patients (57.3%) died and 206 (24.1%) composite events occurred. The 10-years probability of survival as well as of being free from the composite event was statistically significantly higher in patients with paroxysmal AF (log-rank p<0.001). The type of AF was an independent predictor of 10-years all-cause mortality. Conclusion: Long-term mortality and stroke recurrence in patients with ischemic stroke and atrial fibrillation are associated with the type of atrial fibrillation.


40


Blood pressure change and outcome in acute ischemic stroke: the impact of baseline values, previous hypertensive disease and previous antihypertensive treatment Ntaios G, Lambrou D, Michel P Journal of Hypertension 2011; 29:1583-9 Background: Management of blood pressure (BP) in acute ischemic stroke is controversial. The present study aims to explore the association between baseline BP levels and BP change and outcome in the overall stroke population and in specific subgroups with regards to the presence of arterial hypertensive disease and prior antihypertensive treatment. Methods: All patients registered in the Acute STroke Registry and Analysis of Lausanne (ASTRAL) between 2003 and 2009 were analyzed. Unfavorable outcome was defined as mRS>2. A local polynomial surface algorithm was used to assess the effect of BP values on outcome in the overall population and in predefined subgroups. Results: Up to a certain point, as initial BP was increasing, optimal outcome was seen with a progressively more substantial BP decrease over the next 24-48hours. Patients without hypertensive disease and an initially low BP seemed to benefit from an increase of BP. In patients with hypertensive disease, initial BP and its subsequent changes seemed to have less influence on clinical outcome. Patients previously treated with antihypertensives did not tolerate initially low blood pressures well. Conclusions: Optimal outcome in acute ischemic stroke may be determined not only by initial BP levels but also by the direction and magnitude of associated BP change over the first 24-48hours. Temporal distribution and magnitude of the vulnerability period around stroke depend on stroke subtype Ntaios G, Michel P Cerebrovascular Diseases 2011; 32:246-53 Ανηρτημένη ανακοίνωση στο 20ο European Stroke Congress, Hamburg, 24-27 May 2011 Background: We aimed to analyze the rate and time distribution of pre- and postmorbid cerebrovascular events in a single ischemic stroke population, and whether it depends on the etiology of the index stroke. Methods: In 2203 consecutive patients admitted to a single stroke center registry (ASTRAL), the ischemic stroke that led to admission was considered the index event. Frequency distribution and cumulative relative distribution graphs of the most recent and first recurrent event (ischemic stroke, transient ischemic attack, intracranial or subarachnoid haemorrhage) were drawn in weekly and daily intervals for all strokes and for stroke types. Results: The frequency of events at identical time points before and after the index stroke was mostly reduced in the first week after (vs. before) stroke (1.0% vs. 4.2%, p<0.001), and the first month (2.7 % vs. 7.4%, p<0.001), and then ebbed out over the first year (8.4% vs. 13.1%, p<0.001). On daily basis, the peak frequency was noticed at day -1 (1.6%) with a reduction to 0.7% on the index day and 0.17% 24h hours after. The event rate in patients with atherosclerotic stroke was particularly high around the index event, but 1-year cumulative recurrence rate was similar in all stroke types. Conclusions: We confirm a short window of increased vulnerability in ischemic stroke and show a 4-, 3- and 2-fold reduction of post-stroke events at one week, one month and one year respectively compared to identical pre-stroke periods. This break in the “stroke wave” is particularly striking after atherosclerotic and lacunar strokes. Stroke, obesity and gender: a review of the literature Katsiki N, Ntaios G, Vemmos K. Maturitas 2011; 69:239-43 Cerebrovascular disease constitutes one of the main causes of morbidity, disability and mortality worldwide. Obesity, a major health problem reaching global epidemic proportions, is also associated with morbidity and mortality. The present review provides an update on the current knowledge regarding the association of gender and obesity with stroke prevalence and outcome. We also discuss the areas that future research needs to point towards. In general, gender differences in relation to stroke are increasingly being recognized and evaluated. Age-specific stroke incidence is generally higher in men, except in the elderly. Women are treated less frequently with intravenous thrombolysis compared with men stroke patients and the two genders seem to respond differently to aspirin and statins. Regarding obesity, although it is a well-known predictor of cardiovascular disease, there is a growing body of evidence revealing the presence of an inverse relationship between obesity and outcome in patients with stroke or established cardiovascular disease, the so-called obesity paradox. Further research is warranted on these important topics, as human population is continuously aging and becoming more obese. In this context, the causes of gender differences in stroke prevalence and outcome and the obesity-stroke paradox should be further investigated in future studies. CT angiography helps to differentiate acute from chronic carotid occlusion: the "carotid ring sign" P. Michel, G. Ntaios, MG. Delgado, DC. Bezerra, R. Meuli, S. Binaghi Neuroradiology 2012; 54:139-46 Purpose: Currently, there is no reliable method to differentiate acute from chronic carotid occlusion. We propose a novel CTA


41


based method to differentiate acute from chronic carotid occlusions that could potentially aid clinical management of patients. Methods: We examined 72 patients with 89 spontaneously-occluded extracranial internal carotids with CT-angiography. All occlusions were confirmed by another imaging modality and classified as acute (imaging <1 week of presumed occlusion) or chronic (imaging >4 weeks), based on circumstantial clinical and radiological evidence. A neuroradiologist and a neurologist blinded to clinical information determined the site of occlusion on axial sections of CT-angiography. They also looked for a) hypodensity in the carotid artery (thrombus), b) contrast within the carotid wall (vasa vasorum), c) the site of the occluded carotid, and d) the “carotid ring-sign” (defined as presence of a and/or b). Results: Of 89 occluded carotids, 24 were excluded because of insufficient circumstantial evidence to determine timing of occlusion, 4 because of insufficient image quality, and 3 because of subacute timing of occlusion. Among the remaining 45 acute and 13 chronic occlusions, inter-rater agreement (kappa) for the site of proximal occlusion was 0.88, 0.45 for distal occlusion, 0.78 for luminal hypodensity, 0.82 for wall contrast and 0.90 for carotid ring-sign. The carotid-ring sign had 88.9% sensitivity, 69.2% specificity, and 84.5% accuracy to diagnose acute occlusion. Conclusions: The carotid ring-sign helps to differentiate acute from chronic carotid occlusion. If further confirmed, this information may be helpful in studying ischemic symptoms and selecting treatment strategies in patients with carotid occlusions. Long-term outcome in posterior cerebral artery stroke G. Ntaios, K. Spengos, A. Vemmou, P. Savari, E. Koroboki, G. Stranjalis, K. Vemmos European Journal of Neurology 2011; 18:1074-80 Introduction: Previous studies on posterior cerebral artery (PCA) strokes focused mainly on topography and underlying pathophysiology. However, there are no data on long-term prognosis and its association with the localization of the infarct. Methods: All consecutive PCA strokes registered in the Athens Stroke Outcome Project between 01/1998 and 12/2009 were included in the analysis. The New England Posterior Circulation Registry criteria were applied to classify them in relation to topography: a) pure PCA infarcts, including pure cortical-only and combined cortical/deep PCA infarcts (groups A and B respectively), and b) PCA-plus strokes, including cortical-only and combined cortical/deep PCA strokes with ≥1 concomitant infarcts outside PCA territory (groups C and D respectively). Patients were prospectively followed up to 10 years after stroke. Results: Among 185 (8.1%) PCA patients that were followed up for 49.6±26.7 months, 98 (53%), 24 (13%), 36 (19.5%) and 27 (14.6%) were classified in group A, B, C and D respectively. Infections and brain oedema with mass effect were more frequently encountered in PCA-plus strokes compared to pure PCA (p<0.05 and <0.01 respectively). 56% of cortical-only PCA patients had no or minor disability at 6 months, compared to 37%, 36% and 26% in the other groups (p=0.015). The 10-years probability of death was 55.1% (95%CI: 42.2-68.0) for pure PCA compared to 72.5% (95%CI: 58.8-86.2) for PCA-plus (log-rank 14.2, p=0.001). Long-term mortality was associated with initial neurologic severity and underlying stroke mechanism. Conclusions: Patients with pure PCA stroke have significantly lower risk of disability and long-term mortality compared to PCA strokes with coincident infarction outside the PCA territory. Response to Letter by Doehner et al. Regarding Article, "The association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox" G. Ntaios, K. Vemmos Stroke 2011, in press In their letter, Doehner et al. comment that we “seem hesitant to rely on our results for clinical application” pointing on a growing body of evidence which is in line with the results of our work. Indeed we tried to be very careful and moderate when discussing the clinical implications of our study. We also agree with their comment that the use of the term paradox to describe our results actually denotes our expectations for the association between obesity and stroke mortality -mainly driven by the positive association in the general population- rather than the available evidence. However, it should be kept in mind that our conclusions were drawn by a retrospective analysis of prospectively collected non-randomized data of a hospital-based registry. As such, our study is subject to limitations such as selection bias and lack of data about potential confounders like body weight changes during the follow-up period, crossover treatment allocations and patient adherence to treatment. Similar limitations are also recognized in the previous studies which, as Doehner et al. mention, yielded similar results. Although we agree with Doehner et al. that there is increasing evidence of a reverse association between obesity and mortality in patients with established cardiovascular disease, we still remain cautious in the translation of our results to clinical implications; clinical recommendations need to be based on prospective randomized data when available. Judging from the concluding phrase of Doehner et al., we feel that despite the existing data, they share our cautious approach to recommendations about weight management in stroke patients until prospective randomized data become available. Response to Letter by Kalita et al. Regarding Article, "The association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox" G. Ntaios, K. Vemmos Stroke 2011, in press


42


Among others, Kalita et al. address the issue of the putative association between nutritional deficiency and stroke outcome, and comment that it is not clear whether biochemical markers of nutrition like hemoglobin, calcium or albumin were evaluated in our analysis. As mentioned in our article, only haematocrit was included in the Cox proportional hazard model which was used to identify predictors of mortality, but there was no association identified -not even in univariate analysis. Unfortunately, we had only limited data about serum calcium and albumin and therefore we did not include them in the model. We would like also to emphasize that among the 1138 patients in our analysis with body mass index (BMI) <25kg/m2, only 28 (2.5%) had a BMI<18.5, which makes it rather improbable that it was nutritional deficiency which underlied the observed association between BMI and stroke mortality. Perhaps the observation in our population that obese and overweight patients had lower rates of brain oedema and mass effect could offer a more plausible explanation for the identified association between BMI and mortality. Also, we disagree with their concluding comment that our work “raises doubts about the conventional notion of obesity as a risk factor of stroke”. Although we had tried hard in the concluding paragraph of our article to make clear that “our results cannot support recommendations to overweight or obese patients not to lose weight after acute ischemic stroke” and that “prevention of weight gain should be strongly promoted”, the last phrase in the letter by Kalita et al. shows that we were not successful. As already discussed in the introduction of our article, there are overwhelming data associating obesity with increased stroke risk and cardiovascular mortality. Moreover, it is clear that our study did not investigate the association between obesity and stroke risk, but rather the association of obesity with short- and long-term mortality in stroke survivors. We would like to seize the opportunity of this response-letter to emphasize once again that our results do not raise doubts about the association of obesity with stroke risk and cardiovascular mortality. Finally, regarding the question by Kalita et al. whether BMI was estimated during the follow-up of our study, we already acknowledged this limitation in our article. The effect of thrombolysis on short-term improvement depends on initial stroke severity Ntaios G, Faouzi M, Michel P. Journal of Neurology 2012;259(3):524-9 Ανακοινώθηκε στο FBM Research Day, 27/01/2011 Ανακοινώθηκε στο International Stroke Congress, Los Angeles, 7-9/02/2011 Introduction: A large number of parameters have been identified as predictors of early outcome in patients with acute ischemic stroke. The present work analyzes a wide range of demographic, metabolic, physiological, clinical, laboratory and neuroimaging parameters in a large population of consecutive patients with acute ischemic stroke and aims to identify independent predictors of early clinical course. Subjects and methods: We used prospectively collected data from the Acute STroke Registry and Analysis of Lausanne (ASTRAL). All consecutive patients with ischemic stroke admitted to our stroke unit and/or intensive care unit between 01/2003 and 12/2008 within 24 hours after last-well time were analyzed. Univariate and multivariate analysis was performed to identify significant associations with NIHSS score at admission and at 24 hours. We also sought for any interactions between identified predictors. Results: Of the 1730 consecutive patients with acute ischemic stroke that were included in the analysis, 260 (15.0%) were thrombolyzed (mostly intravenously) within the recommended time window. In multivariate analysis, NIHSS at 24 hours was associated with NIHSS at admission (β=1, p<0.001), initial glucose (β=0.05, p<0.002) and thrombolytic intervention (β=-2.91, p<0.001). There was a significant interaction between thrombolysis and NIHSS at admission (p<0.001), indicating that the effect of thrombolysis decreases with increasing initial stroke severity. Conclusions: Thrombolytic treatment, lower initial glucose and lower initial stroke severity predict favourable early clinical course. The effect of thrombolysis appears mainly in minor and moderate strokes, and decreases with increasing initial stroke severity. Response to Letter by Fuentes et al Regarding Article, "J-Shaped Association Between Serum Glucose and Functional Outcome in Acute Ischemic Stroke" Ntaios G, Egli M, Michel P. Stroke 2010, in press We thank Fuentes et al. for their interest in our work and their comments. We agree that hypoglycemic values occur only rarely at admission in stroke patients. To further confirm it, we performed an updated evaluation of our registry which showed that between 02-01-2003 and 03-11-2010 there were only 4 (0.18%) and 10 (0.44%) patients with admission glucose levels of <3.7 and <4 mmol/l respectively. However, although the association of hypoglycemic values with unfavorable outcome as described by the J-curve seems to be of little clinical significance due to these small numbers, it provides further pathophysiological insight into the effect of hypoglycemia on outcome. Furthermore, it suggests that physicians treating acute post-stroke hyperglycemia with insulin should be careful to avoid iatrogenic hypoglycemia. Similar to our results, Fuentes et al. recently showed that hyperglycemic values above a threshold value of 155mg/dl at any time during the first 48 hours after admission is associated with unfavorable outcome. Both studies underline the significant effect of post-stroke glycemic on stroke outcome. We agree with Fuentes et al. that not only admission glucose levels but also


43


the overall kinetics of glucose during the acute phase have a significant effect on stroke outcome. However, the association between post-stroke glucose levels with outcome seems to be a multifactorial situation which involves several other parameters aside from the glucose levels per se. The diabetic status of the patient might be of significance since it seems rational that the brain of a patient with previously diagnosed diabetes could be preconditioned to hyperglycemia and hence withstand hyperglycemic values more efficiently. This possibility is exemplified by the recent observation that intravenous thrombolysis was shown to attenuate infarct growth in non-diabetics, but not in diabetics. Also, the underlying pathophysiologic stroke mechanism further modulates the effect of post-stroke glycemia on outcome; moderate hyperglycemia was shown to be detrimental in non-lacunar stroke, but beneficial in lacunar stroke. In conclusion, we believe that further studies are warranted to identify more effectively the patient subgroups that might benefit from aggressive glucose management as well as the appropriate glucose thresholds, the interventions applied and the targets intended, which should then be tested in randomized controlled trials. Evaluation of a fixed enalapril/nitrendipine combination and concomitant atorvastatin treatment in the management of obese hypertensive patients with or without cardiovascular disease and/or diabetes Katsiki N, Baltatzi M, Savopoulos C, Agapakis D, Ntaios G, Karlafti H, Tziomalos K, Hatzitolios AI. Ανακοινώθηκε στο 1st International Diabetes and Obesity Forum, Athens, 21–23/10/2010 Περίληψη δημοσιεύθηκε στο περιοδικό Diabetes, Obesity and Metabolism 2010; 12:69 Introduction: The management of concomitant risk factors, such as hypertension and dyslipidemia, in obese patients is of major importance Purpose: To evaluate the effectiveness of a fixed antihypertensive drug combination and concomitant hypolipidemic treatment in the management of obese hypertensive patients with or without cardiovascular disease (CVD) and/or diabetes (DM2) Patients and methods: Hundred obese hypertensive outpatients (49.4% men; 63.7 ± 11.9 years) were enrolled and divided into two groups: Group A (50 patients with CVD/ DM2) and Group B (50 patients with ‡3 CV-risk factors but without CVD/DM2) All patients had uncontrolled hypertension (>130/80 and >140/90 mmHg respectively) under monotherapy and were put on an antihypertensive fixed dose combination of ACEi enalapril 10 mg and CCB-nitrendipine 20 mg, along with atorvastatin 10–20 mg (when LDL-cholesterol was higher than recommended). Blood pressure (BP) and lipids were measured every 4-weeks for a 24-week-period. Framingham CV-risk score was calculated for patients without CVD/DM2. Results: No adverse effects or drop-outs were observed Conclusions: In obese hypertensive patients with or without CVD/DM2, treatment with a fixed dose combination of enalapril 10 mg/nitrendipine 20 mg was proved both safe and effective achieving BP goals. Concomitant supplementation of atorvastatin, according to guidelines, attributes to further CV-risk reduction. The observed greater reduction in BP and LDL-cholesterol levels in high risk patients without CVD/DM2 underlines the importance of combined primary CV prevention therapeutic strategy in these patients Red cell distribution width does not predict stroke severity or functional outcome

Ntaios G, Gurer O, Faouzi M, Aubert C, Michel P.

International Journal of Stroke, 2010; 7:2-6 Introduction: Red cell distribution width (RDW) was recently identified as a predictor of cardiovascular and all-cause mortality in patients with previous stroke. RDW is also higher in patients with stroke compared to those without. However, there are no data on the association of RDW, assessed during the acute phase of ischemic stroke, with stroke severity and functional outcome. In the present study, we sought to investigate this relation and determine the main determinants of RDW in this population. Methods: We used data from the ASTRAL registry for patients between 01/2003 and 12/2008. RDW was generated at admission by the Sysmex XE-2100 automated cell counter from EDTA blood samples stored at room temperature until measurement. x2 test was performed to compare frequencies of categorical variables between different RDW quartiles, and one way analysis of variance (ANOVA) for continuous variables. The effect of RDW on severity and functional outcome was investigated in univariate and multivariate robust regression analysis. Level of significance was set at 95%. Results: 1504 patients (72±15.76 years, 43.9% females) were included in the analysis. RDW was significantly associated to NIHSS (β value=0.24, p=0.01) and functional outcome (OR=10.73 for poor outcome, p<0.001) at univariate analysis but not multivariate. Pre-hospital Rankin score (β=0.19, p<0.001), serum creatinine (β=0.008, p<0.001), hemoglobin (β=-0.009, p<0.001), MPV (β=0.09, p<0.05), age (β=0.02, p<0.001), low ejection fraction (β=0.66, p<0.001) and antihypertensive treatment (β=0.32, p<0.001) were independent determinants of RDW. Conclusions: RDW, assessed during the early phase of acute ischemic stroke, does not predict severity or functional outcome. Pharmaceutical modulation of the renin angiotensin aldosterone system for stroke prevention: a review of experimental and clinical evidence E. Moutzouri, G. Ntaios, M. Elisaf, H. Milionis CNS spectrums 2010, in press


44


The renin angiotensin aldosterone system (RAAS) has been implicated in the pathogenesis of cerebrovascular diseases. During the past decades RAAS has gained attention as an important therapeutic target in cardiovascular medicine. Modulation of the RAAS for primary and secondary stroke prevention seems an appealing strategy. Several experimental studies have showed that pretreatment with RAAS inhibitors prior to the initiation of ischemia exerts favorable effects on infarct volume, brain edema, and cerebral blood flow in the marginal zone. Furthermore, the activation of angiotensin receptor type 2 has been associated with neuroprotective effects. Accumulating evidence based on recent clinical trials indicate that blockade of RAAS has a potential role in stroke prevention. This review summarizes the pathophysiological aspects of brain RAAS and its constituents, presents experimental data on the neuroprotective actions of RAAS inhibitors and available evidence regarding their effects on stroke risk and discuss future directions for research. Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis G. Ntaios, C. Savopoulos, S. Chatzopoulos, D. Mikhailidis, A. Hatzitolios

Atherosclerosis 2010; 214(1):11-9 Metabolic syndrome (MetS) is associated with increased cardiovascular mortality and its management incorporates hypolipidemic, antidiabetic and antihypertensive drugs. However, several classes of these drugs, such as biguanides, fibrates and hydrochlorothiazide have been reported to raise circulating total homocysteine (tHcy) levels. During the last decades, numerous large-scale epidemiological studies have identified Hcy as a moderate independent cardiovascular risk factor. Therefore, drug-induced hyperhomocysteinemia in MetS patients may add 1 cardiovascular risk factor in these high-risk patients. The present systematic review summarizes data from studies which investigated the effects of the above-mentioned drugs on tHcy, and calculates the treatment effect of each drug class on tHcy levels. We also discuss the underlying pathophysiology and the issues that should be addressed in the future. Two unusual cases of primary hyperaldosteronism C. Savopoulos, P. Kotsaftis, G. Ntaios, N. Katsiki, A. Adamidou, A. Hatzitolios Ανακοινώθηκε στο 20th European Meeting on Hypertension, Oslo, 18-21/06/2010 Primary hyperaldosteronism (PHA) is a main cause of secondary hypertension. We present two rare cases of PHA. Case 1: A 73-year-old hypertensive man(on amlodipine for ten years) was admitted with severe muscle weakness. Examination revealed high BP, severe hypokalemia, sinus rhythm and U wave, rhabdomyolysis and metabolic alkalosis. He was immediately treated with potassium-rich solutions, spironolactone and irbesartan. On day 6, muscle weakness was completely restored with decrease of BP and further improvement of laboratory tests. Combination of hypokalemia with hypertension raised the suspicion of PHA; the abdominal CT revealed a 15 mm nodular mass in the left adrenal gland. Renin activity was low while aldosterone was increased. Total resection of the left adrenal gland was performed and the histopathological examination revealed unilateral hyperplasia. Case 2: A 67-year old man was admitted due to a TIA with motor aphasia and right arm weakness. He was treated for resistant hypertension the last ten years with four different antihypertensive drugs; in that period an abdominal CT revealed a mass in the left adrenal gland, which was considered inactive, but scintigraphy was not performed. Laboratory investigation at admission included hypokalemia and metabolic alkalosis (refractory to withdrawal of diuretics and potassium administration), increased aldosterone and decreased renin activity. CT, MRI and I-131-scintigraphy confirmed the presence of an aldosterone producing left adrenal mass, but the patient refused any operative intervention. Conclusion: We present two rare cases of PHA in which a) unilateral adrenal hyperplasia was the cause of PHA, b) an initially inert incidentalloma progressed into an active adenoma. Αποτελεσματικότητα και ασφάλεια συνδυασμένης αντιυπερτασικής και υπολιπιδαιμικής αγωγής σε ασθενείς με σακχαρώδη διαβήτη ή/και καρδιαγγειακή νόσο Ν. Κατσίκη, Μ. Μπαλτατζή, Χ. Σαββόπουλος, Γ. Ντάιος, Δ. Αγαπάκης, Σ. Φωτιάδης, Χ. Δημητρούλα, Α. Νικοπούλου, Α. Χατζητόλιος Ανακοινώθηκε στο 6ο Ετήσιο Συνέδριο Αθηροσκλήρωσης της Εταιρείας Αθηροσκλήρωσης Βορείου Ελλάδος, Θεσσαλονίκη, 11-13/03/2010 Σκοπός: η αποτελεσματικότητα και ασφάλεια συνδυασμένης αντιυπερτασικής και υπολιπιδαιμικής αγωγής σε ασθενείς πολύ υψηλού ΚΑ κινδύνου. Ασθενείς – Μέθοδος: Εντάχθηκαν 50 παχύσαρκοι υπερτασικοί ασθενείς με ΣΔ ή/και ΚΑ νόσο (43,3% άντρες, 70,8±10,9 χρονών) των εξωτερικών ιατρείων μας. Οι ασθενείς ελάμβαναν μονοθεραπεία, χωρίς ικανοποιητική ρύθμιση της αρτηριακής πίεσης (ΑΠ>130/80mmHg) και τέθηκαν σε αντιυπερτασική αγωγή με σταθερό συνδυασμό α-ΜΕΑ(εναλαπρίλη 10mg) και ανταγωνιστή ασβεστίου(νιτρενδιπίνη 20mg) και σύγχρονη χορήγηση ατορβαστατίνης 10-20mg (όταν LDL-χοληστερόλη>70mg/dl). Για κάθε ασθενή καταγράφηκε η ΑΠ και προσδιορίστηκαν τα λιπίδια τόσο αρχικά, όσο και 6 μήνες μετά.


45


Αποτελέσματα: 33,3% των ασθενών είχαν στεφανιαία νόσο-46,7% ΑΕΕ-53,3% τύπου 2 διαβήτη-16,7% υπερλιπιδαιμία και 3,3% ήταν καπνιστές. Τόσο το ποσοστό των ασθενών με αρρύθμιστη ΑΠ, όσο και εκείνων με LDL-χοληστερόλης>70mg/dl, μειώθηκαν σημαντικά (100%vs.34,3% για την ΑΠ και 70%vs.43% για την LDL-χοληστερόλη), αν και χωρίς να επιτευχθούν στο μ.όρο τιμές LDL<70mg/dl, πιθανόν λόγω των χαμηλών δόσεων ατορβαστατίνης. Δεν παρατηρήθηκαν ανεπιθύμητες ενέργειες (υποτασικά επεισόδια, αύξηση ηπατικών/μυικών ενζύμων). Συμπεράσματα: Ο σταθερός συνδυασμός εναλαπρίλης-νιτρενδιπίνης αποτελεί αποτελεσματική και ασφαλή επιλογή στην αντιμετώπιση της υπέρτασης ασθενών πολύ υψηλού ΚΑ κινδύνου. Η προσθήκη ατορβαστατίνης συμβάλλει περαιτέρω στην ολοκληρωμένη αντιμετώπιση των ασθενών αυτών. Prevalence of atrial fibrillation in Greece: the Arcadia Rural Study in Atrial Fibrillation G. Ntaios, E. Manios, M. Synetou, P. Savvari, A. Vemmou, E. Koromboki, M. Saliaris, K. Blanas, K. Vemmos Acta Cardiologica 2012; 67:65-9 Ανακοινώθηκε στο 19ο European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Introduction: Atrial fibrillation (AF) is a major factor for stroke and stroke-associated mortality, and its incidence is increasing during the last decades. There are only scarce data about its prevalence in Greece. We designed an epidemiologic cross-sectional study to estimate the prevalence of AF in Greece and evaluate the adequacy of anticoagulant treatment in AF patients. Subjects and Methods: The Arcadia Rural Study of Atrial Fibrillation (ARSAF) was conducted between 2002-2003 in five rural villages of the Arcadia province (Greece) with a permanent population of 1312 individuals. Patients had a thorough medical examination and electrocardiogram, and information was collected about their medical history and comorbidities. CHADS2 score was used to determine stroke risk for participants with AF. Results: 1155 subjects (88% of the entire population) participated in the study. The overall prevalence of AF was 3.9% showing an increasing trend with increasing age ranging from 0.4% in patients <55 years to 10.7% in patients >84 years. Among patients with AF, 14 (32%) had paroxysmal AF. The presence of AF was associated with increasing age (OR:1.67 for every 10 years increase, 95%CI:1.26-2.15), hypertension (OR:2.12, 95%CI:1.02-4.14), heart failure (OR:11.85, 95%CI:4.92-28.56) and prior cerebrovascular disease (OR:4.17, 95%CI:1.44-12.06). Among patients with AF, 12 (26.6%) were considered as low-risk (CHADS2=0), 18 (40.0%) as intermediate-risk (CHADS2=1), and 15 (33.3%) as high-risk (CHADS2>1) for stroke. 25 (55.5%) patients with AF did not receive appropriate antithrombotic treatment. Conclusion: The prevalence of AF in Greece is similar with other countries and increases with increasing age. Predictors of severity and early course in acute ischemic stroke G. Ntaios, M. Faouzi, C. Aubert, P. Maeder, P. Michel Ανακοινώθηκε στο 19ο European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Introduction: Previous studies identified more than 50 parameters to be associated with stroke severity. However, many were limited by methodological issues and small sample size. The present work analyzes a wide range of demographic, metabolic, physiological, clinical, radiological and laboratory parameters to identify independent predictors of severity and early progression in a large population of patients with acute ischemic stroke. Subjects and methods: We prospectively studied all consecutive patients between 01/2003 and 12/2008 admitted to our stroke unit within 24 hours after onset of symptoms. A wide range of were recorded in our registry. Univariate and multivariate analysis was performed to identify significant association with admission- and 24hour-NIHSS. Results: 1446 patients were included in our analysis. Stroke severity (NIHSS at admission) was significantly correlated with heart rate (β=1.44), white blood cell count (β=0.19), early ischemic changes in CT scan (β=4.74), significant arterial stenosis/occlusion in the ischemic territory (β=6.33), prehospital Rankin score (β=0.68) and stroke subtype. NIHSS at 24 hours was correlated with admission NIHSS (β=1), serum glucose (β=0.05) and thrombolytic intervention (β=-2.91). Admission blood pressure was not correlated with NIHSS at admission or at 24 hours (p>0.05). The interaction between admission NIHSS and intervention was statistically significant (p<0.001). Conclusions: Among others, heart rate, white blood cell count and arterial pathology in the ischemic territory, but not blood pressure and serum glucose, are independently associated with stroke severity. Stroke severity, acute recanalisation treatment, and serum glucose are independent predictors of course in the first 24 hours. The predictive effect of stroke severity on early progression is different between patients receiving rTPA and those that do not. J-shaped association between serum glucose and functional outcome in patients with acute ischemic stroke G. Ntaios, M. Egli, M. Faouzi, P. Michel Stroke 2010; 41:2366-70 Ανακοινώθηκε στο 19ο European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Background and purpose: Post-stroke hyperglycemia is associated with larger infarct volume and poor functional outcome. In


46


an animal stroke model, the association between serum glucose and infarct volume is described by a U-shaped curve with a nadir of approximately 7mmol/L. However, a similar curve in human studies was never reported. The objective of the present study is to investigate the association between serum glucose levels and functional outcome in patients with acute ischemic stroke. Methods: We analyzed 1446 consecutive patients with acute ischemic stroke. Serum glucose was measured on admission to the emergency department together with multiple other metabolic, clinical and radiological factors. NIHSS was recorded at 24 hours, and Rankin score at 3 and 12 months. The association between serum glucose and favorable outcome (Rankin ≤2) was explored in univariate and multivariate analysis. The model was further analyzed in a robust regression model based on Fractional Polynomial (FP(-2 -2)) functions. Results: Serum glucose is independently correlated with functional outcome at 12 months (OR: 1.15, p=0.01). Other predictors of outcome include age (OR: 1.06, p<0.001), pre-stroke Rankin score (OR: 20.8, p=0.004), admission NIHSS (OR: 1.18, p<0001) and leukoaraiosis (OR: 2.21, p=0.016). Using these factors in multiple logistic regression analysis, the area under ROC curve is 0.869. The association between serum glucose and 3 and 12-months Rankin score is described by a J-shaped curve with a nadir of 5mmol/L. Glucose values between 3.7 - 7.3mmol/lt are associated with favourable outcome. A similar curve was generated for the association of glucose and 24-hours NIHSS, where glucose values between 4.0 - 7.2mmol/lt are associated with a NIHSS<7. Discussion: Both hypoglycemia and hyperglycemia are dangerous in acute ischemic stroke as shown by a J-shaped association between serum glucose and 12 months outcome. Initial serum glucose values between 3.7 and 7.3mmol/lt are associated with favourable outcome. Association between obesity on long-term mortality after acute first-ever stroke: the obesity stroke paradox G. Ntaios, P. Savvari, S. Skalidi, A. Vemmou, A. Skafida, K. Spengos, K. Vemmos Stroke 2010; 42:30-6 Προφορική ανακοίνωση στο 19ο European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Ανακοινώθηκε στο 2ο Συνέδριο Παθολογίας Κεντρικής Ελλάδος, Λάρισα, 18-20/03/2010 Background: Limited data exist concerning obesity and survival in patients after an acute stroke. The objective of this study was to investigate the impact of obesity on early and long-term survival in patients after an acute first-ever stroke. Methods: Patients were prospectively investigated based on a standard diagnostic protocol over a period of 16 years (Athens Stroke Outcome Project). Evaluation was performed on admission and at 7 days, 1, 3, 6 months after discharge and yearly thereafter, up to 10 years after stroke. The study patients were divided in 3 groups according to Body Mass Index values (BMI): normal-weight (<25kg/m2), overweight (25-29.9kg/m2) and obese (≥30kg/m2). Overall survival during follow-up was the primary end-point. Results: Based on our inclusion criteria 2785 patients were recruited. According to BMI 40.9% patients were normal-weight, 41.0% overweight and 18.1% obese. NIHSS score on admission (mean 11.28+/-8.65) was not different among the study groups. Early survival (first week) in obese 96.4% (95%CI 94.8-97.9) and overweight 92.8% (95%CI 91.2-94.4) patients was significantly higher compared to normal-weight 90.2% (95%CI 88.4-92.0). Similarly, 10-year survival was 52.5% (95%CI 46.4-58.6) in obese, 47.4% (95%CI 43.5-51.3) in overweight and 41.5% (95%CI 39.7-45.0) in normal-weight patients (log-rank test=17.7, p<0.0001). Overweight (HR 0.82, 95%CI 0.74-0.96) and obese patients (HR 0.72, 95%CI 0.61-0.86) had significantly lower risk of 10-year mortality compared to normal-weight after adjusting for all confounding variables. Conclusion: Based on BMI estimation, obese and overweight stroke patients have significantly better short and long-term survival compared to those with normal BMI. The Acute STroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging P. Michel, C. Odier, M. Rutgers, M. Reichhart, P. Maeder, Re. Meuli, M. Wintemark, A. Maghraoui, M. Faouzi, A. Croquelois, G. Ntaios Stroke 2010; 41:2491-8 Ανακοινώθηκε στο ZAS meeting, Lausanne, Switzerland, 4/02/2010 Προφορική ανακοίνωση στο 19ο European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Προφορική ανακοίνωση στο International Stroke Conference, San Antonio, USA, 23-26/02/2010 Introduction: Stroke registries are valuable tools to obtain information about stroke epidemiology and management. The Acute STroke Registry and Analysis of Lausanne (ASTRAL) prospectively collects epidemiological, clinical, laboratory and multimodal brain imaging data of acute ischemic stroke patients in the Centre Hospitalier Universitaire Vaudois (CHUV). Here, we provide design and methods used to create ASTRAL and present baseline data (2003–2008) of our patients. Methods : All consecutive patients admitted in CHUV from 01/01/2003 until 31/12/2008 with acute ischemic stroke arriving within 24 hours were included in ASTRAL. Patients arriving beyond 24 hours, with transient ischemic attack, intracerebral hemorrhage, subarachnoidal hemorrhage or cerebral sinus venous thrombosis were excluded. Recurrent ischemic strokes were registered as new events. Results : Between 2003-2008, 1742 events of 1633 patients were registered in ASTRAL. There was a preponderance of males,


47


even in the elderly. Cardioembolic stroke was the most frequent type of stroke. Most strokes were of minor severity (NIHSS 4 in 40.8% of patients). Cardioembolic stroke and dissections presented with the most severe clinical picture. There was a significant number of patients with unknown onset stroke, including wake-up stroke (n=568, 33.1%). Median time from last-well time to hospital arrival was 142 minutes for known onset and 759 minutes for unknown onset stroke. The rate of intravenous or intraarterial thrombolysis increased between 2003-2008 from 10.8% to 20.8% in these patients admitted withing 24 hours of last well time. Acute brain imaging was performed in 1695 patients (97.3%) within 24 hours. In 1358 (78%) patients who underwent acute CT-angiography, 717 (52.8%) had significant abnormalities. Of the 1068 supratentorial strokes who underwent acute perfusion CT (61.3%), focal hypoperfusion was demonstrated in 786 (73.6%). Conclusions : This hospital-based prospective registry of consecutive acute ischemic strokes incorporates demographic, clinical, metabolic and acute perfusion and arterial imaging. It is characterized by a high proportion of minor and unknown-onset strokes, short onset-to-admission time for known-onset patients, rapidly increasing thrombolysis rates and significant vascular and perfusion imaging abnormalities in the majority of patients. Anticoagulation management in patients with atrial fibrillation K. Tziomalos, K. Psianou, A. Konstantakou, I. Raptis, A. Hatzopoulos, I. Iordanidou, M. Apostolopoulou, A. Nikopoulou, G.

Ntaios, A. Adamidou, C. Savopoulos, A.Hatzitolios Ανακοινώθηκε στο 19ο European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Ανακοινώθηκε στο 2ο Συνέδριο Παθολογίας Κεντρικής Ελλάδος, Λάρισα, 18-20/03/2009 Background: Anticoagulation management of patients with non-valvular atrial fibrillation (AF) depends on the patients’ additional risk factors for stroke. Current guidelines recommend the use of the CHADS2 score, which assigns 1 point for the

presence of heart failure, hypertension, type 2 diabetes mellitus and age 75 years and 2 points when there is a history of stroke. Patients with CHADS2 score 0 should receive aspirin, those with score 1 should be given aspirin or warfarin and those

with score 2 should receive warfarin. However, a considerable proportion of patients with AF are not given the appropriate anticoagulation management. The aim of the present study was to assess the proportion of patients with AF who are given the recommended anticoagulation management. Methods: The study included 191 consecutive patients with AF (48.7% males, age 76.7±8.1 years) who were hospitalized in our Department. Results: The proportion of patients who had CHADS2 score 0, 1 and

2 was 11.5, 22.0 and 66.5%, respectively. The proportion of patients with CHADS2 score 0, 1 and 2 who was being given the appropriate anticoagulation management on admission was 13.6, 61.9 and 35.4%, respectively (p = 0.002). Patients who were receiving the recommended anticoagulation management did not differ from patients who were inappropriately managed in

gender, age or coexisting cardiovascular diseases. Among patients with CHADS score 0, 1 and 2, 59.1, 38.1 and 26.8%, respectively, was not receiving any anticoagulation. Conclusion: Only a small proportion of patients with AF are given the appropriate anticoagulation management and this proportion is even lower in patients at the greatest risk for stroke (i.e. with

CHADS2 score 2). Πριν την εκλογή στη θέση Λέκτορα Mean platelet volume in the early phase of acute ischemic stroke is not associated with severity or functional outcome G. Ntaios, O. Gurer, M. Faouzi, C. Aubert, P. Michel Cerebrovascular Diseases 2010; 29:484-9 Ανακοινώθηκε στο 2ο Συνέδριο Παθολογίας Κεντρικής Ελλάδος, Λάρισα, 18-20 Μαρτίου Background: Previous studies reported an increase of mean platelet volume (MPV) in patients with acute ischemic stroke. However, its correlation with stroke severity has not been investigated. Moreover, studies on the association of MPV with functional outcome yielded inconsistent results. Methods: We included all consecutive ischemic stroke patients admitted to CHUV Neurology Service within 24 hours after stroke onset. The association of MPV with stroke severity (NIHSS at admission and at 24 hours) and outcome (Rankin at 3 and 12 months) was analyzed in univariate analysis. x2 test was performed to compare the frequency of minor strokes (NIHSS≤4) and good functional outcome (Rankin ≤2) across MPV quartiles. ANOVA test was used to compare MPV between stroke subtypes according to TOAST classification. Student`s two-tailed unpaired t-test was performed to compare MPV between lacunar and non-lacunar strokes. MPV was generated at admission by the Sysmex XE-2100 automated cell counter (Sysmex Corporation, Kobe, Japan) from EDTA blood samples. Results: There was no significant difference in the frequency of minor strokes (p=0.46) and good functional outcome (p=0.06) across MPV quartiles. MPV was not associated with stroke severity or outcome in univariate analysis. There was no significant difference in MPV between stroke subtypes according to TOAST classification (p=0.173) or between lacunar and non-lacunar strokes (10.50±0.91 vs. 10.40±0.81fl, p=0.322). Conclusions: MPV, assessed within 24 hours after ischemic stroke onset, is not associated with stroke severity or functional outcome.


48


To όφελος της αυξημένης πρόσληψης φυτικών ινών στη Χρόνια Δυσκοιλιότητα, στο Σύνδρομο Ευερέθιστου Εντέρου και στην εμφάνιση Ορθοκολικών πολυπόδων και Καρκίνου: Πραγματικότητα ή Μύθος; Κ. Αργυρίου, Γ. Ντάιος, Α. Χατζητόλιος Αρχεία Ελληνικής Ιατρικής 2010; 27:907-917 Οι φυτικές ίνες είναι γνωστές από παλιά, αλλά μόλις τα τελευταία χρόνια η αξία τους στη διατροφή έχει αναγνωριστεί σε σημείο ώστε σήμερα να θεωρούνται βασικές για τη θεμελίωση της υγείας και την προφύλαξη από πολλές ασθένειες. Μια δίαιτα πλούσια σε φυτικές ίνες και φτωχή σε λίπη, μπορεί να μειώσει τον κίνδυνο για καρκίνο του παχέος εντέρου. Επίσης, εκτεταμένες μελέτες που έχουν γίνει με αντικείμενο τη διατροφή που είναι πλούσια σε φυτικές ίνες επιβεβαιώνουν τη χρησιμότητα τους σε περιπτώσεις δυσκοιλιότητας, καρδιαγγειακών παθήσεων, σακχαρώδη διαβήτη, αλλά και παχυσαρκίας. Ωστόσο, νεότερα δεδομένα από τη διεθνή βιβλιογραφία, θέτουν υπό αμφισβήτηση αυτή τους τη χρησιμότητα. Κύριο χαρακτηριστικό μιας δίαιτας που είναι πλούσια σε φυτικές ίνες είναι η περιορισμένου βαθμού πέψη που υφίστανται στο έντερο. Η πλημμελής αυτή πέψη και απορρόφηση των φυτικών ινών οδηγεί, τόσο στο σχηματισμό διαλυμάτων με μεγάλο ιξώδες που καθυστερούν να μεταβούν από το ένα τμήμα του γαστρεντερικού σωλήνα στο άλλο, όσο και στην αυξημένη παραγωγή αερίων στο έντερο που συνδέονται με την εμφάνιση δυσπεπτικών ενοχλημάτων. Στο άρθρο μας ανασκοπείται η φυσιολογία της πέψης των φυτικών ινών και συζητείται η επίδραση της αυξημένης πρόσληψής τους στη χρόνια δυσκοιλιότητα, στο σύνδρομο ευερέθιστου εντέρου και στην εμφάνιση ορθοκολικής νεοπλασίας. Is COPD a risk factor for sepsis? D. Agapakis, E. Massa, G. Ntaios, M. Papagianni, A. Zantidis, C. Savopoulos, A. Satsoglou, A. Hatzitolios Sepsis 2009, International Symposium, Amsterdam, 11-14/11/ 2009 Introduction: Previous studies have been shown that pneumonia is a very strong predictor of sepsis. The goal of our study was to examine chronic obstructive pulmonary disease (COPD) as a risk factor for sepsis. Materials and methods: Our study included 57 patients with COPD (46 males, 11 females) of mean age 73 years (53-84) who were hospitalized because of pneumonia. A diagnosis of COPD was made using modified GOLD criteria. Sepsis was defined according to ACCP/SCCM criteria. They were compared with 64 patients (42 males, 22 females) of mean age 67 years (59-74) with pneumonia and other underlying disease without COPD. Results: The patients of first group had higher score of CURB- 65 and 8.7% of them developed sepsis versus 3.5% of the patients of second group (P<0.05). No patients died. Conclusions: Our study shows that patients with COPD are more likely to get sepsis. That was happened probably due to more severe pneumonia among these. Correlation of the QT dispersion and sepsis D. Agapakis, E. Massa, G. Ntaios, M. Papagianni, P. Kotsaftis, C. Savopoulos, A. Satsoglou, A. Hatzitolios Sepsis 2009, International Symposium, Amsterdam, 11-14/11/ 2009. Sepsis as an uncontrolled generalized inflammatory response is associated also with disturbance of function of autonomic nervous system that contributes to cardiac depression. In addition, the above disturbance is correlated with an increase of QT dispersion. The aim of our study was to evaluate the incidence of QT dispersion in septic patients. Materials and methods This study included 73 patients (49 females, 24 males) of mean age 71 years (63-78) who were hospitalized because of febrile infection. Sepsis was defined according to ACCP/SCCM criteria. The QT dispersion was defined as the difference between the maximum and the minimum value of the QT in different leads of electrocardiogram. It was measured in all patients on the first day of their hospitalization and whenever their clinical features changed. Results Nine of the patients (12.3%) developed sepsis and 2 of them had septic shock (2.7%). None died. The QT was significant increased in septic individuals (35±9 ms versus 29±7 ms, P<0.05). Especially, the patients with septic shock had even more QT increase (41ms). When the patients were recovered, the QT decreased too. Conclusions: The result of our study indicates a positive relationship between increase of QT dispersion and sepsis evolution in patients with febrile infection. So we could suggest that measurement of QT dispersion may be a concomitant marker of sepsis development. Low frequency of aprataxin gene mutations in a Greek cohort with Friedreich ataxia phenotype Daiou C, Christodoulou K, Xiromerisiou G, Panas M, Dardiotis E, Kladi A, Speletas M, Ntaios G, Papadimitriou A, Germenis A, Hadjigeorgiou GM Neurological Sciences 2010; 31:393-7 Phenotype of patients with the aprataxin gene mutation varies and according to previous studies, screening of aprataxin gene could be useful once frataxin gene mutation is excluded in patients with normal GAA expansion in frataxin gene. In present


49


study, we sought to determine possible causative mutations in aprataxin gene (all exons and flanking intronic sequences) in fourteen Greek patients with sporadic cerebellar ataxia all but one without GAA expansion in frataxin gene (one patient was heterozygous). No detectable point mutation or deletion was found in the aprataxin gene of all the patients. Our results do not confirm previous studies. This difference may be attributed to the different populations studied and possible different genetic background. It is still questionable whether the screening for aprataxin mutation in Greek patients Friedreich ataxia phenotype is of clinical importance. Larger, multicenter studies are necessary to clarify this issue. Hypertension is an indepedent predictor of mean platelet volume in patients with acute ischemic stroke G. Ntaios, O. Gurer, M. Faouzi, C. Aubert, P. Michel Internal Medicine Journal 2011; 41:691-5 Ανακοινώθηκε στο 2ο Συνέδριο Παθολογίας Κεντρικής Ελλάδος, Λάρισα, 18-20 Μαρτίου Introduction: Mean platelet volume (MPV) was shown to be significantly increased in patients with acute ischemic stroke, especially in non-lacunar strokes. Moreover, some studies concluded that increased MPV is related to poor functional outcome after ischemic stroke, although this association is still controversial. However, the determinants of MPV in patients with acute ischemic stroke have never been investigated. Subjects and methods: We recorded the main demographic, clinical and laboratory data of consecutive patients with acute (admitted within 24 hours after stroke onset) ischemic stroke admitted in our Neurology Service between 01/2003 and 12/2008. MPV was generated at admission by the Sysmex XE-2100 automated cell counter (Sysmex Corporation, Kobe, Japan) from EDTA blood samples stored at room temperature until measurement. The association of these parameters with MPV was investigated in univariate and multivariate analysis. Results: 636 patients were included in our study. The median MPV was 10.4 ± 0.82fl. In univariate analysis, glucose (β=0.03, p=0.05), serum creatinine (β=0.002, p=0.02), hemoglobin (β=0.009, p<0.001), platelet count (β=-0.002, p<0.001) and history of arterial hypertension (β=0.21, p=0.005) were found to be significantly associated with MPV. In multivariate robust regression analysis, only hypertension and platelet count remained as indepedent determinants of MPV. Conclusions: In patients with acute ischemic stroke, platelet count and history of hypertension are the only determinants of MPV. Arterial Hypertension in diabetic mellitus and diabetic nephropathy C. Savopoulos, G. Ntaios, A. Hatzitolios Ελληνικά Διαβητολογικά Χρονικά 2009; 22 (3): 218-219 The incidence of arterial hypertension is 1.5-3 times higher in diabetics compared to non-diabetics. Moreover, the co-existence of hypertension and diabetes mellitus (DM) increases cardiovascular risk and mortality (up to 86%) in diabetics. The manifestation and pathophysiology of hypertension are different between DM-I and DM-II patients. In particular, hypertension complicates approximately 30% of DM-I patients usually many years after the diagnosis of DM and it signifies the presence of diabetic nephropathy (DN). On the contrary, 20-60% of DM-II patients already suffer from hypertension at the time of diagnosis. Hypertension occurs in 71% of non-albuminuric patients, in 90% of patients with microalbuminuria and in 93% in macroalbuminuria. The prevalence of hypertension in DM-II is 1.5 times higher compared to non diabetics of similar age and body mass index (BMI). Insulin resistance is the main pathophysiologic mechanism of hypertension in diabetics via several pathways like hyperglycemia, endothelial dysfunction, dyslipidemia, visceral obesity, microalbuminuria, inflammation and hyperplasia of smooth muscle and mesangial cells. Several studies in diabetic patients, like UKPDS, Π√Δ, Steno-2, PROCAM, ALLHAT, Syst-Eur and SHEP showed that hypertension is a major cardiovascular risk factor and that its optimal management results in significant reduction of cardiovascular mortality. The first step in the management of hypertension is to exclude rare causes of secondary hypertension, to recognize the degree of involvement of target organ damage, and identify other modifiable risk factors like dyslipidemia and obesity. Statin treatment and reaching low density lipoprotein cholesterol targets in elderly patients with ischemic stroke K. Tziomalos, N. Papastergiou, K. Psianou, I. Raptis, E. Siehou, I. Merakis, A. Pavlidis, S. Fotiadis, G. Ntaios, A. Adamidou, C. Savopoulos, A. Hatzitolios Ανακοινώθηκε στο 19ο European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Ανακοινώθηκε στο 4ο Πανελλήνιο Συνέδριο Αγγειακών Εγκεφαλικών Νόσων Background: Treatment goals for low density lipoprotein cholesterol (LDL-C) are similar (i.e. < 100 mg/dl) in patients with either ischemic stroke (IS) or coronary heart disease (CHD). However, many patients with IS are not receiving statins. The aim of the present study was to determine the proportion of patients with IS who are being treated with statins and to assess the factors that determine the prescription of statins in this population. Methods: The study included 89 consecutive patients (age 73.8±9.7 years) who were hospitalized in our Department and had a history of IS. Thirty-seven patients had only IS, 19 had


50


both IS and CHD, 19 had both IS and type 2 diabetes mellitus (T2DM) and 14 patients had IS, CHD and T2DM. Results: Among patients with LDL-C levels > 100 mg/dl who had IS, IS+CHD, IS+T2DM and IS+CHD+T2DM the rates of statin treatment were 37.8, 52.6, 31.6 and 57.1%, respectively (p=0.351). Patients who were receiving statins did not differ from patients who were not on statins in other cardiovascular risk factors (i.e. age, gender, history of hypertension or high density lipoprotein cholesterol levels). Among patients who were on statins, no patient with IS or with IS+T2DM were on LDL-C goals (i.e. < 100 mg/dl); in contrast, all patients with IS+CHD or with IS+CHD+T2DM had LDL-C < 100 mg/dl (p=0.029). Conclusion: Very few patients who have only IS are given statins and among those who receive statins, LDL-C goals are not achieved. In contrast, the presence of CHD in patients with IS is associated with higher statin prescription rates and more frequent achievement of LDL-C targets. The concept of ischemic stroke as a CHD-risk equivalent is not widely adopted and this places patients with IS at high risk for recurrent cardiovascular events. Αγωγή με στατίνες και επίτευξη στόχων LDL χοληστερόλης σε ηλικιωμένους ασθενείς με στεφανιαία νόσο, ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο και/ή σακχαρώδη διαβήτη ΙΙ. Κ. Τζιόμαλος, Κ. Ψιάνου, Ν. Παπαστεργίου, Ι. Ράπτης, Η. Μεράκης, Ε. Σιέχου, Α. Παυλίδης, Γ. Ντάιος, Α. Αδαμίδου, Χ. Σαββόπουλος, Α. Χατζητόλιος Ανακοινώθηκε στο 15ο Επετειακό Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας Εισαγωγή: Πολλοί ασθενείς με στεφανιαία νόσο (ΣΝ), ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο (ΑΕΕ) ή σακχαρώδη διαβήτη τύπου 2 (ΣΔ) δεν λαμβάνουν στατίνες ή δεν επιτυγχάνουν τους στόχους της LDL. Σκοπός: Ο προσδιορισμός του ποσοστού χορήγησης στατίνης σε ασθενείς με ΣΝ, ΑΕΕ ή ΣΔ και παραγόντων που σχετίζονται με την χορήγηση στατινών. Υλικό: Μελετήθηκαν 188 ασθενείς (ηλικίας 72,8±9,7 ετών, 42 με ΣΝ, 37 με ΑΕΕ, 31 με ΣΔ και 78 με συνδυασμό ΣΝ και/ή ΑΕΕ και/ή ΣΔ) που νοσηλεύτηκαν στην κλινική μας μεταξύ Ιουλίου 2005 και Δεκεμβρίου 2006. Μέθοδος: Ανασκόπηση φακέλων νοσηλείας. Αποτελέσματα: Το ποσοστό χορήγησης στατινών στους ασθενείς με LDL > 100 mg/dl και με ΣΝ, ΑΕΕ, ΣΔ ή συνδυασμό ήταν 35,7%, 37,8%, 22,6% και 50% αντίστοιχα (p=0,056). Οι ασθενείς που λάμβαναν στατίνες ήταν νεότεροι από αυτούς που δεν λάμβαναν (70,8±9,6 και 74,4±9,6 ετών αντίστοιχα, p=0,043). Ασθενείς με ΣΝ (και/ή ΑΕΕ και/ή ΣΔ) λάμβαναν πιο συχνά στατίνες σε σχέση με ασθενείς που είχαν μόνο ΑΕΕ και/ή ΣΔ (48,0% και 30,7% αντίστοιχα, p=0,023). Ασθενείς που είχαν μόνο ΣΔ λάμβαναν στατίνη λιγότερο συχνά σε σχέση με διαβητικούς ασθενείς που είχαν και ΣΝ ή ΑΕΕ (22,6% και 49,2% αντίστοιχα, p=0,023). Το ποσοστό επίτευξης των στόχων LDL (< 100 mg/dl) στους ασθενείς με ΣΝ, ΑΕΕ, ΣΔ, ή συνδυασμό ήταν 50,0%, 0%, 66,7% και 69,2% αντίστοιχα (p=0,105). Μόνο το 7,8% των ασθενών λάμβαναν την μέγιστη εγκεκριμένη δόση στατίνης. Συμπεράσματα: Στατίνες χορηγούνται σε μικρό μόνο ποσοστό ηλικιωμένων ασθενών με ΣΝ, ΑΕΕ και/ή ΣΔ και σε χαμηλές δόσεις με αποτέλεσμα πολλοί να μην επιτυγχάνουν τους συνιστώμενους στόχους. The controversial role of B vitamins on cardiovascular risk: an update G. Ntaios, C.Savopoulos, D. Grekas, A. Hatzitolios Archives of Cardiovascular diseases, 2009; 102:847-54 Cardiovascular disease is the leading cause of death in Western countries. Since 1969, homocysteine has been implicated in the atherosclerotic process and numerous observational studies suggested that hyperhomocysteinemia should be considered as an independent cardiovascular risk factor. B-vitamins and in particular, folic acid effectively reduce homocysteine levels and therefore, it was suggested that supplementation with these vitamins could decrease the cardiovascular risk and reduce morbidity and mortality of stroke, coronary heart disease and peripheral artery disease. However, the results of clinical trials conducted to investigate this issue have been inconsistent. This review discusses the findings of these trials and attempts to provide an updated overview on the ‘homocysteine hypothesis’. Blood pressure in acute ischemic stroke: a review of studies and recommendations G. Ntaios, P. Bath, P. Michel Current Opinion in Neurology 2009; 23:46-52 Elevated blood pressure (BP) is frequent in patients with acute ischemic stroke. Although pathophysiological data support its usefulness to maintain adequate perfusion of the ischemic penumba, emerging clinical data suggest a possible beneficial effect of its treatment on late clinical outcome. This review article aims to summarize the avalaible evidence from clinical studies that examined the prognostic role of blood pressure during the acute phase of ischemic stroke and intervention trials that assessed the efficacy of active blood pressure alteration. We found 34 observational studies (33,470 patients), with results being inconsistent among the studies; most studies reported a negative association between increased levels of BP and clinical outcome, whereas a few studies showed clinical improvement with higher BP levels, clinical deterioration with decreased BP or no association at all. Similarly, the conclusions drawn by the 18 intervention trials included in this review (1,637 patients) were also heterogeneous. We discuss different explanations that may account for the conflicting results and present the current guidelines for the management of acute post-stroke hypertension.


51


Hypokalemia induced myopathy as first manifestation of primary hyperaldosteronism - an elderly patient with unilateral adrenal hyperplasia: a case report P. Kotsaftis, C. Savopoulos, D. Agapakis, G. Ntaios, V. Tzioufa, V. Papadopoulos, E. Fahantidis, A. Hatzitolios Cases Journal 2009; 2:6813 Case report: A 73-year-old hypertensive man (treated with 10mgs amlodipinefor the last ten years) presented in the emergency department with severe muscle weakness of all limbs. The initial physical and laboratory examination revealed normal blood pressure, muscle weakness, severe hypokalemia, sinus rhythm and U wave, rhabdomyolysis and metabolic alkalosis. The patient was immediately treated with intravenous administration of potassium-rich solutions, 25mgs spironolactone with progressive dose titration up to 100mgs. Because of high arterial blood pressure, irbesartan was added. On day 6, muscle weakness was completely restored with decrease of arterial blood pressure and further improvement of laboratory tests. The combination of hypokalemia with arterial hypertension raised the suspicion of primary hyperaldosteronism; therefore, we performed abdomen computed tomography scan, which revealed a nodular mass (15mm in diameter) in the left adrenal gland. Plasma renin activity was in the lower normal range with a three-fold increase of plasma aldosterone concentration. We performed total resection of the left adrenal gland and the histopathological examination revealed hyperplasia of the left adrenal gland. Conclusions: Our case – added to the 32nd published cases – is the 33rd which presents primary hyperaldosteronism due to unilateral adrenal hyperplasia, although the initial findings from the imaging techniques pointed towards the diagnosis of adrenal adenoma. Amiodarone: pharmacological profile and animal-model experimental data on its vasodilating effect A. Hatzitolios, G. Ntaios, C. Savopoulos International angiology, 2009; 28:353-62 Ανακοινώθηκε στο 16th World Congress on Basic and Clinical Pharmacology, 17-23/07/2010, Copenhagen, Denmark Amiodarone, the major representative of class III antiarrhythmic agents, is widely used in the treatment of ventricular and hyperventricular arrhythmias, being specifically useful in the therapy of patients suffering from life threatening ventricular arrhythmias. The combination of antianginal and antiarrthythmic actions of amiodarone is an extremely significant advantage regarding the treatment of patients with chronic atherosclerotic cardiopathy, as heart rate disorders are frequently fatal in coronary heart disease and, reversely, a high percentage of cardiac arrhythmias are caused by coronary heart disease. Since 1980s, several experimental in vitro and in vivo data as well as clinical studies, regarding both systematic and coronary circulation, support the vasodilative effects of amiodarone. We have previously showed that amiodarone in vitro exerts a vasodilator effect in isolated vessel tissue, mainly via the activation of intracellular calcium binding mechanisms, a fact that differentiates this agent from other coronary vasodilative drugs, such as calcium receptors antagonists, that affect calcium extracellular levels. Thus, the vasodilative, antianginal and antiarrhythmic actions of amiodarone may be further enhanced by the simultaneous supplementation of calcium receptors antagonists via synergistic mechanisms, supporting the clinical use of such drug combinations. Finally, as amiodarone and noradrenaline have been reported to exert antagonistic actions, the application of amiodarone is particularly indicated in pathologic conditions characterized by the stimulation of sympathetic nervous system (sympathicotonia). The differential diagnosis and treatment of a primary cutaneous anaplastic large cell lymphoma: Not always an easy task M. Diamantidis, A. Papadopoulos, G. Kaiafa, G. Ntaios, G. Karayannopoulou, I. Kostopoulos, F. Girtovitis, Z. Saouli, Z. Kontoninas, I. Raptis, C. Savopoulos, A. Hatzitolios International Journal of Hematology, 2009 90:226-9. Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare and distinct neoplasm appearing de novo in skin. We present a case of a 75-year-old man diagnosed with PCALCL in his left femoral region. We describe the morphology of lesions along with the differential diagnosis, treatment, clinical course and prognosis. The unusual aspect in our case is the therapeutic approach to a localized form of PC-ALCL. We focus on the necessity of our treatment decision, providing novel information. We further discuss parameters concerning treatment that should be considered when a PC-ALCL is diagnosed. Our case report demonstrates the complexity in classification, staging, differential diagnosis and therapy selection of PC-ALCLs. It is crucial to emphasize to the importance of clinical criteria in selecting the appropriate treatment of a PC-ALCL in combination with the limitations of immunohistochemistry. Novel extended reference range for serum κ/λ free light chain ratio in diagnosing monoclonal gammopathies in renal insufficient patients M. Diamantidis, E. Ioannidou-Papagiannaki, G. Ntaios

Clinical Biochemistry 2009; 42(10-11):1202-3


52


It has been suggested that urine electrophoresis should not be replaced yet by serum κ/λ free light chain (FLC) ratio in the detection of monoclonal gammopathies. Katzmann et al conclude that κ/λ FLC ratio is not affected by reduced renal function. Moreover, Bochtler et al declare that the FLC test is a diagnostic tool in patients with systemic AL amyloidosis and renal insufficiency. In agreement, Vermeersch et al do not observe an important increase in false-positive results for κ/λ FLC ratio in patients with decreased renal function, although they suggest that there is reduced specificity of serum κ/λ FLC ratio compared to serum plus urine IFE. On the contrary, there are studies suggesting that renal insufficiency, indeed, can cause false-positive results for serum κ/λ FLC ratio in patients investigated for monoclonal gammopathies. Therefore, the above conflicting results pose a discrepancy on this issue. In our opinion, a modified extended reference range increases specificity, without loss of sensitivity, as stated by Hutchison et al in patients with multiple myeloma and acute renal failure. The extended reference range (0.37-3.1) improves specificity to 99% and reduces the number of false positives. In addition, it has been described that all κ/λ FLC results should be interpreted against a reference interval appropriate for the analyser in use and the population under study. If renal function is abnormal, a ratio in the range of 1.65-3.0 is probably a result of the renal impairment. However, further investigation of such patients might be necessary. Red blood cell flags for the differential diagnosis between thalassemia trait and iron deficiency anemia G. Ntaios Hematology 2009; 14:304 I read with great interest the article by Eivazi-Ziaei et al. that was recently published in Hematology. In this paper, the authors investigated the role of red cell flags (RCF) and in particular its first digit (RCF1) -which is a rough estimate of red cell distribution width (RDW)- in the differential diagnosis between thalassemia trait (TT) and iron deficiency anemia (IDA). Their paper is of particular interest, since it is the first study to evaluate the efficiency of RCF1 in the discrimination between these two conditions. They found a statistically significant difference between TT and IDA for RCF1=0 (64.1% vs. 20%) and RCF1=2 (6.3% vs. 42%) and concluded that RCF1 is sensitive and specific enough to be used to differentiate iron deficiency anemia from beta-thalassemia trait. I would like to express my concern about the conclusion drawn by Eivazi-Ziaei et al. There is indeed a statistical difference between the two conditions for RCF1=0 and RCF1=2; however, RCF1 is by no means sensitive and specific to differentiate TT from IDA, according to the values provided by the investigators. For example, if RCF1=0 is to be considered as a diagnostic tool for the diagnosis of TT, then, according to table 1 in their paper, there would be 10 IDA patients (20% of all IDA patients) that would have been misdiagnosed as TT (false positive results). Moreover, there would be 23 TT patients (35.9% of all TT patients) that would be missed, since they have RCF1>0 (false negative results). Similar results can be obtained if we use RCF1=2 as a diagnostic tool for IDA. These percentages are unacceptably high in order to consider RCF1 as a reliable, sensitive and specific index for the discrimination between TT and IDA. Similarly to RCF1, RDW, which is in close correlation with RCF1, has also been found to be not reliable for the differential diagnosis between TT and IDA by many studies. Summarizing, I believe that the results by Eivazi-Ziaei et al. show that RCF1 may provide an indicative clue for the discrimination between TT and IDA but is not a reliable, sensitive or specific index for this purpose. Ο ρόλος της ερυθροποιητίνης στην οξεία αντιμετώπιση των ισχαιμικών αγγειακών εγκεφαλικών επεισοδίων και στην εξέλιξη της Χρόνιας Νεφρικής Ανεπάρκειας Χ. Σαββόπουλος, Γ. Ντάιος, Α. Χατζητόλιος, Εισήγηση στο 10ο Κύκλο των ‘Αλκυονίδων ημερών νεφρολογίας’ με θέμα: «Η Επίδραση των Ορμονών στη Νεφρική και Καρδιαγγειακή Βλάβη» Περίληψη δημοσιεύθηκε στον Τόμο Περιλήψεων του Συνεδρίου Εισήγηση σχετικά με το ρόλο της ερυθροποιητίνης στην οξεία αντιμετώπιση των ισχαιμικών αγγειακών εγκεφαλικών επεισοδίων. Παρουσιάζονται τα νεότερα πειραματικά δεδομένα, καθώς και οι κλινικές μελέτες που υποστηρίζουν τη δράση της ερυθροποιητίνης και σε άλλους ρόλους, πέραν του αρχικού της ρόλου στην αιμοποίηση. Συμπεραίνεται ότι η ανασυνδυασμένη ερυθροποιητίνη αποτελεί ένα μόριο που σύντομα θα καταφέρει να ‘αποδράσει’ από το στενό αρχικό φάσμα της αιμοποίησης και θα αποκτήσει ένα πιθανώς σημαντικό ρόλο στον καρδιαγγειακό τομέα όπως η στεφανιαία νόσος, η καρδιακή ανεπάρκεια και τα ισχαιμικά αγγειακά εγκεφαλικά επεισόδια. Επίδραση του φυλλικού οξέος στο πάχος του έσω-μέσου χιτώνα των καρωτίδων Διδακτορική Διατριβή Τριμελής συμβουλευτική επιτροπή: Δ. Καραμήτσος (επιβλέπων), Ι. Οικονόμου, Χ. Σαββόπουλος Τομέας Παθολογίας, Ιατρική Σχολή ΑΠΘ International Journal of Cardiology 2009; 143:16-9


53


Μελέτη η οποία διερεύνησε την επίδραση της μείωσης της ομοκυστεΐνης μέσω της χορήγησης φυλλικού οξέος στην αθηροσκληρωτική διαδικασία εξετάζοντας το πάχος του έσω-μέσου χιτώνα των καρωτίδων, το οποίο θεωρείται αξιόπιστος δείκτης αθηροσκλήρωσης. Στη μελέτη εντάχθηκαν σταδιακά 114 άτομα ηλικίας 65 – 88 ετών. Από αυτούς, 62 ήταν άνδρες και 52 ήταν γυναίκες. Από τους 114 ασθενείς οι οποίοι αρχικά εντάχθηκαν στη μελέτη, οι έντεκα δεν κατάφεραν να ολοκληρώσουν τη μελέτη για τους παρακάτω λόγους: α) σε τρεις περιπτώσεις διαπιστώθηκε σημαντική στένωση της μίας ή και των δύο καρωτίδων και οι ασθενείς χρειάστηκε να υποβληθούν σε ενδαρτερεκτομή, β) οχτώ ασθενείς δεν επανήλθαν στον προγραμματισμένο επανέλεγχο. Κατά συνέπεια, η μελέτη ολοκληρώθηκε με 103 ασθενείς. Οι ασθενείς αυτοί χωρίστηκαν τυχαία σε δύο ομάδες: Η πρώτη ομάδα ετέθη σε αγωγή με 5mg φυλλικού οξέος ημερησίως. Το σκεύασμα που χρησιμοποιήθηκε είχε το εμπορικό όνομα ‘Filicine’ της εταιρίας ‘Adelco’. Την ομάδα αυτή αποτέλεσαν 53 ασθενείς (30 άντρες, 23 γυναίκες) ηλικίας 65-88 ετών. Η δεύτερη ομάδα περιέλαβε 50 ασθενείς (27 άντρες, 23 γυναίκες) ηλικίας 65-84 ετών στους οποίους χορηγήθηκε εικονικό φάρμακο. Όλοι οι συμμετέχοντες υποβλήθηκαν σε υπερηχογραφικό έλεγχο σε τρεις χρονικές στιγμές: πριν την τυχαιοποίηση, μετά από 6-8 μήνες και στο τέλος της μελέτης 17-19 μήνες μετά την τυχαιοποίηση. Η μέτρηση του πάχους του έσω-μέσου χιτώνα έγινε με υπερηχογραφική εξέταση των καρωτίδων με τεχνική Β-mode με ηχοβολέα 7,5 MHz - Sonoline Elegra. Ο υπερηχογραφικός έλεγχος διενεργήθηκε αποκλειστικά από δύο έμπειρους υπερηχογραφιστές του νοσοκομείου ΑΧΕΠΑ. Οι μετρήσεις έγιναν σε επιμήκη τομή και στις δυο καρωτίδες και αφορούσαν το πρόσθιο καθώς και το οπίσθιο τοίχωμα των εξής σημείων: το διχασμό των καρωτίδων, την κοινή καρωτίδα σε απόσταση 1cm από το διχασμό και τέλος, την έσω καρωτίδα σε απόσταση 1cm από το διχασμό. Από αυτές τις δώδεκα θέσεις υπολογίστηκε η μέση τιμή του πάχους του έσω-μέσου χιτώνα σε κάθε μέτρηση. Η σύγκριση των αρχικών μέσων τιμών των ποσοτικών μεταβλητών των δύο δειγμάτων καθώς και η σύγκριση των μέσων τιμών του φυλλικού, της ομοκυστεΐνης και του ΙΜΤ πριν, στους 6 και στους 18 μήνες μετά την τυχαιοποίηση έγινε με εφαρμογή του independent group t-test (2-tail), καθώς οι παραπάνω παράμετροι περιγράφονται με αξιοπιστία από την κανονική κατανομή. Η σύγκριση των ποιοτικών χαρακτηριστικών των δύο δειγμάτων έγινε με εφαρμογή του z-test. Τα αποτελέσματα της μελέτης συνοψίζονται στα εξής: Ήδη από τους τρεις πρώτους μήνες μετά την τυχαιοποίηση των ασθενών, τα επίπεδα φυλλικού οξέος μεταξύ των δύο ομάδων παρουσίασαν σημαντική απόκλιση, η οποία ήταν στατιστικά ισχυρά σημαντική (p<0,001) και παρέμεινε μέχρι και την ολοκλήρωση της μελέτης 18 μήνες μετά (44,6±1,6 nmol/l στην πρώτη ομάδα vs. 17,1±5,4 nmol/l στην ομάδα ελέγχου, p<0,001). Σε σχέση με τα αρχικά επίπεδα φυλλικού πριν από την τυχαιοποίηση, η τελική διαφορά των μέσων τιμών ήταν 24,5±1,3 nmol/l (122%) στην πρώτη ομάδα και -1,04±0,31 nmol/l (-5,5%) στην ομάδα ελέγχου, μια διαφορά που ήταν επίσης στατιστικά ισχυρά σημαντική (p<0.001). Οι μέσες τιμές ομοκυστεΐνης των δύο ομάδων άρχισαν να αποκλίνουν ήδη από τους τρεις πρώτους μήνες μετά την τυχαιοποίηση των ασθενών. Συγκεκριμένα μειώθηκαν στην πρώτη ομάδα, ενώ αντίθετα αυξήθηκαν στους μάρτυρες. Αυτή η στατιστικά ισχυρή απόκλιση διατηρήθηκε και μάλιστα αυξήθηκε τους επόμενους μήνες. Στο τέλος της μελέτης -18 μήνες μετά την τυχαιοποίηση των ασθενών-, οι μέσες τιμές ομοκυστεΐνης ήταν 10,6±3,6μmol/l στην πρώτη ομάδα και 15,4±4,6μmol/l στην ομάδα ελέγχου, μια διαφορά που ήταν στατιστικά ισχυρά σημαντική (p<0,001). Σε σχέση με τα αρχικά επίπεδα ομοκυστεΐνης πριν από την τυχαιοποίηση, η τελική διαφορά των μέσων τιμών ήταν -2,98±0,26 μmol/l (-21,4%) στην πρώτη ομάδα και 1,35±0,21μmol/l (9,5%) στην ομάδα ελέγχου, μια διαφορά που ήταν επίσης στατιστικά ισχυρά σημαντική (p<0.001). Μετά από έξι μήνες αγωγής με φυλλικό οξύ, ήδη είχε γίνει αντιληπτή μια απόκλιση του ΙΜΤ μεταξύ των δύο ομάδων η οποία όμως δεν ήταν ακόμα στατιστικά σημαντική, κάτι το οποίο επιτεύχθηκε στο τέλος της μελέτης μετά από 18 μήνες (0.933±0.077mm vs. 0.984±0.094mm, p=0.003). Ήδη από το πρώτο εξάμηνο, η πρώτη ομάδα είχε εμφανίσει μείωση του ΙΜΤ (-0.016±0.014mm), ενώ αντίθετα η ομάδα ελέγχου παρουσίασε αύξηση (0.0009±0.0057mm). Η διαφορά των μεταβολών αυτών ήταν στατιστικά σημαντική (p<0.001) και συνεχίστηκε μέχρι και το τέλος της μελέτης (-0.028±0.004mm vs. 0.0198±0.0024mm, p<0.001). Επομένως, συμπεραίνεται ότι: η χορήγηση φυλλικού οξέος σε δόση 5mg ημερησίως μπορεί να οδηγήσει σε σημαντική μείωση του πάχους του έσω-μέσου χιτώνα των καρωτίδων μέσα σε 18 μήνες, ενώ ήδη από τους έξι μήνες παρατηρείται τάση μείωσης του ΙΜΤ. Η μείωση του ΙΜΤ από τους 6 στους 18 μήνες ήταν εξίσου σημαντική με αυτή που παρατηρήθηκε στο πρώτο εξάμηνο και επιβραδύνθηκε μόνο σε μικρό βαθμό. Δεν αποκλείεται να υπάρχει σημαντικό περιθώριο για περαιτέρω μείωση του ΙΜΤ, πέραν δηλαδή αυτής που παρατηρήθηκε στους 18 μήνες της μελέτης. η χορήγηση φυλλικού οξέος επιφέρει σημαντική μείωση των επιπέδων της ομοκυστεΐνης. Η μείωση αυτή επιτυγχάνεται κατά κύριο λόγο μέσα στους πρώτους έξι μήνες, ενώ στη συνέχεια παρατηρείται μόνο μικρή περαιτέρω μείωση. Solitary large hepatic metastasis in an elderly patient with anaplastic thyroid carcinoma: a case report A. Adamidou, P. Kotsaftis, A. Zantidis, M. Vlachou, A. Haritandi, I. Xanthakis, G. Ntaios

Cases Journal 2009; 2:41 Περιγράφεται ενδιαφέρουσα περίπτωση ασθενούς με αναπλαστικό καρκίνο του θυρεοειδούς στον οποίο διαπιστώθηκε μονήρης μεταστατικός όζος στο ήπαρ. Επισημαίνεται ότι αν και οι ηπατικές μεταστάσεις από αναπλαστικό καρκίνο του θυρεοειδούς είναι πολύ σπάνιες (αφού συνήθως μεθίσταται στους πνεύμονες, τα οστά και τον εγκέφαλο), η κλινική εξέταση του θυρεοειδούς είναι απαραίτητη.


54


Improper use of tumour markers as cancer screening tests among Greek physicians G. Ntaios, A. Hatzitolios, C. Savopoulos European Journal of Internal Medicine, 2009;20:e128 Αναφέρεται σε εργασία στην οποία μελετήθηκε η χρήση των καρκινικών δεικτών από ιατρούς της πρωτοβάθμιας περίθαλψης στην Ελλάδα και διαπιστώθηκε κακή χρήση, καθώς 45% των πρωτοβάθμιων ιατρών χρησιμοποιεί συχνά τους καρκινικούς δείκτες στο πλαίσιο screening. Επισημαίνεται ότι παρόμοια αποτελέσματα προέκυψαν από σχεδόν ταυτόχρονη μελέτη της ομάδας μας σε τριτοβάθμιο νοσοκομείο της Ελλάδας και τονίζεται η ανάγκη αντιμετώπισης αυτού του προβλήματος, το οποίο δημιουργεί σημαντική οικονομική επιβάρυνση στο Εθνικό Σύστημα Υγείας. Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease G. Ntaios, C. Savopoulos, A. Hatzitolios JAMA 2008; 300:2852-2853 Αναφέρεται στη μελέτη WENBIT η οποία έδειξε ότι η χορήγηση φυλλικού οξέος σε ασθενείς που υποβλήθηκαν σε στεφανιαία αγγειογραφία δεν οδήγησε σε μείωση του καρδιαγγειακού κινδύνου παρά τη μείωση της ομοκυστεΐνης. Επισημαίνεται ότι τόσο τα αρχικά επίπεδα, όσο και τα τελικά επίπεδα ομοκυστεΐνης ήταν μέσα στα φυσιολογικά πλαίσια, δηλαδή οι ασθενείς της μελέτης δεν ήταν υπερομοκυστεϊναιμικοί. Σημειώνεται ότι θα πρέπει να μελετηθεί η επίδραση του φυλλικού οξέος σε υπερομοκυστεϊναιμικους ασθενείς. Telmisartan and carotid intima-media thickness regression: a class effect of angiotensin-receptor blockers? G. Ntaios, C. Savopoulos, A. Hatzitolios Hypertension Research, 2008; 31:2187 Αναφέρεται σε μελέτη των Nakamura et al. στην οποία διαπιστώθηκε ότι η χορήγηση τελμισαρτάνης οδήγησε σε μείωση του πάχους του έσω-μέσου χιτώνα των καρωτίδων (ΙΜΤ) σε υπερτασικούς ασθενείς με ήπια νεφρική ανεπάρκεια. Οι συγγραφείς της εν λόγω μελέτης αναφέρουν ότι δεν είναι σαφές αν το αποτέλεσμα αυτό είναι χαρακτηριστικό για την τελμισαρτάνη ή αφορά γενικότερα την ομάδα των ανταγωνιστών της αγγειοτενσίνης ΙΙ. Συνοψίζονται οι παλαιότερες μελέτες της επίδρασης των διαφόρων μορίων της ομάδας των ανταγωνιστών της αγγειοτενσίνης ΙΙ και επισημαίνεται ότι τα αποτελέσματα είναι αντικρουόμενα και επισημαίνεται η ανάγκη για μεγαλύτερες μελέτες. Stroke and conditions that mimic it: a protocol secures a safe, early recognition A Hatzitolios, C. Savopoulos, G. Ntaios, F. Papadidaskalou, E. Dimitrakoudi, M. Kosmidou, M. Baltatzi, D. Karamitsos Hippokratia 2008; 12:98-102 Αναδρομική κλινική μελέτη σε 362 ασθενείς που νοσηλεύθηκαν στην Α΄ Προπαιδευτική Παθολογική Κλινική με διάγνωση εισόδου οξύ αγγειακό εγκεφαλικό ισχαιμικό επεισόδιο (ΑΕΕ). Μελετήθηκαν οι φάκελοι των ασθενών ώστε να διαπιστωθεί αν η τελική διάγνωση ήταν η ίδια με την διάγνωση εισόδου. Περιγράφεται ο διαγνωστικός αλγόριθμος που ακολουθείται στο Τμήμα Επειγόντων Περιστατικών για τη διάγνωση των ΑΕΕ. Διαπιστώθηκε ότι η αρχική διάγνωση ήταν ορθή σε ποσοστό 95% των ασθενών. Increased incidence of iron deficiency anemia secondary to inadequate iron intake in institutionalized, young patients with cerebral palsy A. Papadopoulos, G. Ntaios, G. Kaiafa, F. Girtovitis, Z. Saouli, Z. Kontoninas, M. Diamantidis, C. Savopoulos, A. Hatzitolios International Journal of Hematology 2008: 88; 495-497 Κλινική μελέτη σε 108 ασθενείς που νοσηλεύονται σε ιδιωτικό νοσηλευτικό ίδρυμα λόγω εγκεφαλικής παράλυσης και στους οποίους διαπιστώθηκε υψηλός επιπολασμός σιδηροπενικής αναιμίας. Διαπιστώθηκε ότι 33% των ασθενών έπασχαν από σιδηροπενική αναιμία. Η σιδηροπενία και κατ’ επέκταση η αναιμία, αποδόθηκαν στην μειωμένη πρόσληψη σιδήρου. Προτείνεται ότι στη συγκεκριμένη κατηγορία ασθενών και σε περίπτωση σιδηροπενικής αναιμίας, θα πρέπει πρώτα να εμπλουτίζεται η διατροφή με σίδηρο και μόνο στην περίπτωση μη ανταπόκρισης των δεικτών αναιμίας στην παρέμβαση αυτή, να διεξάγεται περαιτέρω ενδοσκοπικός έλεγχος. Separating Thalassemia Trait and Iron Deficiency by Simple Inspection G. Ntaios American Journal of Clinical Pathology, 2009; 131:445


55


Πρόκειται για την απάντηση σε σχόλιο του Burdick ότι για τη διαφοροδιάγνωση μεταξύ της ετερόζυγης β-μεσογειακής αναιμίας και της σιδηροπενικής αναιμίας αρκεί απλά η παρατήρηση της γενικής αίματος (και συγκεκριμένα του βαθμού της αναιμίας, του αριθμού των ερυθροκυττάρων και της τιμής του RDW) που προκύπτει από τον αυτόματο αναλυτή, σε αντιδιαστολή με τους προτεινόμενους ερυθροκυτταρικούς δείκτες. Επισημαίνεται ότι αν και σε πολλές περιπτώσεις η απλή παρατήρηση της γενικής αίματος μπορεί να οδηγήσει σε σαφή διαφοροδιάγνωση μεταξύ των δύο καταστάσεων, στην κλινική πράξη υπάρχουν πολλές ‘μη τυπικές’ περιπτώσεις στις οποίες οι παράμετροι που εξετάζονται είναι διαφορετικές από αυτές που θα αναμένονταν σύμφωνα με την τελική διάγνωση, όπως αυτή προκύπτει από την ηλεκτροφόρηση της αιμοσφαιρίνης. Τονίζεται ότι αυτές οι μη τυπικές περιπτώσεις είναι τόσο συχνές που καθιστούν τελικά τους ερυθροκυτταρικούς δείκτες αναξιόπιστους για τη διαφοροδιάγνωση μεταξύ των δύο καταστάσεων. Παρατίθεται, τέλος, η άποψη ότι οι ίδιοι περιορισμοί που ισχύουν στην περίπτωση των δεικτών, ισχύουν και για την απλή παρατήρηση της γενικής αίματος. Letter by Ntaios et al Regarding Article, ‘Impact of Statin Therapy on Left Ventricular Function and Carotid Arterial Stiffness in Patients With Hypercholesterolemia’ G. Ntaios, C. Savopoulos, A. Hatzitolios Circulation Journal 2008; 72:2101 Αναφέρεται σε μελέτη στην οποία διερευνήθηκε η επίδραση της πιταβαστατίνης στο πάχος του έσω-μέσου χιτώνα των καρωτίδων (ΙΜΤ) σε υπερχοληστερολαιμικούς ασθενείς και στην οποία διαπιστώθηκε ότι το ΙΜΤ δε μειώθηκε μετά από χορήγηση πιταβαστατίνης για ένα έτος. Σχολιάζεται ότι τα αποτελέσματα της μελέτης ήταν αναπάντεχα, από τη στιγμή που οι περισσότερες μελέτες έχουν δείξει ευνοϊκή επίδραση των στατινών στο ΙΜΤ. Προτείνεται ότι η μικρή διάρκεια και το μικρό μέγεθος της μελέτης αποτελούν τις δύο πιο πιθανές αιτίες των αρνητικών αποτελεσμάτων αυτής της μελέτης και αναδεικνύεται η ανάγκη για μεγαλύτερες μελέτες σχετικά με την επίδραση της πιταβαστατίνης στο ΙΜΤ και κατ’ επέκταση, στον καρδιαγγειακό κίνδυνο. Veno-occlusive disease of the liver during induction therapy for acute lymphoblastic leukemia A. Papadopoulos, G. Ntaios, G. Kaiafa, F. Girtovitis, Z. Saouli, Z. Kontoninas, M. Diamantidis, C. Savopoulos, A. Hatzitolios Δημοσιεύθηκε στο International Journal of Hematology 2008; 88:441–442 Ανακοινώθηκε στο 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 2008 Περίληψη δημοσιεύθηκε στο Blood 2008; 112:3949 Περιγράφεται ενδιαφέρουσα περίπτωση ασθενούς που παρουσίασε αγγειοαποφρακτική νόσο του ήπατος μετά από χημειοθεραπεία εφόδου με vincristine (1.5mg/m2 τις μέρες 1 και 8), daunorubicin (ημερήσια δόση 45mg/m2 για δύο μέρες), prednisone (40mg/m2 ημερησίως), L-asparaginase (6000u/m2 κάθε δεύτερη μέρα) και methotrexate (12.5mg intrathecally κάθε 14 μέρες) σε ασθενή με οξεία λεμφοβλαστική λευχαιμία. Επισημαίνεται ότι η περίπτωση αυτή είναι η πρώτη θανατηφόρος περίπτωση που περιγράφεται στη διεθνή βιβλιογραφία. An audit of tumour marker utilization in Greece G. Ntaios, A. Hatzitolios, A. Chatzinikolaou, P. Karalazou, C. Savopoulos, M. Karamouzis, I. Pidonia European Journal of Internal Medicine 2009; 20(3):e66-9 Κλινικοεργαστηριακή μελέτη με σκοπό τη διερεύνηση παραπομπής καρκινικών δεικτών χωρίς αιτιολόγηση σε 10921 παραπεμπτικά νοσηλευόμενων ασθενών για διάφορα αίτια σε τριτοβάθμιο πανεπιστημιακό νοσοκομείο. Με βάση τα αποτελέσματα συμπεραίνεται ότι παρατηρούνται σε σημαντικά μεγάλο ποσοστό (73.3%) μη αιτιολογημένες παραπομπές για καρκινικούς δείκτες, με το υψηλότερο ποσοστό να αφορά το δείκτη CA 19-9 (95.4%) και την AFP (94.3%), γεγονός που οδηγεί σε αντίστοιχα μεγάλη οικονομική επιβάρυνση του συστήματος υγείας της τάξεως των 24.000 ευρώ μηνιαίως. Effect of Folic Acid and B Vitamins on Cardiovascular disease in women G. Ntaios, C. Savopoulos, D. Karamitsos JAMA 2008; 300:1409 Αναφέρεται στη μελέτη WAFACS στην οποία διαπιστώθηκε ότι η χορήγηση φυλλικού οξέος δεν μείωσε την επίπτωση καρδιαγγειακών συμβαμάτων παρά τη μείωση στα επίπεδα ομοκυστεΐνης. Σημειώνεται ότι τα αποτελέσματα της μελέτης αυτής σε συνδυασμό με ανάλογα αποτελέσματα προηγούμενων μελετών δείχνουν ότι πιθανώς η φαρμακευτική χορήγηση φυλλικού οξέος δε μειώνει τελικά τον καρδιαγγειακό κίνδυνο, σε αντιθεση με τις αρχικές εκτιμήσεις. Επισημαίνεται όμως ότι δεν αποκλείεται η μακροχρόνια διαιτητική χορήγηση φυλλικού οξέος μέσω του εμπλουτισμού των τροφών με φυλλικό οξύ (που ήδη έχει θεσμοθετηθεί και καθιερωθεί ως υποχρεωτικός στη Βόρειο Αμερική) να επιφέρει αξιόλογη μέσο- και μακροπρόθεσμη μείωση του καρδιαγγειακού κινδύνου.


56


M/H ratio for the differential diagnosis of microcytic anemia G. Ntaios, A. Chatzinikolaou International Journal of Laboratory Hematology, 2009; 31:248-249 Αναφέρεται σε μελέτη στην οποία μελετήθηκε η αξιοπιστία ενός νεότερου δείκτη (M/H ratio, δηλαδή το κλάσμα του %μικροκυττάρων προς το %υπόχρομων ερυθροκυττάρων) στη διαφοροδιάγνωση μετξύ ετερόζυγης β-μεσογειακής αναιμίας και σιδηροπενικής αναιμίας. Επισημαίνονται ορισμένες επιφυλάξεις σχετικά με τη μεθοδολογία της μελέτης και συγκεκριμένα, την επιλογή των ασθενών, καθώς ένα σημαντικό ποσοστό αυτών (περίπου 16%) δεν παρουσίαζαν μικροκυττάρωση και επομένως, δεν υπήρχε θέμα διαφοροδιάγνωσης μεταξύ των δύο παθήσεων. Evaluation of mean platelet volume in the differential diagnosis of thrombocytopenia G. Ntaios, A. Papadopoulos, A. Chatzinikolaou, F. Girtovitis, G. Kaiafa, C. Savopoulos, A. Hatzitolios International Journal of Laboratory Hematology, Online early view Αναφέρεται σε μελέτη στην οποία εξετάσθηκε ο ρόλος του μέσου όγκου των αιμοπεταλίων (MPV) στη διαφοροδιάγνωση των αιτιών θρομβοπενίας (αυξημένη καταστροφή των αιμοπεταλίων ή μειωμένη παραγωγή) και διαπιστώθηκε ότι η τιμή 8fl έχει ευαισθησία 82.3% και ειδικότητα 92.5%, καθιστώντας το MPV έναν αξιόπιστο δείκτη για τη διαφοροδιάγνωση μεταξύ των δύο καταστάσεων. Τα αποτελέσματα αυτής της μελέτης συγκρίνονται με τα αποτελέσματα ανάλογης μελέτης που δημοσιεύθηκε από την ομάδα μας σχεδόν ταυτόχρονα με την προαναφερθείσα εργασία και στην οποία η ευασθησία και η ειδικότητα του δείκτη MPV ήταν 100%. Προτείνεται ότι ο διαφορετικός αυτόματος αναλυτής (Coulter STKS και Sysmex XE-2100 αντίστοιχα) που χρησιμοποιήθηκε στις δύο μελέτες είναι πιθανώς η αιτία στην ποσοτική (αλλά όχι και ποιοτική) διαφορά των αποτελεσμάτων. Are UK South Asians still a low-risk population for gastrointestinal cancer? G. Ntaios, A. Chatzinikolaou Indian Journal of Gastroenterology 2008; 27:175 Αναφέρεται σε μελέτη από τους Ellul et al. η οποία έδειξε ότι η συχνότητα του γαστρεντερικού καρκίνου είναι μικρότερη σε Ασιάτες που διαμένουν στο Ηνωμένο Βασίλειο σε σχέση με τους Καυκάσιους. Σημειώνεται ότι παλαιότερες μελέτες (προ εικοασαετίας) είχαν δείξει ανάλογα αποτελέσματα, καθώς επίσης ότι αυτή η διαφορά αμβλύνονταν στις μικρότερες ηλικίες. Σχολιάζεται ότι η μελέτη των Ellul et al. είναι μικρή σε μέγεθος και χρειάζονται μεγαλύτερες προοπτικές μελέτες. Coexistence of B-cell non-Hodgkin lymphoma and cutaneous T-cell lymphoma in a patient with chronic hepatitis C and cryoglobulinemia F. Girtovitis, A. Papadopoulos, G. Ntaios, V. Kaloutsi, V. Kotoula, G. Kaiafa Internal Medicine Journal, in press Παρουσιάζεται ενδιαφέρουσα περίπτωση ασθενούς με χρόνια ηπατίτιδα C, κρυοσφαιριναιμία και Non-Hodgkin λέμφωμα Β-κυτταρικής αρχής, ο οποίος αργότερα παρουσίασε και δερματικό λέμφωμα Τ κυτταρικής αρχής. Σημειώνεται ότι πρόκειται για την πρώτη περίπτωση που περιγράφεται στη διεθνή βιβλιογραφία. The spleen in beta thalassemia minor: splenomegaly or just “scanomegaly”? G. Ntaios, A. Chatzinikolaou British Journal of Haematology 2008; 143:143 Αναφέρεται σε μελέτη στην οποία δε διαπιστώθηκε σημαντική διαφορά στη συχνότητα σπληνομεγαλίας (με τη μέθοδο της ψηλάφησης) μεταξύ ατόμων με ετερόζυγη β-μεσογεικαή αναιμία και μαρτύρων. Τα αποτελέσματα αυτά αντιπαραβάλλονται με άλλη ανάλογη μελέτη, στην οποία διαπιστώθηκε ότι ο σπλήνας είναι αυξημένος σε όγκο κατά 29.4% (με τη βοήθεια υπερήχογραφήματος) σε σχέση με τους μάρτυρες. Σημειώνεται ότι σύμφωνα με προηγούμενες μελέτες, ο σπλήνας θα πρέπει να αυξηθεί >40% ώστε να είναι ψηλαφητός. Συμπεραίνεται λοιπόν ότι οι τα αποτελέσματα των παραπάνω μελετών δείχνουν ότι ο σπλήνας είναι διογκωμένος στην ετερόζυγη β-μεσογειακή αναιμία, χωρίς όμως συνήθως να είναι ψηλαφητός. Evaluation of cardiotoxicity five years after 2D planned, non-simulated, radiation therapy for left breast cancer K. Pistevou-Gompaki, A. Hatzitolios, N. Eleftheriadis, E. Boultoukas, G. Ntaios, I. Andronikidis, I. Tzitzikas Therapeutics and Clinical Risk Management, 2008; 4(6):1359-62.


57


Κλινική μελέτη σε 62 γυναίκες με καρκίνο αριστερού μαστού, χειρουργηθέντα, που ακτινοβολήθηκαν και επανεκτιμήθηκαν κλινικά και παρακλινικά με ΗΚΓφημα και ΕCHO καρδιάς, 6 μήνες και 5 χρόνια μετά. Με βάση τα κλινικά και απεικονιστικά ευρήματα του επανελέγχου και κατόπιν σύγκρισής τους με τα αντίστοιχα προ της θεραπευτικής ακτινοβολίας, συμπεραίνεται, σε αντίθεση με πολλές άλλες ανάλογες δημοσιεύσεις, η ασφάλεια της θεραπευτικής αυτής μεθόδου των ακτινοβολιών, δεδομένου ότι δεν παρατηρήθηκε αύξηση στην νοσηρότητα και θνησιμότητα από καρδιακά αίτια. Increased values of mean platelet volume and platelet size deviation width may provide a safe positive diagnosis of idiopathic thrombocytopenic purpura G. Ntaios, A. Papadopoulos, A. Chatzinikolaou, Z. Saouli, P. Karalazou, G. Kaiafa, F. Girtovitis, Z. Kontoninas, C. Savopoulos, A. Hatzitolios, S. Alexiou-Daniel Acta Haematologica 2008; 119:173-177 Κλινικοεργαστηριακή μελέτη 134 ασθενών (63 με ιδιοπαθή θρομβοπενική πορφύρα ΙΘΠ και 71 με μυελοκαταστολή μετά χημειοθεραπεία για αιματολογικά νοσήματα), με σκοπό τη διερεύνηση του ρόλου των αιμοπεταλιακών δεικτών MPV, PDW και P-LCR στη διαφοροδιάγνωση των αιτιών θρομβοπενίας.. Συμπεραίνεται ότι οι παραπάνω δείκτες εξασφαλίζουν ακριβή διαφοροδιάγνωση μεταξύ της ΙΘΠ και θρομβοπενίας από μυελοκαταστολή, με ποσοστό ευαισθησίας 100% για τους πρώτους δύο δείκτες. The neuroprotective role of erythropoietin in the management of acute ischemic stroke: from bench to bedside G. Ntaios, C. Savopoulos, A. Chatzinikolaou, A. Hatzitolios Acta Neurologica Scandinavica 2008;118:362-6 Ανασκόπηση των πειραματικών δεδομένων τα οποία απέδειξαν την νευροπροστατευτική δράση της ερυθροποιητίνης, καθώς και των κλινικών μελετών οι οποίες βασίστηκαν σε αυτά τα δεδομένα και φιλοδοξούν να αναδείξουν το ρόλο της ερυθροποιητίνης στην αντιμετώπιση των οξεέων ισχαιμικών αγγειακών εγκεφαλικών επεισοδίων. Well done folate, the little boy was born healthy without spina bifida. But will he suffer a stroke when elderly? G. Ntaios, A. Chatzinikolaou, C. Savopoulos, A. Hatzitolios European Journal of Internal Medicine, 2009; 20:2 Editorial στο οποίο επισημαίνεται η θετική δράση του εμπλουτισμού των τροφών στις Ηνωμένες Πολιτείες με φυλλικό οξύ στην επίπτωση των γεννήσεων νεογνών με βλάβη του νωτιαίου σωλήνα. Σχολιάζονται επίσης τέσσερις πρόσφατες μελέτες σχετικά με το ρόλο του φυλλικού οξέος στην πρόληψη των καρδιαγγειακών νοσημάτων και σημειώνεται ότι ο εμπλουτισμός με φυλλικό οξύ πιθανώς να επιφέρει και ανάλογη μεσοπρόθεσμη μείωση του καρδιαγγειακού κίνδυνου. Incorporation of erythrocytic and reticulocytic parameters in a common formula: will it provide a more accurate differentiation between iron deficiency anemia and β-thalassemic trait? G. Ntaios, A. Chatzinikolaou International Journal of Laboratory Hematology, in press Αναφέρεται σε μελέτη στην οποία εξετάσθηκε ο ρόλος δικτυοκυτταρικών παραμέτρων όπως ο απόλυτος αριθμός των δικτυοκυττάρων, το διορθωμένο ποσοστό των δικτυοκυττάρων, η μέση συγκέντρωση αιμοσφαιρίνης στα δικτυοκύτταρα και ο μέσος όγκος των δικτυοκυττάρων στη διαφοροδιάγνωση μεταξύ της ετερόζυγης β-μεσογειακής αναιμίας και της σιδηροπενικής αναιμίας. Τα αποτελέσματα της μελέτης αντιπαραβάλλονται με δύο προηγούμενες μελέτες και προτείνεται ότι ο συνδυασμός ερυθροκυτταρικών και δικτυοκυτταρικών παραμέτρων πιθανώς να προσφέρει χρήσιμα συμπεράσματα στη διαφοροδιάγνωση μεταξύ των δύο καταστάσεων. Is there a beneficial effect of folic acid on carotid intima-media thickness? G. Ntaios, C. Savopoulos, A. Hatzitolios, A. Chatzinikolaou, D. Karamitsos International Journal of Cardiology, Online early view Αναφέρεται σε μελέτη στην οποία διαπιστώθηκε ότι μετά από ημερήσια χορήγηση 2.5mg φυλλικού οξέος δεν παρατηρήθηκε στατιστικά σημαντική μείωση του πάχους του έσω-μέσου χιτώνα των καρωτίδων (ΙΜΤ) σε στεφανιαίους ασθενείς σε σχέση με τους μάρτυρες που έλαβαν εικονικό φάρμακο, αν και παρατηρήθηκε μείωση του ΙΜΤ. Προτείνεται ότι τα αρνητικά αποτελέσματα της μελέτης πιθανώς να οφείλονται στη ταυτόχρονη λήψη από τους ασθενείς άλλων φαρμάκων όπως ανταγωνιστές του μετατρεπτικού ενζύμου της αγγαοτενσίνης, στατίνες και β-αποκλειστές, τα οποία έχει αποδειχθεί ότι


58


οδηγούν σε σημαντική μείωση του ΙΜΤ. Is there a geographic variation in the seasonal distribution of acute myocardial infarction and sudden cardiac death? C. Savopoulos, G. Ntaios, A. Hatzitolios International Journal of Cardiology, Online early view Αναφέρεται σε μελέτη στην οποία μελετήθηκε η εποχιακή και εβδομαδιαία κατανομή των περιστατικών οξέος εμφράγματος του μυοκαρδίου στην Ουγγαρία και διαπιστώθηκε ότι ήταν συχνότερα την άνοιξη και σπανιότερα το καλοκαίρι. Τα αποτελέσματα της μελέτης αντιπαραβάλλονται με τα αποτελέσματα παλαιότερης μελέτης της ομάδας μας στην οποία διαπιστώθηκε ότι τα περιστατικά αιφνίδιου καρδιακού θανάτου ήταν συχνότερα το καλοκαίρι και προτείνονται εξηγήσεις που θα μπορούσαν να δικαιολογήσουν αυτά τα αντιφατικά συμπεράσματα. Ticlopidine-induced myelosuppression spontaneously remitted after five years: a possible causative link with amlodipine co-administration F. Girtovitis, G. Ntaios, M. Baltatzi, G. Kaiafa, G. Ioannidis, A. Chatzinikolaou, A. Hatzitolios, A. Papadopoulos Internal Medicine Journal, in press Eνδιαφέρουσα περίπτωση 63χρονης ασθενούς με στεφανιαία νόσο, που παρουσίασε εμπύρετο σε έδαφος πανκυτταροπενίας, 44 μέρες μετά την λήψη τικλοπιδίνης ως αντιαιμοπεταλιακής αγωγής, ενώ από τριετίας ελάμβανε και τον ανταγωνιστή ασβεστίου αμλοδιπίνη. Μετά διακοπή των φαρμάκων, υποστηρικτική αγωγή και χορήγηση αντιβιοτικών ευρέος φάσματος ο πυρετός υφέθη, ενώ η λευκοπενία και αναιμία διορθώθηκαν πλήρως εντός τριετίας. Η θρομβοπενία επέμενε για 5 χρόνια μετά την διακοπή των φαρμάκων. Συζητείται τόσο η ενοχοποίηση της τικλοπιδίνης στην πρόκληση παρατεταμένης πανκυτταροπενίας, όσο και η συγχορήγηση ανταγωνιστών ασβεστίου, όπως αμλοδιπίνης, στην παθοφυσιολογία πρόκλησης αυτής της διαταραχής. Red cell distribution width in iron deficiency anemia and beta-thalassemia minor G. Ntaios, A. Chatzinikolaou American Journal of Clinical Pathology 2008; 130:313 Αναφέρεται σε μελέτη στην οποία διαπιστώθηκε ότι ο δείκτης RDW είναι αξιόπιστος για τη διαφοροδιάγνωση μεταξύ της ετερόζυγους β-μεσογειακής αναιμίας και της σιδηροπενικής αναιμίας., κάτι το οποίο έρχεται σε αντίθεση με αρκετές ανάλογες προηγούμενες μελέτες. Σημειώνεται ότι μια πιθανή εξήγηση των αποτελεσμάτων αυτής της μελέτης μπορεί να είναι το γεγονός ότι τα επίπεδα αιμοσφαιρίνης στους σιδηροπενικούς ασθενείς που μελετήθηκαν ήταν σημαντικά χαμηλότερα από τα επίπεδα στους ασθενείς με ετερόζυγη β-μεσογειακή αναιμία και προτείνεται η επανεκτίμηση των αποτελεσμάτων περιορίζοντας τον πληθυσμό των σιδηροπενικών ασθενών σε αυτούς που έχουν αιμοσφαιρίνη >8.7g/dl. Appropriateness of the use of serum ferritin or serum transferrin saturation as a diagnostic tool for the evaluation of anaemia G. Ntaios, A. Chatzinikolaou Southern Medical Journal 2008; 101:853-854 Αναφέρεται σε μελέτη η οποία κατέληξε στο συμπέρασμα ότι η χρήση της φερριτίνης στη διερεύνηση των περιστατικών αναιμίας δεν γίνεται με ορθό τρόπο από τους ιατρούς γενικής ιατρικής, καθώς διαπιστώθηκε ότι μετρήθηκε μόνο στο 43% των αναιμικών ασθενών. Σχολιάζεται ότι στη συγκεκριμένη μελέτη, ο συγγραφείς δεν απέκλεισαν διάφορες ομάδες ασθενών στις οποίες η αιτία της αναιμίας είναι έκδηλη όπως ασθενείς με χρόνια νεφρική ανεπάρκεια ή μυελοδυσπλαστικά σύνδρομα. Fatal pulmonary and cerebral aspergillosis after a short course of corticosteroids for idiopathic thrombocytopenic purpura A. Papadopoulos, G. Ntaios, G. Kaiafa, F. Girtovitis, G. Charisopoulos, I. Chryssogonidis Annals of Hematology 2008; 87:685-6 Περιγράφεται η ενδιαφέρουσα περίπτωση ασθενούς που παρουσίασε θανατηφόρο πνευμονική και εγκεφαλική ασπεργίλλωση μετά από βραχύχρονη λήψη κορτικοστεροειδών λόγω ιδιοπαθούς θρομβοπενικής πορφύρας. Σημειώνεται ότι πρόκειται για την πρώτη περίπτωση που περιγράφεται στη διεθνή βιβλιογραφία. Both spontaneous pneumothorax and spontaneous pneumomediastinum may constitute a complication in underweight patients


59


A. Hatzitolios, G. Ntaios, M. Sion Chest 2008; 134:216-7 Αναφέρεται σε δύο μελέτες η οποία εξέτασαν τους παράγοντες που σχετίζονται με την εμφάνιση ετερόπλευρης υποτροπής και αμφοτερόπλευρου πρωτοπαθούς αυτόματου πνευμοθώρακα αντίστοιχα, στις οποίες διαπιστώθηκε ότι ένας από τους παράγοντες ήταν και ο χαμηλός δείκτης μάζας-σώματος (ΒΜΙ). Τα αποτελέσματα αυτών των μελετών συνδυάζονται με τη δημοσιευμένη παρατήρηση της ομάδας μας ότι η εμφάνιση του αυτόματου πνευμομεσοθωρακίου αποτελεί σπάνια επιπλοκή ασθενών με νευρογενή ανορεξία και επισημαίνεται ότι και οι δύο αυτές καταστάσεις μπορεί να αποτελέσουν επιπλοκή σε ασθενείς με χαμηλό BMI. Inadequate awareness of the role of erythrocytic parameters in the detection of beta-thalassemia minor G. Ntaios, A. Chatzinikolaou Journal of Postgraduate Medicine 2008; 54:61 Αναφέρεται σε μελέτη η οποία διεξήχθη με σκοπό να εκτιμηθεί η γνώση από τους ιατρούς της σωστής χρήσης των ερυθροκυτταρικών δεικτών στη διαφοροδιάγνωση της ετερόζυγης β-μεσογειακής αναιμίας από τη σιδηροπενική αναιμία. Επισημαίνεται ότι τα αποτελέσματα δεν είναι ικανοποιητικά και ότι είναι παρόμοια με παλαιότερη μελέτη προ εικοσαετίας. Homocysteine and carotid intima-media thickness in ischemic stroke patients are not correlated G. Ntaios, C. Savopoulos, A. Hatzitolios, I. Ekonomou, E. Destanis, I. Chryssogonidis, A. Chatzinikolaou, I. Pidonia, D. Karamitsos Neuropsychiatric Disease and Treatment 2008; 4:477-479 Κλινικοεργαστηριακή μελέτη σε 97 ασθενείς με ισχαιμικό ΑΕΕ, που χωρίσθηκαν σε δύο ομάδες ανάλογα με τα επίπεδα ομοκυστεΐνης ορού (<15μmol/l ή > 15μmol/l), με σκοπό την διερεύνηση της συσχέτισης της υπερομοκυστεϊναιμίας με την αθηροσκλήρυνση στις καρωτίδες, όπως αυτή εκτιμήθηκε με τον υπερηχωγραφικό προσδιορισμό του λόγου (πάχους) έσω/μέσου χιτώνα (ΙΜΤ) αυτών. Δεν παρατηρήθηκε στατιστικά σημαντική διαφορά του ΙΜΤ στις δύο ομάδες (1,012 mm έναντι 1,015), γεγονός που ερμηνεύεται ως μη συσχέτιση των επιπέδων ομοκυστεΐνης με αθηρωματικές βλάβες των καρωτίδων σε ασθενείς με ισχαιμικό ΑΕΕ. Αντίθετα, τόσο τα επίπεδα φολικού οξέος, όσο και αυτά της Β12 ανευρέθησαν αυξημένα στατιστικά σημαντικά στην ομάδα των ασθενών με ΑΕΕ και επίπεδα ομοκυστεΐνης ορού <15μmol/l. Detection of CD55 and CD59 deficient granulocytic populations in patients with myelodysplastic syndrome G. Kaiafa, A. Papadopoulos, G. Ntaios, Z. Saouli, C. Savopoulos, N. Tsesmeli, Z. Kontoninas, A. Chatzinikolaou, V. Tsavdaridou, I. Klonizakis, A. Hatzitolios Annals of Hematology 2008; 87:257-62 Ερευνητική κλινικοεργαστηριακή μελέτη σε 110 άτομα (90 με ΜΔΣ που ταξινομήθηκαν στις 5 υποομάδες αυτού και 20 μάρτυρες) μέσης ηλικίας 38-89 ετών. Μελετήθηκε με τη μέθοδο της κυτταρομετρίας ροής η συχνότητα της ανεπάρκειας των μορίων CD55 και CD59 ξεχωριστά, αλλά και η ταυτόχρονη ανεπάρκειά τους (κλώνος της νυχτερινής παροξυσμικής αιμοσφαιρινουρίας-ΠΝΑ κλώνος) στα πολυμορφοπύρηνα των 110 αυτών ατόμων. Το αντιγόνο CD59 στα πολυμορφοπύρηνα ασθενών με ΜΔΣ αποτελεί περισσότερο ευαίσθητο δείκτη από το αντιγόνο CD55 για την παρουσία του ΠΝΑ κλώνου. Η εντονότερη παρουσία του ΠΝΑ φαινότυπου και ιδιαίτερα της ανεπάρκειας του CD59 στις 3 τελευταίες, χειρότερες προγνωστικά, υποομάδες των ΜΔΣ αποδίδεται στο γεγονός των συνθηκών ανεπάρκειας του μυελού των οστών, που παρέχουν ένα «πλεονέκτημα» επιβίωσης και περαιτέρω εξάπλωσης στους GPI-ανεπαρκείς. Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency in Northern Greece G. Ntaios, A. Chatzinikolaou, C. Tomos, C. Manolopoulos, P. Karalazou, A. Nikolaidou, S. Alexiou-Daniel Internal Medicine Journal 2008; 38:204-6 Αναδρομική εργαστηριακή μελέτη με σκοπό να εκτιμηθεί η επίπτωση της έλλειψης της γλυκόζο-6-φωσφορικής αφυδρογονάσης στη Βόρειο Ελλάδα. Μελετήθηκαν 5161 νεογέννητα μεταξύ 06/2001 και 03/2007. Διαπιστώθηκε ότι 6.3% των νεογέννητων παρουσίασαν έλλειψη του ενζύμου. Η επίπτωση που υπολογίστηκε είναι μεγαλύτερη σε σχέση με την υπόλοιπη Ελλάδα. Επίσης, διαπιστώθηκε ότι είναι μεγαλύτερη στον ανδρικό πληθυσμό σε σχέση με το γυναικείο πληθυσμό – σχεδόν διπλάσια. Recurrent peripheral facial paresis may constitute the sole clinical manifestation in Neuro-Behcet Disease A. Hatzitolios, C. Savopoulos, G. Ntaios, E. Tsirogianni, M. Baltatzi, M. Apostolopoulou, E. Dimitrakoudi


60


The Neurologist 2008; 14:77 Αναφέρεται σε κριτική πρόσφατης δημοσίευσης μίας ανασκόπησης του περιοδικού Neurologist, αναφορικά με τις κλινικές εκδηλώσεις της νόσου Neuro-Behcet. Επισημαίνεται ότι ως μοναδική κλινική εκδήλωση μπορεί να είναι η περιφερική πάρεση του προσωπικού νεύρου, κάτι που ήδη δημοσιεύθηκε από την ομάδα μας προ ετών, ως ενδιαφέρον περιστατικό. Vitamins and stroke: the homocysteine hypothesis still in doubt G. Ntaios, C. Savopoulos, A. Chatzinikolaou, G. Kaiafa, A. Hatzitolios The Neurologist 2008; 14:2-4 Ανασκόπηση του ρόλου της ομοκυστεΐνης ως καρδιαγγειακού παράγοντα κινδύνου, των μηχανισμών πρόκλησης αγγειακών βλαβών, των καταστάσεων που προκαλούν υπερομοκυστεϊναιμία και τον θεραπευτικό ρόλο της χορήγησης φυλικού οξέος και βιταμινών Β6 και Β12 στην ελάττωση των επιπέδων ομοκυστεΐνης στον ορό και συνεπώς στην υποστροφή των αθηρωματικών πλακών στα αγγεία και ιδίως στις καρωτίδες. Influence of infections on lipids parameters D. Agapakis, C. Savopoulos, A. Hatzitolios, G. Ntaios, A. Zantidis, E. Massa, V. Tatola, D. Karamitsos Ανακοινώθηκε στο 77th Congress of the European Atherosclerosis Society, April 26-29, 2008, Istanbul, Turkey Περίληψη δημοσιεύθηκε στο Atherosclerosis Supplements (2008) 9(1): 51 Aνακοινώθηκε στο 10ο Συνέδριο Ελληνικής Εταιρείας Λιπιδιολογίας και Αθηροσκλήρωσης Κλινικοεργαστηριακή μελέτη με σκοπό την εκτίμηση της επίδρασης των βακτηριακών λοιμώξεων σε λιπιδαιμικές παραμέτρους, όπως η ολική χοληστερόλη, τα τριγλυκερίδια και οι HDL και LDL. Οι παραπάνω παράμετροι μετρήθηκαν σε 35 ασθενείς που νοσηλεύθηκαν λόγω βακτηριακής λοίμωξης κατά την εισαγωγή και 20 μέρες μετά από τη θεραπεία. Διαπιστώθηκε αύξηση των τριγλυκεριδίων και ελάττωση των υπολοίπων παραμέτρων σε σχέση με τα αρχικά επίπεδα. Implementation of strategy for the management of overt dyslipidemia. The IMPROVE study A. Hatzitolios, V. G. Athyros, A. Karagiannis, C. Savopoulos, C. Charalambous, G. Kyriakidis, Th. Milidis, C. Papathanakis, A. Bitli, I. Vogiatsis, G. Makridis, G. Ntaios, N. Katsiki, A. Symeonidis, D. P. Mikhailidis Aνακοινώθηκε στο 3ο Πανελλήνιο Συνέδριο Αθηροσκλήρωσης, Αθήνα, 3-6 Δεκεμβρίου 2008 Δημοσιεύθηκε στο International Journal of Cardiology, 2009; 134(3):322-9 Πολυκεντρική κλινική μελέτη με σκοπό την εκτίμηση της αποτελεσματικότητας εφαρμογής συγκεκριμένης στρατηγικής με σκοπό τη βελτίωση της αντιμετώπισης του καρδιαγγειακού κινδύνου σε ασθενείς με δυσλιπιδαιμία με ή χωρίς καρδιαγγειακή νόσο. Μελετήθηκαν 1127 ασθενείς, στους οποίους υπήρξε μια αρχική επίσκεψη, η οποία ακολουθήθηκε από προσπάθεια βελτίωσης του lifestyle και φαρμακευτικής αντιμετώπισης όλων των παραγόντων καρδιαγγειακού κινδύνου. Μετά από έξι μήνες, οι ασθενείς επανεξετάσθηκαν. Οι μηχανές PROCAM και Framingham χρησιμοποιήθηκαν για την εκτίμηση του καρδιαγγειακού κινδύνου. Η στρατηγική που ακολουθήθηκε μείωσε κατά 45% (Framingham) και 63% (PROCAM) τον εκτιμώμενο καρδιαγγειακό κίνδυνο στην πρωτογενή πρόληψη. Θρομβοκυττάρωση και υπερκαλιαιμία Ζ. Σαούλη, Φ. Γκιρτοβίτης Χ. Μαργαριτίδης, Ζ. Κοντονίνας, Γ. Χαρισόπουλος, Γ. Ντάιος, Α. Παπαδόπουλος Aνακοινώθηκε στο 33ο Πανελλήνιο Ιατρικό Συνέδριο, Αθήνα 2007 Μελέτη με σκοπό την εκτίμηση της συχνότητας εμφάνισης υπερκαλιαιμίας σε ασθενείς με θρομβοκυττάρωση, τόσο σε ασθενείς με μυελοϋπερπλαστικό σύνδρομο αλλά και σε ασθενείς με δευτεροπαθή θρομβοκυττάρωση, στους οποίους έχουν αποκλεισθεί οι υπόλοιπες αιτίες υπερκαλιαιμίας. Μελετήθηκαν αναδρομικά οι φάκελοι 57 ασθενών (25 άνδρες, 32 γυναίκες με μέσο όρο ηλικίας 62 έτη) οι οποίοι νοσηλεύθηκαν στην Α’ Προπαιδευτική Παθολογική Κλινική του νοσοκομείου ΑΧΕΠΑ από τον Ιανουάριο έως τον Σεπτέμβριο του 2006. Στην διαφορική διάγνωση της υπερκαλιαιμίας πρέπει να λαμβάνονται υπόψιν τα μυελοϋπερπλαστικά νοσήματα και ιδιαίτερα η ιδιοπαθής θρομβοκυττάρωση, μιας και το ποσοστό των ασθενών που εμφανίζουν υπερκαλιαιμία είναι τριπλάσιο του ποσοστού των ασθενών με δευτεροπαθή θρομβοκυττάρωση. Από τους 57, οι 21 ασθενείς παρουσίασαν επίπεδα καλίου ορού >5,1mmol/L αποτελώντας το 37,5% των ασθενών. Ειδικότερα: υπερκαλιαιμία παρατηρήθηκε σε 9 από τους 12 ασθενείς με μυελοϋπερπλαστικό σύνδρομο (3 με ιδιοπαθή πολυερυθραιμία και 6 με ιδιοπαθή θρομβοκυττάρωση), ποσοστό 69% και 10 στους 45 με δευτεροπαθή θρομβοκυττάρωση), ποσοστό 22,2%, (2 με λοιμώξεις, 3 με χρόνια φλεγμονώδη νοσήματα, 3 με νεοπλασίες και 2 με σιδηροπενική αναιμία). Οι τιμές των αιμοπεταλίων κυμάνθηκαν αντίστοιχα από 494x109/μL έως 2.200x109/μL.


61


Spontaneous pneumomediastinum may be associated with both anorexia nervosa and obesity A. Hatzitolios, G. Ntaios

Lung 2007; 185:373 Αναφέρεται σε πρόσφατη δημοσίευση σχετικά με την συσχέτιση του αυτόματου πνευμομεσοθωρακίου με την παχυσαρκία, και με την μορφή επιστολής προς το περιοδικό επισημαίνει ανάλογη συσχέτιση και με περιπτώσεις νευρογενούς ανορεξίας, όπως περιστατικού νεαρής ασθενούς, που προ ετών οι υποφαινόμενοι συγγραφείς δημοσίευσαν. Εικάζεται ότι ακραίες μεταβολές του δείκτου μάζας σώματος, όπως σε καταστάσεις νευρογενούς ανορεξίας ή νοσογόνου παχυσαρκίας μπορεί να υπεισέρχονται στην παθοφυσιολογία πρόκλησης της νόσου με διαφορετικούς προφανώς μηχανισμούς. Re: Discrimination indices as screening tests for β-thalassemic trait G. Ntaios, A. Chatzinikolaou Annals of Hematology 2007; 87:329-30 Απάντηση στο σχολιασμό της μελέτης ‘Discrimination indices as screening tests for β- thalassemic trait’ (Annals of Hematology 2007; 86:487–491) από τους Beyan et al. όπου είχε προταθεί ότι ο αποκλεισμός από τη μελέτη των σιδηροπενικών ασθενών με αιμοσφαιρίνη <8.7g/dl θα μπορούσε να δώσει διαφορετικά αποτελέσματα. Παρουσιάζονται τα αποτελέσματα της μελέτης τροποποιημένα σύμφωνα με την πρόταση των Beyan et al. και διαπιστώνεται ότι τα αποτελέσματα είναι παρόμοια και επομένως, τα συμπεράσματα παραμένουν τα ίδια με αυτά της αρχικής μελέτης Beta-thalassemic trait cannot be safely differentiated from iron deficiency anemia G. Ntaios, A. Chatzinikolaou European Journal of Hematology 2007; 79:554 Αναφέρεται σε δύο πρόσφατες δημοσιεύσεις οι οποίες εξέτασαν την αξιοπιστία των κυριότερων δεικτών που έχουν προταθεί για τη διαφοροδιάγνωση μεταξύ της ετερόζυγης β- μεσογειακής αναιμίας και της σιδηροπενικής αναιμίας. Συγκρίνονται τα αποτελέσματα των δύο μελετών και σημειώνονται οι κυριότερες διαφορές τους, καθώς και το κοινό συμπέρασμα ότι οι παραπάνω δείκτες δεν είναι αξιόπιστοι για τη διαφοροδιάγνωση των δύο παθήσεων Defective platelet aggregation in myelodysplastic syndromes F. Girtovitis, G. Ntaios, A. Papadopoulos, G. Ioannidis, P. Makris Acta Haematologica 2007; 118:117-122 Κλινικοεργαστηριακή μελέτη της λειτουργίας των αιμοπεταλίων με προσδιορισμό της συσσώρευσής τους με τη χρήση ριστοσετίνης, κολλαγόνου, ADP, και αδρεναλίνης σε ασθενείς με μυελοδυσπλαστικό σύνδρομο. Διαπιστώθηκε διαταραχή της συσσώρευσης των αιμοπεταλίων Haemarthrosis after superwarfarin poisoning P. Kotsaftis, F. Girtovitis, A. Boutou, G. Ntaios, P. Makris European Journal of Hematology 2007; 79:255-257 Περιγράφεται ενδιαφέρουσα περίπτωση ασθενούς ο οποίος αποπειράθηκε να αυτοκτονήσει με τρωκτικοκτόνο και παρουσίασε αιμορραγία ανωτέρου πεπτικού, επίσταξη και αίμαρθρο. Σημειώνεται ότι πρόκειται για την πρώτη περίπτωση αίμαρθρου μετά από δηλητηρίαση με τρωκτικοκτόνο που περιγράφεται στη διεθνή βιβλιογραφία Χρόνιες επιπλοκές σε σακχαροδιαβητικούς ασθενείς αγροτικής περιοχής Α. Μακρής, Γ. Ντάιος, Α. Χατζηνικολάου, Κ. Καρδάρας, Θ. Μάνια, Α. Σαργιανίδου, Ι. Χατζηνικολάου Aνακοινώθηκε στο 33ο Πανελλήνιο Ιατρικό Συνέδριο, Αθήνα 2007 Μελέτη με σκοπό τη διερεύνηση της κατανομής και της συχνότητας των χρόνιων επιπλοκών σε σακχαροδιαβητικούς ασθενείς αγροτικής περιοχής. Μελετήσαμε συνολικά 216 σακχαροδιαβητικούς ασθενείς. Αρτηριακή υπέρταση παρουσίαζαν οι 173 (93 άντρες, 80.1%). Χρόνια νεφρική ανεπάρκεια παρουσίαζαν οι 134 (74 άντρες, 62%). Σε 61 ασθενείς (34 άντρες, 28.2%) είχε διαπιστωθεί στεφανιαία νόσος. Δυσλιπιδαιμία παρουσίαζαν οι 43 (21 άντρες, 19.9%). Διαλείπουσα χωλότητα είχε διαπιστωθεί σε 23 (15 άντρες, 10.6%). Δεκαεννιά ασθενείς (10 άντρες, 8.8%) είχαν υποστεί τουλάχιστον ένα αγγειακό εγκεφαλικό επεισόδιο. Αμφιβληστροειδοπάθεια διαπιστώθηκε σε 19 (11 άντρες, 8.8%). Οι ασθενείς της μελέτης παρουσίαζαν σε σημαντικό βαθμό δυσρύθμιστη αρτηριακή πίεση (ΑΠ). Αντίθετα, δυσλιπιδαιμία παρατηρήθηκε σε σχετικά μικρό ποσοστό. Εντύπωση προκαλεί, επίσης, το αρκετά μικρό ποσοστό ασθενών με αμφιβληστροειδοπάθεια, σε σχέση με τα βιβλιογραφικά δεδομένα.


62


Heparin affecting lipid metabolism D. Agapakis, C. Savopoulos, A. Hatzitolios, A. Xanthis, G. Ntaios, D. Karamitsos Ανακοινώθηκε στο 7th International Congress on Coronary Artery Disease – From Prevention to Intervention, Venice, Italy, 7-10/10/07 Περίληψη δημοσιεύθηκε στο περιοδικό «The Journal of Coronary Artery Disease» 7(1):185 Κλινικοεργαστηριακή μελέτη σε 38 ασθενείς που νοσηλεύθηκαν για ισχαιμικό ΑΕΕ, με σκοπό την εκτίμηση της επίδρασης της ηπαρίνης χαμηλού μοριακού βάρους στον μεταβολισμό των λιπιδίων. Συμπεραίνεται ότι η χορήγηση ηπαρίνης χαμηλού μοριακού βάρους συνδέεται με ελάττωση των επιπέδων των τριγλυκεριδίων και με αύξηση των αντιστοίχων της HDL- χοληστερόλης, πιθανώς λόγω ενεργοποίησης της λιποπρωτεϊνικής λιπάσης. Trend in incidence of cardiovascular risk factors in elderly and over-aged stroke patients between 2003 and 2007 in Greece P. Kotsaftis, G. Ntaios, C. Savopoulos, R. Kiparoglou, D. Agapakis, M. Baltatzi, N. Tsesmeli, A. Hatzitolios, Aνακοινώθηκε στο 21ο Συνέδριο της Διαβητολογικής Εταιρείας Βορείου Ελλάδος, Θεσσαλονίκη 2007 Ανακοινώθηκε στο 77th Congress of the European Atherosclerosis Society,26-29/04/08, Istanbul, Turkey Δημοσιεύθηκε στο περιοδικό ‘Διαβητολογικά Χρονικά’, in press Περίληψη δημοσιεύθηκε στο περιοδικό ‘Διαβητολογικά Χρονικά’ 2007; 20:144 Περίληψη δημοσιεύθηκε στο Atherosclerosis Supplements (2008) 8(1): 221 Δημοσιεύθηκε στο Archives of Gerontology and Geriatrics, 2009, in press Κλινική μελέτη σε 175 ασθενείς (124 ηλικιωμένοι 65-80 ετών και 51 υπέργηροι ηλικίας > 80 ετών), που νοσηλεύθηκαν εντός έτους με ισχαιμικό ΑΕΕ (ι-ΑΕΕ), με σκοπό την καταγραφή των παραγόντων καρδιαγγειακού κινδύνου (ΠΚΚ), καθώς και του ρόλου του ΣΔ ως παράγοντα κινδύνου στους ασθενείς αυτούς. Συγχρόνως έγινε και σύγκριση με τα αποτελέσματα ανάλογης παλαιότερης (προ 5ετίας) μελέτης μας σε 160 ασθενείς. Με βάση τα αποτελέσματα των δύο μελετών, συμπεραίνεται ότι η ΑΥ μόνη ή σε συνδυασμό με άλλους ΠΚΚ αποτελεί τον κυρίαρχο ΠΚΚ για ι-ΑΕΕ. Ο ΣΔ δεν αποτελεί συχνό μεμονωμένο ΠΚΚ, ωστόσο, η συνύπαρξη-παθοφυσιολογική συσχέτισή του με τους άλλους ΠΚΚ, τον καθιστά δεύτερο κατά σειρά σημαντικότητας ΠΚΚ, ιδιαίτερα στην ομάδα των ηλικιωμένων. Συγκριτικά με την παλαιότερη μελέτη μας, η σημαντικότερη διαφορά που παρατηρήθηκε αφορά το μειωμένο ποσοστό προηγούμενου ι-ΑΕΕ, παρά μάλιστα την αυξημένη παρουσία του σημαντικότερου ΠΚΚ δηλαδή της ΑΥ, γεγονός που θα μπορούσε να αποδοθεί στην βελτίωση της αντιμετώπισης της ΑΥ στα πλαίσια της πρωτογενούς πρόληψης τα τελευταία χρόνια. Αντίθετα δεν παρατηρήθηκε διαφορά στην παρουσία του ΣΔ ως ΠΚΚ στους ασθενείς των δύο μελετών. Eίδος αντιθρομβωτικής αγωγής που χορηγήθηκε σε ασθενείς με ισχαιμικό ΑΕΕ σε πανεπιστημιακή παθολογική κλινική Α.Π.Θ Α.Ξάνθης, Γ. Ντάιος, Α.Ι.Χατζητόλιος, Χ.Σαββόπουλος, Δ.Αγαπάκης, Ε.Μπουλτούκας Aνακοινώθηκε στο 33ο Πανελλήνιο Ιατρικό Συνέδριο, Αθήνα 2007 Αναδρομική μελέτη που καταγράφει το είδος της αντιθρομβωτικής αγωγής που χορηγήθηκε σε ασθενείς που νοσηλεύθηκαν με οξύ ισχαιμικό ΑΕΕ σε πανεπιστημιακή παθολογική κλινική Α.Π.Θ. Βρέθηκε ότι 57% έλαβε κλοπιδογρέλη, 23% ασπιρίνη, 13% δικουμαρόλη και 5% ηπαρίνη ΧΜΒ, ενώ μόνο 2% έλαβε το συνδυασμό ασπιρίνης και κλοπιδογρέλης. Hypertrophic pulmonary osteoarthropathy secondary to bronchial adenocarcinoma and coexisting pulmonary tuberculosis: a case report G. Ntaios, A. Adamidou, D. Karamitsos Προφορική ανακοίνωση στο 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Περίληψη δημοσιεύθηκε στο περιοδικό «Ελληνική Ιατρική» 73 (Supl):72, 2007 Δημοσιεύθηκε στο περιοδικό Cases Journal 2008; 1:221 Περιγράφεται ενδιαφέρουσα περίπτωση ασθενούς με επώδυνο οίδημα και αρθρίτιδα των καρπών και των σφυρών, έντονο πόνο στις κνήμες και πληκτροδακτυλία, στον οποίο διεγνώσθη αδενοκαρκίνωμα του δεξιού κάτω πνευμονικού λοβού. Παράλληλα, διαπιστώθηκε ότι ο ασθενής έπασχε επίσης από πνευμονική φυματίωση, καθώς απομονώθηκε το μυκοβακτηρίδιο της φυματίωσης σε καλλιέργεια πτυέλων. Επισημαίνεται η συνύπαρξη δύο διαφορετικών καταστάσεων (φυματίωση και πνευμονικός καρκίνος) που προκάλεσαν από κοινού υπερτροφική οστεοαρθροπάθεια. Evaluation of use of proton pump inhibitors in Greece


63


G. Ntaios, A. Chatzinikolaou, G. Kaiafa, C. Savopoulos, A. Hatzitolios, D. Karamitsos Ανακοινώθηκε στο 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Περίληψη δημοσιεύθηκε στο περιοδικό «Ελληνική Ιατρική» (Supl):76, 2007 Δημοσιεύθηκε στο περιοδικό European Journal of Internal Medicine 2009; 20(2):171-3. Κλινική αναδρομική μελέτη 1693 νοσηλευομένων στην Α΄ Προπαιδευτική Παθολογική Κλινική το χρονικό διάστημα 7/2005-9/2006, στην οποία καταγράφηκαν οι περιπτώσεις συνταγογράφησης ανασταλτών αντλίας πρωτεϊνης (PPIs) ή Η2 αναστολέων με τις αντίστοιχες διαγνώσεις. Με βάση τα αποτελέσματα της μελέτης, συμπεραίνεται ότι οι PPIs μονοπωλούν την προτίμηση των ιατρών στις γαστροοισοφαγικές παθήσεις (430 έναντι μόνο 11 συνταγογραφήσεις Η2 αναστολέων), με τη συχνότερη αιτία συνταγογράφησής τους την γαστροπροστασία, παρά το γεγονός ότι δεν αποτελεί επίσημη ένδειξη χορήγησής τους. Τονίζεται η ανάγκη συνυπολογισμού της επιβάρυνσης στο κόστος της Δημόσιας Υγείας, ειδικά σε περιπτώσεις που οι λόγοι συνταγογράφησης δεν είναι ιδιαίτερα ισχυροί. Συσχέτιση αιμορραγίας πεπτικού έλκους και ομάδας αίματος. Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Α. Ξάνθης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Χ. Σαββόπουλος, Α. Χατζητόλιος Ανακοινώθηκε στο 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Περίληψη δημοσιεύθηκε στο περιοδικό «Ελληνική Ιατρική» (Supl):76, 2007 Κλινικοεργαστηριακή αναδρομική μελέτη σε 102 νοσηλευόμενους για αιμορραγία ανωτέρου πεπτικού ασθενείς, με σκοπό την ανεύρεση κάποιας συσχέτισης μεταξύ κάποιας ομάδας αίματος και της αιμορραγίας αυτής. Μετά αντίστοιχο προσδιορισμό της ομάδας αίματος και σε 102 εθελοντές αιμοδότες που χρησιμοποιήθηκαν ως ομάδα ελέγχου, συμπεραίνεται ότι στην ομάδα Α παρατηρούνται συχνότερα αιμορραγίες πεπτικού (41,5%), σε σχέση με το τι θα αναμένονταν με βάση τη συχνότητα της ομάδας αυτής στο γενικό πληθυσμό (34,7%). Αντίθετα δεν παρατηρήθηκε στατιστικά σημαντική διαφορά μεταξύ των ποσοστών των ομάδων αίματος Β, ΑΒ και Ο, ανάμεσα στην υποομάδα των ασθενών και μαρτύρων. Συσχετισμός επιπέδων φερριτίνης με το υποκείμενο νόσημα. Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Χ. Σαββόπουλος, Α. Χατζητόλιος Ανακοινώθηκε στο 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Περίληψη δημοσιεύθηκε στο περιοδικό «Ελληνική Ιατρική» (Supl):74, 2007 Κλινικοεργαστηριακή αναδρομική μελέτη 1513 νοσηλευόμενων ασθενών στην Α΄ Προπαιδευτική Παθολογική Κλινική κατά το χρονικό διάστημα 6/2005-9/2006. Ως ανώτερες φυσιολογικές τιμές φερριτίνης, ορίσθηκαν τα 320 mg/dl στους άνδρες και τα 120 mg/dl στις γυναίκες. Συμπεραίνεται ότι η συχνότερη αιτία αύξησης της φερριτίνης ήταν οι λοιμώξεις 31,2%, 673 mg/dl), ενώ ακολουθεί η αιμοσιδήρωση στους πολυμεταγγιζόμενους ασθενείς (27,3%, 1312 mg/dl), όπου παρατηρείται και η υψηλότερη τιμή φερριτίνης. Αντίθετα, είναι αρκετά χαμηλότερη σε κακοήθειες (22,4%, 849 mg/dl) και χρόνιες παθήσεις (3,1 %, 902 mg/dl σε νοσήματα συνδετικού ιστού, 12,1%, 570 mg/dl σε αλκοολική ηπατίτιδα/κίρρωση ήπατος). Soluble receptor of advanced glycation end products is related to coronary atheromatosis estimated by quantitative coronary angiography in diabetic men A Xanthis, A. Hatzitolios, G Koliakos, S Hatzimiltiadis, S Fidani, G.Ntaios, G. Giannakoulas Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07 Κλινικοεργαστηριακή μελέτη στην οποία συσχετίστηκαν τα επίπεδα των ‘soluble Receptor of Advanced Glycation End-products’ (sRAGE) με το αθηροσκληρωτικό φορτίο στα στεφανιαία αγγεία διαβητικών ασθενών, όπως αυτό υπολογίστηκε με τη βοήθεια στεφανιαίας αγγειογραφίας. Τα επίπεδα sRAGE μετρήθηκαν με ELISA και τεχνικές φθορισμού. Διαπιστώθηκε ότι τα επίπεδα sRAGE παρουσίασαν αντίστροφη συσχέτιση με το αθηροσκληρωτικό φορτίο και τονίζεται η ανάγκη διερεύνησης της σημασίας των sRAGE σαν προγνωστικός δείκτης καρδιαγγειακών νοσημάτων. Levels of serum β2 microglobulin and lactate dehydrogenase in myeloproliferative disorders Z. Kontoninas, Z. Saouli, A. Papadopoulos, G. Kaiafa, V. Tsavdaridou, F. Girtovitis, G. Charisopoulos, G. Ntaios

Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07 Κλινικοεργαστηριακή μελέτη με σκοπό να καθοριστούν τα επίπεδα β-2 μικροσφαιρίνης σε ασθενείς με μυελοϋπερπλαστικά σύνδρομα και η συσχέτιση τους με τα επίπεδα της γαλακτικής αφυφρογονάσης (LDH). Μελετήθηκαν 19 ασθενείς και διαπιστώθηκαν αυξημένα επίπεδα β-2 μικροσφαιρίνης σε 26% αυτών, οι οποίοι παρουσίασαν επίσης αυξημένα επίπεδα LDH. Προτείνεται η μέτρηση των επιπέδων β-2 μικροσφαιρίνης σε ασθενείς με μυελοϋπερπλαστικά σύνδρομα, καθώς είναι πιθανό


64


να συσχετίζονται με την πρόγνωση της νόσου. Hyponatremia caused by syndrome of inappropriate antidiuretic hormone secretion D Agapakis, K Tzavella, G Ntaios, Ch Margaritidis, E Massa, Ch Savopoulos, A Hatzitolios, D Karamitsos. Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07 Κλινική μελέτη με σκοπό την εκτίμηση της συχνότητας και των αιτιών που προκάλεσαν σύνδρομο απρόσφορης έκκρισης αντιδιουρητικής ορμόνης (SIADH) σε ασθενείς με υπονατριαιμία που νοσηλεύθηκαν στην Α΄ Προπαιδευτική Παθολογική Κλινική. Μελετήθηκαν 150 ασθενείς με υπονατριαιμία. Διαπιστώθηκε ότι οι συχνότερες αιτίες ήταν τα κακοήθη νοσήματα, βλάβες του κεντρικού νευρικού συστήματος, φάρμακα και πνευμονικά νοσήματα, καθώς και ότι το SIADH αποτελεί τη συχνότερη αιτία υπονατριαιμίας. Homocysteine levels in patients with Myeloproliferative and cerebrovascular disease G. Ntaios, C. Savopoulos, Z. Saouli, G. Kaiafa, A. Papadopoulos, A. Hatzitolios, Z. Kontoninas, D. Agapakis, A. Chatzinikolaou, C. Margaritidis Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07 Κλινικοεργαστηριακή μελέτη με σκοπό τη σύγκριση των επιπέδων ομοκυστεΐνης μεταξύ ασθενών με μυελοϋπερπλαστικό σύνδρομο (ομάδα Α), με οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο (ΑΕΕ, ομάδα Β)και υγιείς μάρτυρες (ομάδα Γ). Διαπιστώθηκε ότι τα επίπεδα ομοκυστεΐνης στις ομάδες Α και Β ήταν σημανιτκά αυξημένα σε σχέση με την ομάδα Γ. Προτείνεται ότι πιθανώς τα υψηλά επίπεδα ομοκυστεΐνης να συμβάλλουν στην αυξημένη επίπτωση θρομβοτικών επεισοδίων στους ασθενείς με μυελοϋπερπλαστικά σύνδρομα. Cardiac valvular lesions in patients with Myeloproliferative diseases A. Papadopoulos, Ch. Pliakos, Z. Kontoninas, Z. Saouli, G. Kaiafa, F. Girtovitis, G. Charisopoulos, V. Tsavdaridou, G. Ntaios

Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07 Κλινικοεργαστηριακή μελέτη με σκοπό να εκτιμηθεί η συχνότητα εμφάνισης βαλβιδοπάθειας σε ασθενείς με μυελοϋπερπλαστικά σύνδρομα. Εξετάσθηκαν 19 ασθενείς με μυελοϋπερπλαστικό σύνδρομο και παρατηρήθηκαν βαλβιδικές διαταραχές (κυρίως ανεπάρκειες των βαλβίδων) σε ποσοστό 57.8%. Προτείνεται η καρδιολογική εξέταση με τη βοήθεια υπερηχογραφήματος στους ασθενείς με μυελοϋπερπλαστικό σύνδρομο με σκοπό την εκτίμηση της καρδιακής λειτουργίας Copper and iron status in myelodysplastic syndromes Z. Saouli, G. Kaiafa, Z. Kontoninas, H. Tsoukali, N. Raikos, F. Girtovitis, G. Charisopoulos, G. Ntaios, A. Papadopoulos Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07 Ανακοινώθηκε στο 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 8-11/12/07 Περίληψη δημοσιεύθηκε στο Blood 2007; 110:3B Κλινικοεργαστηριακή μελέτη με σκοπό την εκτίμηση των επιπέδων χαλκού και σιδήρου σε ασθενείς με μυελοδυσπλαστικό (ΜΔΣ) σύνδρομο. Μελετήθηκαν 36 ασθενείς με ΜΔΣ, οι οποίοι χωρίστηκαν σε δύο ομάδες: η πρώτη ομάδα συμπεριέλαβε τους πολυμεταγγιζόμενους ασθενείς, ενώ οι δεύτερη αυτού που δε χρείζονταν μετάγγιση ή χρειάζονταν σπάνια. Παρατηρήθηκε μείωση των επιπέδων του χαλκού και αύξηση των επιπέδων του σιδήρου στους ασθενείς της πρώτης ομάδας, ενώ στη δεύτερη τα επίπεδα και των δύο ήταν φυσιολογικά. Προτείνεται ότι τα χαμηλά επίπεδα χαλκού στους πολυμεταγγιζόμενους ασθενείς με ΜΔΣ πιθανώς να οφείλονται στην υπερφόρτωση με σίδηρο. Copper Levels in Patients with Hematological Malignancies Z. Saouli, M. Diamantidis, A. Papadopoulos, G. Kaiafa, F. Girtovitis, Z. Kontoninas, G. Ntaios, C. Andreadis, C. Savopoulos, A. Hatzitolios Ανακοινώθηκε στο 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 2008 Κλινικοεργαστηριακή μελέτη με σκοπό την εκτίμηση των επιπέδων χαλκού σε διάφορα αιματολογικά νοσήματα, καθώς και τη συσχέτιση των επιπέδων του χαλκού με την έκταση της νόσου και τον πιθανό ρόλο τους στη σταδιοποίηση της νόσου. Μελετήθηκαν 77 ασθενείς με διάφορα αιματολογικά νοσήματα και 50 υγιείς μάρτυρες. Τα επίπεδα χαλκού ήταν φυσιολογικά στους υγιείς μάρτυρες. Σε ασθενείς με υποτροπές της νόσου παρατηρήθηκαν αυξημένα επίπεδα χαλκού, ενώ σε ασθενείς με ύφεση της νόσου διαπιστώθηκαν φυσιολογικά επίπεδα. Τονίζεται η ανάγκη διενέργειας περισσότερων μελετών με σκοπό τη διερεύνηση του ρόλου των επιπέδων χαλκού στη σταδιοποίηση αιματολογικών νοσημάτων.


65


Factor V Deficiency in a Patient with Polycythemia Vera and Huntington’s Chorea F. Girtovitis, M. Diamantidis, G. Kaiafa, N. Constantinou, D. Lazaridou, Z. Saouli, G. Ntaios, Z. Kontoninas, C. Andreadis, A. Papadopoulos Ανακοινώθηκε στο 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 2008 Περιγράφεται ενδιαφέρουσα περίπτωση ασθενούς, η οποία έπασχε από αληθή πολυκυτταραιμία και χορεία του Huntington και στην οποία διαπιστώθηκε παράταση του PT και του aPTT. Από τον εργαστηριακό έλεγχο διαπιστώθηκε σημαντική μείωση του παράγοντα V. Σημειώνεται ότι η έλλειψη του παράγοντα V είναι μια ιδιαίτερα σπάνια κατάσταση. Correlation of red blood cells and platelets parameters Z. Saouli, G. Kaiafa, F. Girtovitis, Z. Kontoninas, G. Ntaios, G. Charisopoulos, V. Tsavdaridou, C. Aggouridaki, A. Papadopoulos Ανακοινώθηκε στο 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 8-11/12/07 Περίληψη δημοσιεύθηκε στο Blood 2007; 110:7B Εργαστηριακή μελέτη με σκοπό να εξεταστεί εάν υπάρχει συσχέτιση μεταξύ των αιμοπεταλιακών δεικτών MPV (μέσος όγκος αιμοπεταλίων), PCT (αιμοπεταλιοκρίτης), PDW (platelet volume deviation width) και των ερυθροκυτταρικών δεικτών HCT (αιματοκρίτης), MCV (μέσος όγκος ερυθροκυττάρων), RDW (red blood cell volume deviation width). Μελετήθηκαν 303 υγιείς εθελοντές αιμοδότες. Ο αυτόματος αναλυτής; Που χρησιμοποιήθηκε ήταν ο Coulter®LH780. Διαπιστώθηκε ότι α) δεν υπάρχει σημαντική συσχέτιση μεταξύ HCT και PCT και μεταξύ των MCV και MPV, β) υπάρχει σημαντική συσχέτιση μεταξύ RDW και PDW, κάτι που δείχνει ότι η ανισοκυττάρωση των ερυθρών και των αιμοπεταλίων μπορεί να συνυπάρχει. Macrocytosis in COPD and course of the disease Z. Kontoninas, F. Girtovitis, G. Kaiafa, G. Ntaios, Z. Saouli, A. Hatzitolios, G. Charisopoulos, C. Savopoulos, A. Papadopoulos Ανακοινώθηκε στο 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 8-11/12/07 Περίληψη δημοσιεύθηκε στο Blood 2007; 110:3B Κλινικοεργαστηριακή μελέτη με σκοπό να διερευνηθεί αν υπάρχει συσχέτιση μεταξύ της μακροκυττάρωσης και της βαρύτητας της Χρόνιας Αποφρακτικής Πνευμονοπάθειας (ΧΑΠ). Διαπιστώθηκε ότι αυξημένες τιμές του μέσου όγκου των ερυθροκυττάρων (MCV) συσχετίστηκε με λιγότερες παροξύνσεις της νόσου. Διερεύνηση αιτιών ικτέρου σε ασθενείς παθολογικής κλινικής Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Χ. Σαββόπουλος, Α. Χατζητόλιος Ανακοινώθηκε στο 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Περίληψη δημοσιεύθηκε στο περιοδικό «Ελληνική Ιατρική» (Supl):74, 2007 Κλινικοεργαστηριακή αναδρομική μελέτη 1612 νοσηλευόμενων ασθενών κατά το χρονικό διάστημα 7/2005-9/2006, με σκοπό την καταγραφή και διερεύνηση των νοσημάτων που προκαλούν ίκτερο σε ασθενείς νοσηλευόμενους σε Παθολογική κλινική. Η ηπατική κίρρωση αποτελεί τη συχνότερη αιτία εμφάνισης ικτέρου (20%, 5,6 mg/dl), ενώ και οι αιμολυτικές αναιμίες αντιπροσωπεύουν ένα εξίσου σημαντικό ποσοστό (17,6%, 2,9 mg/dl). Σε 3,6% δεν εξακριβώθηκε αιτία εμφάνισης ικτέρου, ενώ σε περιπτώσεις αλκοολικής ηπατίτιδας παρατηρήθηκαν οι υψηλότερες τιμές χολερυθρίνης (6,9 mg/dl). Discrimination indices as screening tests for β- thalassemic trait G. Ntaios, A. Chatzinikolaou, Z. Saouli, F. Girtovitis, M. Tsapanidou, G. Kaiafa, Z. Kontoninas, A. Nikolaidou, C. Savopoulos, I. Pidonia, S. Alexiou-Daniel Ανακοινώθηκε στο 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Περίληψη δημοσιεύθηκε στο περιοδικό «Ελληνική Ιατρική» (Supl):75, 2007 Ανακοινώθηκε στο 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 8-11/12/07 Περίληψη δημοσιεύθηκε στο Blood 2007; 110:21B Δημοσιεύθηκε στο περιοδικό Annals of Hematology 2007; 86:487–491 Εργαστηριακή μελέτη στην οποία μελετήθηκε η ευαισθησία, η ειδικότητα και η αξιοπιστία των κυριότερων δεικτών που έχουν προταθεί για τη διαφοροδιάγνωση μεταξύ της ετερόζυγης β- μεσογειακής αναιμίας και της σιδηροπενικής αναιμίας. Συγκεκριμένα, μελετήθηκαν οι δείκτες Mentzer, Green & King), RDW , England & Fraser, RDW και RBC count σε 373 ασθενείς με ετερόζυγη β- μεσογειακή αναιμίας και 120 ασθενείς με σιδηροπενική αναιμία. Διαπιστώθηκε ότι οι παραπάνω δείκτες δεν είναι αξιόπιστοι για τη διαφοροδιάγνωση μεταξύ των δύο παθήσεων, αλλά ούτε καν για την ανίχνευση (screening) περιπτώσεων ετερόζυγης β- μεσογειακής αναιμίας.


66


Ρύθμιση της Αρτηριακής Πίεσης και Βλάβη σε Όργανα Στόχους σε θεραπευόμενους υπερτασικούς ασθενείς, πάσχοντες και μη από μεταβολικό σύνδρομο Μ. Μπαλτατζή, Α. Χατζητόλιος, Χ. Σαββόπουλος, Χ. Δημητρούλα, Ν. Κατσίκη, Γ. Ντάιος, Π. Κοτσάφτης, Μ. Αποστολοπούλου Ανακοινώθηκε στο 3ο Ετήσιο Συνέδριο Αθηροσκλήρωσης, Θεσσαλονίκη 2007 Κλινικοεργαστηριακή μελέτη σε 729 υπερτασικούς ασθενείς με συνύπαρξη ή μη Μεταβολικού Συνδρόμου (ΜΣ), που παρακολουθούνται στα Εξωτερικά Ιατρεία Υπέρτασης της Α΄ Προπαιδευτικής Παθολογικής Κλινικής, με σκοπό τον καθορισμό του ποσοστού ρύθμισης της ΑΠ σε σχέση και με την ανεύρεση βλάβης στα όργανα- στόχους (ΒΟΣ). 26,3% έπασχαν από ΜΣ, βλάβη σε όργανα-στόχο (ΒΟΣ) εμφάνιζε το 72,9 των ασθενών με ΜΣ και το 27,9% χωρίς, αρρύθμιση ΑΠ το 30,21% των ασθενών με ΜΣ και το 15,1% χωρίς, ενώ τέλος οι ασθενείς με ΜΣ ελάμβαναν 3 ή περισσότερα φάρμακα σε σχέση μ’ αυτούς χωρίς (p< 0,0001). Συμπεραίνεται ότι οι υπερτασικοί με ΜΣ ρυθμίζουν την ΑΠ σε μικρότερο ποσοστό, με περισσότερες κατηγορίες φαρμάκων, εμφανίζουν δε υψηλότερα ποσοστά ανθεκτικής ΑΥ και ΒΟΣ, συγκριτικά με όσους δεν πάσχουν από ΜΣ, ακόμα και υπό παρακολούθηση σε εξειδικευμένο ιατρείο ΑΥ. Κακοήθης υπέρταση νεφραγγειακής αιτιολογίας σε μονόνεφρο νεφρό Α. Μύρου, Χ. Σαββόπουλος, Α. Χατζητόλιος, Μ. Μπαλτατζή, Γ. Ντάιος, Φ. Ηλιάδης, Χ. Δημητρούλα, Κ. Γιαβρόγλου Ανακοινώθηκε στο 10ο Πανελλήνιο Συνέδριο Αρτηριακής Υπέρτασης, Θεσσαλονίκη, 1-3 /02/07 Παρουσιάζεται ενδιαφέρουσα περίπτωση κακοήθους υπέρτασης σε νεαρή ενήλικα, λειτουργικά μονόνεφρο ΑΡ, ως πρώτη εκδήλωση νεφραγγειακής υπέρτασης, λόγω ινομυωματώδους δυσπλασίας της ΔΕ νεφρικής αρτηρίας. Συζητείται η ενδελεχής κλινικοεργαστηριακή διερεύνηση επί υποψίας νεφραγγειακής υπέρτασης, καθότι η ασφαλής διάγνωση και έγκαιρη παρέμβαση προλαμβάνει σοβαρές επιπλοκές και οδηγεί σε μόνιμη ίαση. Serum cholesterol levels and sepsis G. Ntaios, D. Agapakis, C. Savopoulos, E. Massa, A. Chatzinikolaou, G. Kaiafa, A. Hatzitolios Ανακοινώθηκε στο 76th Congress of the European Atherosclerosis Society, Helsinki, Finland, 10-13/06/07 Περίληψη δημοσιεύθηκε στο Atherosclerosis supplements 2007; 8: 34 Κλινικοεργαστηριακή μελέτη με σκοπό τη εκτίμηση των τιμών της ολικής χοληστερόλης σε σηπτικούς ασθενείς και η αξιολόγηση της σημασίας αυτών των αλλαγών. Μετρήθηκαν τα επίπεδα ολικής χοληστερόλης σε 29 ασθενείς. Διαπιστώθηκε ότι στους σηπτικούς ασθενείς οι οποίοι τελικά κατέληξαν, τα επίπεδα ολικής χοληστερόλης μειώθηκαν την 5-7η μέρα σε σχέση με τα επίπεδα κατά την εισαγωγή. Αντίθετα, αυξήθηκαν στους ασθενείς που τελικά επέζησαν. Προτείνεται ότι οι αλλαγές των επιπέδων ομοκυστεΐνης στους σηπτικούς ασθενείς θα μπορούσαν να χρησιμεύσουν στην πρόγνωση της τελικής έκβασης. Διερεύνηση αιτιών υπονατριαιμίας σε παθολογική κλινική Δ. Αγαπάκης, Κ. Τζαβέλλα, Χ. Μαργαριτίδης, Γ. Ντάιος, Α. Ξάνθης, Α. Χατζηχηδήρογλου, Δ. Καραμήτσος Ανακοινώθηκε στο 21o Ιατρικό Συνέδριο Ενόπλων Δυνάμεων, Θεσσαλονίκη, 23-26/11/2006 Προοπτική μελέτη παρατήρησης των αιτιών υπονατριαιμίας ασθενών που νοσηλεύθηκαν στην Α’ Προπαιδευτική Παθολογική Κλινική κατά τη διάρκεια ενός έτους. Μελετήθηκαν 120 ασθενείς που εμφάνισαν υπονατριαιμία. Προκύπτει ότι η πλειονότητα των περιπτώσεων αφορά σε υποωσμωτικές υπονατριαιμίες και συγκεκριμένα τις υπερογκαιμικές με κύριο αίτιο την καρδιακή ανεπάρκεια, ενώ σε μεγάλο ποσοστό ανευρίσκεται και το SIADH. Θρομβοεμβολικές επιπλοκές και καρκίνος Φ. Γκιρτοβίτης, Κ. Τζαβέλλα, Γ. Ντάιος, Γ. Χαρισόπουλος, Π. Κοτσάφτης, Α. Μύρου, Π. Μακρής, Σ. Παπαμίχος, Π.Ε. Μακρής Ανακοινώθηκε στο 17ο Πανελλήνιο Αιματολογικό Συνέδριο, Αθήνα, 22-26/11/2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Αίμα-Haema» (επίσημο όργανο του Ελληνικής Αιματολογικής Εταιρείας), 2006;9 Suppl(1): 126 Παρουσιάζονται οι περιπτώσεις τριών ασθενών που εμφάνισαν θρομβοεμβολικές επιπλοκές συνδεόμενες άμεσα με νεοπλασία και σημειώνεται η συσχέτιση μεταξύ καρκίνου και θρομβοεμβολικής νόσου. Predictive value of lactate dehydrogenase in myelodysplastic syndromes A. Papadopoulos, F. Girtovitis, Z. Saouli, G. Kaiafa, Z, Kontoninas, G. Charisopoulos, G. Ntaios, D. Sioutis Ανακοινώθηκε στο 17ο Πανελλήνιο Αιματολογικό Συνέδριο, Αθήνα, 22-26/11/2006


67


Περίληψη δημοσιεύθηκε στο περιοδικό «Αίμα-Haema» (επίσημο όργανο του Ελληνικής Αιματολογικής Εταιρείας), 2006;9 Suppl(1): 126 Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/007 Κλινικοεργαστηριακή μελέτη με σκοπό να εκτιμηθούν τα επίπεδα των τιμών της γαλακτικής αφυδρογονάσης (LDH) στον ορό ασθενών με πρωτοπαθές μυελοδυσπλαστικό σύνδρομο (ΜΔΣ) και να συσχετιστούν με την πρόγνωση των ΜΔΣ όπως αυτή εκτιμάται με την κατάταξη τους κατά FAB. Από τα αποτελέσματα προέκυψε ότι η LDH μπορεί να συμβάλλει στον καθορισμό της πρόγνωσης ασθενών με ΜΔΣ. Guillain Barre syndrome after influenza immunization G. Ntaios, A. Adamidou, A. Chatzinikolaou, D. Agapakis, Z. Saouli, A. Karlovasitou, D. Karamitsos Ανακοινώθηκε στο 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10-3/11/06 Περίληψη δημοσιεύθηκε στο περιοδικό «Ιατρικό Βήμα» (επίσημο όργανο του Πανελλήνιου Ιατρικού Συλλόγου) Suppl : σελ. 73, 2006 Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/007 Δημοσιεύθηκε στο Ελληνική Ιατρική 2005, 71(4): 292-295 Περιγράφεται ενδιαφέρουσα περίπτωση ασθενούς ο οποίος εκδήλωσε σύνδρομο Guillain-Barre, το οποίο πιθανότατα προκλήθηκε από αντιγριπικό εμβολιασμό που είχε προηγηθεί. Χορηγήθηκε ανοσοσφαιρίνη για πέντε μέρες και ο ασθενής παρουσίασε σημαντική βελτίωση. Τονίζεται ότι σπάνια, ο αντιγριπικός εμβολιασμός μπορεί να οδηγήσει σε εκδήλωση του συνδρόμου και ότι για αυτό το λόγο, συστήνεται η αποφυγή του εμβολίου σε άτομα που έχουν νοσήσει από το σύνδρομο παλαιότερα. Συχνότητα νοσημάτων σε ασθενείς παθολογικής κλινικής τριτοβάθμιου νοσοκομείου Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Μ. Μπαλτατζή, Φ. Ηλιάδης, Α. Χατζηνικολάου, Γ. Καϊάφα, Δ. Καραμήτσος. Ανακοινώθηκε στο 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Ιατρικό Βήμα» (επίσημο όργανο του Πανελλήνιου Ιατρικού Συλλόγου) Suppl : σελ. 73, 2006 Κλινική αναδρομική μελέτη 1280 ασθενών, μέσης ηλικίας 64,97 έτη, που νοσηλεύθηκαν το χρονικό διάστημα 7/2005-9/2006, με σκοπό την καταγραφή και τον προσδιορισμό της συχνότητας των κυριότερων κατηγοριών νοσημάτων σε νοσηλευόμενους σε Παθολογική Κλινική Τριτοβάθμιου Νοσοκομείου. Μετά την ανάλυση των αποτελεσμάτων, προέκυψε ότι ο ΣΔ είναι το συχνότερο νόσημα, το οποίο απαντά στους νοσηλευθέντες ασθενείς της Κλινικής μας (19,3%), οι λοιμώξεις ακολουθούν σε ποσοστό 16%, ενώ η ΧΑΠ, η ΣΝ, η ΚΑ, τα ΑΕΕ και τα αιματολογικά νοσήματα ανευρέθηκαν σε εξίσου σημαντικό ποσοστό ασθενών (από 10,8 έως 11,8%). Οξεία Πυελονεφρίτιδα: κλινικό-επιδημιολογικά στοιχεία Γ. Ντάιος, Χ. Σαββόπουλος, Δ. Αγαπάκης, Α. Χατζητόλιος, Ι. Οικονόμου, Ε. Δεστάνης, Α. Χατζηνικολάου, Γ. Καϊάφα. Ανακοινώθηκε στο 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Ιατρικό Βήμα» (επίσημο όργανο του Πανελλήνιου Ιατρικού Συλλόγου) Suppl : σελ. 80, 2006 Κλινικοεργαστηριακή αναδρομική μελέτη 27 νοσηλευομένων για οξεία πυελονεφρίτιδα ασθενών, με σκοπό την καταγραφή των κλινικοεπιδημιολογικών στοιχείων τους. 14/27 (51%), δηλαδή περισσότεροι από τους μισούς αναφέρουν ιστορικό ουρολοιμώξεων, 2/27 (7,4%) ιστορικό ΣΔ, 6/27 (22,2%) ουροκαθετήρα πριν το επεισόδιο της λοίμωξης και 8/27 (29,6%) νοσηλεία σε νοσοκομείο το τελευταίο δίμηνο. Το συχνότερο μικρόβιο που ταυτοποιήθηκε ήταν η E. Coli (64%), με μεγάλη διαφορά στη συχνότητα απομόνωσης από τα υπόλοιπα (Proteus sp. 7,4%, Klebsiella Pneumonia 3,7%, κ.α). Σε όλα τα περιστατικά υπήρξε θετική έκβαση με ίαση, η αγωγή ήταν αρχικά εμπερική και υπήρξε τροποποίηση μόνο σε 3 περιπτώσεις, με βάση το αντιβιόγραμμα. Το σχήμα που χορηγήθηκε ήταν κινολόνη (66,6%) και συνδυασμός αμοξυκιλλίνης/κλαβουλανικού οξέος (11,1%). Λιπιδαιμικό προφίλ ηλικιωμένων ασθενών παθολογικής κλινικής τριτοβάθμιου νοσοκομείου Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Μ. Μπαλτατζή, Φ. Ηλιάδης, Δ. Αγαπάκης, Α. Χατζηνικολάου, Γ. Καϊάφα Ανακοινώθηκε στο 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Ιατρικό Βήμα» (επίσημο όργανο του Πανελλήνιου Ιατρικού Συλλόγου) Suppl : σελ. 7, 2006 Κλινικοεργαστηριακή μελέτη σε τυχαίο δείγμα 504 ασθενών ηλικίας > 65 ετών που νοσηλεύθηκαν στην Κλινική για διάφορες


68


αιτίες, με σκοπό την καταγραφή του λιπιδαιμικού τους προφίλ και την εφαρμογή υπολιπιδαιμικής αγωγής. 125/504 (24,8%) είχαν τιμές ολικής χοληστερόλης > 200mg/dl και 110/504 (21,8%) επίπεδα LDL χοληστερόλης > 120 mg/dl κατά την ημέρα της εισαγωγής τους στην Κλινική. Με βάση το γεγονός ότι η ηλικία αποτελεί μη τροποποιήσιμο παράγοντα κινδύνου για καρδιαγγειακά νοσήματα, συμπεραίνεται ότι ο συνδυασμός της με ακόμη έναν παράγοντα κινδύνου, όπως η δυσλιπιδαιμία, απαιτεί τροποποίηση των διαιτητικών συνηθειών και του τρόπου διαβίωσης των ασθενών αυτών, με παράλληλη φαρμακευτική αγωγή όπου κρίνεται απαραίτητη, ώστε να εξασφαλισθεί η ήδη διαπιστωμένη αύξηση του μέσου όρου επιβίωσης. Parathyroid crisis as first manifestation of primary hyperparathyroidism G. Ntaios, C. Savopoulos, A. Chatzinikolaou, G. Kaiafa, A. Hatzitolios, D. Karamitsos. Ανακοινώθηκε στο 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Ιατρικό Βήμα» (επίσημο όργανο του Πανελλήνιου Ιατρικού Συλλόγου) Suppl : σελ. 57, 2006 Δημοσιεύθηκε στο περιοδικό Ελληνική Ιατρική 73(2):1-4 Δημοσιεύθηκε στο περιοδικό European Journal of Internal Medicine 2007; 18:551-552 Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/007 Παρουσιάζεται ενδιαφέρουσα περίπτωση 61χρονης ασθενούς, που προσήλθε με κλινική συμπτωματολογία κεντρικού νευρικού συστήματος (κεφαλαλγία, έμετοι, βυθιότητα, διαταραχές συμπεριφοράς) και από τον εργαστηριακό έλεγχο διαπιστώθηκε βαριά υπερασβεστιαιμία (Ca++ ορού 17,6 mg/dl), η οποία φαίνεται ότι εμφανίσθηκε οξέος, αφού σε εργαστηριακό έλεγχο ρουτίνας προ λίγων μηνών η τιμή του Ca++ ήταν φυσιολογική. Αντιμετωπίσθηκε συμπτωματικά επιτυχώς με ενυδάτωση, φουροσεμίδη και ζολενδρονάτη και από την διερεύνηση με απεικονιστικό έλεγχο, αποκαλύφθηκε αδένωμα στον κάτω δεξιό παραθυρεοειδικό αδένα, το οποίο και αφαιρέθηκε χειρουργικά την όγδοη ημέρα νοσηλείας της ασθενούς. Συζητείται ο διαγνωστικός και θεραπευτικός αλγόριθμος της υπερασβεστιαιμίας, ενώ τονίζεται η σημασία αποκλεισμού του πρωτοπαθούς υπερπαραθυρεοειδισμού (παραθυρεοειδική κρίση), σε κάθε περίπτωση σοβαρής υπερασβεστιαιμίας. Διερεύνηση αιτιών σιδηροπενικής αναιμίας σε ασθενείς παθολογικής κλινικής Γ. Ντάιος, Γ. Καϊάφα, Ζ. Σαούλη, Χ. Σαββόπουλος, Α. Χατζητόλιος, Α. Χατζηνικολάου, Ε. Τσιαούση, Α. Παπαδόπουλος Ανακοινώθηκε στο 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Ιατρικό Βήμα» (επίσημο όργανο του Πανελλήνιου Ιατρικού Συλλόγου) Suppl : σελ. 101, 2006 Κλινικοεργαστηριακή μελέτη 1280 ασθενών (μέσης ηλικίας 65,7 έτη) νοσηλευόμενων για διάφορες αιτίες κατά το χρονικό διάστημα 8/2005-9/2006. Σε 53 (4,1%) ανευρέθη σιδηροπενική αναιμία με τιμές Fe ορού < 60mg/dl και φερριτίνης < 30mg/dl. Συμπεραίνεται, με βάση τα αποτελέσματα της μελέτης, ότι το πεπτικό έλκος είναι η πιο σημαντική αιτία σιδηροπενικής αναιμίας σε νοσηλευόμενους της παθολογικής κλινικής (33,96%), με άλλα συχνά αίτια την προηγηθείσα γαστρεκτομή, την μηνορραγία και τις κακοήθειες του πεπτικού σωλήνα (7,5 % αντίστοιχα για εκάστη εξ’ αυτών). Ανάλυση περιστατικών εκούσιας φαρμακευτικής δηλητηρίασης Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Δ. Αγαπάκης, Α. Χατζηνικολάου, Σ. Μαγειρία, Α. Χατζηχηδήρογλου, Γ. Καϊάφα Ανακοινώθηκε στο 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Ιατρικό Βήμα» (επίσημο όργανο του Πανελλήνιου Ιατρικού Συλλόγου) Suppl : σελ., 2006 Κλινική αναδρομική μελέτη 24 ασθενών, μέσης ηλικίας 31,9 έτη, που νοσηλεύθηκαν για εκούσια φαρμακευτική δηλητηρίαση. Σε 17/24 (70,83%) χρησιμοποιήθηκε μόνο μία ουσία, ενώ στις υπόλοιπες 7/24, περισσότερες. Σε 6/24 υπήρχε ιστορικό ψυχιατρικού νοσήματος, ενώ σε 3/24 (12,5%) ταυτόχρονη λήψη αλκοόλ. Όλοι οι ασθενείς εξετάσθηκαν από ψυχίατρο, σε 2/24 (8,3%) συστήθηκε άμεση εισαγωγή σε ψυχιατρική κλινική, ενώ σε 14/24 (58,3%) παραπομπή σε τακτικά ιατρεία ψυχιατρικής. Φαρμακευτική δηλητηρίαση παρατηρήθηκε συχνότερα στις γυναίκες, με κύρια χρήση μη στεροειδών αντιφλεγμονωδών φαρμάκων και βενζοδιαζεπινών. Τέλος, συμπεραίνεται ότι η τελική έκβαση είναι κατά κανόνα άριστη, αλλά οι ασθενείς χρήζουν συνήθως περαιτέρω ψυχιατρικής παρακολούθησης. Causes of microcytosis in the general Greek population G. Ntaios, Z. Saouli, C. Savopoulos, A. Chatzinikolaou, G. Kaiafa, Z. Kontoninas, D. Agapakis Ανακοινώθηκε στο 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Ιατρικό Βήμα» (επίσημο όργανο του Πανελλήνιου Ιατρικού Συλλόγου) Suppl : σελ. 73, 2006 Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/007


69


Κλινική αναδρομική μελέτη με σκοπό τη διερεύνηση των συνηθέστερων αιτιών μικροκυττάρωσης/υποχρωμίας σε ασθενείς που νοσηλεύονται σε παθολογική κλινική. Μελετήθηκαν αναδρομικά οι φάκελοι 83 ασθενών στους οποίους διαπιστώθηκε μικροκυττάρωση ή/και υποχρωμία και καταγράφηκαν οι αιτίες. Διαπιστώθηκε ότι η ετερόζυγη β-μεσογειακή αναιμία είναι η συχνότερη αιτία ενώ ακολουθεί σε συχνότητα η χρόνια γαστρίτιδα. Διερεύνηση τριψήφιας ΤΚΕ σε ασθενείς παθολογικής πανεπιστημιακής κλινικής του ΑΠΘ Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζηνικολάου, Ζ. Σαούλη, Δ. Αγαπάκης, Γ. Καϊάφα, Δ. Καραμήτσος Ανακοινώθηκε στο 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Ιατρικό Βήμα» (επίσημο όργανο του Πανελλήνιου Ιατρικού Συλλόγου) Suppl : σελ. 73, 2006 Κλινική αναδρομική μελέτη με σκοπό να διερευνηθούν οι συχνότερες αιτίες τρψήφιας ταχύτητας καθίζησης των ερυθρών (ΤΚΕ) μεταξύ των ασθενών της Παθολογικής Κλινικής. Μελετήθηκαν αναδρομικά οι φάκελοι 53 ασθενών που νοσηλεύθηκαν με τριψήφια ΤΚΕ και διαπιστώθηκε ότι οι συχνότερη αιτία ήταν οι σοβαρές βακτηριακές λοιμώξεις, οι νεοπλασίες και τα νοσήματα του συνδετικού ιστού. Atypical petechial rash at the lower extremities due to Parvovirus B19 infection G. Ntaios, A. Chatzihidiroglou, A. Chatzinikolaou, F. Iliadis, A. Adamidou, D. Karamitsos Ανακοινώθηκε στο 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Ιατρικό Βήμα» (επίσημο όργανο του Πανελλήνιου Ιατρικού Συλλόγου) Suppl : σελ., 2006 Δημοσιεύθηκε στο περιοδικό International Journal of Dermatology 2008; 47:760-762 Δημοσιεύθηκε στο περιοδικό Ελληνική Ιατρική 2007, 73(3): 243-246 Ανακοινώθηκε στο 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/007 Περιγράφεται ενδιαφέρουσα περίπτωση ασθενούς ο οποίος παρουσίασε πορφυρικό εξάνθημα στα κάτω άκρα που αποδόθηκε σε λοίμωξη από ιό Parvo B19. Σημειώνεται ότι πρόκειται για την πρώτη περίπτωση λοίμωξης από Parvo B19 που εκδηλώνεται με τέτοιας κατανομής πορφυρικό εξάνθημα. Υπομαγνησιαιμία σε οξύ ΑΕΕ Δ. Αγαπάκης, Χ. Σαββόπουλος, Ε. Μάσσα, Γ. Ντάιος, Α. Ξάνθης, Α. Χατζητόλιος Ανακοινώθηκε στο 7ο Παμπελοποννησιακό Ιατρικό Συνέδριο, Πάτρα 2006 Κλινικοεργαστηριακή μελέτη σε 40 ασθενείς με οξύ ΑΕΕ (πρώτο επεισόδιο) και σε 25 υγιείς μάρτυρες αντίστοιχων ανθρωπομετρικών στοιχείων, στους οποίους προσδιορίσθηκαν τα επίπεδα Mg του ορού το 1ο 24ωρο, με σκοπό την διερεύνηση της διαταραχής των επιπέδων Mg σε ασθενείς με οξύ ΑΕΕ (όλες οι άλλες αιτίες υπομαγνησιαιμίας απεκλείσθησαν). Με βάση την υπομαγνησιαιμία που παρουσίασαν οι περισσότεροι ασθενείς (28) έναντι των μαρτύρων, συμπεραίνεται ότι κατά το οξύ ΑΕΕ δυνατόν να παρατηρηθεί υπομαγνησιαιμία, που οφείλεται πιθανώς στην εσωτερική ανακατανομή του κατιόντος αυτού στον οργανισμό, λόγω της αυξημένης απελευθέρωσης κατεχολαμινών. Επίσης, θεωρείται αναγκαία η έγκαιρη αντιμετώπιση της υπομαγνησιαιμίας τις πρώτες ώρες εκδήλωσης του ΑΕΕ, με σκοπό την βελτίωση της κλινικής εικόνας και πιθανώς και της απώτερης πρόγνωσης των ασθενών (νευροπροστατευτικός ρόλος Mg). Cholesterol-to-HDL ratio in patients with chronic obstructive pulmonary disease D. Agapakis, G. Ntaios, C. Savopoulos, E. Massa, A. Chatzinikolaou, G. Kaiafa, A. Hatzitolios Ανακοινώθηκε στο 10ο Συνέδριο της Ελληνικής Εταιρείας Λιπιδιολογίας και Αθηροσκλήρωσης, Αθήνα, 26-27/05/06 Ανακοινώθηκε στο 76th Congress of the European Atherosclerosis Society, Finland, 2007 Περίληψη δημοσιεύθηκε στο Atherosclerosis Supplements (2006) 8(1): 34 Κλινικοεργαστηριακή μελέτη του λιπιδαιμικού προφίλ ασθενών που πάσχουν από χρόνια αποφρακτική πνευμονοπάθεια (ΧΑΠ). Μελετήθηκαν 24 άνδρες ασθενείς με ΧΑΠ και διαπιστώθηκε ότι είχαν αυξημένη HDL, ενώ δεν παρουσίαζαν αυξημένη τάση για αθηρογένεση όπως έμμεσα προκύπτει από τη μέτρηση των λιπιδίων. Σπάνια εκδήλωση θρομβοπενίας σε νεαρό ενήλικα με HIV λοίμωξη Ι. Χατζηζήσης, Ζ. Σαούλη, Γ. Χαρισόπουλος, Γ. Ντάιος, Γ. Καϊάφα, Α. Παπαδόπουλος Ανακοινώθηκε στο 21Ο Βορειοελλαδικό Ιατρικό Συνέδριο, ,2006 Περίληψη δημοσιεύθηκε στο περιοδικό «Ελληνική Ιατρική» 72 (supl 1):161, 2006


70


Κλινική μελέτη στην οποία παρουσιάζεται ενδιαφέρουσα περίπτωση 44χρονου ασθενούς με θρομβοπενία (20.000 PLT/μl) ως πρώτη εκδήλωση λοίμωξης HIV (διάγνωση με μέθοδο Elisa και επιβεβαίωση με WESTERN BLOT μέθοδο). Συμπεραίνεται ότι σε κάθε ασθενή νεαρής ηλικίας, με θρομβοπενία, θα πρέπει να μπαίνει στη διαφοροδιάγνωση και η HIV λοίμωξη. Εν τω βάθει φλεβική θρόμβωση ως πρώτη εκδήλωση καρκίνου παχέος εντέρου Κ. Τζαβέλλα, Γ. Ντάιος, Δ. Αγαπάκης, Φ. Γκιρτοβίτης, Α. Χατζημπαλόγλου, Κ. Γιαβρόγλου, Ε. Δεστάνης, Δ. Κολιούσκας, Π. Μακρής Ανακοινώθηκε στις Ελληνικές Ημέρες Θρόμβωσης – Καρκίνος και Θρόμβωση, Θεσσαλονίκη, 10-11/02/2006 Περιγράφεται ενδιαφέρουσα περίπτωση ασθενούς που παρουσίασε εν τω βάθει φλεβική θρόμβωση στο αριστερό κάτω άκρο, η οποία ήταν παρανεοπλαστική εκδήλωση αδιάγνωστου μέχρι εκείνη τη στιγμή καρκίνου του παχέος εντέρου με ηπατικές μεταστάσεις. Τονίζεται ότι σε κάθε περίπτωση εν τω βάθει φλεβικής θρόμβωσης θα πρέπει να αποκλείεται η περίπτωση κακοήθειας, ιδιαίτερα στις περιπτώσεις που η θρόμβωση δε μπορεί να αποδοθεί σε άλλη αιτία. Apolipoprotein A-1, apolipoprotein B and lipoprotein (a) levels at patients with ischemic stroke D. Agapakis, G. Ntaios, E. Massa, C. Savopoulos, G. Kaiafa, A. Hatzitolios Ανακοινώθηκε στο XIV International Symposium on Atherosclerosis, Rome, Italy, 18-22/06/2006 Περίληψη δημοσιεύθηκε στο Atherosclerosis Supplements (2006) 8(1): 34 Κλινικοεργαστηριακή μελέτη με σκοπό τη μέτρηση των επιπέδων ApoA-1, ApoB1 και LP(a) σε ασθενείς με οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο (ΑΕΕ) και η συσχέτιση τους με την επίπτωση των ΑΕΕ. Μετρήθηκαν οι τιμές των παραπάνω παραμέτρων σε 52 ασθενείς με ΑΕΕ. Διαπιστώθηκε ότι τα αυξημένα επίπεδα Lp(a) και ApoB και τα μειωμένα επίπεδα ApoA-1 σχετίζονται με αυξημένο κίνδυνο εμφάνισης ΑΕΕ. Προτείνεται η μέτρηση των παραπάνω παραμέτρων στο πλαίσιο εκτίμησης του συνολικού καρδιαγγειακού κινδύνου. Hyperhomocysteinemia as a risk factor for stroke D. Agapakis, G. Ntaios, E. Massa, C. Savopoulos, G. Kaiafa, A. Hatzitolios Ανακοινώθηκε στο XIV International Symposium on Atherosclerosis, Rome, Italy, 18-22/06/2006 Περίληψη δημοσιεύθηκε στο Atherosclerosis Supplements (2006) 7(3): 108 Κλινικοεργαστηριακή μελέτη με σκοπό να συγκριθούν τα επίπεδα ομοκυστεΐνης μεταξύ των ασθενών με οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο (ΑΕΕ) που νοσηλεύθηκαν στην Α΄ Προπαιδευτική Παθολογική Κλινική και υγιών μαρτύρων και να διερευνηθεί η συσχέτιση μεταξύ των επιπέδων ομοκυστεΐνης και ΑΕΕ. Μετρήθηκαν τα επίπεδα ομοκυστεΐνης σε 58 ασθενείς με ΑΕΕ και 40 υγιείς μάρτυρες. Διαπιστώθηκε σημαντική διαφορά μεταξύ των δύο ομάδων (40% vs. 17.5%) όσον αφορά την επίπτωση της υπερομοκυστεϊναιμίας. Συμπεραίνεται ότι η υπερομοκυστεϊναιμία συσχετίζεται με υψηλό κίνδυνο για ΑΕΕ. Προτείνεται η μέτρηση των επιπέδων ομοκυστεΐνης σε υγιή άτομα στο πλαίσιο εκτίμησης του καρδιαγγειακού κινδύνου, ιδιαίτερα σε αυτά που παρουσιάζουν και άλλους παράγοντες καρδιαγγειακού κινδύνου. Νεοπλασματικοί ασθενείς στην αιμοκάθαρση Μ. Μαλλιάρα, Ι. Παπαδόπουλος, Π. Σπανού, Γ. Ντάιος, Α. Σαργιαννίδου, Ο. Λιάμος, Ι. Φωτιάδης Ανακοινώθηκε στο 11ο Παγκρήτιο Ιατρικό Συνέδριο, Χανιά, 1-3/11/02 Αναδρομική μελέτη στην οποία εξετάσθηκε η συχνότητα και συμπεριφορά των ασθενών με νεόπλασμα στην αιμοκάθαρση κατά την πενταετία 1996-2001 στο Γενικό Νοσοκομείο Κατερίνης. Διαπιστώθηκε ότι η εμφάνιση νεοπλάσματος δεν είναι ασυνήθης σε ασθενείς του τεχνητού νεφρού, καθώς και ότι ανέχονται καλώς τη συνεδρία, επομένως δε θα πρέπει να αποκλείονται από αυτή εξαιτίας του νεοπλάσματος. Προβλήματα των διαβητικών ασθενών στην αιμοκάθαρση Μ. Μαλλιάρα, Γ. Ντάιος, Π. Σπανού, Α. Σαργιαννίδου, Ο. Λιάμος, Ι. Φωτιάδης Ανακοινώθηκε στο 11ο Παγκρήτιο Ιατρικό Συνέδριο, Χανιά, 1-3/11/02 Αναδρομική μελέτη στην οποία εξετάσθηκαν τα προβλήματα των διαβητικών ασθενών στη μονάδα τεχνητού νεφρού του Γενικού Νοσοκομείου Κατερίνης. Διαπιστώθηκε ότι οι διαβητικοί ανέχονται ικανοποιητικά τη συνεδρία αιμοκάθαρσης με αποτέλεσμα την παράταση και βελτίωση της ποιότητας ζωής τους.


71

ΚΑΤΑΤΑΞΗ ΕΡΓΑΣΙΩΝ & ΒΙΒΛΙΟΓΡΑΦΙΚΕΣ ΑΝΑΦΟΡΕΣ 23 Φεβρουαρίου 2016

ΚΑΤΑΤΑΞΗ ΕΡΓΑΣΙΩΝ & ΒΙΒΛΙΟΓΡΑΦΙΚΕΣ ΑΝΑΦΟΡΕΣ


72


ΠΛΗΡΕΙΣ ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΞΕΝΑ ΠΕΡΙΟΔΙΚΑ

Κατευθυντήριες Οδηγίες

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή The European Stroke Organisation Guidelines: a standard operating procedure

George Ntaios, Natan M. Bornstein, Valeria Caso, Hanne Christensen, Jacques De Keyser, Hans-Christoph Diener, Exuperio Diez-Tejedor, Jose M. Ferro, Gary A. Ford, Armin Grau, Emanuella Keller, Didier Leys, David Russell, Danilo Toni, Guillaume Turc, Bart Van der Worp, Nils Wahlgren, and Thorsten Steiner for the European Stroke Organisation

International Journal of Stroke 2015, online early IF: Αναφορές: 2

1. G. Ntaios, G. Lip. Difficult situations in anticoagulation after stroke: between Scylla and Charybdis. Curent Opinion in Neurology 2016, online early

2. Anani N, et al. Changes in European Label and Guideline Adherence After Updated Recommendations for Stroke Thrombolysis. Circulation: Cardiovascular Quality and Outcomes. 2015; 8: S155-S162

European Stroke Organisation (ESO) guidelines for the management of temperature in patients with acute ischemic stroke

George Ntaios, Tomasz Dziedzic, Patrik Michel, Vasileios Papavasileiou, Jesper Petersson, Dimitre Staykov, Brenda Thomas, and Thorsten Steiner for the European Stroke Organisation

International Journal of Stroke 2015, online early

IF:


73


Πρωτότυπες εργασίες

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή Continuing versus Stopping Prestroke Antihypertensive Therapy in Acute Intracerebral Hemorrhage: A Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke Trial

Kailash Krishnan, Polly Scutt, Lisa Woodhouse, Alessandro Adami, Jennifer L. Becker, Lesley A. Cala, Ana M. Casado, Christopher Chen, Robert A. Dineen, John Gommans, Panos Koumellis, Hanna Christensen, Ronan Collins, Anna Czlonkowska, Kennedy R. Lees, George Ntaios, Serefnur Ozturk, Stephen J. Phillips, Nikola Sprigg, Szabolcs Szatmari, Joanna M. Wardlaw, Philip M. Bath, DSc, FRCP* for the ENOS Investigators


IF: Prediction of Large Vessel Occlusions in Acute Stroke: NIHSS is hard to beat Peter Vanacker, Mirjam Heldner, Michael Amiguet, Mohamed Faouzi, Patrick Cras, George Ntaios, Marcel Arnold, Heinrich P. Mattle, Jan Gralla, Urs Fischer, Patrik Michel Critical Care Medicine 2016, online early IF: Glyceryl trinitrate for acute intracerebral haemorrhage: results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial, a subgroup analysis

Kailash Krishnan, Polly Scutt, Lisa Woodhouse, Alessandro Adami, Jennifer L Becker, Eivind Berge, Lesley A Cala, Ana M Casado, Valeria Caso, Christopher Chen, Hanna Christensen, Ronan Collins, Anna Czlonkowska, Robert A Dineen, John Gommans, Panos Koumellis, Ken Lees, George Ntaios, Serefnur Ozturk, Stephen J Phillips, Stuart J Pocock, Asita de Silva, Nikola Sprigg, Szabolcs Szatmari, Joanna M Wardlaw, Philip M Bath Stroke 2015, online early IF:

Effect of hyperacute (within 6 hours) transdermal glyceryl trinitrate, a nitric oxide donor, on outcome after stroke Lisa Woodhouse, Polly Scutt, Kailash Krishnan, Eivind Berge, John Gommans, George Ntaios, Joanna Wardlaw, Nikola Sprigg, Philip M Bath Stroke 2015, online early IF:

External validation of the ISAN score for predicting stroke-associated pneumonia in the Athens Stroke Registry Vasileios Papavasileiou, Haralampos Milionis, Craig J. Smith, Konstantinos Makaritsis, Benjamin D. Bray, Patrik Michel, Jane Molloy, Efstathios Manios, Konstantinos Vemmos, George Ntaios

Journal of Stroke and Cerebrovascular Diseases 2015, online early IF:

Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis George Ntaios, Vasileios Papavasileiou, Haralampos Milionis, Konstantinos Makaritsis, Anastasia Vemmou, Eleni Koroboki, Efstathios Manios, Konstantinos Spengos, Patrik Michel, Konstantinos Vemmos

Stroke 2015, online early

IF:

Improving the Prediction of Spontaneous and post-thrombolytic Recanalisation in Ischemic Stroke patients P. Vanacker, D. Lambrou, A. Eskandari, M. Cordier, G. Ntaios, P. Maeder, R. Meuli, P. Michel Journal of Stroke and Cerebrovascular Diseases 2015, online early IF:

Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. The ENOS Trial Investigators Lancet 2015; 385:617-28 IF: Αναφορές: 19 (εκ των οποίων, οι 3 αυτοαναφορές) 1. Rothwell P. Blood pressure in acute stroke: which questions remain? Lancet 2015; 385:582-5 2. Krishnan K, Mukhtar S, Lingard J, et al. Performance characteristics of methods for quantifying spontaneous intracerebral

haemorrhage: data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. J Neurol Neurosurg Psychiatry, 2015, online early. doi:10.1136/jnnp-2014-309845


74


3. Gorelick P. Should blood pressure be lowered in acute ischemic stroke? The CATIS trial. Journal of the American Society of hypertension 2015; online early

4. Huang Y, Sharma V, Robinson T, et al. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment. International Journal of Stroke 2015, online early

5. Hornslien A, Sandset E, Igland J, et al. Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). . International Journal of Stroke 2015, online early

6. Toyoda K. Blood pressure management in acute stroke. Respiration and Circulation 2015 ; 63 :682-8 7. Kent T, et al. Improving early clinical trial phase identification of promising therapeutics 8. Lee M, et al. Effect of Blood Pressure Lowering in Early Ischemic Stroke Meta-Analysis. Stroke 2015, online early 9. Sander R. Managing high blood pressure after a stroke. Nursing Older People ; 2015, online early 10. Lin M, et al. Imaging of prehospital stroke therapeutics. Expert Review of Cardiovascular Therapy 2015, online early 11. Hart R, et al. What's new in stroke? Phase III randomized clinical trials of 2012–2014. International Journal of Stroke 2015, online

early 12. Manning L, et al. Short-Term Blood Pressure Variability in Acute Stroke. Post Hoc Analysis of the Controlling Hypertension and

Hypotension Immediately Post Stroke and Continue or Stop Post-Stroke Antihypertensives Collaborative Study Trials. 2015; 46: 1518-1524

13. Carcel C, et al. Timing of Blood Pressure Lowering in Acute Ischemic Stroke. Current atherosclerosis reports 2015 ; 17 :42-6 14. Manning L, et al. Prognostic Significance of Short-Term Blood Pressure Variability in Acute Stroke. Stroke 2015, online early 15. Ferse C, et al. Soll der Blutdruck gesenkt werden? DNP - Der Neurologe und Psychiater 2015 ; 16 :18-20 16. Woodhouse L, et al. Effect of hyperacute (within 6 hours) transdermal glyceryl trinitrate, a nitric oxide donor, on outcome after

stroke. Stroke 2015, online early 17. K. Krishnan, et al. Glyceryl trinitrate for acute intracerebral haemorrhage: results from the Efficacy of Nitric Oxide in Stroke (ENOS)

trial, a subgroup analysis. Stroke 2015, online early 18. Sato S, et al. Blood Pressure Management After Intracerebral Hemorrhage. Current Treatment Options in Neurology 2015; 17:49 19. Krishnan et al. Continuing versus Stopping Prestroke Antihypertensive Therapy in Acute Intracerebral Hemorrhage: A Subgroup

Analysis of the Efficacy of Nitric Oxide in Stroke Trial. Journal of Stroke and Cerebrovascular Diseases 2016, online early

Leukoaraiosis and recurrent stroke risk in patients with and without atrial fibrillation: the Athens Stroke Registry George Ntaios, Gregory Lip, Dimitris Lambrou, Vasileios Papavasileiou, Efstathios Manios, Haralampos J. Milionis, Konstantinos Spengos, Konstantinos P. Makaritsis, and Kostas N Vemmos Neurology 2015, online early IF: 8.30 Αναφορές: 1 (εκ των οποίων η 1 αυτοαναφορά)


ASTRAL-R score Predicts absence of Recanalization after Intravenous Thrombolysis in Acute Ischemic Stroke

Peter Vanacker, Dimitris Lambrou, Mirjam Heldner, David Seiffge, Hubertus Mueller, Ashraf Eskandari, George Ntaios,

Pascal J Mosimann, Roman Sztajzel, Vitor Mendes Pereira, Patrick Cras, Stefan Engelter, Philippe Lyrer, Urs Fischer, Marcel Arnold, and Patrik Michel

Thrombosis and haemostasis 2015, online early

IF: 5.760

Embolic strokes of undetermined source (ESUS) in the Athens Stroke Registry: a descriptive analysis G. Ntaios, V. Papavasileiou, H. Milionis, K. Makaritsis, E. Manios, K. Spengos, P. Michel, K. Vemmos

Stroke 2015;46:176-181

IF: 5.729

Αναφορές: 11 (εκ των οποίων, οι 4 αυτοαναφορές) 1. Llombart V, Antolin-Fontes A, Bustamante A, et al. B-Type Natriuretic Peptides Help in Cardioembolic Stroke Diagnosis: Pooled

Data Meta-Analysis. Stroke 2015, online early

2. Mahagne M, Lachaud S, Suissa L. Letter by Mahagne et al Regarding Article,“Embolic Strokes of Undetermined Source in the Athens Stroke Registry: A Descriptive Analysis”. Stroke 2015, online early

3. Ntaios G, Vemmos K. Response to Letter by Mahagne et al Regarding Article,“Embolic Strokes of Undetermined Source in the Athens Stroke Registry: A Descriptive Analysis”. Stroke 2015, online early

4. Yaghi S, Moon Y, et al. Left Atrial Enlargement and Stroke Recurrence: The Northern Manhattan Stroke Study. Stroke Stroke. 2015; 46:1488-1493

5. Ntaios G, et al. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke 2015, online early

6. Mont L, Marin F, et al. Clinical development of rivaroxaban: emerging new clinical evidences? Future cardiology 2015, online early

7. Papavasileiou V, et al. External validation of the ISAN score for predicting stroke-associated pneumonia in the Athens Stroke Registry. Journal of Stroke and Cerebrovascular Diseases 2015, online early


75


8. Putaala J, et al. Undetermined stroke with an embolic pattern-a common phenotype with high early recurrence risk. Annals of Medicine 2015; online early

9. Li, L., Yiin, G.S., Geraghty, O.C., Schulz, U.G., Kuker, W., Mehta, Z., Rothwell, P.M. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: A population-based study. The Lancet Neurology 2015; 14:903 - 913 .

10. Diener HC, et al. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). International journal of stroke 2015; online early

11. Γ. Εμβολικά εγκεφαλικά απροσδιόριστης προέλευσης. Μια νέα κατηγορία ασθενών με ισχαιμικό εγκεφαλικό επεισόδιο

Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K. Makaritsis, H. Milionis, E. Manios, P. Michel, G.Y.H. Lip, K. Vemmos International Journal of Cardiology 2014; 177:129-33 IF: 6.175

Anaemia on admission predicts short and long-term outcome in patients with acute ischaemic stroke H. Milionis, V. Papavasileiou, A. Eskandari, S. D’Ambrogio-Remillard, G. Ntaios, P. Michel International Journal of Stroke 2014, online early

IF: 4.01

Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-sectional national survey in Greece G. Ntaios, V. Melikoki,, G. Perifanos, K. Perlepe, F. Gioulekas, A. Karagiannaki, I. Tsantzali, C. Lazarou, N. Beradze, E. Poulianiti, M. Poulikakou, F. Palantzas, S. Kaditi, F. Perlepe, G. Sidiropoulos, K. Papageorgiou, V. Papavasileiou, K. Vemmos, K. Makaritsis, G.N. Dalekos Journal of Stroke and Cerebrovascular Diseases 2014, online early

IF: 1.984

Baseline characteristics of the 4011 patients recruited into the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial The ENOS investigators International Journal of Stroke 2014, online early IF: 2.748 Αναφορές: 7 (εκ των οποίων οι 3 αυτοαναφορές) 1. Krishnan K, Mukhtar S, Lingard J, et al. Performance characteristics of methods for quantifying spontaneous intracerebral

haemorrhage: data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. J Neurol Neurosurg Psychiatry 2015; online early, doi:10.1136/jnnp-2014-309845

2. Jordan J. Acute Treatment of Blood Pressure After Ischemic Stroke and Intracerebral Hemorrhage. Neurologic Clinics 2015, online early

3. Woodhouse L, et al. Effect of hyperacute (within 6 hours) transdermal glyceryl trinitrate, a nitric oxide donor, on outcome after stroke. Stroke 2015, online early

4. Κ. Krishnan, et al. Glyceryl trinitrate for acute intracerebral haemorrhage: results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial, a subgroup analysis. Stroke 2015, online early

5. Alawieh A, et al. A rich-club organization in brain ischemia protein interaction network. Scientific reports 2015; 5:13513 6. Sato S, et al. Blood Pressure Management After Intracerebral Hemorrhage. Current Treatment Options in Neurology 2015; 17:49 7. Krishnan et al. Continuing versus Stopping Prestroke Antihypertensive Therapy in Acute Intracerebral Hemorrhage: A Subgroup

Analysis of the Efficacy of Nitric Oxide in Stroke Trial. Journal of Stroke and Cerebrovascular Diseases 2016, online early

Acute imaging does not improve ASTRAL score’s accuracy despite having a prognostic value G. Ntaios, V. Papavasileiou, M. Faouzi, P. Vanacker, M. Wintermark, P. Michel International Journal of Stroke 2014, in press IF: 2.748 Αναφορές: 1 (εκ των οποίων η 1 αυτοαναφορά) 1. G. Ntaios, V. Papavasileiou, P. Michel, et al. Predicting functional outcome and symptomatic intracranial hemorrhage in patients

with acute ischemic stroke: a glimpse into the crystal ball? Stroke 2015, online early

Improving Prediction of Recanalization in Acute Large Vessel Occlusive Stroke P. Vanacker, D. Lambrou, A. Eskandari, P. Maeder, R. Meuli, G. Ntaios, P. Michel Journal of Thrombosis and Haemostasis 2014, in press IF: 6.081 Αναφορές: 2 (εκ των οποίων οι 2 αυτοαναφορές) 1. Vanacker P, Lambrou D, Eskandari A, et al. Improving the Prediction of Spontaneous and post-thrombolytic


76


Recanalisation in Ischemic Stroke patients. Journal of Stroke and Cerebrovascular Diseases 2015, online early 2. Vanacker P, et al. Prediction of large vessel occlusion in acute stroke: NIHSS is hard to beat. Critical Care Medicine

2016, online early Association of ischemic stroke subtype with long-term cardiovascular events G. Ntaios, V. Papavasileiou, K. Makaritsis, H. Milionis, M. Patrik, K. Vemmos European Journal of Neurology 2014, in press IF: 4.162 Αναφορές: 5 (εκ των οποίων οι 2 αυτοαναφορές) 1. Redfors P. Long-term post-stroke outcome. University of Gothenburg. ISBN 978-91-628-9211-1 2. G. Ntaios, V. Papavasileiou, K. Makaritsis, et al. Statin treatment is associated with improved prognosis in patients

with AF-related stroke. International Journal of Cardiology 2014; 177:129-33 3. Song J, et al. Distal Hyperintense Vessels Alleviate Insula Infarction in Proximal Middle Cerebral Artery Occlusion.

International Journal of Neuroscience 2015; DOI:10.3109/00207454.2015.1102139 4. Γ. Ντάιος. Εμβολικά εγκεφαλικά απροσδιόριστης προέλευσης. Μια νέα κατηγορία ασθενών με ισχαιμικό εγκεφαλικό

επεισόδιο 5. Schapira A. Neurology in evolution 2014-2015. Eur J Neurology 2015; 22:1493-1502

Μετά την εκλογή στη θέση Λέκτορα Early major worsening in ischemic stroke: predictors and outcome G. Ntaios, D. Lambrou, D. Cuendet, P. Michel NeuroCritical Care 2013, in press IF: 3.038 Αναφορές: 2 1. Folyovich A, et al. Anomalous equivalent potential temperature: an atmospheric feature predicting days with higher

risk for fatal outcome in acute ischemic stroke—a preliminary study. Enviromental monitoring and assessment 2015; 187:547

2. Aysenne A, et al. Supportive Care and Management of Inhospital Complications. In: Ischemic stroke therapeutics. Srpinger eds 2015:53-68

Low ankle-brachial index predicts 5-year mortality but not recurrent stroke in patients with acute first-ever ischemic stroke H. Milionis, A. Vemmou, G. Ntaios, K. Makaritsis, E. Koroboki, V. Papavasileiou, P. Savvari, K. Spengos, K. Vemmos European Journal of Neurology 2013; 20:1471-8 IF: 4.162 Αναφορές: 5 1. Tziomalos K, Giampatzis V, Bouziana S, et al. The prognostic role of ankle brachial index in patients with acute ischemic stroke.

Hellenic Journal of Atherosclerosis 2014; 5:60-66 2. Schapira A. Recent advances in Neurology 2013-2014. European Journal of Neurology 2014; 211425-34 3. Del Brutto O, Sedler M, Mera R, et al. The association of ankle-brachial index with silent cerebral small vessel disease: results of the

Atahualpa Project. International Journal of Stroke 2015; 10:589-93 4. Ishizuka K, Hoshino T, Uchiyama S. Ankle-brachial index and neurologic deterioration in acute ischemic stroke. Journal of Stroke

and Cerebrovascular Diseases 2014; 23:2506-2510 5. Aboyans V. Polyvascular disease: definition, epidemiology and relevance. Panvascular Medicine 2014, pp. 1-37

The ASTRAL score predicts 5-year dependence and mortality in acute ischemic stroke V. Papavasileiou, H. Milionis, P. Michel, K. Makaritsis, A. Vemmou, E. Koroboki, E. Manios, K. Vemmos, G. Ntaios Stroke 2013;44:1616-1620 IF: 5.729 Αναφορές: 10 (αυτοαναφορές: 2) 1. Kelly A, Bogachan S, Holloway R. Ethical considerations in stroke patients. Current Opinion in Neurology 2014; 27:61-65 2. Ntaios G, Papavasileiou V, Faouzi M, et al. Acute imaging does not improve ASTRAL score’s accuracy despite having a prognostic

value. International Journal of Stroke 2014, in press 3. Tziomalos K, Giampatzis V, Bouziana S, et al. The prognostic role of ankle brachial index in patients with acute ischemic stroke.

Hellenic Journal of Atherosclerosis 2014; 5:60-66 4. Thompson D, Murray G, Sudlow C, et al. Comparison of Statistical and Clinical Predictions of Functional Outcome after Ischemic

Stroke. PLoS ONE 9(10): e110189. doi:10.1371/journal.pone.0110189 5. Tsetsou S, Rossetti A, Michel P, et al. News in Neurology 2014. Revue Medicale Suisse 2015; 11:456-7 6. Baek J, Kim K, Lee Y, et al. Predicting stroke outcome using clinical- versus imaging-based scoring system. Journal of Stroke and

Cerebrovascular Diseases 2015; 24:642-8


77


7. Abilleira S, Ribera A, Quesada H, et al. Applicability of the SPAN-100 index in a prospective and contemporary cohort of patients treated with intravenous rtPA in Catalonia. Neurologia 2014 online early

8. Ntaios G, et al. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke 2015, online early

9. Richoz B, Hugli I, Dami F, et al. Acute stroke chameleons in a university hospital. Neurology 2015; 85:505-11 10. Abdul-Rahim et al. Derivation and Validation of a Novel Prognostic Scale (Modified-Stroke Subtype, Oxfordshire Community

Stroke Project Classification, Age, and Prestroke Modified Rankin) to Predict Early Mortality in Acute Stroke. Stroke 2015, online early

External validation of ASTRAL score to predict 3- and 12-month functional outcome in the China National Stroke Registry G. Liu, G. Ntaios, H. Zheng, Y. Wang, P. Michel, D. Zheng Wang, J. Fang, V. Papavasileiou, L. Liu, K. Dong, C. Wang, X. Zhao, Y. Wang Stroke 2013; 44:1443-5 IF: 5.729 Αναφορές: 8 (αυτοαναφορές: 3) 1. Rempe D. Predicting Outcomes After Transient Ischemic Attack and Stroke. CONTINUUM: Lifelong Learning in Neurology 2014;

20:412-428 2. Reid JM, Dai D, Thompson K, Christian C, Reidy Y, et al. (2014) Five-Simple-Variables Risk Score Predicts Good and Devastating

Outcome after Stroke. Int J Phys Med Rehabil 2:186. doi: 10.4172/2329-9096.1000186 3. Ntaios G, Papavasileiou V, Faouzi M, et al. Acute imaging does not improve ASTRAL score’s accuracy despite having a prognostic

value. International Journal of Stroke 2014, in press 4. Tziomalos K, Giampatzis V, Bouziana S, et al. The prognostic role of ankle brachial index in patients with acute ischemic stroke.

Hellenic Journal of Atherosclerosis 2014; 5:60-66 5. G. Ntaios, V. Papavasileiou, P. Michel, et al. Predicting functional outcome and symptomatic intracranial hemorrhage in patients

with acute ischemic stroke: a glimpse into the crystal ball? Stroke 2015, online early 6. Tsetsou S, Rossetti A, Michel P, et al. News in Neurology 2014. Revue Medicale Suisse 2015; 11:456-7 7. Ntaios G, et al. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke 2015, online early 8. Bustamante et al. Ischemic stroke outcome: A review of the influence of post-stroke complications within the different scenarios of

stroke care. European Journal of Internal Medicine 2015, online early

Aseptic meningoencephalitis mimicking transient ischaemic attacks V. Papavasileiou, H. Milionis, M. Cordier, A. Eskandari, G. Ntaios, P. Michel Infection 2013; 41:485-91 IF: 2.440 Αναφορές: 2 1. Cuinat L, Nasr N, Kamsu J, et al. Meningeal disease masquerading as transient ischemic attack. Journal of Stroke and

Cerebrovascular Diseases 2014; 23:1738-43 2. Marini S, Caruso A, Falcini M, et al. Listeria monocytogenes brainstem infection (rhombencephalitis) mimicking ischemic stroke.

Journal of Clinical Neuroscience 2014; 21:2006-8

CHADS2, CHA2DS2-VASc and long-term stroke outcome in patients without atrial fibrillation G. Ntaios, G.Y.H. Lip, K. Makaritsis, V. Papavasileiou, H. Milionis, A. Vemmou, E. Koroboki, P. Savvari, E. Manios, H. Milionis, K. Vemmos Neurology 2013; 80:1009-17 IF: 8.249 Αναφορές: 39 (εκ των οποίων οι 3 αυτοαναφορές) 1. A. Paoletti Perini, S. Bartolini, P. Pieragnoli, et al. CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart

failure patients candidates to cardiac resynchronization therapy. Europace 2014; 16:71-80 2. M. Cappellari, P. Bovi, N. Micheletti, G. Tomelleri, G. Moretto. The risk stratification based on the CHA2DS2-VASc may predict the

response to intravenous thrombolysis after stroke 3. G. Lip, D. Lane, H. Buller, et al. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation:

The AMADEUS study. Chest 2013, in press 4. Tu H, Campbell B, Meretoja A, et al. Pre-Stroke CHADS2 and CHA2DS2-VASc Scores Are Useful in Stratifying Three-Month

Outcomes in Patients with and without Atrial Fibrillation. Cerebrovasc Dis 2013;36:273-280 5. Lip G. Using the CHADS2 and CHA2DS2-VASc Scores for Stroke Risk Prediction as well as the Identification of Stroke Outcomes

and Cardiac Complications in Patients with and without Atrial Fibrillation. Cerebrovasc Dis 2013;36:281-282 6. Kim J. Chapter 4: Pathophysiology of transient ischemic attack and ischemic stroke. In: Oxford Textbook of Stroke and

Cerebrovascular Disease. Oxford Editions 2013. Edited by Bo Norrving. 7. Chen Q, Yan Y, Zhang L, et al. Effect of Hyperthyroidism on the Hypercoagulable State and Thromboembolic Events in Patients

with Atrial Fibrillation. Cardiology 2014;127:176-182 8. Wyse G, Van Gelder I, Ellinor P, et al. Lone Atrial Fibrillation: Does It Exist? A “White Paper” of the Journal of the American College

of Cardiology. J Am Coll Cardiol. 2014;():. doi:10.1016/j.jacc.2014.01.023 9. Lo Shu-Ya, Wang Yi-Long, Wang Yong-Jun. Developments in Ischemic Stroke with Atrial Fibrillation. Chin J Stroke 2014; 9:252-261 10. Gomez-Doblas JJ, et al. Nuevos datos sobre fibrilacio΄n auricular, observaciones al estudio OFRECE. Respuesta. Rev Esp Cardiol.

2014. http://dx.doi.org/10.1016/j.recesp.2014.02.006 11. Mitchell B, Southern D, Galbraith D, et al. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and


78


CHA2DS2-VASc scores. Heart 2014, online early. doi:10.1136/heartjnl-2013-305303 12. Hankey G, Norrving B, Hacke W, Steiner T. Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke

2014, in press 13. Greve AM, Dalsgaard M, Bang CN et al. Stroke in Patients With Aortic Stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis

Study. Stroke 2014; 2014;45:1939-1946 14. Falsetti L, Viticchi G, Tarquinio N, et al. CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or

pharmacological cardioversion. Journal of Cardiovascular Medicine 2014; 15:636-41 15. G. Lip, C. Laroche, P. Ioachim, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year

Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). European Heart Journal 2014, online early

16. Potpara TS, Polovina MM, Djikic D, Marinkovic JM, Kocev N, et al. (2014) The Association of CHA2DS2-VASc Score and Blood Biomarkers with Ischemic Stroke Outcomes: The Belgrade Stroke Study. PLoS ONE 9(9): e106439. doi:10.1371/journal.pone.0106439

17. G. Ntaios, V. Papavasileiou, H. Milionis, K. Makaritsis, E. Manios, K. Spengos, P. Michel, K. Vemmos. Embolic strokes of undetermined source (ESUS) in the Athens Stroke Registry: a descriptive analysis. Stroke 2014, in press

18. Lau Y, Lip G. Atrial Fibrillation During Sepsis:A Determinant of Long-term Outcomes? Chest. 2014;146(5):1138-1140. 19. Ntaios G, Lip G, Lambrou D, et al. Leukoaraiosis and recurrent stroke risk in patients with and without atrial fibrillation: the Athens

Stroke Registry. Neurology 2015, online early 20. Schmidt B, Chun K. Antithrombotic therapy after left atrial appendage closure. Expert Review of Cardiovascular Therapy 2014,

online early doi:10.1586/14779072.2015.988612 21. Morillas P, Pallares V, Facila L, et al. The CHADS2 Score to Predict Stroke Risk in the Absence of Atrial Fibrillation in Hypertensive

Patients Aged 65 Years or Older. Revista Española de Cardiología 2015 ;68 :485-91. 22. Lo R, Figueroa K, Pulst S, et al. Vascular risk factors and clinical progression in spinocerebellar ataxias. Tremor and other

hyperkintetic movements 2015 ; 5 : doi: 10.7916/D89885S0 23. Glotzer T, Hellkamp A, Lee K, et al. CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Pacemaker Patients

with Sinus Node Dysfunction Independent of Atrial Fibrillation. Canadian Journal of Cardiology 2015 ; 31 :1004-11 24. Apiyasawat S, Tangchareon T, Wisaratapong et al. CHA2DS2-VASc scores Predict Mortality after Hospitalization for atrial

Fibrillation. International Journal of Cardiology 2015, online early 25. Jacobs V, May H, Bair T, et al. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial

fibrillation ablation. Heart Rhythm 2015; 12:681-6 26. Podolecki T, Lenarczyk R, Kowalczyk J, et al. Stroke and death prediction with CHA2DS2-vasc score after myocardial infarction in

patients without atrial fibrillation. Journal of Cardiovascular Medicine 2015, online early 27. Sakamoto Y, Sato S, Hama Y, et al. The relationship between the pre-admission CHA2DS2-VASc score and proximal artery occlusion

in patients with acute stroke and atrial fibrillation. European Journal of Neurology 2015; online early 28. Ntaios G, et al. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke 2015, online early 29. Wolsk E, Lamberts M, et al. Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a

nationwide cohort study. European Journal of Heart Failure 2015, online early 30. Yuan Z, et al. Incidence of ischemic stroke or transient ischemic attack in patients with multiple risk factors with or without atrial

fibrillation: A retrospective cohort study. Current Medical Research and Opinion 2015; 31:1257-1266 31. Fauchier L, et al. Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study. Stroke 2015; 46:2432-7 32. Andersen D, et al. Recurrent Stroke: The Value of the CHA2DS2VASc Score and the Essen Stroke Risk Score in a Nationwide Stroke

Cohort. Stroke. 2015; 46:2491-2497 33. Polenz G, et al. CHA2DS2VASc Score as a Predictor of Cardiovascular Events in Ambulatory Patients without Atrial Fibrillation.

Pacing and Clinical Electrophysiology 2015, online early 34. G. Ntaios, G. Lip. Difficult situations in anticoagulation after stroke: between Scylla and Charybdis. Curent Opinion in Neurology

2016, online early 35. Szymanski F, et al. Can thromboembolic risk be associated with erectile dysfunction in atrial fibrillation patients? Cardiology Journal

2015; 22:446-52 36. Muniz J, et al. Nuevos datos sobre fibrilación auricular, observaciones al estudio OFRECE. Respuesta. Revista Espa de Cardiologia

06/2014; 67(6). DOI:10.1016/j.recesp.2014.02.006 37. Hamid T, et al. Does the CHA2DS2-Vasc score predict procedural and short-term outcomes in patients undergoing transcatheter

aortic valve implantation? Open Heart 2015; 2 38. Kim J. General Concepts: Stroke Mechanisms, Subtyping, and Workup. In: Ischemic stroke therapeutics. Springer eds. 2015:77-92 39. Hayden et al. Rates and determinants of 5-year outcomes after atrial fibrillation-related stroke: A population study. Stroke

2015;46:3488-3493

Blood pressure changes in the acute ischemic stroke and outcome with respect to stroke etiology G. Ntaios, D. Lambrou, P. Michel Neurology 2012; 79:1440 - 1448 IF: 8.249 Αναφορές: 6 (εκ των οποίων η 1 αυτοαναφορά) 1. S Lattanzi, M Silvestrini, L Provinciali. Elevated blood pressure in the acute phase of stroke and the role of angiotensin receptor

blockers. International Journal of Hypertension 2013, in press 2. Zhang, L., Fang, X.-H., Zhang, Z.-Y. Research status of blood pressure management in acute ischemic stroke. 2013; 10:153 - 157 3. Yang, Yingchang (Palo Alto, CA, US). metod and continuously wearable noninvasive apparatus for automatically detecting a stroke

and other abnormal health conditions. United States Patent Application 20140276123. 09/18/2014 4. Muiesan M, Salvetti M, Amadoro V, et al. An update on hypertensive emergencies and urgencies. Journal of cardiovascular

medicine 2015; 16:372-82 5. Kakaletsis N, Ntaios G, Milionis H, et al. Prognostic value of 24-h ABPM in acute ischemic stroke for short, medium and long-term

outcome: A systematic review and meta-analysis. Internationl Journal of Stroke 2015, online early


79


6. Koziolek M, et al. Blood pressure treatment in the acute stage of stroke. Deutsche Medizinische Wochenschrift 140: 1587 - 1592

The type of atrial fibrillation is associated with long- term outcome in patients with acute ischemic stroke G. Ntaios, A. Vemmou, E. Koroboki, P. Savvari, K. Makaritsis, M. Saliaris, G. Andrikopoulos, K. Vemmos International Journal of Cardiology, 2013; 167:1519-23 IF: 5.509 Αναφορές: 5 (εκ των οποίων η 1 αυτοαναφορά) 1. H. Du, J. Fan, Z. Ling, et al. Effect of Nifedipine Versus Telmisartan on Prevention of Atrial Fibrillation Recurrence in Hypertensive

Patients. Hypertension. 2013; 61:786-792. 2. Baturova M, Lindgren A, Shubik Y, et al. Documentation of atrial fibrillation prior to first-ever ischemic stroke. Acta Neurologica

Scandinavica 2014; 129:412-9 3. G. Ntaios, V. Papavasileiou, H. Milionis, K. Makaritsis, E. Manios, K. Spengos, P. Michel, K. Vemmos. Embolic strokes of

undetermined source (ESUS) in the Athens Stroke Registry: a descriptive analysis. Stroke 2014, in press 4. Putaala J, et al. Undetermined stroke with an embolic pattern-a common phenotype with high early recurrence risk. Annals of

Medicine 2015; online early 5. Chang ETY, et al. Modelling the progression of atrial fibrillation: A stochastic individual-based approach. arXiv:1507.07358v2

An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score G Ntaios, M Faouzi, J Ferrari, W Lang, K Vemmos, P Michel Neurology 2012; 78:1916-22 IF: 8.249 Αναφορές: 60 (εκ των οποίων οι 11 αυτοαναφορές)

1. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Response to Saposnik et al. Neurology 2012, in press

2. Rabinstein A, Rundek T. Prediction of outcome after ischemic stroke. The value of clinical scores. Neurology 2012, in press 3. G. Saposnik, A. Guzik, M. Reeves, et al. Stroke Prognostication using Age and NIH Stroke Scale : SPAN-100. Neurology 2012, in press 4. G. Liu, G. Ntaios, H. Zheng, et al. External validation of ASTRAL score to predict 3- and 12-month functional outcome in the China

National Stroke Registry. Stroke 2013, press 5. Ntaios G, Lip G, Makaritsis K, et al. CHADS2, CHA2DS2-VASc and long-term stroke outcome in patients without atrial fibrillation.

Neurology 2013, in press 6. Gian Marco De Marchis, Mira Katan, Anja Weck,et al. Copeptin adds prognostic information after ischemic stroke: Results from the

CoRisk study. Neurology 2013; 80: 1278 - 1286. 7. V. Papavasileiou, H. Milionis, P. Michel, K. Makaritsis, A. Vemmou, E. Koroboki, E. Manios, K. Vemmos, G. Ntaios. The ASTRAL

score predicts 5-year dependence and mortality in acute ischemic stroke. Stroke 2013, in press 8. TH Park, G Saposnik, HJ Bae, et al. iScore Predicts Functional Outcome in Korean Patients With Ischemic Stroke. Stroke 2013, in press.

doi: 10.1161/STROKEAHA.111.000748 9. Turc G, Apoil M, Naggara O, et al. Magnetic resonance imaging-DRAGON score: 3-month outcome prediction after intravenous

thrombolysis for anterior circulation stroke. Stroke 2013; 44:1323-28 10. Wang Yongjun. Stroke: Review of 2012. Chin J Stroke 2013; 8:1-8 11. T. García-Berrocosoa, A. Penalbaa, C. Boada. From brain to blood: New biomarkers for ischemic stroke prognosis. Journal of

proteomics 2013, in press 12. Flint A, Faigeles B, Cullen S, et al. THRIVE Score Predicts Ischemic Stroke Outcomes and Thrombolytic Hemorrhage Risk in VISTA.

Stroke 2013 ; 94 :138-148 13. Flint A, Xiang B, Gupta R, et al. THRIVE Score Predicts Outcomes With a Third-Generation Endovascular Stroke Treatment Device in

the TREVO-2 Trial. Stroke 2013, in press 14. Ntaios G, Papavasileiou V, Makaritsis K, et al. Intravenous insulin treatment in acute stroke: a systematic review and meta-analysis of

randomized controlled trials. International Journal of Stroke 2013, in press 15. Saposnik G. Validation of Stroke Prognostic Scores: What Do Clinicians Need to Know? Neuroepidemiology 2013;41:219-220 16. Otite F, Mink S, Ozan Tan C, et al. Impaired Cerebral Autoregulation Is Associated With Vasospasm and Delayed Cerebral Ischemia

in Subarachnoid Hemorrhage. Stroke 2014, in press 17. Chapman S, et al. Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of

acute ischemic stroke. Vascular Health and Risk Management 2014, in press 18. Kelly A, Bogachan S, Holloway R. Ethical considerations in stroke patients. Current Opinion in Neurology 2014; 27:61-65 19. Vanacker P, Lambrou D, Eskandari A, et al. Improving prediction of recanalization in acute large vessel occlusive stroke. Journal of

Thrombosis and Haemostasis 2014, online early 20. Lo Shu-Ya, Wang Yi-Long, Wang Yong-Jun. Developments in Ischemic Stroke with Atrial Fibrillation. Chin J Stroke 2014; 9:252-261 21. Mendelsohn D, Haw S, Illes J. Convergent Expert Views on Decision-Making for Decompressive Craniectomy in Malignant MCA

Syndrome. Neuroethics 2014, in press. DOI: 10.1007/s12152-014-9206-3 22. Geurts M, Macleod M, van Thiel G, et al. End-of-life decisions in patients with severe acute brain injury. Lancet Neurology 2014, in

press 23. Rempe D. Predicting Outcomes After Transient Ischemic Attack and Stroke. CONTINUUM: Lifelong Learning in Neurology 2014;

20:412-428 24. Mobius C. Prognose des ischamischenschlaganfalls in der alteren bevolkerung: evaluation des SPAN-100 index. PhD dissertation.

Medizinischen Fakultat der Friedrich-Alexander-Universitat, Erlangen-Nurnberg, 2014 25. Dashe J. Stroke prognosis in adults. UpToDate 2014. Topic:14086, Version 9.0 26. Saposnik G. The art of estimating outcomes and treating patients with stroke in the 21st century. Stroke 2014, online early 27. Reid JM, Dai D, Thompson K, Christian C, Reidy Y, et al. (2014) Five-Simple-Variables Risk Score Predicts Good and Devastating

Outcome after Stroke. Int J Phys Med Rehabil 2:186. doi: 10.4172/2329-9096.1000186 28. Ntaios G, Papavasileiou V, Faouzi M, et al. Acute imaging does not improve ASTRAL score’s accuracy despite having a prognostic


80


value. International Journal of Stroke 2014, in press 29. Fugate J, Rabinstein A. Update on Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke. Mayo Clinic

Proceedings 2014, online early 30. Tziomalos K, Giampatzis V, Bouziana S, et al. The prognostic role of ankle brachial index in patients with acute ischemic stroke.

Hellenic Journal of Atherosclerosis 2014; 5:60-66 31. Ovbiagele B, Reeves M, Nasiri M, et al. A Simple Risk Index and Thrombolytic Treatment Response in Acute Ischemic Stroke. JAMA

Neurology 2014, online early 32. Kwah LK, Diong J. National Institutes of Health Stroke Scale (NIHSS). Journal of Physiotherapy 2014; 60:61 33. Aleman A, Loli P, Sanchez M, et al. Implementation of the DRAGON score to assessment of early mortality and risk of symptomatic

intracranial hemorrhage after thrombolysis. Neurologia Argentina 2014, online early 34. Sato S, Uehara T, Ohara T, et al. Factors associated with unfavorable outcome in minor ischemic stroke. Neurology. 2014 Jul

8;83(2):174-81 35. Nowinski WL, Gupta V, Qian G, Ambrosius W, Kazmierski R (2014) Population-Based Stroke Atlas for Outcome Prediction: Method

and Preliminary Results for Ischemic Stroke from CT. PLoS ONE 9(8): e102048. doi:10.1371/journal.pone.0102048 36. Asuzu D, Nystrom K, Amin H, et al. Comparison of 8 Scores for predicting Symptomatic Intracerebral Hemorrhage after IV

Thrombolysis. Neurocritical Care 2014, online early 37. Mazya M. Intracerebral haemorrhage in patients treated with intravenous thrombolysis for acute ischemic stroke. 2014; Karolinska

Institutet. Dissertation. 2014 38. Pan Y, Jing J, Zhang R, et al. Poor Performance of Stroke Prognostication using Age and National Institutes of Health Stroke Scale-100

to Predict 3- and 12-month Outcomes of Ischemic Stroke in China National Stroke Registry. Journal of Stroke and cerebrovascular diseases. 2014, in press.

39. Thompson D, Murray G, Sudlow C, et al. Comparison of Statistical and Clinical Predictions of Functional Outcome after Ischemic Stroke. PLoS ONE 9(10): e110189. doi:10.1371/journal.pone.0110189

40. Medlin F, Amiguet M, Vanacker P, Michel P. Influence of Arterial Occlusion on Outcome after Intravenous Thrombolysis for Acute Ischemic Stroke. Stroke 2014, online early

41. G. Ntaios, V. Papavasileiou, H. Milionis, K. Makaritsis, E. Manios, K. Spengos, P. Michel, K. Vemmos. Embolic strokes of undetermined source (ESUS) in the Athens Stroke Registry: a descriptive analysis. Stroke 2014, in press

42. P. Vanacker, M. Heldner, D. Seiffge, et al. ASTRAL-R score Predicts Non-Recanalization after Intravenous Thrombolysis in Acute Ischemic Stroke. Thormbosis and Haemostasis 2015, online early

43. Ruijun Ji, Wanliang Du, Haipeng Shen, et al. Web-based tool for dynamic functional outcome after acute ischemic stroke and comparison with existing models. BMC Neurology 2014, 14:214

44. Bustamante A, Garcia-Berrocoso, et al. Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: overcoming the major hurdles. Expert Review of Neurotherapeutics 2014; 14:1391-1403

45. Kuster GW. Outcome determianants of stroke in a Brazilian primary stroke center. 2014, online early 46. Mazya M. Thesis: Intracerebral haemorrhage in patients treated with intravenous thrombolysis for acute ischemic stroke. Karolinska

Institutet, Stockholm, 2014. 47. Asuzu D, Nystrom K, Amin H, et al. Modest Association between the Discharge Modified Rankin Scale Score and Symptomatic

Intracerebral Hemorrhage after Intravenous Thrombolysis. Journal of Stroke and Cerebrovascular Diseases 2015, online early 48. G. Ntaios, V. Papavasileiou, P. Michel, et al. Predicting functional outcome and symptomatic intracranial hemorrhage in patients with

acute ischemic stroke: a glimpse into the crystal ball? Stroke 2015, online early. 49. Cooray, C., Fekete, K., Mikulik, R., Lees, K. R., Wahlgren, N. and Ahmed, N. (2015), Threshold for NIH stroke scale in predicting

vessel occlusion and functional outcome after stroke thrombolysis. International Journal of Stroke. doi: 10.1111/ijs.1245 50. Asuzu D, Nystrom K, Amin H, et al. Cohort-Based Identification of Predictors of Symptomatic Intracerebral Hemorrhage After IV

Thrombolysis. Neurocritical Care 2015, online early 51. Garcia-Berrocoso T, Montaner J. Biomarkers for the prognosis of ischemic stroke. European Patent Application. EP 2 725 360 A1.

30.04.2014 Bulletin 2014/18 52. Topcuoglu M, Murat Arsava E, Akpinar E. Clot Characteristics on Computed Tomography and Response to Thrombolysis in Acute

Middle Cerebral Artery Stroke. Journal of Stroke and cerebrovascular diseases 2015; 24:1363-72 53. Asuzu D, et al. TURN Score Predicts 90-day Outcome in Acute Ischemic Stroke Patients After IV Thrombolysis. Neurocritical Care

2015, online early 54. Ntaios G, et al. Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis. Stroke 2015, online early 55. Biomarkers for the prognosis of ischemic stroke. United States Patent Application 20150276763, 10/01/2015 56. Harvey R. Predictors of functional outcome following stroke. Physical Medicine and Rehabilitation Clinics of North America 2015;

26:583-98 57. Decker C, et al. Patient-Centered Decision Support in Acute Ischemic Stroke Qualitative Study of Patients’ and Providers’

Perspectives. Circulation: Cardiovascular Quality and Outcomes. 2015; 8: S109-S116 58. Abdul-Rahim et al. Derivation and Validation of a Novel Prognostic Scale (Modified-Stroke Subtype, Oxfordshire Community Stroke

Project Classification, Age, and Prestroke Modified Rankin) to Predict Early Mortality in Acute Stroke. Stroke 2015, online early 59. Asuzu et al. On-versus Off-Hour Patient Cohorts at a Primary Stroke Center: Onset-to-Treatment Duration and Clinical Outcomes

after IV Thrombolysis. Journal of Stroke and Cerebrovascular Diseases 2015, online early 60. Bustamante et al. Ischemic stroke outcome: A review of the influence of post-stroke complications within the different scenarios of

stroke care. European Journal of Internal Medicine 2015, online early

Stroke etiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study Vemmos K, Ntaios G, Savvari P, Vemmou AM , Koroboki E, Manios E, Kounali A, Lip GYH European Journal of Heart Failure 2012; 14:211-8 IF: 5.247 Αναφορές: 18 (εκ των οποίων οι 2 αυτοαναφορές)

1. Bart A. Mulder, Pieter Willem Kamphuisen, and Isabelle C. Van Gelder. Stroke aetiology in heart failure: towards patient-tailored


81


prevention of stroke. Eur J Heart Fail. 2012; 14:230-231. 2. Kociol R, Greiner M, Hammill B, et al. B-type natriuretic peptide level and postdischarge thrombotic events in older patients

hospitalized with heart failure: Insights from the Acute Decompensated Heart Failure National Registry. American Heart Journal 2012 ; 163 :994-1001

3. Ntaios G, Lip G, Makaritsis K, et al. CHADS2, CHA2DS2-VASc and long-term stroke outcome in patients without atrial fibrillation. Neurology 2013, in press

4. Milionis H, Faouzi M, Cordier M, et al. Characteristics and early and long-term outcome in patients with acute ischemic stroke and low ejection fraction. International Journal of Cardiology 2013, in press

5. Y. Guo, G. Lip, S. Apostolakis. The Challenge of Antiplatelet Therapy in Patients with Atrial Fibrillation and Heart Failure. 2012, in press

6. H. Kazlauskas, R. adziuviene, V. Janusonis. Impact of atrial fibrillation on patients with acute stroke. Health sciences 2012 ; 22:47-51 7. V. Papavasileiou, H. Milionis, P. Michel, K. Makaritsis, A. Vemmou, E. Koroboki, E. Manios, K. Vemmos, G. Ntaios. The ASTRAL

score predicts 5-year dependence and mortality in acute ischemic stroke. Stroke 2013, in press 8. Dušica Simić-Panić. Faktori koji uticu na ishod medicinske rehabilitacije kod pacjenata sa ishemicnim mozdanim udarom..

Dissertation thesis 2013, Universitet u Novom Sadu, Medicinski Fakultet, Doktorske studije klinicke medicine 9. I. Van Gelder, D. Van Veldhuisen, G. Lip. New oral anticoagulants in heart failure. European Journal of Heart Failure 2013; 15:966-973 10. Baturova M, Lindgren A, Shubik Y, et al. Documentation of atrial fibrillation prior to first-ever ischemic stroke. Acta Neurologica

Scandinavica 2013, in press 11. Liu L, et al. Heart failure highlights in 2012-2013. European Journal of Heart Failure 2014, in press. 12. Gurbel P, Tantry U. Antiplatelet and Anticoagulant Agents in Heart FailureCurrent Status and Future Perspectives. JACC Heart

Failure 2014, in press 13. Kim J, Gall S, Nelson M, et al. Lower systolic blood pressure is associated with poorer survival in long-term survivors of stroke.

Journal of Hypertension 2014; 32:904-11 14. Byun J-I, Jung K-H, Kim Y-D, Kim J-M, Roh J-K (2014) Cardiac Function and Outcome in Patients with Cardio-Embolic Stroke. PLoS

ONE 9(4): e95277. doi:10.1371/journal.pone.0095277 15. Ahmadi A, Soori H, Mobasheri M, et al. Heart failure, the outcomes, predictive and related factors in Iran. Journal of Mazandaran

University of Medical Sciences 2014; 24:180-88 16. Scherbakov N, Haeusler K, Doehner W. Ischemic stroke and heart failure: facts and numbers. ESC Heart Failure, online early 17. Hamatani Y, et al. Incidence and predictors of ischemic stroke during hospitalization for congestive heart failure. Heart Vessels 2015,

online early 18. Gregory Lip, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart

failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015, online early

Prevalence of atrial fibrillation in a Greek rural Population: the Arcadia Rural Study in Atrial Fibrillation Ntaios G, Synetou M, Saliaris M, Xynos K, Pappa D, Savvari P, Spengos K, Vemmos K Acta Cardiologica 2012; 67:65-9 IF: 0.607 Αναφορές: 9

1. Hoyt W, Snyder C. The asymptomatic Wolff–Parkinson–White syndrome. Progress in pediatric cardiology 2013, in press 2. Kai-Hu Shi, Hui Tao, Jing-Jing Yang, et al. Role of microRNAs in atrial fibrillation: New insights and perspectives. Cellular Signalling

2013; 25 :2079-84. 3. A. Assiri, O. Al-Majzoub, A. Kanaan, et al. Mixed Treatment Comparison Meta-Analysis of Aspirin, Warfarin, and New

Anticoagulants for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation. Clinical Therapeutics 2013 ; 35:967-984 4. Krijthe B, Kunst A, Benjamin E, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from

2000 to 2060. European Heart Journal 2013, in press 5. Farmakis D, Pipilis A, Antoniou A, et al. Clinical Profile and Therapeutic Management of Patients with Atrial Fibrillation in Greece:

Results from the Registry of Atrial Fibrillation to Investigate New Guidelines (RAFTING). Hellenic J Cardiol 2013; 54: 368-375 6. Hung C, Wu T, Wang K, et al. Falls and atrial fibrillation in elderly patients. Acta Cardiol Sin 2013;29:436-443 7. Stroink J, van Boven N, Ruiter J, et al. Success of electrocardioversion on the elderly. Netherlands Heart Journal 2014, online early.

DOI : 10.1007/s12471-014-0519-y 8. Andrikopoulos G, Pastromas S, Mantas I, et al. Management of Atrial Fibrillation in Greece: the MANAGE-AF Study. Hellenic J

Cardiol 2014; 55: 281-287 9. Pipilis A, Farmakis D, Kaliambakos S, et al. Anticoagulant therapy is prescribed less often in paroxysmal atrial fibrillation regardless

of thromboembolic risk: Results from the Registry of Atrial Fibrillation to Investigate New Guidelines (RAFTING. International Journal of Cardiology 2014; 175:569-70

10. Svennberg E, et al. Mass screening for untreated atrial fibrillation the STROKESTOP study. Circulation 2015 ; 131 :2176-84

An intravenous insulin protocol for strict glycemic control in acute ischaemic stroke G. Ntaios, M. Egli, A. Arsovka, D. Joye, Y. Bettex, E. Lauber, A. Eskandari, S. D’Ambrogio, B. Richoz, J. Ruiz, P. Michel, European Journal in Neurology 2012; 19:443-51 IF: 4.162 Αναφορές: 10 (εκ των οποίων οι 2 αυτοαναφορές) 1. G. Ntaios, C. Abatzi, M. Alexandrou, et al. Persistent hyperglycemia at 24-48 hours in acutely hyperglycemic stroke patients is not

associated with worse functional outcome. Cerebrovascular Diseases 2011, in press 2. Yaghi S, Hinduja A, Bianchi N. The effect of admission hyperglycemia in stroke patients treated with thrombolysis. International

Journal of Neuroscience 2012, in press 3. Scherbaum WA. Diabetes-update. Was gibt es neues? Der diabetologe 2012, in press 4. Sauer EM, KohrmannM, Schwab S. Post-stroke hyperglycemia. Der Diabetologe 2013, DOI: 10.1007/s11428-012-0950-x


82


5. Ntaios G, Papavasileiou V, Makaritsis K, et al. Intravenous insulin treatment in acute stroke: a systematic review and meta-analysis of randomized controlled trials. International Journal of Stroke 2013, in press

6. Schapira A. Progress in European Neurology 2012-2013. 2013 ; 20:1499-1507 7. Watila M, Nyandaiti Y, AHifjo A, et al. Effect of Admission Hyperglycaemia on Infarct Size and Clinical Outcome in Black Patients

with Acute ischaemic Stroke, Northeast Nigeria. British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol.: 4, Issue.: 34 8. Zhang C, Zhang H, Shi Q, et al. Analysis of correlation between diabetes and prognosis in thrombolytic patients with acute ischemic

stroke. Chinese Journal of Contemporary Neurology and Neurosurgery 2014; 14: 1019-22 9. Tsetsou S, Rossetti A, Michel P, et al. News in Neurology 2014. Revue Medicale Suisse 2015; 11:456-7 10. Koivunen R, Haapaniemi E, Satopaa J, et al. Medical acute complications of intracerebral hemorrhage in young adults. Stroke

Research and treatment 2015; online early

The effect of thrombolysis on short-term improvement depends on initial stroke severity G. Ntaios, M. Faouzi, P. Michel Journal of Neurology 2012;259(3):524-9 IF: 3.578 Αναφορές: 10 1. Boulouis G, Dumont F, Cordonier C, et al. Intravenous thrombolysis for acute cerebral ischaemia in old stroke patients >80 years of

age. Journal of Neurology 2012, in press. DOI 10.1007/s00415-011-6359-4 2. Dariusz Gąsecki, Agnieszka Rojek, Mariusz Kwarciany, et al. Pulse wave velocity is associated with early clinical outcome after

ischemic stroke. Atherosclerosis 2012, in press 3. Bill O, Zufferey P, Faouzi M, Michel P. Severe stroke: patient profile and predictors of favourable outcome. J Thromb Haemost. 2012

Nov 12. doi: 10.1111/jth.12066. 4. D. Strbian, P. Ringleb, P. Michel, et al. Ultra-early intravenous stroke thrombolysis : do all patients benefit similarly ? Stroke 2013, in

press 5. R. Salvesen, G. Eldeen. Behandling av hjerneinfarkt ved slagenheten i Bodø 2011-2012. Tidsskr Nor Legeforen 2013; 133:1824-6 6. Huang Q, Ma Q, Wu J. Intravenous thrombolysis for minor stroke and rapidly improving symptoms: a quantitative overview.

Neurological Sciences 2014, online early 7. Ntaios G, Melikoki V, Perifanos G, et al. Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-

sectional national survey in Greece. Journal of Stroke and Cerebrovascular Diseases 2014, online early 8. Medlin F, Amiguet M, Vanacker P, Michel P. Influence of Arterial Occlusion on Outcome after Intravenous Thrombolysis for Acute

Ischemic Stroke. Stroke 2014, online early 9. Shi L, Zhang M, Song B, et al. Safety and Outcome of Thrombolysis in Mild Stroke: A Meta-Analysis. Med Sci Monit 2014; 20:2117-

2124 10. Qian Jiang, et al. Bakkenolide-IIIa Protects Against Cerebral Damage Via Inhibiting NF-κB Activation. CNS Neuroscience &

Therapeutics 2015, online early

Persistent hyperglycemia at 24-48 hours in acutely hyperglycemic stroke patients is not associated with worse functional outcome G. Ntaios, C. Abatzi, M. Alexandrou, D. Lambrou , S. Chatzopoulos, M. Egli, J. Ruiz , N. Bornstein , P. Michel Cerebrovascular Diseases 2011; 32:561-6 IF: 2.814 Αναφορές: 7

1. Merel J A Luitse, Geert Jan Biessels, Guy E H M Rutten, L Jaap Kappelle. Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol 2012; 11: 261–71

2. Yaghi S, Hinduja A, Bianchi N. The effect of admission hyperglycemia in stroke patients treated with thrombolysis. International Journal of Neuroscience 2012, in press

3. Bill O, Zufferey P, Faouzi M, Michel P. Severe stroke: patient profile and predictors of favourable outcome. J Thromb Haemost. 2012 Nov 12. doi: 10.1111/jth.12066.

4. Mohamed KA, Saad A. Outcome of critically ill hyperglycemic stroke patients admitted to the intensive care unit. Egypt J Intern Med 2013;25:185-90

5. Zhang S, Zuo W, Guo F, et al. Cerebral glucose transporter: The possible therapeutic target for ischemic stroke. Neurochemistry international 2014, online early

6. Hewitt J. Treatment of hyperglycemia in patients with acute stroke. Revista Clínica Española 07/2015; DOI:10.1016/j.rce.2015.06.005 7. Hassan Abu Zaid, et al. Influence of Diabetes Mellitus on Stroke. British Journal of Medicine & Medical Research 12(11): XX-XX, 2016,

Article no.BJMMR.22937

Perfusion-CT guided intravenous thrombolysis in patients with unknown-onset stroke: a randomized, double-blind, placebo controlled, pilot feasibility trial Michel P, Ntaios G, Reichhart M, Schindler C, Bogousslavsky J, Maeder P, Meuli R, Wintermark M Neuroradiology 2011; 54:579-88 IF: 2.700 Αναφορές: 20

1. Miller, J., C. Hartwell, Lewandovsky C. Stroke Treatment Using Intravenous and Intra-Arterial Tissue Plasminogen Activator. In: Current Treatment Options in Cardiovascular Medicine 2012, 1-11. DOI: 10.1007/s11936-012-0176-7

2. A. Rai, K Raghuram, J Carpenter, J Domico, G Hobbs. Pre-intervention cerebral blood volume predicts outcomes in patients undergoing endovascular therapy for acute ischemic stroke. J NeuroIntervent Surg doi:10.1136/neurintsurg-2012-010293

3. G. Zhu, P. Michel, W. Zhang, M. Wintermark. Standardization of Stroke Perfusion CT for Reperfusion Therapy. Translational Stroke


83


Research 2012, in press. DOI: 10.1007/s12975-012-0156-y 4. G Zhu, T Jovin, A Aghaebrahim, P Michel, W Zhang, M Wintermark. Does perfusion imaging add value compared with plain

parenchymal and vascular imaging? J NeuroIntervent Surg 2012;4:4 246-250 5. M. Lev. Perfusion imaging of acute stroke : its role in current and future clinical practice. Radiology 2013 ;266 :22-27 6. Dulka Manawadu, Shankaranand Bodla, Jeff Keep, et al. An Observational Study of Thrombolysis Outcomes in Wake-Up Ischemic

Stroke Patients. Stroke 2013, in press 7. HP Adams. Treatment of Patients With Suspected Ischemic Stroke of Undetermined Onset and Negative Head Computed

Tomography Scan: Caution is Advised. Stroke. 2013;44:1494-1495 8. F. Ahlhelm, N. Naumann, S. Ulmer, R. Benz, C. Nern, S. Wetzel. Fokussierte neuroradiologische Diagnostik beim akuten Hirnschlag.

Therapeutische Umschau 2013 ; 69:543-548 9. D Manawadu, S Bodla, J Jarosz, J Keep, L Kalra. A Case-Controlled Comparison of Thrombolysis Outcomes Between Wake-Up and

Known Time of Onset Ischemic Stroke Patients. Stroke 2013, in press 10. A. Kheradmand, M. Fisher, D. Paydarfar. Ischemic Stroke in Evolution: Predictive Value of Perfusion Computed Tomography.

Journal of Stroke and Cerebrovascular Diseases 2014 ; 23 :836 11. A. Gopal, D. Shavelle, R. Matthews, et al. Peripheral thrombolysis of arterial distribution. Endovascular Interventions 2014, pp557-576 12. Hou Q, Zuo Z, Michel P, et al. Influence of Chronic Hyperglycemia on Cerebral Microvascular Remodeling. An In Vivo Study Using

Perfusion Computed Tomography in Acute Ischemic Stroke Patients. Stroke 2013, in press 13. Donahue J, Sumer S, Wintermark M. Assessment of collateral flow in patients with cerebrovascular disorders. Journal of

Neuroradiology 2014, online early 14. Song S. Advanced imaging in acute ischemic stroke. Seminar in Neurology 2013 ; 33 :436-440 15. Luis Amorim R, Ferreira de Andrade A, Gattas G, et al. Improved Hemodynamic Parameters in Middle Cerebral Artery Infarction

After Decompressive Craniectomy. Stroke 2014, online early, doi: 10.1161/STROKEAHA.113.003670 16. Ghobrial G, Chalouhi N, Zohra M, et al. Saving the ischemic penumbra: Endovascular thrombolysis versus medical treatment. Journal

of clinical neuroscience 2014, online early 17. Wouters A, Lemmens R, Dupont P, et al. Wake up stroke and stroke of unknown onset: a critical review. Front. Neurol. 5:153.

doi:10.3389/fneur.2014.00153 18. Burton K, Dhanoa D, Aviv R, et al. Perfusion CT for Selecting Patients with Acute Ischemic Stroke for Intravenous Thrombolytic

Therapy. Radiology 2014, online early 19. Rubin M, Barrett K. What to do with wake-up stroke. The neurohospitalist 2015, online early 20. Thomalla G, Gerloff C. Treatment Concepts for Wake-Up Stroke and Stroke With Unknown Time of Symptom Onset. Stroke.

2015;46:2707-2713

Blood pressure change and outcome in acute ischemic stroke: the impact of baseline values, previous hypertensive disease and previous antihypertensive treatment Ntaios G, Lambrou D, Michel P Journal of Hypertension 2011; 29:1583-9 IF: 3.806 Αναφορές: 15 (εκ των οποίων η 1 αυτοαναφορά)

1. Berge E. Should high blood pressure be lowered in the acute stroke? Journal of Hypertension 2011, 29:1478–1479 2. Grise E, Adeoye O. Blood pressure control for acute ischemic and hemorrhagic stroke. Current Opinion in Critical Care 2012; 18:132-

138 3. G. Ntaios, D. Lambrou, P. Michel. Association between blood pressure changes in the acute phase of stroke and outcome with

respect to stroke etiology. Neurology 2012; 79:1440-1448 4. Sandset E, Murray G, Bath P, et al. Relation between change in blood pressure in acute stroke and risk of early adverse events and

poor outcome. Stroke 2012, in press 5. Dimiter I. Hadjiev, Petya P. Mineva. Elevated blood pressure management in acute ischemic stroke remains controversial: Could

this issue be resolved?. Medical hypotheses 2012, in press 6. S Lattanzi, M Silvestrini, L Provinciali. Elevated blood pressure in the acute phase of stroke and the role of angiotensin receptor

blockers. International Journal of Hypertension 2013, in press 7. Cappellari M, et al. The THRombolysis and STatins (THRaST) study. Neurology, Feb 2013; 80: 655 – 661 8. WL Baker, JC Marrs, LE Davis. Key Articles and Guidelines in the Acute Management and Secondary Prevention of Ischemic

Stroke. Pharmacotherapy 2013, in press 9. Zhang, L., Fang, X.-H., Zhang, Z.-Y. Research status of blood pressure management in acute ischemic stroke. 2013; 10:153 – 157 10. F. Vela, D. Ramirez. Tratamiento de la hypertension arterial en accidente cerebrovascular. Universidad del Rosario 2013. 11. Talke P, et al. Society for Neuroscience in Anesthesiology and Critical Care Expert Consensus Statement: Anesthetic Management of

Endovascular Treatment for Acute Ischemic Stroke*: Endorsed by the Society of NeuroInterventional Surgery and the Neurocritical Care Society. Journal of Neurosurgical Anesthesiology 2014; 26:95-108

12. Talke P, et al. Republished: Society for Neuroscience in Anesthesiology and Critical Care Expert Consensus Statement: Anesthetic Management of Endovascular Treatment for Acute Ischemic Stroke. Stroke. 2014; 45:e138-e150

13. Chi X, Yu Y, Wang D, et al. Antihypertensive treatment in the prevention and treatment of ischemic stroke: the J-curve phenomenon. Int J Cerebrovasc Dis 2013; 21:459-68

14. Kakaletsis N, Ntaios G, Milionis H, et al. Prognostic value of 24-h ABPM in acute ischemic stroke for short, medium and long-term outcome: A systematic review and meta-analysis. Internationl Journal of Stroke 2015, online early

15. E. Kjeldsen, E. Berge. Blood pressure and early neurological deterioration in acute ischemic stroke. Journal of Hypertension 2015; 33:2020-1

Temporal distribution and magnitude of the vulnerability period around stroke depend on stroke subtype Ntaios G, Michel P Cerebrovascular Diseases 2011; 32:246-53

http://stroke.ahajournals.org/search?author1=Dulka+Manawadu&sortspec=date&submit=Submit

http://stroke.ahajournals.org/search?author1=Shankaranand+Bodla&sortspec=date&submit=Submit

http://stroke.ahajournals.org/search?author1=Jeff+Keep&sortspec=date&submit=Submit


84


IF: 2.814 Αναφορές: 9 (εκ των οποίων οι 4 αυτοαναφορές)

1. G. Ntaios, A. Vemmou, E. Koroboki, et al. The type of atrial fibrillation is associated with long- term outcome in patients with acute ischemic stroke. International Journal of Cardiology, 2013; 167:1519-23

2. Nakajima M, Field T, Benavente O. Treatment approaches for lacunar strokes. In : Cerebral Small Vessel Disease. Edited by Pantoni L, Gorelick B. Cambridge University Press, 2014

3. Pagola J, Gonzalez-Alujas T, Muchada M, et al. Stroke Echoscan Protocol: A Fast and Accurate Pathway to Diagnose Embolic Strokes. Journal of Neuroimaging 2014, online early

4. G. Ntaios, V. Papavasileiou, K. Makaritsis, et al. Statin treatment is associated with improved prognosis in patients with AF-related stroke. International Journal of Cardiology 2014, online early

5. Papavasileiou V, Milionis H, Hirt L, Michel P. Strokes and TIAs during and after Carotid Artery Doppler: Cause or Coincidence? Ultrasound in Medicine and Biology 2015 ; 41 :418-22

6. Pagola J, et al. Stroke Echoscan Protocol: A Fast and Accurate Pathway to Diagnose Embolic Strokes. Journal of neuroimaging 2015 ; 25 :365-9


8. Γ. Ντάιος. Εμβολικά εγκεφαλικά απροσδιόριστης προέλευσης. Μια νέα κατηγορία ασθενών με ισχαιμικό εγκεφαλικό επεισόδιο. Heart Vessels & Brain 2015, online early

9. Valenti R, Pantoni L. Secondary Prevention After Ischemic Lacunar Stroke. In: Ischemic Stroke therapeutics. Springer eds 2015:137-46

CT angiography helps to differentiate acute from chronic carotid occlusion: the "carotid ring sign" P. Michel, G. Ntaios, MG. Delgado, DC. Bezerra, R. Meuli, S. Binaghi Neuroradiology 2012; 54:139-46 IF: 2.700 Αναφορές: 2

1. A. carotis: Ringzeichen hilft bei Differenzierung von akutem und chronischem Verschluss. Neuroradiol Scan 2012; 02(04): 248-249. DOI: 10.1055/s-0032-1309455

2. El-Koussy M, Schroth G, Brekenfeld C, Arnold M. Imaging of acute ischemic stroke. European Neurology 2014 ; 72 :309-16

Long-term outcome in posterior cerebral artery stroke G. Ntaios, K. Spengos, A. Vemmou, P. Savari, E. Koroboki, G. Stranjalis, K. Vemmos European Journal of Neurology 2011; 18:1074-80 IF: 4.162 Αναφορές: 12

1. Arboix A. Posterior cerebral artery infarction: an understudied vascular topography of ischaemic stroke. European Journal of Neurology 2011, in press

2. Arboix A, Arbe G, Garcia-Eroles L, Oliveres M, Parra O, Massons J. Infarctions in the vvascular territory of the posterior cerebral artery: clinical features in 232 patients. BMC Research Notes 2011; 4:329

3. Kamchatnov PR. Vertebro-basilar insufficiency. Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova 2011; 111(9):3-9

4. Schapira, A. H., Hillbom, M. Advances in neurology 2011–12. European Journal of Neurology 2012; 19: 1267–1275. doi: 10.1111/j.1468-1331.2012.03870.x

5. Khasanov I. Perculiarities of posterior cerebral artery infarctions. Neurological Bulletin 2012; XLIV:69-74

6. A. Kraft, C.. Grimsen, S. Kehrer. Neurological and neuropsychological characteristics of occipital, occipito-temporal and occipito-parietal infarction. Cortex 2012, in press.

7. Korn-Lubetzki I, Molshatzki N, Benderly M, Steiner I. The Relatively Good Outcome of Cerebellum-Brainstem Ischemic Strokes. Eur Neurol 2013;69:8-13

8. Carey S. Posterior Circulation Stroke in Manitoba Children: A Population Based Longitudinal Study of Clinical Presentation and Outcome. University of Manitoba. Bachelor of Science (Medicine). October 2011. http://hdl.handle.net/1993/5154

9. Artzi M, Aizenstein O, Abramovitch R, et al. MRI Multiparametric Hemodynamic Characterization of the Normal Brain. Neuroscience 2013; 240: 269-276

10. Wijdicks E, Sheth K, Carter B, et al. Recommendations for the Management of Cerebral and Cerebellar Infarction With Swelling A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2014, online early

11. Gogela S, et al. Beyond textbook neuroanatomy: The syndrome of malignant PCA infarction. British Journal of Neurosurgery 2015; DOI:10.3109/02688697.2015.1080220

12. Aydin S, et al. Mechanisms, clinical features and risk factors for stroke in the posterior cerebral artery infarcts. Turc Noroloji Dergisi 2015; 21:49-54

Red cell distribution width does not predict stroke severity or functional outcome Ntaios G, Gurer O, Faouzi M, Aubert C, Michel P. International Journal of Stroke, 2010; 7:2-6 IF: 2.748 Αναφορές: 12

1. Tonbul A, et al. Red Cell Distribution Width (RDW) in the newborn: normative data. Journal of Clinical Laboratory Analysis 2011, in press

2. Horne B. A Changing Focus on the Red Cell Distribution Width: Why Does It Predict Mortality and Other Adverse Medical Outcomes? Cardiology 2012;122:213-215

http://hdl.handle.net/1993/5154


85


3. Majercik S, Fox J, Knight S, Horne B. Red cell distribution width is predictive of mortality in trauma patients. Journal of Trauma and Acute Care Surgery2013; 74: 1021–1026

4. A. Kaya, T. Isik, Y. Kaya, et al. Relationship Between Red Cell Distribution Width and Stroke in Patients With Stable Chronic Heart Failure: A Propensity Score Matching Analysis. Clin Appl Thromb Hemost 2013, in press

5. J. Ramirez-Moreno, M. Gonzalez-Gomez, A. Ollero-Oriz, et al. Relation between red blood cell distribution width and ischemic stroke: a case-control study. International Journal of Stroke 2013; 8:E36

6. Akinci E, Dogan N, Gumus H, et al. Can we use serum gamma-glutamyl transferase levels to predict early mortality in stroke? Pakistan Journal of Medical Sciences 2014, online early

7. Paulus, Elena M.; Weinberg, Jordan A.; Magnotti, Louis J, et al. Admission Red Cell Distribution Width: A Novel Predictor of Massive Transfusion after Injury. The American Surgeon 2014; 80:685-689.

8. Vay A, Hernandez Z, Rivera L, et al. Red blood cell distribution width in patients with cryptogenic stroke. Clinical and Applied Thrombosis and Hemostasis 2015; 21:241-5

9. Vijayashree R, Abirami V, Govindaraju S, et al. Relevance of Red Cell Distribution Width (RDW) Determination in Stroke: A Case Control Study. International Journal of Scientific and Research Publications 2014; 4:1-5

10. Zhihong X, Dongquan S, Dongyang C, et al. The level of red cell distribution width cannot identify deep vein thrombosis in patients undergoing total joint arthroplasty. Blood Coagulation & Fibrinolysis 2014; online early. doi: 10.1097/MBC.0000000000000239

11. Horne B, Muhlestein J, Bennett S, et al. Association of the dispersion in red blood cell volume with mortality. European Journal of Clinical Investigation 2015, online early

12. Xu Z, Li L, Shi D, et al. The level of red cell distribution width cannot identify deep vein thrombosis in patients undergoing total joint arthroplasty. Blood coagulation and fibrinolysis 2015; 26:298-301

13. Kara H, et al. Red cell distribution width does not predict stroke severity or functional outcome. Neuropsychiatric Disease and Treatment 2015; 18:733-739.

Association between obesity on long-term mortality after acute first-ever stroke: the obesity stroke paradox K. Vemmos, G. Ntaios, K. Spengos, P. Savvari, A. Vemmou, Pappa T, Manios E, Georgiopoulos G, Alevizaki M. Stroke 2011; 42:30-36 IF: 5.729 Αναφορές: 107 (εκ των οποίων οι 3 αυτοαναφορές)

1. Kalita et al. Letter regarding article, "The association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox". Stroke 2011, in press

2. Ntaios et al. Response to Letter by Kalita et al. regarding Article, "The association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox" Stroke 2011, in press

3. Doehner et al. Letter regarding article, "The association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox". Stroke 2011, in press

4. Ntaios et al. Response to Letter by Dohener et al. regarding Article, "The association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox" Stroke 2011, in press

5. Katsiki N, Ntaios G, Vemmos K. Stroke, obesity and gender. Maturitas 2011 in press 6. Aoki J, Uchino K. Treatment of Risk Factors to Prevent Stroke. Neurotherapeutics. 2011, in press 7. Ryu W et al. Body mass index, initial neurological severity and long term mortality in ischemic stroke. Cerebrovascular Diseases

2011, in press 8. Scherbakov N, Dirnagl U, Doehner W. Body Weight After Stroke: Lessons From the Obesity Paradox. Stroke 2011, in press 9. Ovbiagele B, Bath PM, Cotton D, Vinisko R, Diener HC. Obesity and Recurrent Vascular Risk After a Recent Ischemic Stroke. Stroke

2011, in press 10. Katsnelson M, Rundek T. Obesity Paradox and Stroke: Noticing the (Fat) Man Behind the Curtain. Stroke 2011, in press 11. Rhéaume C, Leblanc MÈ, Poirier P.Adiposity assessment: explaining the association between obesity, hypertension and stroke.

Expert Rev Cardiovasc Ther. 2011 Dec;9(12):1557-64. 12. Hennerici M. Report of the 20th European Stroke Conference, Hamburg, May 24–27, 2011. Cerebrovasc Dis 2011;32:589–613 13. Skali H, et al. Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin

Alfa: The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience. Circulation. 2011; 124:2903-2908 14. Kanhai, D.A., Visseren, F.L.J., Algra, A., Kappelle, L.J. Lifestyle factors and the risk of stroke. Cerebrovascular Diseases 2011; 32:

611-613 15. Kuklina E, Tong X, George M, Bansil P. Epidemiology and prevention of stroke: a worldwide perspective. Expert Review of

Neurotherapeutics 2012; 12:199-208. DOI 10.1586/ern.11.99 16. G.-C. Hu, S.-F. Hsieh, Y.-M. Chen, H.-H. Hsu, Y.-N. Hu and K.-L. Chien. Relationship of initial glucose level and all-cause death in

patients with ischaemic stroke: the roles of diabetes mellitus and glycated hemoglobin level. European Journal of Neurology 2012, in press. doi:10.1111/j.1468-1331.2011.03647.x

17. D. H. Lee, J. Kim, H. S. Lee, M.-J. Cha, Y. D. Kim, H. S. Nam, C. M. Nam, J. H. Heo. Low ankle–brachial index is a predictive factor for initial severity of acute ischaemic stroke. European Journal of Neurology 2012, in press DOI: 10.1111/j.1468-1331.2011.03652.x

18. M Lainscak, S von Haehling, W Doehner, S Anke. The obesity paradox in chronic disease: facts and numbers. J Cachexia Sarcopenia Muscle (2012) 3:1.

19. Jackson RS, Black JH, Lum YW, et al. Class I obesity is paradoxically associated with decreased risk of postoperative stroke after carotid endarterectomy. Journal of Vascular Surgery 2012; 55:1306–1312

20. Seet R. Zhang Y, Wijdicks E, et al. Thrombolysis Outcomes among Obese and Overweight Stroke Patients: An Age-and National Institutes of Health Stroke Scale–matched Comparison. Journal of Stroke and Cerebrovascular Diseases 2012, in press.

21. Peters A. The egoistic brain: How the human weight diversity is created [Das egoistische Gehirn: Wie die menschliche Gewichtsvielfalt entsteht]. 2012; 59:210-218

22. Y. J. Alderazi, J. Chang, J. P. Yang, M. Teleb, K. Chapple, A. Awad, and Lucas Restrepo. Impact of Protocol Deviations in Acute Ischemic Stroke Treated With Intravenous rt-PA Within 4.5 Hours After Symptom Onset. The Neurohospitalist. 2012; 2:82-86

23. Kastorini CM, Panagiotakos DM. The obesity paradox: Methodological considerations based on epidemiological and clinical


86


evidence - New insights. Maturitas 2012; 72: 220-224 24. Icks A, Claessen H, Morbach S, et al. Time-Dependent Impact of Diabetes on Mortality in Patients With Stroke. Survival up to 5

years in a health insurance population cohort in Germany. Diabetes Care 2012, in press 25. Kubera P, Hubold C, Zug S, et al. The brain's supply and demand in obesity. Front Neuroenergetics. 2012; 4: 4 26. BJ Kim, SH Lee, KH Jung, et al. Dynamics of obesity paradox after stroke, related to time from onset, age, and causes of death.

Neurology 2012, in press 27. Plow M, Finlayson M, Cho C. Correlates of nutritional behavior in individuals with multiple sclerosis. Disability and Health Journal

2012, in press 28. Stephan von Haehling, Oliver Hartmann, and Stefan D. Anker. Does obesity make it better or worse: insights into cardiovascular

illnesses. Eur Heart Journal 2012, in press. DOI: 10.1093/eurheartj/ehs237 29. Persson J, Folkersen L, Ekstrand J, et al. High plasma adiponectin concentration is associated with all-cause mortality in patients

with carotid atherosclerosis. Atherosclerosis 2012, in press 30. Doehner W, Schenkel J, Anker S, et al. Overweight and obesity are associated with improved survival, functional outcome, and

stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial. Eur Jeart J 2012, in press 31. Rönnemaa, Elina. Predictors of Dementia: Insulin, Fatty Acids and Vascular Risk Factors. Doctoral thesis. Uppsala University,

Disciplinary Domain of Medicine and Pharmacy 2012 32. Soo Hyun Cho, Wang-Soo Lee, Sang-Wook Kim. The Relationship Between Body Mass Index and Left Main Coronary Artery

Architecture: A Virtual Histology Intravascular Ultrasound Analysis. Korean J Obes. 2012 Sep;21(3):148-157 33. Mi D, Jia Q, Zheng H, Hoff K, Zhao X, et al. (2012) Metabolic Syndrome and Stroke Recurrence in Chinese Ischemic Stroke Patients –

The ACROSS-China Study. PLoS ONE 7(12): e51406. doi:10.1371/journal.pone.0051406 34. A. Turer, J. Hill, J. Elmquist, P. Scherer. Adipose Tissue Biology and Cardiomyopathy: Translational Implications. Circ. Res. 2012;

111:1565-1577 35. LA Orci, PE Majno, T Berney, P Morel. The impact of wait list body mass index changes on the outcome after liver

transplantation. Transplant International, 2012, in press. DOI: 10.1111/tri.12017 36. Kernan W, Inzucchi S, Sawan C, et al. Obesity: a stubbornly obvious target for stroke prevention. Stroke 2013; 44:278-286 37. A. M. Poms, M. Turner, H. Farber, et al. Comorbid Conditions and Outcomes in Patients With Pulmonary Arterial Hypertension: A

REVEAL Registry Analysis. Chest 2013, in press 38. Andersen K, Olsen T. The obesity paradox in stroke: Lower mortality and lower risk of readmission for recurrent stroke in obese

stroke patients. International Journal of Stroke 2013, in press 39. R. Mohebi, M. Bozorgmanesh, F. Azizi, F. Hadaegh. Effects of Obesity on the Impact of Short-Term Changes in Anthropometric

Measurements on Coronary Heart Disease in Women. Mayo Clinic Proceedings, 2013; 88:487-494 40. Banack H, Kaufman JS. The “Obesity Paradox” Explained. Epidemiology 2013;24:461–462 41. Peters A, Kubera B, Hubold C, et al. The corpulent phenotype – how the brain maximixes survival in stressful enviroments.

Frontiers in Neuroscience 2013; 7:Article 47 (doi: 10.3389/fnins.2013.00047) 42. Wang A, Wu J, Zhou Y, et al. Measures of Adiposity and Risk of Stroke in China: A Result from the Kailuan Study. PLoS ONE 8(4):

e61665. doi:10.1371/journal.pone.0061665 43. Platz, J; Güresir, E; Schuss, P; Konczalla, J; Seifert, V; Vatter, H. The Impact of the Body-Mass-Index on Outcome After Subarachnoid

Hemorrhage: Is There an Obesity Paradox in SAH? A Retrospective Analysis. Neurosurgery 2013; 72:201-8 44. Lammintausta A. Effects of socioeconomic status and sociodemographic features on cardiovascular disease mortality and morbidity

in Finland. Doctoral Thesis. From the Department of Medicine, University of Turku and Turku University Hospital. Annales Universitatis Turkuensis, Medica-Odontologica, Turku, Finland 2013.

45. Plow M, Moore S, Kirwan J, et al. Randomized controlled pilot study of a SystemCHANGETM weight management intervention in stroke survivors: rationale and protocol. Trials 2013; 14:130

46. Smith C, Lawrence C, Rodriguez-Grande B, et al. The immune system in Stroke: clinical challenges and their translation to experimental research. J Neuroimmune Pharmacol 2013, in press. DOI 10.1007/s11481-013-9469-1

47. Haslam D. Obesity co-morbidities and the obesity paradox. Practical diabetes 2013; 30:132-35 48. Zhang, Y., Han, T.-T., Su, B., Jiang, D.-D., Li, Y.-X., Hu, Y.-M. Responsive ability of obese non-diabetic rats to acute inflammatory

stimulus. Journal of Shanghai Jiaotong University (Medical Science) 2013; 33:400-403. 49. DA Kanhai. Adiposity, Adipocytokines and Microvesicles in the Etiology of Vascular Disease. PhD dissertation, Utrecht Univesity,

Utrecht, the Netherlands 2013 50. Chiquete E, Ruiz-Sandoval J, Murillo-Bonilla L, et al. Central Adiposity and Mortality after First-Ever Acute Ischemic Stroke. Eur

Neurol 2013;70:117-123 51. Andersen K, Olsen T. Body Mass Index and Stroke: Overweight and Obesity Less Often Associated with Stroke Recurrence. Journal

of Stroke and Cerebrovascular Diseases 2013, in press 52. C. Bell, A. LaCroix, K. Masaki, et al. Prestroke Factors Associated with Poststroke Mortality and Recovery in Older Women in the

Women's Health Initiative. Journal of the American Geriatrics Society 2013, in press 53. V. Hainer, I. Aldhoon-Hainerova. Obesity paradox does exist. Diabetes Care 2013; 36:S276-S281 54. Dangas G, Maehara A, Evrard S, et al. Coronary artery calcification is inversely related to body morphology in patients with

significant coronary artery disease: a three-dimensional intravascular ultrasound study. Eur Heart J Cardiovasc Imaging 2013, in press. doi: 10.1093/ehjci/jet139

55. A. Wirth, H. Hauner, M. Roden. Komorbiditaten. Adipositas 2013; 173-257 56. Bell C, Rantanen T, Chen R, et al. Pre-Stroke Weight Loss is Associated with Post-Stroke Mortality among Men in the Honolulu-Asia

Aging Study. Archives of Physical Medicine and Rehabilitation 2013, in press 57. ScherbakoV N, Anker S, Dirnagl U, Doehner W. Stroke induced Sarcopenia: Muscle wasting and disability after stroke.

International Journal of Cardiology 2013, in press 58. Saini M, Saqqur M, Shuaib A, et al. Body mass index and acute ischemic stroke outcomes. International Journal of Stroke 2013, in

press 59. Zhao L, Du W, Zhao X, et al. Favorable Functional Recovery in Overweight Ischemic Stroke Survivors: Findings from the China

National Stroke Registry. Journal of Stroke and Cerebrovascular disorders 2014; 23:e201-6. 60. Skolarus L, Sanchez B, Levine D, et al. Association of body mass index and mortality after acute ischemic stroke. Circulation:

http://www.scopus.com/alert/results/record.url?AID=547170&ATP=authcite&eid=2-s2.0-84878497524&origin=SingleRecordEmailAlert

http://www.scopus.com/alert/results/record.url?AID=547170&ATP=authcite&eid=2-s2.0-84878497524&origin=SingleRecordEmailAlert


87


Cardiovascular quality and outcomes 2013, in press 61. Goel K, Lopez-Jimenez F, De Schutter A, et al. Obesity paradox in different populations: evidence and controversies. Future

Cardiology 2014; 10:81-91 62. Lackland D, et al. Factors Influencing the Decline in Stroke Mortality. A Statement From the American Heart Association/American

Stroke Association. Stroke 2014; 45: 315-353 63. Chiquete E, et al. The Quételet index revisited in children and adults. Endocrinologia y Nutricion. 2013, in press 64. Prior A, Laursen T, Larsen K, et al. Post-Stroke Mortality, Stroke Severity, and Preadmission Antipsychotic Medicine Use – A

Population-Based Cohort Study. PLoS ONE 9(1): e84103. 65. Chuang SY, et al. Skeletal Muscle Mass and Risk of Death in an Elderly Population. Nutrition, metabolism and cardiovascular

diseases 2014, online early 66. Song B, Wang Y, Zhao X, et al. Association between Statin Use and Short-Term Outcome Based on Severity of Ischemic Stroke: A

Cohort Study. PLoS ONE 9(1): e84389. doi:10.1371/journal.pone.0084389 67. Schweizerische Hirnschlaggesellschaft (SHG). Sekundärprävention des ischämischen Hirnschlags. Schweiz Med Forum

2014;14(4):54–57 68. Seo JH, Jeong HY, Noh S, et al. Relationship of Body Mass Index and Mortality for Acute Ischemic Stroke Patients after

Thrombolysis Therapy. J Neurocrit Care 2013;6:92-96 69. Dashe J. Stroke prognosis in adults. UpToDate 2014. Topic:14086, Version 9.0 70. Kernan W, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2014, in press 71. Al-Mrayat M, Vloemans M. Type 2 diabetes, mortality and the obesity paradox: the weight management dilemma. Practical

Diabetes 2014; 31:96-8 72. Kuwashiro T, Ago T, Kamouchi M, et al. Significance of plasma adiponectin for diagnosis, neurological severity and functional

outcome in ischemic stroke - Research for Biomarkers in Ischemic Stroke (REBIOS). Metabolism : clinical and experimental 2014 ; 63 :1093-1103

73. Christian Dehlendorff, Klaus K. Andersen, Tom S. Olsen. Body Mass Index and Death by Stroke. No Obesity Paradox. JAMA Neurol., online early. doi:10.1001/jamaneurol.2014.1017

74. Canepa M, Ameri P, et al. Role of bone mineral density in the inverse relationship between body size and aortic calcification: Results from the Baltimore Longitudinal Study of Aging. Atherosclerosis 2014; 235:169-175

75. Hookway C, Gomes F, Weekes C. Royal College of Physicians Intercollegiate Stroke Working Party evidence-based guidelines for the secondary prevention of stroke through nutritional or dietary modification. Journal of Human Nutrition and Dietetics 2015; 79:107-25

76. Moga D, Abner E, Brouwer E. Dementia and “Obesity Paradox”: Is This for Real or Are We Missing Something? An Epidemiologist's Perspective. The journal of post-acute and long-term care medicine 2014, online early

77. Tziomalos K, Bouziana S, Spanou M, et al. Increased augmentation index is paradoxically associated with lower in-hospital mortality in patients with acute ischemic stroke. Atherosclerosis 2014; 236:150-3

78. Sharma M, Pearce L, et al. Predictors of Mortality in Patients With Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial. Stroke. 2014; 45:2989-2994

79. Dorrance A, Nusrat M, Paulo P. The Effects of Obesity on the Cerebral Vasculature. Current Vascular Pharmacology 2014; 12:462-72 80. Kim Y, Kim C, Jung S, et al. Obesity-stroke paradox and initial neurological severity. J Neurol Neurosurg Psychiatry 2015; 86:743-

747 81. Lucke-Wold B, Turner R, Logsdon A, et al. Metabolic Syndrome and Its Profound Effect onPrevalence of Ischemic Stroke. AMSRJ

2014; 1(1):29—38. http://dx.doi.org/10.15422/amsrj.2014.05.004 82. Tawk R, Grewal S, Heckman M, R Navarro, JL Ferguson, EL Starke, et al. Influence of Body Mass Index and Age on Functional

Outcomes in Patients With Subarachnoid Hemorrhage. Neurosurgery 2015; online early. doi: 10.1227/NEU.0000000000000588 83. Doehner W, Auebert H. The Impact of Body Weight on Mortality After StrokeThe Controversy Continues. JAMA

Neurol. 2015;72(1):126-127 84. Barba R. Marco J, Ruiz J, et al. The Obesity Paradox in Stroke: Impact on Mortality and Short-term Readmission. Journal of Stroke

and Cerebrovascular Diseases 2015, online early 85. Scherbakov N, Sandek A, Doehner W. Stroke-related sarcopenia: specific characteristics Journal of the American Medical Directors

Association 2015, online early 86. Bagheri M, Speakman J, Shabbidar S, et al. A dose‐response meta‐analysis of the impact of body mass index on stroke and all‐cause

mortality in stroke patients: a paradox within a paradox. Obesity reviews 2015, online early 87. Fernandez-Bustamante A, Seres T, Agazio A, Pennington AT, Christians U, et al. (2015) Exhaled Breath Condensate Nitrate Levels

Are Inversely Associated With the Body Mass Index of Patients without Respiratory Disease. J Pulm Respir Med 5: 243 88. Uzoni A, Ciobanu O, Sandu RE, Buga AM, Popa-Wagner A. Life style, Perfusion deficits and Comorbidities Precipitate

Inflammation and Cerebrovascular Disorders in Aged Subjects. Discoveries 2015, JanMar; 3(1): e39. DOI: 10.15190/d.2015.31 89. Wohlfahrt P, Lopez-Jimenez F, et al. The Obesity Paradox and Survivors of Ischemic Stroke. Journal of Stroke and Cerebrovascular

Diseases 2015; 24:1443-50 90. Winter Y. Obesity and Neurological Diseases. Aktuelle Neurologie 2015; 42:141-7 91. Uzoni A, Ciobanu O, Sandu E, et al. Aging, inflammation and depressive behavior: a review. Reviews in Health Care 2015; 6,

http://dx.doi.org/10.7175/rhc.v6i2.1170 92. Smithard D, Weekes C, et al. Swallowing and nutritional complications. Management of post-stroke complications 2015; pp 99-155 93. Anand Jacob. Implementing eform-based baseline risk data extraction from high quality papers for the brisket database and tool.

Thesis, McMaster University, 2015 94. Gill L, Bartels S, Batsis J. Weight Management in Older Adults. Current obesity reports 2015. 95. Vaughan L, et al. Global cognitive function before, surrounding, and after ischemic stroke: the role of risk and protective factors

varies with time among ischemic stroke survivors. Aging, Neuropsychology, and Cognition: A Journal on Normal and Dysfunctional Development. 2015, online early

96. Liebeskind D, Sanossian N, et al. The coffee paradox in stroke: increased consumption linked with fewer strokes. Nutritional neuroscience 2015, DOI: 10.1179/1476830515Y.0000000035

97. Yerim Kim, Chi Kyung Kim, Seunguk Jung, et al. Prognostic importance of weight change on short-term functional outcome in

http://dx.doi.org/10.7175/rhc.v6i2.1170


88


acute ischemic stroke. International Journal of Stroke 2015, online early 98. Camici M, Galetta F, et al. Obesity paradox. Integrative Obesity and Diabetes 2015; 1:61-5 99. Peters A, et al. Stress habituation, body shape and cardiovascular mortality. Neuroscience & Biobehavioral Reviews 2015, online

early 100. Brzecka A, Ejma M. Obesity Paradox in the Course of Cerebrovascular Diseases. Adv Clin Exp Med 2015; 24: 379–383 101. Kazemi-Bajestani, et al. Obesity paradox versus frailty syndrome in first‐ever ischemic stroke survivors. International Journal of

Stroke 2015; 10:E75 102. Sandu R, et al. Neuroinflammation and comorbidities are frequently ignored factors in CNS pathology. Neural regeneration

research 2015; 10:1349-55 103. Nishihara R, et al. Molecular pathological epidemiology gives clues to paradoxical findings. European Journal of Epidemiology

2015; 30:1129-35 104. Prins A. The nutritional management of a central venous incident. South African Journal of Clinical Nutrition 2015; 28:105-115 105. Armario et al. Secondary prevention of ischemic non cardioembolic stroke. Clinica e Investigacion en Arteriosclerosis 2015;27:287 –

300 106. Lee J, et al. Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson's disease. Neurobiology of

Aging 2015, online early 107. Yang et al. Effect of obesity on functional outcomes at 6 months post-stroke among elderly Koreans: a prospective multicentre

study. BMJ Open 2015;5:e008712

The Acute STroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging P. Michel, C. Odier, M. Rutgers, M. Reichhart, P. Maeder, Re. Meuli, M. Wintemark, A. Maghraoui, M. Faouzi, A. Croquelois, G. Ntaios

Stroke 2010; 41:2491-8 IF: 5.729 Αναφορές: 70 (εκ των οποίων οι 22 αυτοαναφορές)

1. Ntaios G, Gurer O, Faouzi M, Aubert C, Michel P. Red cell distribution width does not predict stroke severity or functional outcome. International Journal of Stroke, 2010, in press.

2. Ntaios G, Egli M, Michel P. Response to Letter by Fuentes et al Regarding Article, "J-Shaped Association Between Serum Glucose and Functional Outcome in Acute Ischemic Stroke". Stroke 2010 in press

3. Rey V, Faouzi M, Huchmand-Zadeh M, Michel P. Stroke initial severity and outcome relative to insurance status in a universal health care system in Switzerland. European Journal of Neurology

4. G. Ntaios, K. Spengos, A. Vemmou, P. Savari, E. Koroboki, G. Stranjalis, K. Vemmos. Long-term outcome in posterior cerebral artery stroke. European Journal of Neurology 2011, in press

5. P. Michel, G. Ntaios, MG. Delgado, DC. Bezerra, R. Meuli, S. Binaghi. CT angiography helps to differentiate acute from chronic carotid occlusion: the "carotid ring sign". Neuroradiology 2011, in press

6. Katsiki N, Ntaios G, Vemmos K. Stroke, obesity and gender. Maturitas 2011 in press 7. Ntaios G, Michel P. Temporal distribution and magnitude of the vulnerability period around stroke depend on stroke subtype.

Cerebrovascular Diseases 2011, in press 8. Ntaios G, Lambrou D, Michel P. Blood pressure change and outcome in acute ischemic stroke: the impact of baseline values,

previous hypertensive disease and previous antihypertensive treatment. Journal of Hypertension 2011, in press 9. Blomstrom Lundqvist C, Lip GY, Kirchhof P. What are the costs of atrial fibrillation? Europace. 2011 May;13 Suppl 2:ii9-12. 10. Lip G, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart

Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace (2011) 13 (5): 723-746.

11. Scacciatela P, et al. Percutaneous Closure of Patent Foramen Ovale in Patients with Anatomical and Clinical High-Risk Characteristics: Long-Term Efficacy and Safety. Journal of Interventional Cardiology 2011; 24(5):477-84

12. Michel P, Ntaios G, Reichhart M, Schindler C, Bogousslavsky J, Maeder P, Meuli R, Wintermark M. Perfusion-CT guided intravenous thrombolysis in patients with unknown-onset stroke: a randomized, double-blind, placebo controlled, pilot feasibility trial. Neuradiology 2011, in press

13. G. Ntaios, C. Abatzi, M. Alexandrou, D. Lambrou , S. Chatzopoulos, M. Egli, J. Ruiz , N. Bornstein , P. Michel . Persistent hyperglycemia at 24-48 hours in acutely hyperglycemic stroke patients is not associated with worse functional outcome. Cerebrovascular diseases 2011, in press

14. G. Ntaios, M. Faouzi, P. Michel. The short-term effect of thrombolysis decreases with increasing stroke severity. Journal of Neurology 2011, in press

15. G. Ntaios, M. Egli, A. Arsovka, D. Joye, Y. Bettex, E. Lauber, A. Eskandari, S. D’Ambrogio, B. Richoz, J. Ruiz, P. Michel. A safe and efficacious intravenous insulin protocol for strict glycemic control in acute ischaemic stroke. European Journal in Neurology 2011, in press

16. Goldstein L. Left atrial enlargement: A cause of Stroke? CMAJ 183; 10:1129-1130 17. G. Ntaios, E. Manios, M. Synetou, P. Savvari, A. Vemmou, E. Koromboki, M. Saliaris, K. Blanas, K. Vemmos. Prevalence of atrial

fibrillation in Greece: the Arcadia Rural Study in Atrial Fibrillation. Actra Cardiologica 2011, in press 18. Novy J, Castelao E, Preisig M, et al. Psychiatric co-morbidities and cardiovascular risk factors in people with lifetime history of

epilepsy of an urban community. Clinical Neurology and Neurosurgery 2011, in press 19. Tsai SH, Lin YY, Hsu CW, et al. Hypoglycemia revisited in acute care setting. Yonsei Med J 2011; 52:898-908 20. Kim DE, Park KJ, Schellingerhout D, et al. A New Image-Based Stroke Registry Containing Quantitative Magnetic Resonance

Imaging Data. Cerebrovasc Dis 2011;32:567–576 21. Arkuszewski M, Targosz-Gajniak M, Swiat M, Patalong-Ogiewa M, Pieta M, Opala G. Intravenous thrombolysis in acute ischemic

stroke after POLKARD: one center analysis of program impact on clinical practice. Advances in Medical Sciences, 2011, in press

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kirchhof%20P%22%5BAuthor%5D


89


DOI: 10.2478/v10039-011-0045-8 22. G.-C. Hu, S.-F. Hsieh, Y.-M. Chen, H.-H. Hsu, Y.-N. Hu and K.-L. Chien. Relationship of initial glucose level and all-cause death in


23. G Ntaios, M Faouzi, J Ferrari, W Lang, K Vemmos, P Michel. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology 2012, in press

24. G. Ntaios, D. Lambrou, P. Michel. Association between blood pressure changes in the acute phase of stroke and outcome with respect to stroke etiology. Neurology 2012; 79:1440-1448

25. Thomas S, Sanders O. Catheter Ablation for Atrial Fibrillation. Heart, lung and circulation 2012; 21:395-401 26. Alvarez V, Rossetti A, Papavasileiou V, Michel P. Acute seizures in acute ischemic stroke: does thrombolysis have a role to play?

Journal of Neurology 2012, in press 27. Maarten M. H. Lahr, Gert-Jan Luijckx, Patrick C. A. J. Vroomen, et al. The chain of care enabling tPA treatment in acute ischemic

stroke: a comprehensive review of organisational models. Journal of Neurology 2013;260:960-8 28. A. Ciccone, P. Proserpio, D. Roccatagliata, et al. Wake-up stroke and TIA due to paradoxical embolism during long obstructive

sleep apnoeas: a cross-sectional study. Thoras 2012, in press 29. Osama O. Zaidat, Marc Lazzaro, Emily McGinley, et al. Demand-supply of neurointerventionalists for endovascular ischemic stroke

therapy. Neurology 2012; 79 (13 SUPPL. 1):S35 - S41 30. Ntaios G, Lip G, Makaritsis K, et al. CHADS2, CHA2DS2-VASc and long-term stroke outcome in patients without atrial fibrillation.

Neurology 2013, in press 31. Milionis H, Faouzi M, Cordier M, et al. Characteristics and early and long-term outcome in patients with acute ischemic stroke and

low ejection fraction. International Journal of Cardiology 2013, in press 32. Papavasileiou V, et al. Aseptic meningoencehalitis mimicking transient ischemic attacks. Infection 2013, in press 33. G. Liu, G. Ntaios, H. Zheng, et al. External validation of ASTRAL score to predict 3- and 12-month functional outcome in the China

National Stroke Registry. Stroke 2013, press 34. Sacks D, Black C, Cognard C, et al. Multisociety consensus quality improvement guidelines for intraarterial catheter-directed

treatment of acute ischemic stroke. Journal of Vascular and Interventional Radiology 2013; 24: 151-163 35. V. Papavasileiou, H. Milionis, P. Michel, K. Makaritsis, A. Vemmou, E. Koroboki, E. Manios, K. Vemmos, G. Ntaios. The ASTRAL

score predicts 5-year dependence and mortality in acute ischemic stroke. Stroke 2013, in press 36. Chawalparit O, Chareewit S. Ischemic cerebrovascular disease and calcified intracranial vertebrobasilar artery: A case-control study

by using cranial CT. Journal of the Medical Association of Thailand 2013; 96:346-50 37. Altunbas G, Ercan S, Davutoglu V, Al B. Overview of warfarin treatment and answers to questions. Journal of Academic Emergency

Medicine 2013; 12:38-42 38. Tsetsou S, Eeckhout E, Qanadli SD, et al. Nonaccidental Arterial Cerebral Air Embolism: A Ten-Year Stroke Center Experience.

Cerebrovasc Dis 2013;35:392–395 39. G. Ntaios, D. Lambrou, D. Cuendet, P. Michel. Early major worsening in ischemic stroke: predictors and outcome. NeuroCritical

Care 2013, in press 40. Milionis H, Michel P. Acute ischemic cerebrovascular events on antiplatelet therapy: What is the optimal prevention strategy?

Current pharmaceutical design 2013; 19:3788-94 41. Sacks D, Black C, Cognard C, et al. Multisociety consensus quality improvement guidelines. Catheterization and Cardiovascular

Interventions 2013; 82: E52-E68 42. G. Ntaios, V.Papavasileiou, K. Makaritsis. P. Michel. PFO closure vs. medical therapy in cryptogenic stroke: a systematic review and

meta-analysis. 2013, in press 43. M. Rahbar, N. Gonzales, et al. The University of Texas Houston Stroke Registry (UTHSR): implementation of enhanced data quality

assurance procedures improves data quality. BMC Neurology 2013, 13:61 44. Bogiatzi, Chrysi, "Secular Trends in Ischemic Stroke Subtypes" (2013). University of Western Ontario - Electronic Thesis and Dissertation

Repository. Paper 1356 45. Ntaios G, Papavasileiou V, Makaritsis K, et al. Intravenous insulin treatment in acute stroke: a systematic review and meta-analysis

of randomized controlled trials. International Journal of Stroke 2013, in press 46. Gensicke H, Zinkstok SM, Roos YB, et al. IV thrombolysis and renal function. Neurology 2013; 81:1780-8 47. Milan M, Aleu A, Almendrote M, et al. Safety and Effectiveness of Endovascular Treatment of Stroke with Unknown Time of Onset.

Cerebrovasc Dis 2014;37:134-140 48. Vanacker P, Lambrou D, Eskandari A, et al. Improving prediction of recanalization in acute large vessel occlusive stroke. Journal of

Thrombosis and Haemostasis 2014, online early 49. Hart R, Diener C, Coutts S, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurology

2014; 13:429-38 50. Dorin D, Badea M, Rogozea L, et al. Management of laboratory analyses in emergency Unit- at Brasov county hospital; a

preliminary study made in November 2011; Brasoc Medical Journal 2013; 1:24-31 51. Ntaios G, Papavasileiou V, Faouzi M, et al. Acute imaging does not improve ASTRAL score’s accuracy despite having a prognostic

value. International Journal of Stroke 2014, in press 52. Jang M, Hong J, Kang J, et al. Current Status of Recanalization Therapy in Acute Ischemic Stroke with Symptomatic Intracranial

Arterial Occlusion in Korea. Journal of Stroke and Cerebrovascular Diseases 2014; online early 53. Barros A, Duchateau FX, Huff J, et al. Nonurgent Commercial Air Travel After Nonhemorrhagic Cerebrovascular Accident. Air

medical journal 2014; 33:106-8 54. Kang D, Kim Y, Hwang Y, et al. Instant Reocclusion following Mechanical Thrombectomy of in situ Thromboocclusion and the Role

of Low-Dose Intra-Arterial Tirofiban. Cerebrovasc Dis 2014;37:350–355 55. Ntaios G, Melikoki V, Perifanos G, et al. Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-

sectional national survey in Greece. Journal of Stroke and Cerebrovascular Diseases 2014, online early 56. Milionis H, Papavasileiou V, Eskandari A, et al. Anaemia on admission predicts short and long-term outcome in patients with acute

ischaemic stroke. Intrernational Journal of Stroke 2014, online early 57. G. Ntaios, V. Papavasileiou, K. Makaritsis, et al. Statin treatment is associated with improved prognosis in patients with AF-related


90


stroke. International Journal of Cardiology 2014, online early 58. Medlin F, Amiguet M, Vanacker P, Michel P. Influence of Arterial Occlusion on Outcome after Intravenous Thrombolysis for Acute

Ischemic Stroke. Stroke 2014, online early 59. Vanacker P, Faouzi M, Eskandari A, et al. How to predict the affected circulation in Large Vessel Occlusive Stroke? EJMINT 2014:

1444000227 60. Vanacker P, Cordier M, Janbieh J, et al. Floating Arterial Thrombus Related Stroke Treated by Intravenous Thrombolysis.

Cerebrovasc Dis 2014;38:117-120 61. Li Q, Zhu X, Fang M, et al. Duration of symptom and ABCD2 score as predictors of risk of early recurrent events after transient

ischemic attack: A hospital-based case series study. Medical Science Monitor 2015; 21:262-7 62. Vanacker P, Lambrou D, Eskandari A, et al. Improving the Prediction of Spontaneous and post-thrombolytic Recanalisation in

Ischemic Stroke patients. Journal of Stroke and Cerebrovascular Diseases 2015, online early 63. Soler P, et al. The Mataró Stroke Registry: A 10-year registry in a community hospital. Neurologia 2015; 30:283-9

F, et al. Diastolic myocardial dysfunction by tissue Doppler imaging predicts mortality in patients with cerebral infarction. The International Journal of Cardiovascular Imaging 2015, online early

64. Chen H, et al. Intracranial versus extracranial artery dissection cases presenting with ischemic stroke. Journal of Stroke and Cerebrovascular Diseases 2015; 24:852-859

65. Richoz B, Hugli I, Dami F, et al. Acute stroke chameleons in a university hospital. Neurology 2015; 85:505-11 66. Vanacker P, et al. Prediction of Large Vessel Occlusion in acute stroke. Critical Care Medicine 2016, online early. 67. Van den Wijngaard, et al. Value of Whole Brain Computed Tomography Perfusion for Predicting Outcome after TIA or Minor

Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases 2015; 24:2081 – 2087 68. Liebeskind D. Innovative Interventional and Imaging Registries: Precision Medicine in Cerebrovascular Disorders. Interventional

neurology 2015, online early 69. Saengsuwan J, et al. Feasibility of cardiopulmonary exercise testing and training using a robotics-assisted tilt table in dependent-

ambulatory stroke patients. Journal of NeuroEngineering and Rehabilitation. 2015; 12:88 70. Saposnik G, et al. Translational stroke research: Where have we been and where are we going? Interviewing Dr. Marc Fisher (editor

of Stroke). Canadian Journal of Neurological Sciences 2015; 42:2-6

J-shaped association between serum glucose and functional outcome in patients with acute ischemic stroke G. Ntaios, M. Egli, M. Faouzi, P. Michel Stroke 2010; 41:2366-70 IF: 5.729 Αναφορές: 42 (εκ των οποίων οι 8 αυτοαναφορές)

1. Fuentes et al. Letter regarding Article, "J-Shaped Association Between Serum Glucose and Functional Outcome in Acute Ischemic Stroke”, Stroke 2010, in press

2. Ntaios et al. Response to Letter by Fuentes et al Regarding Article, "J-Shaped Association Between Serum Glucose and Functional Outcome in Acute Ischemic Stroke”, Stroke 2010, in press

3. Natarajan S, et al. Prediction of adverse outcomes by blood glucose level after andovascular therapy for acute ischemic stroke. Journal of Neurosurgery 2011, in press

4. Haratz S, et al. Diabetes, hyperglycemia and the management of cerebrovascular disease. Current Opinion in Neurology 2011, in press

5. Xu P, Liu J. The management of blood pressure, serum glucose and serum lipid in acute ischemic stroke. Chinese Journal of Contemporary Neurology and Neurosurgery 2011; 11:143 – 147

6. Ntaios, C. Abatzi, M. Alexandrou, D. Lambrou , S. Chatzopoulos, M. Egli, J. Ruiz , N. Bornstein , P. Michel . Persistent hyperglycemia at 24-48 hours in acutely hyperglycemic stroke patients is not associated with worse functional outcome. Cerebrovascular diseases 2011, in press

7. G. Ntaios, M. Faouzi, P. Michel. The short-term effect of thrombolysis decreases with increasing stroke severity. Journal of Neurology 2011, in press

8. G. Ntaios, M. Egli, A. Arsovka, D. Joye, Y. Bettex, E. Lauber, A. Eskandari, S. D’Ambrogio, B. Richoz, J. Ruiz, P. Michel. A safe and efficacious intravenous insulin protocol for strict glycemic control in acute ischaemic stroke. European Journal in Neurology 2011, in press

9. Tai Hwan Park, Min Ky Kim. Glucose control in neurocritical patients. J Neurocrit Care 2011; 4 Suppl 1:S1-S5 10. Tsai SH, Lin YY, Hsu CW, et al. Hypoglycemia revisited in acute care setting. Yonsei Med J 2011; 52:898-908 11. G.-C. Hu, S.-F. Hsieh, Y.-M. Chen, H.-H. Hsu, Y.-N. Hu and K.-L. Chien. Relationship of initial glucose level and all-cause death in


12. G Ntaios, M Faouzi, J Ferrari, W Lang, K Vemmos, P Michel. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology 2012, in press

13. Katja Piironen, Jukka Putaala, Charlotte Rosso, and Yves Samson. Glucose and Acute Stroke: Evidence for an Interlude. Stroke; 43: 898-902.

14. P.Mandava, C. Krumpelman, S. Murthy, T. Kent. A Critical Review of Stroke Trial Analytical Methodology: Outcome Measures, Study Design, and Correction for Imbalances. In: TRANSLATIONAL STROKE RESEARCH Springer Series in Translational Stroke Research , 2012, Part 7, 833-861

15. Ergul A, Kelly-Cobbs A, Abdalla M, Fagan S. Cerebrovascular complications of diabetes: focus on stroke. Endocrine, metabolic and immune disorders – drug targets. 2012; 12:148-158

16. Abdelhafiz AH, Bailey C, Sinclair A. Hypoglycaemia in hospitalized non-diabetic older people. Review. European Geriatric Medicine 2012; 3:174-178

17. S, Hinduja A, Bianchi N. The effect of admission hyperglycemia in stroke patients treated with thrombolysis. International Journal of Neuroscience 2012; 122:637-640

18. Perry, J.M.a, McCabe, K.K. Recognition and Initial Management of Acute Ischemic Stroke. Emergency Medicine Clinics of North


91


America. 2012; 30:637-657 19. Denise M. Arrick, Hong Sun and William G. Mayhan. Influence of exercise training on ischemic brain injury in type 1 diabetic rats. J

Appl Physiol 2012; 113:1121-1127. 20. Vasilescu R, et al. Insulin thrapy in hospitalized patients. Proc. Rom. Acad., Series B, 2012, 2, p. 113–121 21. Bill O, Zufferey P, Faouzi M, Michel P. Severe stroke: patient profile and predictors of favourable outcome. J Thromb Haemost. 2012

Nov 12. doi: 10.1111/jth.12066. 22. G. Liu, G. Ntaios, H. Zheng, et al. External validation of ASTRAL score to predict 3- and 12-month functional outcome in the China

National Stroke Registry. Stroke 2013, press 23. Sauer EM, KohrmannM, Schwab S. Post-stroke hyperglycemia. Der Diabetologe 2013, DOI: 10.1007/s11428-012-0950-x 24. Bruno A, Durkalski V, Hall C, et al. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized,

blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. International Journal of Stroke 2013, in press

25. Yang Li, Li Chang-qing. Blood biological markers and neurological outcome in patients with acute ischemic stroke. International Journal of Cerebrovascular Diseases, in press. DOI: 10.3760/cma.j.issn.1673-4165.2012.03.014

26. Markaki I. Molecular and clinical markers in iscahemic cerebrovascular disease. PhD dissertation. Karolisnka Institution, Stockholm 2013

27. Ntaios G, Papavasileiou V, Makaritsis K, et al. Intravenous insulin treatment in acute stroke: a systematic review and meta-analysis of randomized controlled trials. International Journal of Stroke 2013, in press

28. Katzan IL, Spertus J, Bettger JP, et al. Risk adjustment of ischemic stroke outcomes for comparing hospital performance: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014, online early

29. Rosenberg N, Prabhakaran S. Ischemic stroke in hospital management. In: Handbook of Stroke and Neurocritical Care. 2013; 175-196

30. Zhang S, Zuo W, Guo F, et al. Cerebral glucose transporter: The possible therapeutic target for ischemic stroke. Neurochemistry international 2014, online early

31. Mandava P, Martini S, Munoz M, et al. Hyperglycemia Worsens Outcome After rt-PA Primarily in the Large-Vessel Occlusive Stroke Subtype. Translational Stroke Research 2014, online early

32. Watila M, Nyandaiti Y, AHifjo A, et al. Effect of Admission Hyperglycaemia on Infarct Size and Clinical Outcome in Black Patients with Acute Ischaemic Stroke, Northeast Nigeria. British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol.: 4, Issue.: 34

33. Medlin F, Amiguet M, Vanacker P, Michel P. Influence of Arterial Occlusion on Outcome after Intravenous Thrombolysis for Acute Ischemic Stroke. Stroke 2014, online early

34. Zhou H, Zhang X, Lu J. Progress on diabetic cerebrovascular diseases. Bosnian Journal of basic medical sciences 2014; online early 35. Sonneville R, Vanhorebeek I, den Hertog H, et al. Critical illness-induced dysglycemia and the brain. Intensive Care Medicine 2014;

41:192-202. 36. G. Ntaios, V. Papavasileiou, P. Michel, et al. Predicting functional outcome and symptomatic intracranial hemorrhage in patients

with acute ischemic stroke: a glimpse into the crystal ball? Stroke 2015, online early 37. Barnett S, Nozari A. The preoperative evaluation of the neurosurgical patient. International ANeshesiology Clinics 2015; 53:1-22 38. Koivunen R, Haapaniemi E, Satopaa J, et al. Medical acute complications of intracerebral hemorrhage in young adults. Stroke

Research and treatment 2015; online early 39. Amaro S, Llull L, Renu A, et al. Uric acid improves glucose-driven oxidative stress in human ischemic stroke. Annals of Neurology

2015, online early 40. Kent T, et al. Improving early clinical trial phase identification of promising therapeutics. Neurology 2015; 85:274-83 41. Wang Li. DISSERTATION: Association between White Matter Lesions, Renal Dysfunction and Functional Outcome in Ischemic

Stroke Patients - A Berlin “Cream&Sugar” Substudy. Aus der Klinik für Neurologie der Medizinischen Fakultät Charité – Universitätsmedizin Berlin. 23/07/2015

42. Aysenne A, et al. Supportive Care and Management of Inhospital Complications. In: Ischemic stroke therapeutics. Srpinger eds 2015:53-68

Πριν την εκλογή στη θέση Λέκτορα Mean platelet volume in the early phase of acute ischemic stroke is not associated with severity or functional outcome G. Ntaios, O. Gurer, M. Faouzi, C. Aubert, P. Michel Cerebrovascular Diseases 2010; 29:484-9 IF: 2.814 Αναφορές: 19 (εκ των οποίων η 1 αυτοαναφορά)


2. Meng R. Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke. Clinical Neurology and Neurosurgery 2011, in press

3. Gasparyan Y, et al. Mean Platelet Volume: A Link Between Thrombosis and Inflammation? Curr Pharm Des. 2011;17(1):47-58 4. JC Arévalo-Lorido, J Carretero-Gómez, et al. Mean Platelet Volume in Acute Phase of Ischemic Stroke, as Predictor of Mortality and

Functional Outcome after 1 Year. Journal of Stroke and Cerebrovascular Diseases 2013; 22: 297-303 5. Cil H, Islamoglu Y, Tekbas E, et al. Platelet count and mean platelet volume in patients with in-hospital deep venous thrombosis.

Clinical And Applied Thrombosis/Hemostasis 2012; 18:650-653 6. Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Annals of Medicine, 2012; 00:

1–12 7. Kamisli O, Kamisli S, Gonullu S, et al. Increased mean platelet volume in cervicocephalic artery dissections. Ir J Med Sci 2012;

181:561-565.


92


8. Xia Cao, Xiumei Xie, Jiansong Zhou, et al. Increased platelet volume in a general population with prehypertension: a cross-sectional study of 80 545 participants from China. Hypertension Research 2012; in press. doi:10.1038/hr.2012.62

9. P. Järemo, M. Eriksson, T. L. Lindahl, S. Nilsson, M. Milovanovic. Platelets and acute cerebral infarction. Platelets 2013; 24:407-11 10. Uyanik B, Kavalci C, Arslan E, et al. Role of Mean Platelet Volume in Diagnosis of Childhood Acute Appendicitis. Emergency

Medicine International Volume 2012 (2012), Article ID 823095, doi:10.1155/2012/823095 11. K Turgutalp, O Özhan, E Akbay, et al. Mean Platelet Volume and Related Factors in Patients at Different Stages of Diabetic

Nephropathy: A Preliminary Study. Clin Appl Thromb Hemost. 2012, in press 12. Turfan M, Erdogan E, Ertas G, et al. Usefulness of mean platelet volume for predicting stroke risk in atrial fibrillation patients.

Blood Coagulation & Fibrinolysis 2013; 24:55–58. 13. Ghahremanfard, F., Asghari, N., Ghorbani, R., et al. The relationship between mean platelet volume and severity of acute ischemic

brain stroke. Nerosciences 2013; 18; 147 – 151 14. Arikanoglu A, Yucel Y, Acar A, et al. The relationship of the mean platelet volume and C-reactive protein levels with mortality in

ischemic stroke patients. European Review for Medical and Pharmacological sciences 2013; 17:1774-7 15. E. Erdem, D. Erdem, M. Dilek, et al. Red Cell Distribution Width and Mean Platelet Volume in Amyloidosis. Clinical and applied

thrombosis/hemostasis 2012, in press 16. F. Icme, S. Gokhan, N. Dogan, et al. Prognostic relation between the infarct volume and complete blood count in ischemic

cerebrovascular disease. Acta Medica Mediterranea, 2014, 30: 529 17. Tahir M, Arshid S, Heimbecker AM, et al. Evaluation of the effects of ischemic preconditioning on the hematological parameters of

rats subjected to intestinal ischemia and reperfusion. Clinics 2015; 70:61-8 18. Bayram S, et al. The relationship of mean platelet volume with microalbuminuria in type 2 diabetic patients. 2015, online early 19. II Oz, M Yucel, et al. Is Mean Platelet Volume a Reliable Marker to Predict Ischemic Stroke in the Follow-Up of Patients with

Carotid Stenosis? Journal of Stroke and Cerebrovascular Diseases 2015, online early

Low frequency of aprataxin gene mutations in a Greek cohort with Friedreich ataxia phenotype Daiou C, Christodoulou K, Xiromerisiou G, Panas M, Dardiotis E, Kladi A, Speletas M, Ntaios G, Papadimitriou A, Germenis A, Hadjigeorgiou GM Neurological Sciences 2010; 31:393-7 IF: 1.412 Αναφορές: 2

1. Koutsis G, Kladi A, Karadima G, et al. Friedreich's ataxia and other hereditary ataxias in Greece: An 18-year perspective. Journal of the Neurological sciences 2014; 336:87-92

2. Koutsis G, Kladi A, Karadima G, et al. A study of hereditary ataxias in the Greek population. Archives of Hellenic Medicine , 2014; 31:433 - 445

Hypertension is an indepedent predictor of mean platelet volume in patients with acute ischemic stroke G. Ntaios, O. Gurer, M. Faouzi, C. Aubert, P. Michel Internal Medicine Journal 2011; 41:691-5 IF: 1.823 Αναφορές: 15 (εκ των οποίων η 1 αυτοαναφορά)


2. Liu Qingge,Li Yuhuan,Li Fei,et al. Correlation study of different types of cerebral infarction and metabolic syndrome. Chinese Journal of Practical Nervous Diseases. 2010, in press

3. Gasparyan Y, et al. Mean Platelet Volume: A Link Between Thrombosis and Inflammation? Curr Pharm Des. 2011;17(1):47-58 4. Xia Cao, Xiumei Xie, Jiansong Zhou, et al. Increased platelet volume in a general population with prehypertension: a cross-sectional

study of 80 545 participants from China. Hypertension Research 2012; in press. doi:10.1038/hr.2012.62 5. LI Yongle, LI Xin, WANG Dongliang, WANG Jizuo. Clinical Analysis of Platelet Parameters in Patients with Acute Cerebral

Infarction. Tianjin Med J 2012; 40:449-451. doi:10.3969/j.issn.0253-9896.2012.05.011 6. N Alidaei, S Zarrin, A Eishi, et al. Evaluation of the relationship between platelet count, mean platelet volume and pulmonary

thromboembolism. Razi Journal of Medical Sciences 2012; 19: 20-26 7. Kamisli O, Kamisli S, Kablan Y, et al. The Prognostic Value of an Increased Mean Platelet Volume and Platelet Distribution Width in

the Early Phase of Cerebral Venous Sinus Thrombosis. Clinical and Applied Thrombosis/Haemostasis 2012, in press 8. Han JY, Choi DH, Choi SW, etal. Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2

diabetes mellitus. Platelets 2013; 24:401-6 9. Rui-tao Wang, Di Jin, Ying Li, Qing-cheng Liang. Decreased mean platelet volume and platelet distribution width are associated

with mild cognitive impairment and Alzheimer's disease. Journal of psychiatric research 2013; 47:644-649. 10. G. Lippi, G. Targher, G. Neri, et al. Diagnostic significance of haematological testing in patients presenting at the Emergency

Department. Emergency Care Journal, 2013 in press 11. Verdoia M, Schaffer A, Barbieri L, et al. Diabetes, glucose control and mean platelet volume: a single-centre cohort study. Diabetes

Research and Clinical Practice 2014, online early 12. Karadas S, Gonullu H, Milanlioglu A, et al. Cerebral venous sinus thrombosis presentation in emergency department in Van,

Turkey. JPMA 64: 370; 2014 13. Dundar O, Kanat Petkas M, Bodur S, et al. Recurrent pregnancy loss is associated with increased red cell distribution width and

platelet distribution width. Journal of Obstetrics and Gynaecology Research 2014, online early 14. Verdoia M, Schaffer A, Barbieri L, et al. Impact of age on mean platelet volume and its relationship with coronary artery disease: A

single-centre cohort study. Experimental Gerontology 2015; 62:32-36


93


15. N Sansanayudh, P Numthavaj, D Muntham, et al. Prognostic effect of mean platelet volume in patients with coronary artery disease. Thrombosis and Haemostasis 2015; online early

The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial G. Ntaios, C. Savopoulos, D. Karamitsos, I. Economou, E. Destanis, I. Chryssogonidis, I. Pidonia, P. Zebekakis, C. Polatides, M. Sion, D. Grekas, A. Hatzitolios International Journal of Cardiology 2010; 143:16-9 IF: 5.509 Αναφορές: 20 (εκ των οποίων οι 2 αυτοαναφορές) 1. Acikel S, Dogan M, Akdemir R. Homocysteine-lowering therapy for preventing atherothrombotic events: its role in high risk

population. International Journal of Cardiology, online early view 2. G Ntaios, C.Savopoulos, D. Grekas, A. Hatzitolios. The controversial role of B vitamins on cardiovascular risk: an update. Archives

of Cardiovascular diseases, 2009, in press 3. G. Zhao, E. Ford, C. Li, A. Mokdad.The prevalence and correlates of taking folic acid and vitamin supplements among adults aged

>45 years with CVD. Public Health Nutr. 2010, in press 4. G. Ntaios, C.Savopoulos, S. Chatzopoulos, D. Mikhailidis, A. Hatzitolios. Iatrogenic hyperhomocysteinemia in patients with

metabolic syndrome: a systematic review and metaanalysis. Atherosclerosis, 2010, in press 5. Athyros V, Tziomalos K, Karagiannis A, Mikhailidis DP. Homocysteine: an emerging cardiovascular risk factor that never really

made it. The open Clinical Chemistry Journal 2010; 3:19-24 6. Swan M, Hathaway K, Hogg C, McCauley R, Vollrath A. Citizen science genomics as a model for crowdsourced preventive

medicine research. J Participat Med. 2010 Dec 23; 2:e20 7. Chopra V, Eagle KA. Cardiac biomarkers in the diagnosis, prognosis and management of coronary artery disease: A primer for

internists. Indian J Med Sci 2011 8. Durga J, et al. Effect of 3 y of folic acid supplementation on the progression of carotid intima-media thickness and carotid arterial

stiffness in older adults. Am J Clin Nutr 2011, in press 9. Debreceni B, Debreceni L. Why Do Homocysteine-Lowering B Vitamin and Antioxidant E Vitamin Supplementations Appear To Be

Ineffective in the Prevention of Cardiovascular Diseases? Cardiovascular therapeutics 2011; in press 10. Fabian E, Bogner M, Kickinger A, Wagner KH, Elmadfa I. Vitamin status in elderly people in relation to the use of nutritional

supplements. The Journal of Nutrition, Health and aging. 2011, in press, DOI: 10.1007/212603-011-0159-5 11. Bots ML, Peters SA, Grobbee DE. Carotid Intima-Media Thickness Measurement: A Suitable Alternative for Cardiovascular Risk?

Ultrasound and carotid bifurcation atherosclerosis. 2012, Part 4, 379-395, DOI: 10.1007/978-1-84882-688-5_22 12. Vacek T, Vacek J, Tyagi S. Mitochondrial mitophagic mechanisms of myocardial matrix metabolism and remodelling. Archives of

Physiology and Biochemistry 2011, in press. doi:10.3109/13813455.2011.635660 13. Qin X, Xu M, Zhang Y, et al. Effect of folic acid supplementation on the progression of carotid intima-media thickness: A meta-

analysis of randomized controlled trials. Atherosclerosis 2012; 222: 307-313 14. Chang PC, CHung MC, Lei C, et al. Biocompatibility of PDGF-simvastatin double-walled PLGA (PDLLA) microspheres for

dentoalveolar regeneration: A preliminary study. Journal of biomedical materials research. 2012, early view 15. Galland Leo. Current Controversies in Nutrition: Homocysteine Reduction and the B-Vitamin Controversy. Alternative and

Complementary Therapies 2012; 18(3): 127-129. doi:10.1089/act.2012.18309. 16. Debreceni B, Debreceni L. The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease.

Cardiovascular therapeutics 2014, in press. 17. Basu, A., Jenkins, A.J., Stoner, J.A., et al. Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: A

prospective study. Atherosclerosis 2014; 236:188-95 18. Debreceni B, Debreceni L. Role of vitamins in cardiovascular health and disease. Research Reports in Clinical Cardiology 2014:5 283–

295 19. Torres N, et al. Nutrition and atherosclerosis. Archives of Medical Research 2015, online early

Increased incidence of iron deficiency anemia secondary to inadequate iron intake in institutionalized, young patients with cerebral palsy A. Papadopoulos, G. Ntaios, G. Kaiafa, F. Girtovitis, Z. Saouli, Z. Kontoninas, M. Diamantidis, C. Savopoulos, A. Hatzitolios International Journal of Hematology 2008: 88; 495-497 IF: 1.681

Αναφορές: 6 1. Omeroglu H, et al. Preoperative hematological assessment of pediatric patients with cerebral palsy. Acta Orthop Traumatol Turc

2011;45(1):1-5 2. Santos MT, Batista R, Previtali E, et al. Oral motor performance in spastic cerebral palsy individuals: are hydration and nutritional

status associated? Journal of Oral Pathology and Medicine, 2011, in press. DOI: 10.1111/j.1600-0714.2011.01074.x 3. Esen İspiroğlu, Ekrem Güler, Cengiz Dilber, et al. Anemia, vitamin B12, folic acid and iron deficiency in children who can not feed

themselves due to neurological disease. Turk Arch Ped 2012; 47: 199-203 4. M. Alonso-Mota, CR Moraes Silveira, E Daniel de Mello. Children with cerebral palsy: how can we assess and manage their

Nutritional. Iternational Journal of Nutrology 2013; 6:60-68 5. Kalra S, Aggarwal A, Chillar N, et al. Comparison of Micronutrient Levels in Children with Cerebral Palsy and Neurologically

Normal Controls. The Indian Journal of Pediatrics 2015;82:140-44 6. Penagini F, et al. Dietary Intakes and Nutritional Issues in Neurologically Impaired Children. Nutrients 2015; 7:9400-15


94


An audit of tumour marker utilization in Greece G. Ntaios, A. Hatzitolios, A. Chatzinikolaou, P. Karalazou, C. Savopoulos, M. Karamouzis, I. Pidonia European Journal of Internal Medicine 2009; 20(3):e66-9 IF: 2.049 Αναφορές: 12 (εκ των οποίων οι 2 αυτοαναφορές) 1. G. Ntaios, A. Hatzitolios, C. Savopoulos. Improper use of tumour markers as cancer screening tests among Greek physicians.

European Journal of Internal Medicine, Online early view 2. McMahon C, Crowley V, McCarroll N, Dunne R, Keogan M. Elevated tumour marker: an indication for imaging? Annals of Clinical

Biochemistry 2010;47:327. 3. Sturgeon, C.M., Lai, L.C., Duffy, M.J. Serum tumour markers: How to order and interpret them. BMJ 2009; 339: 852 – 858 4. Weerakkody A. Tumour markers. Sri Lanka Journal of Obstetrics and Gynecology. 2010; 32: 69-70 5. Qin X, Lin L, Mo Z, et al. Reference intervals for serum alpha-fetoprotein and carcinoembryonic antigen in Chinese Han ethnic

males from the Fangchenggang Area Male Health and Examination Survey. International Journal of Biological Markers 2011; 26:65-71

6. Kaiafa G, Saouli Z, Diamantidis M, et al. Copper levels in patients with hematological malignancies. European Journal of Internal Medicine 2012, in press

7. Ntaios G, Gatselis N, Makaritsis K, et al. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis 2013, in press

8. Malik M, Khan D, et al. Injudicious use of laboratory facilities in tertiary care hospitals at Rawalpindi, Pakistan: a cross-sectional descriptive study. BMC Health Services Research 2013, 13:495

9. Gion M, Franceschini R, Rosin C, et al. An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests. Clinical Chemistry and Laboratory Medicine. 2014, online early, DOI: 10.1515/cclm-2013-0708

10. Cerezo Ruiz, A., Rosa Jiménez, F., Lobón Hernández, J.A., Gómez Jiménez, F.J. Diagnostic capability of carcinoembryonic antigen elevation. Gastroenterologia y Hepatologia 2014:37:551-7

11. Torné Cachot, J., Baucells Azcona, J.M., Blanch Falp, J., Blancas Altabella, D. Serum tumour markers in asymptomatic patients. 2015; 145:319-20

12. Ferraro et al. Tumor marker ordering: Do not lose control a prospective clinical trial. American Journal of Clinical Pathology 2015;144:649 - 658

Evaluation of cardiotoxicity five years after 2D planned, non-simulated, radiation therapy for left breast cancer K. Pistevou-Gompaki, A. Hatzitolios, N. Eleftheriadis, E. Boultoukas, G. Ntaios, I. Andronikidis, I. Tzitzikas Therapeutics and Clinical Risk Management 2008; 4:1359-62 IF: - Αναφορές: 5 1. Goyal S, Rao MS, Khan A, Huzzy L, Green C, Haffty BG. Evaluation of Acute Locoregional Toxicity in Patients with Breast Cancer

Treated with Adjuvant Radiotherapy in Combination with Bevacizumab. Int J Radiat Oncol Biol Phys. 2010, in press 2. Galloway T, Amdur R, Morris C, Yeung A, Mendenhall W. Better technology but similar outcomes: Lessons from the University of

Florida experience with primary radiotherapy for early-stage cervix cancer. Journal of the Hong Kong College of Radiologists 2010; 12:154-61

3. Allegra A, Alonci A, Russo S, Cannaco A, Penna G, D’Angelo A, Bellomo G, Musolino C. Cardiac involvement in patients with hematologic malignancies. J Investig Med 2010, in press

4. Kwartler C, Khakoo A. Cardiovascular Complications of Cancer and Radiation Therapy (Chapter in: Pulmonary Involvement in Patients with Hematological Malignancies) 2011 (Publisher: Springer Berlin Heidelberg, Isbn: 978-3-642-15742-4, Doi: 10.1007/978-3-642-15742-4_32).

5. Bonsignore A, Warburton D. Radiation Therapy and Cardiovascular Disease Risk in Breast Cancer. Current Cardiovascular Risk Reports 2013, in press.

Increased values of mean platelet volume and platelet size deviation width may provide a safe positive diagnosis of idiopathic thrombocytopenic purpura G. Ntaios, A. Papadopoulos, A. Chatzinikolaou, Z. Saouli, P. Karalazou, G. Kaiafa, F. Girtovitis, Z. Kontoninas, C. Savopoulos, A. Hatzitolios, S. Alexiou-Daniel Acta Haematologica 2008; 119:173-177 IF: 0.894

Αναφορές: 45 (εκ των οποίων οι 3 αυτοαναφορές) 1. G. Ntaios, A. Papadopoulos, A. Chatzinikolaou, F. Girtovitis, G. Kaiafa, C. Savopoulos, A. Hatzitolios. Evaluation of mean platelet

volume in the differential diagnosis of thrombocytopenia International Journal of Laboratory Hematology, in press 2. N. Sen, N. Basar, O. Maden, F. Özcan, M. Ozlu, O. Gungor, K. Cagli, A. Erbay, Y. Balbay. Increased mean platelet volume in patients

with slow coronary flow. Platelets. 2009; 20: 23-28. 3. Borkataky S, Jain R, Gupta R, Singh S, Krishan G, Gupta, K, et al. Role of platelet volume indices in the differential diagnosis of

thrombocytopenia: a simple and inexpensive method. Hematology, 2009; 14:182-186 4. Young Ae Lim, Sung Ran Cho. Effect of platelet transfusion on the platelet parameters of recipient. Korean J Hematol. 2009; 44:36-41 5. G. Ntaios, O. Gurer, M. Faouzi, C. Aubert, P. Michel. Hypertension is an independent predictor of mean platelet volume in patients

with acute ischemic stroke. Internal Medicine Journal, 2010, in press 6. G. Ntaios, O. Gurer, M. Faouzi, C. Aubert, P. Michel. Mean platelet volume in the early phase of acute ischemic stroke is not

associated with severity or functional outcome. Cerebrovascular Diseases, 2010, in press 7. Chandra H, Chandra S, Rawat A, Verma SK. Role of mean platelet volume as discriminating guide for bone marrow disease in

patients with thrombocytopenia. Int J Lab Hematol. 2010, in press 8. Lee WS, Kim TY. Platelet indices are not suitable for screening of leukaemia. Journal of Pediatric Hematology/Oncology. 2010,

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Goyal%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rao%20MS%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Khan%20A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Huzzy%20L%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Green%20C%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Haffty%20BG%22%5BAuthor%5D


95


online early view 9. Zvorc Z, RB Rafaj, J. Kules, V Mrljak. Erythrocyte and platelet indices in babesiosis of dogs. Veterinarski Arhiv 2010; 80: 259-267 10. Faiz M, Qazi JI. t(12:21) is underrepresented in childhood B-lineage acute lymphoblastic leukemia in Punjab, Pakistan. J Pediatr

Hematol Oncol. 2010; 32(3):249-51. 11. Lee WS, Kim TY. Mean platelet volume and platelet distribution width are useful in the differential diagnosis of aplastic anemia and

idiopathic thrombocytopenic purpura. Clinical Chemistry and Laboratory Medicine 2010, online early view 12. Ten Berg M, et al. Discriminative value of platelet size indices for the identification of the mechanism of chemotherapy-induced

thrombocytopenia. Biomarkers 2010, in press 13. Hussein M, et al. Coagulation profile and platelet parameters of the Arabian sand Gazelle (Gazella subgutturosa marica):

comparison with humans and camels. Journal of Wildlife Diseases 2010; 46: 1165-1171 14. Chandra H, Chandra S, Rawat A, Verma SK. Megaloblastic pancytopenia vis-à-vis non-megaloblastic pancytopenia: is mean platelet

volume useful discriminating indicator. Int J Lab Hematol. 2011, in press 15. Al Ajerami Y, Sirdah M. Effects of X-ray film processing on health status of medical radiographers at Gaza strip, Palestine. Journal of

Al-Azhar University-Gaza (Natural Sciences), 2008; 10:59-76 16. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune

thrombocytopenia. Blood 2011, early on line 17. Adamou D, Laiou E. Utility of platelet indices in clinical practice. Acta Microbiologica Hellenica 2011; 56:5-15 18. Campuzano-Maya G. Utilidad clínica del extendido de sangre periférica: las plaquetas. Medicina & Laboratorio 2008, 14: 511-531. 19. Nascimento M. Plaquetogramas: Faixas Etárias e Sexos. Newslab 2011; 106:210-224 20. Liang Y, Li Z. Progress in platelet activation and hypertensive disorder complicating pregnancy. J Int Obstet Gynecol 2011; 38:186-

188 21. Cil H, Islamoglu Y, Tekbas E, et al. Platelet count and mean platelet volume in patients with in-hospital deep venous thrombosis.

Clinical And Applied Thrombosis/Hemostasis 2012; 18:650-653 22. Latger-Cannard V, Hoarau, M, Salgnac V, et al. Mean platelet volume: comparison of three analysers towards standardization of

platelet morphological phenotype. International Journal of Laboratory Hematology. 2012, in press. doi: 10.1111/j.1751-553X.2011.01396.x

23. WS Lee, TY Kim. Is Mean Platelet Volume a New Predictor in Confirming a Diagnosis of Acute Appendicitis? Clin Appl Thromb Hemost 2011;17:E125-126. DOI: 10.1177/1076029610389024

24. M.J. ten Berg, H. den Breeijen, T.C.G. Egberts, W.W. van Solinge. Biomarkers voor de effecten van geneesmiddelen: het UPODinitiatief. Ned Tijdschr Klin Chem Labgeneesk 2012; 37: 7-1

25. Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Annals of Medicine, 2012; 00: 1–12

26. R. A. Mathers, G. O. Evans, J. Bleby. Platelet measurements in rat, dog and mouse blood samples using the Sysmex XT-2000iV. Comp Clin Pathol 2012, in press. DOI 10.1007/s00580-012-1483-9

27. Xia Cao, Xiumei Xie, Jiansong Zhou, et al. Increased platelet volume in a general population with prehypertension: a cross-sectional study of 80 545 participants from China. Hypertension Research 2012; in press. doi:10.1038/hr.2012.62

28. Giezen T, Mantel-Teeuwisse A, et al. Rituximab-induced thrombocytopenia: a cohort study. European Journal of Hematology 2012, in press. DOI: 10.1111/j.1600-0609.2012.01808.x

29. Ekiz F, Gurbus Y, Basar O, et al. Mean Platelet Volume in the Diagnosis and Prognosis of Crimean–Congo Hemorrhagic Fever. Clin Appl Thromb Hemost 2013; 19:441-4

30. Zhang NB, Li Y, Zing WQ, et al. Association of Polymorphism C1149G of NEAT1 with Hematological and Immune Traits in Landrace Pig(Sus scrofa). Journal of Agricultural Biotechnology 2012, 20(8): 874~879

31. RL Xu, ZJ Zheng, YJ Ma, et al. Platelet volume indices have low diagnostic efficiency for predicting bone marrow failure in thrombocytopenic patients. Exp Ther Med. 2013; 5(1): 209–214.

32. Xu Qian, Liu Wen-Jun. Platelet changes in acute leukemia. Cell biochemistry and biophysics 2013, in press. 33. Chandrashekar V. Plateletcrit as a Screening Tool for Detection of Platelet Quantitative Disorders. Journal of Hematology 2013; 2:22-

26 34. Niu Q, Zhang R, Zhao M, Zeng S, Huang X, et al. (2013) Differences in Platelet Indices between Healthy Han Population and

Tibetans in China. PLoS ONE 8(6): e67203. doi:10.1371/journal.pone.0067203 35. Korkmaz S, Uslu AU, Aydin B, et al. Pre-treatment and post-treatment changes in platelet indices in patients with immune

thrombocytopenia. Saudi Medical Journal 2013; 34:591-6 36. Mathers R, Evans G, Bleby G. Platelet measurements in rat, dog and mouse blood samples using the Sysmex XT-2000iV.

Comparative Clinical Pathology 2013; 22: 815 – 821 37. Khanna R, Nayak D, et al. A retrospective evaluation of mean patelet volume as a discriminating factor in thrombocytopenia of

hypoproductive and hyperdestructive aetiologies. Journal of evolution of medical and dental sciences 2013; 47:9059-65 38. Asuman C, Nermin T, Gokmen Z, et al. Do platelet indices have a role in benign paroxysmal positional vertigo? Neurological

Research 2014, online early 39. Vinholt, P. J., Hvas, A.-M. and Nybo, M. (2014), An overview of platelet indices and methods for evaluating platelet function in

thrombocytopenic patients. European Journal of Haematology, 92: 367–376. doi: 10.1111/ejh.12262 40. Zhang Z, Xu X, Ni H, Deng H. Platelet indices are novel predictors of hospital mortality in intensive care unit patients. Journal of

Critical Care 2014; in press 41. Aponte Barrios, Nelson Hernando (2014) Evaluación del rendimiento diagnóstico de los índices plaquetarios en el diagnóstico

diferencial entre trombocitopenia por destrucción de plaquetas y trombocitopenia por disminución en su producción en la población pediátrica del hospital de la misericordia entre 2012 y 2013. Pregrado thesis, Universidad Nacional de Colombia

42. Elsewefy D, Farweez B, Ibrahim R. Platelet indices: consideration in thrombocytopenia. Egyptian Journal of Hematology 2014; 39:134-8

43. Bashir A, Saeed O, Mohammed B, Ageep A. Role of Platelet Indices in Patients with Dengue Infection in Red Sea State, Sudan. International Journal of Scienc and Research 2013; 4:1573-6

44. Iwaszko-Simonik A, Niedzwiedz A, et al. Expression of surface platelet receptors (CD62P and CD41/61) in horses with recurrent airway obstruction (RAO). Veterinary Immunology and Immunopathology 2015; 164:87-92


96


45. Cicek T, Togan T, Akbaba K, et al. The value of serum mean platelet volume in testicular torsion. Journal of international medical research 2015; 43:452-9

Homocysteine and carotid intima-media thickness in ischemic stroke patients are not correlated G. Ntaios, C. Savopoulos, A. Hatzitolios, I. Ekonomou, E. Destanis, I. Chryssogonidis, A. Chatzinikolaou, I. Pidonia, D. Karamitsos Neuropsychiatric Disease and Treatment 2008; 4:477-479 IF: 2.000 Αναφορές: 8 1. Varoglu A. Na VPA-induced acute ischemic stroke in an epileptic patient with methylenetetrahydrofolate reductase gene

polymorphism, Epilepsy research, 2009, online early view 2. Ben Salem-Berrabah Ο, Fekih-Mrissa Ν, El Oudi Μ, Layouni S, Louati Ι, Aouni Ζ, Mazigh C, N’siri Β, Ben Hamida Α, Machghoul S,

Mrissa R, Gritli N. Hyperhomocysteinemia, C677T MTHFR Polymorphism And Ischemic Stroke In Tunisian Patients. La tunisie Medicale 2010; 88 : 655-659

3. Kenina V, et al. Carotid Artery Stenosis Correlation with Hyperhomocysteinemia in Stroke Patient Group: a Prospective Study. Acta Chirurgica Latvensis 2010; 10:39-41

4. Mackawy A, Badawy M. Methylene tetrahydrofolate reductase gene polymorphism and the risk of ischemic stroke in type 2 diabetic Egyptian patients. Global Journal of Health Science 2011; 3:162-174

5. O Delikan, BP Balci, F Özer. The Relationship Between Carotid Intima-media Thickness and Homosystein in Ischemic Stroke. (Arc hi ves of Neu ropsy chi atry 2012; 49: 53-8

6. Christodorescu R, Dragan S, Serban C, et al. Association between Plasma Homocysteine Concentrations and Carotid Intima-Media Thickness in Patients with Coronary Artery Disease. Recent Researches in Medicine and Medical Chemistry 2012; 202-206. ISBN: 978-1-61804-111-1

7. R. Buzas, C. Serban, I. Suceava, D. Lighezan. Association between Plasma Homocysteine Concentrations and Carotid Intima-Media Thickness in Patients with Coronary Artery Disease. Advances in Environment, Biotechnology and Biomedicine. 2012;289-293. ISBN: 978-1-61804-122-7

8. Devasia AJ, Joy B, Tarey SD. Serum homocysteine as a risk factor for carotid intimal thickening in acute stroke: A cross sectional observational study. Ann Indian Acad Neurol 2016;19:48-51

Detection of CD55 and CD59 deficient granulocytic populations in patients with myelodysplastic syndrome G. Kaiafa, A. Papadopoulos, G. Ntaios, Z. Saouli, C. Savopoulos, N. Tsesmeli, Z. Kontoninas, A. Chatzinikolaou, V. Tsavdaridou, I. Klonizakis, A. Hatzitolios Annals of Hematology 2008; 87:257-62 IF: 2.866

Αναφορές: 12 1. Wang SA, Pozdnyakova O, Jorgensen JL, Medeiros LJ, Stachurski D, Anderson M, Raza A, Woda BA. Detection of paroxysmal

nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica 2009;94:29-36.

2. Young NS. Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure. Haematologica. 2009 Jan;94(1):3-7

3. Myelodysplastic syndromes: pathobiology and clinical management (second edition, edited by David Steensma), 2008, ISBN 9781420074390, 1420074393

4. Orazi A, Czader M. Myelodysplastic syndromes. Am J Clin Pathol 2009; 132:209-305 5. Zhang L, Qi J, Zhang F, Qiu L. Detection of CD-59 deficient granulocytes in a patient with advanced myelodysplastic syndrome.

Chinese Medical Journal 2009; 122:2071-2073 6. Bieliauskas, S., Fine, N., Douglas-Nikitin, V. and Blenc, A. M. , Paroxysmal nocturnal hemoglobinuria clones are not present in HIV

positive patients. Cytometry Part B: Clinical Cytometry 2010, in press. doi: 10.1002/cyto.b.20559 7. Sergeeva A, et al. An anti-PR1/HLA-A2 T cell receptor-like antibody mediates complement dependent cytotoxicity against acute

myeloid leukemia progenitor cells. Blood 2011, in press 8. Won EJ, Kim HR, Lee SY, et al. Paroxysmal nocturnal hemoglobinuria-myelodysplastic syndrome associated with marked

thrombocytosis and acquired clonal cytogenetic abnormality of t(3;12)(q28;q15). Leukemia & Lymphoma 2012; 53:1429-1432

9. K. Miller, I. Rozenvald,. The myelodysplastic syndromes. Neoplastic diseases of the blood 2013; pp 487-518 10. Toomey C, et al. The role of decay accelerating factor in environmentally induced and idiopathic systemic autoimmune

disease. Autoimmune Diseases. 1. Volume: 2014. 2014. 11. Brodsky R. Paroxysmal nocturnal hemoglobinuria. Blood 2014 124: 2804-2811 12. Ahmad E, Alazizi N, Ahmed R. Detection of CD55-and/or CD59-deficient red cell populations in chronic lymphocytic leukemia

Egyptian patients. International Journal of Advanced Research (2015), Volume 3, Issue 3, 1077-1090

Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency in Northern Greece G. Ntaios, A. Chatzinikolaou, C. Tomos, C. Manolopoulos, P. Karalazou, A. Nikolaidou, S. Alexiou-Daniel Internal Medicine Journal 2008; 38:204-6 IF: 1.823


97


Αναφορές: 4 1. Theerathananon W, et al. Prevalence of G6PD deficiency in malaria endemic area: case study in Bongti sub-district, Sai Yok districz,

Kanchanaburi province, Thailand. J Health Res 2010; 24: 55-62 2. Jolly, D., Lévy, E. G6PD deficit: Epidemiological and socio-economic arguments in favour of the need for targeted, systematic

screening. Journal d'Economie Medicale 2010; 28:19 – 30 3. Amini F, et al. Prevalence and molecular study of G6PD deficiency in Malaysian Orang Asli. Internal Medicine Journal 2011; 41: 351–

353 4. Guo J, et al. Neonatal screening for glucose-6-phosphate dehydrogenase deficiency in Shanghai and determination of cut off value.

Journal of Shanghai Jiaotong University (Medical Science); 2015;35:618 - 621

Implementation of strategy for the management of overt dyslipidemia. The IMPROVE study A. Hatzitolios, V. G. Athyros, A. Karagiannis, C. Savopoulos, C. Charalambous, G. Kyriakidis, Th. Milidis, C. Papathanakis, A. Bitli, I. Vogiatsis, G. Makridis, G. Ntaios, N. Katsiki, A. Symeonidis, D. P. Mikhailidis International Journal of Cardiology 2009; 134(3):322-9 IF: 5.509 Αναφορές: 28 1. Athyros V, Hatzitolios A, Karagiannis A, Didangelos T, Iliadis F, Dolgyras S. Initiative for a new diabetes therapeutic approach in a

Mediterranean country: the INDEED study. Current medical research and opinion. 2009, online early view 2. Daskalopoulou, S.S., Doonan, R.J., Mikhailidis, D.P. Undertreatment of hypercholesterolemia. Current Medical Research and

Opinion 2010; 26:439-443 3. Toth P. The role of statins in managing diabetic dyslipidemia. 2010; 59:S23-S29 4. M. Elisaf, N. Nikas. Centralized Pan-European Survey on the Undertreatment of Hypercholesterolemia in Patients Using Lipid

Lowering Drugs: The CEPHEUS-Greece Survey. Angiology 2010, in press 5. Yoon HJ, Jeong MH, Kim KH, Ahn Y, Cho JG, Park JC, Kang JC, Bae JH. Carotid Intima-Media Thickness, Not Carotid Plaque, is

Associated With Large Territory Cerebral Infarction in Patients With Ischemic Stroke. Korean Circ J. 2010; 40:272-6. 6. Katsiki N, et al. Are we getting to lipid targets in real life? Archives of Medical Science 2010, in press 7. Chopra V, Eagle KA. Cardiac biomarkers in the diagnosis, prognosis and management of coronary artery disease: A primer for

internists. Indian J Med Sci 2011 8. Gupta A, Savopoulos C, Ahuja J, Hatzitolios A. Role of phytosterols in lipid-lowering: current perspectives. QJM 2011, in press 9. Yoon HJ, et al. Dyslipidemia, low left ventricular ejection fraction and high wall motion score index are predictors of progressive left

ventricular dilatation after acute myocardial infarction. Korean Circ J. 2011;41(3):124-9 10. Doan Phuoc Thuoc. Assessment of Health Education Outcomes about dyslipidemia, using a network of community health workers

in Hue city. The Journal of Science (Hue University) 2010; 61: 467-479 11. Liberopoulos E, Vlasserou F, Mitrogianni Z, Papageorgantas I, Elisaf M. Prevalence and Risk Distribution of Residual Dyslipidemia

in Statin-Treated Patients in Greece. Angiology 2011, in press 12. Prasad K. Do Statins have a Role in Reduction/Prevention of Post-PCI Restenosis? Cardiovascular Therapeutics, 2011, in press.

doi: 10.1111/j.1755-5922.2011.00302.x 13. Athyros V, Hatzitolios A, et al. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT

disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci. 2011; 7(6): 984–992. 14. Morishita R, Itakura H, Nakaya N.et al. Risk factors for cardiovascular events in Japanese patients treated with fluvastatin from the

long-term event monitoring (LEM) study. Current Vascular Pharmacology 2012; 10: 178-186 15. Athyros, V.G., Gossios, T.D., Katsiki, N., Karagiannis, A., Mikhailidis, D.P. The clinical benefit of implementing guidelines in

cardiovascular disease prevention in real world settings. Archives of Medical Science 2012; 8:6-10 16. Mukhopadhyay SM. Study of Lipid Profile in Obese Individuals and the Effect of Cholesterol Lowering Agents on Them. Al Ameen

J Med Sci (2012) 5 (2):147-151 17. Yoon HJ. Can Pulse Pressure Predict the White-Coat Effect in Treated Hypertensive Patients? Clinical and experimental

hypertension 2012; 34:555-560 18. Tsartsalis A, Dokos C, Kaiafa G, et al. Statins, bone formation and osteoporosis: Hope or hype? Hormones 2012; 11:126-139 19. Kostapanos M, Elisaf M, Mikhailidis DP. Targeting cardiovascular risk: the impact of age, gender and compliance to treatment.

Current medical research and opinion 2012; in press 20. C. Gao, et al. Simvastatin Decreases Stent-Induced In-Stent Restenosis Rate Via Downregulating the Expression of PCNA and

Upregulating that of p27kip1. Journal of Interventional Cardiology 2013; 26:384-391 21. A. Modugu. Inflammatory studies on bone cement. Uppsala Universitet 2012 22. Yoon H, Jeong M, et al. Progressive Dilation of the Left Atrium and Ventricle after Acute Myocardial Infarction Is Associated with

High Mortality Progressive Dilation of the Left Atrium and Ventricle after Acute Myocardial Infarction Is Associated with high Mortality. Korean Circulation Journal 2013; 43:731-38

23. Eremic-Kojic N, Deric M, Dejanovic J. Effect of serum lipid level change on 10-year coronary heart risk distribution estimated by means of seven different coronary risk scores during one-year treatment. Medicinski pregled, 2014; 67:208-15

24. Arafah, M., Al-Hinai, A.T., Mahmeed, W.A., et al. Centralized pan-middle east survey on the undertreatment of hypercholesterolemia: Results from the cepheus study in arabian gulf countries. Angiology 2014; 65:919-26

25. Athyros V, Katsiki N, Rizzo M. Undertreatment of dyslipidemia: From the Arabian Gulf to the USA. Time to solve this problem! Current Medical Research and Opinion 2014; 30:2425-8

26. Stulc T, Snejdrlova M, Ceska R, et al. Prevention of cardiovascular diseases in clinical practice: is it possible to achieve improvement? Vnitrni Lekarstvi 2014; 60:931-6

27. Ceska R, Stulc T. Implementation of cardiovascular disease prevention guidelines into clinical practice: An unmet challenge? Current Pharmaceutical Design 2015; 21:1180-4

28. Yoon HJ, et al. Impaired Diastolic Recovery after Acute Myocardial Infarction as a Predictor of Adverse Events. Journal of cardiovascular ultrasound 2015, online early

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yoon%20HJ%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jeong%20MH%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kim%20KH%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ahn%20Y%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Cho%20JG%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Park%20JC%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kang%20JC%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bae%20JH%22%5BAuthor%5D


98


Defective platelet aggregation in myelodysplastic syndromes F. Girtovitis, G. Ntaios, A. Papadopoulos, G. Ioannidis, P. Makris Acta Haematologica 2007; 118:117-122 IF: 0.894

Αναφορές: 17 1. Kantarjian H, Wolff R, Koller C. MD Anderson Manual of Medical Oncology, 2008 McGraw-Hill (Eds). 2. Boruchov A. Thrombocytopenia in myelodysplastic syndromes and myelofibrosis. Seminars in Hematology. 2009; 46:S37-S43 3. McGlasson D, Fritsma G. Whole Blood Platelet Aggregometry and Platelet Function Testing. Semin Thromb Hemost 2009; 35:168-

180 4. Yavasoglu, I., Acar, B., Kadikoylu, G., Bolaman, Z. Platelet aggregation tests are affected in pseudothrombocytopenia. Laboratory

medicine 2010; 41:483-485 5. Torres M, et al. Medical management of hemorrhagic complications in oncologic paliative care. Salud(i) Ciencia; 2010: 17:802-7 6. Meng R. Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke. Clinical Neurology and

Neurosurgery 2011, in press 7. Hoffman R. Haematology: Basic Principles and Practice, 5t Edition. Chapter 67. Myelodysplastic Syndromes: Biology and Treatment 8. MD Anderson. Manual of Clinical Oncology. Chapter e2. The Myelodysplastic Syndromes 9. Barbara Bain. Leukemia Diagnosis. Chapter 4. The Myelodysplastic syndromes. 4th Edition, Wiley-Blackwell 10. Diane C. Farhi. Pathology of Bone Marrow and Blood Cells. 2th Edition, Στο κεφάλαιο: MDS – Refractory Cytopenias with

Unilineage Dysplasia 11. J Qiao, J Arthur, M Collecutt et al. An Acquired Defect Associated with Abnormal Signaling of the Platelet Collagen Receptor

Glycoprotein VI. Acta Haematol 2012;128:233-241 12. J. Frobel, RP Cadeddu, S. Hartwig, et al. Platelet proteome analysis reveals integrin-dependent aggregation defects in patients with

myelodysplastic syndromes. Molecular and cellular proteomics 2013; 12:1272-1280 13. Martin M, de Paz R, Jimenez-Yuste V, et al. Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes.

Thrombosis and Hemostasis 2013; 109:909-919 14. Xu Qian, Liu Wen-Jun. Platelet changes in acute leukemia. Cell biochemistry and biophysics 2013, in press. 15. Koneti Rao, A. Acquired disorders of platelet function. Platelets 2013; 1049-1073 16. DE Connor, DDF Ma, JE Joseph. Flow cytometry demonstrates differences in platelet reactivity and microparticle formation in

subjects with thrombocytopenia or thrombocytosis due to primary haematological disorders. Thrombosis research 2013, in press 17. Brierley C, Steensma D. Thrombopoiesis-stimulating agents and myelodysplastic syndromes. British Journal of Haematology 2015,

online early

Trend in incidence of cardiovascular risk factors in elderly and over-aged stroke patients between 2003 and 2007 in Greece P. Kotsaftis, G. Ntaios, C. Savopoulos, R. Kiparoglou, D. Agapakis, M. Baltatzi, N. Tsesmeli, A. Hatzitolios Archives of Gerontology and Geriatrics, 2009, in press IF: 1.704 Αναφορές: 7

1. Medeiros Camila Andrade et al. Neck circumference, a bedside clinical feature related to mortality of acute ischemic stroke. Rev. Assoc. Med. Bras. 2011; 57(5): 559-564.

2. Tsai SH, Lin YY, Hsu CW, et al. Hypoglycemia revisited in acute care setting. Yonsei Med J 2011; 52:898-908 3. Savopoulos C, Michalakis K, et al. Adipokines and stroke: A review of the literature. Maturitas 2011, in press 4. Kim M-W, Chung YC, Jung HC, et al. Electroacupuncture enhances motor recovery performance with brain-derived neurotrophic

factor expression in rats with cerebral infarction.Acupunct Med 2012, in press. doi:10.1136/acupmed-2011-010126 5. Y. Zhiwen, G, Zhigiang, L. Xiang. Elderly cardiovascular risk factors in patients with cerebral infarction. Jiangsu Medical Journal

2011; 37 (4) 6. Trapani L, Segatto M, Pallottini V. New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin

treatment in aged people? World J Hepatol 2013 December 27; 5(12): 676-684 7. Arabadzhieva D, et al. Cardiovascular comorbidity in acute ischemic stroke. Scientific cooperations medical workshops 21-22 July,

2015, Istanbul - Turkey

Evaluation of use of proton pump inhibitors in Greece G. Ntaios, A. Chatzinikolaou, G. Kaiafa, C. Savopoulos, A. Hatzitolios, D. Karamitsos European Journal of Internal Medicine 2009; 20(2):171-3. IF: 2.049 Αναφορές: 16 1. M Schaier, C Scholl, D Scharpf, F Hug, S Bonisch, et al. Proton pump inhibitors interfere with the immunosuppressive potency of

mycophenolate mofetil. Rheumatology 2010, in press 2. Ramirez E, et al. Overuse of PPIs in Patients at Admission, During Treatment, and at Discharge in a Terciary Spanish Hospital. Curr

Clin Pharmacol 2010 Nov 1;5(4):288-97. 3. Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among

academic and non-academic hospitalists. Intern Med. 2010;49(23):2561-8 4. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal

reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011, in press 5. Figueras A, et al. The use of drugs is not as rational as we believe… but it can’t be! The emotional roots of prescribing. European

Journal of Clinical Pharmacology 2011, in press 6. Fermín García-Gollarte, José Baleriola-Júlvez, Isabel Ferrero-López and Alfonso J. Cruz-Jentoft. Inappropriate Drug Prescription at

Nursing Home Admission. Journal of the American Medical Directors Association 2011, in press


99


7. Teixeira MZ. Rebound acid hypersecretion after withdrawal of gastric acid suppressing drugs: new evidence of similitude. Homeopathy 2011; 100: 148-156

8. Mouli P, Ahuja V. Proton Pump Inhibitors: concerns over prolonged use. Tropical Gastroenterology 2011;32(3):175–184. 9. Alvarez-Ibanez C, Guerra-Garcia MM. Evaluation of the incidence of upper gastrointestinal bleeding in Spain in relation to the

taking of anti-ulcer agents. Atencion Primaria 2012: 44;478-484 10. Teixeira MZ. Rebound effect of drugs: fatal risk of conventional treatment and pharmacological basis of homeopathic treatment. Int J

High Dilution Res 2012; 11(39): 69-106 11. Hamzat H, Sun H, Ford J, et al. Inappropriate Prescribing of Proton Pump Inhibitors in Older Patients: Effects of an Educational

Strategy. Drugs & Aging 2012, in press, doi: 10.2165/11632700-000000000-00000 12. Machado-Alba J, Fernandez A, Castrillon JD, et al. Prescribing patterns and economic costs of proton pump inhibitors in Colombia.

Colombia Médica 2013; 44:13-18 13. Ponce J, Esplugues JV. Rationalizing the use of PPIs: an unresolved matter. REV ESP ENFERM DIG (Madrid) 2013; 105: 121-124 14. Machado-Alba, J.E., Castrillón-Spitia, J.D., Londoño-Builes, M.J., et al. Análisis económico de la prescripción inadecuada de

antiulcerosos en pacientes hospitalizados en institución de tercer nivel de Colombia. Revista Espanola de Enfermedades Digestivas 2014; 106:77 – 85

15. Dorota Ksiądzyna, Adam Szeląg, Leszek Paradowski. Overuse of proton pump inhibitors. Polish archives of internal medicine 2015, online early

16. Meli M, et al. The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients. International Journal of Clinical Pharmacy 2015; 37:1152-61

Discrimination indices as screening tests for β- thalassemic trait G. Ntaios, A. Chatzinikolaou, Z. Saouli, F. Girtovitis, M. Tsapanidou, G. Kaiafa, Z. Kontoninas, A. Nikolaidou, C. Savopoulos, I. Pidonia, S. Alexiou-Daniel Annals of Hematology 2007; 86:487–491 IF: 2.866 Αναφορές: 75 (εκ των οποίων οι 9 αυτοαναφορές) 1. Beyan, K. Kaptan, A. Ifran. Letter to the Editor: Discrimination indices as screening tests for β- thalassemic trait Annals of

Hematology 2008; 87:61–62 2. G. Ntaios, A. Chatzinikolaou Re: Discrimination indices as screening tests for β-thalassemic trait. Annals of Hematology 2007;

87:329-30 3. G. Ntaios, A. Chatzinikolaou. Beta-thalassemic trait cannot be safely differentiated from iron deficiency anemia European Journal of

Hematology 2007; 79:554 4. B. Kaczorowska-Hac, A. Balcerska. ß Thalassemia a surprising reason for anaemia in North Poland children. Annals of Hematology

2008; 87:425-427 5. G. Ntaios, A. Chatzinikolaou. Inadequate awareness of the role of erythrocytic parameters in the detection of beta-thalassemia

minor. Journal of Postgraduate Medicine 2008; 54:61 6. G. Ntaios, A. Chatzinikolaou Red cell distribution width in iron deficiency anemia and beta-thalassemia minor. American Journal of

Clinical Pathology 2008; 130:313-314 7. G. Ntaios, A. Chatzinikolaou Incorporation of erythrocytic and reticulocytic parameters in a common formula: will it provide a

more accurate differentiation between iron deficiency anemia and β-thalassemic trait. International Journal of Laboratory Hematology, Online early view

8. C. Beyan, K.Kaptan, A.Ifran Discrimination indices have no predictive value in differential diagnosis of iron deficiency anemia and beta-thalassemia trait. International Journal of Laboratory Hematology, Online early view

9. N. Cohan, M. Ramzi Evaluation of sensitivity and specificity of Kerman index I and II in screening beta-thalassemia minor. Scientific Journal of Iranian Blood Transfusion Organization 2008;4(4):297-302

10. E. Urrechaga. Red blood cell microcytosis and hypochromia in the differential diagnosis of iron deficiency and β-thalassaemia trait. International Journal of Laboratory Hematology, Online early view

11. G. Ntaios, A. Chatzinikolaou M/H ratio for the differential diagnosis of microcytic anemia. International Journal of Laboratory Hematology, 2009; 31:248-249

12. Harrington AM. Red cell distribution width in iron deficiency anemia and beta-thalassemia minor – Reply. American Journal of Clinical Pathology 2008; 130:314

13. G. Ntaios Separating Thalassemia Trait and Iron Deficiency by Simple Inspection. American Journal of Clinical Patholog, 2009; 131:445

14. E Urrechaga. M/H ratio for the differential diagnosis of microcytic anemia-reply. International Journal of Laboratory Hematology, 2009; 31:250-51

15. Grotto H. Diferenciação das anemias microcíticas utilizando a determinação do RDW. Rev. Bras. Hematol. Hemoter. 2008; 30(2): 85-88

16. E. Urrechaga. Discriminant value of % microcytic/% hypochromic ratio in the differential diagnosis of microcytic anemia. Clinical Chemistry and Laboratory Medicine 2008; 46:1752–1758

17. Z. Yang, CH. Chaffin, PL. Easley, B. Thigpen, VV. Reddy. Prevalence of elevated hemoglobin A2 measured by the CAPILLARYS system. Am J Clin Pathol. 2009; 131(1):42-8.

18. Okan V, Cigiloglu A, Cifci S, Yilmaz M, Pehlivan M. Red cell indices and functions differentiating patients with the β-thalassemia trait from those with iron deficiency anemia. The Journal of International Medical Research. 2009; 37:25-30

19. Matos J, Carvalho M, Dusse M, Ferreira M, Stubbert R. The role of RDW, erythrocyte morphology and platelet parameters in the differentiation between microcytic and hypochromic anemias. Rev Bras Hematol Hemoter 2008; 30:463-469

20. Ehsani M, Shahgholi E, Rahiminejad M, Seighali F, Rashidi A.A new index for discrimination between iron deficiency anemia and beta-thalassemia minor: results in 284 patients. Pakistan Journal of Biological sciences, 2009, in press

21. Ntaios G. Red blood cell flags for the differential diagnosis between thalassemia trait and iron deficiency anemia. Hematology, 2009, in press


100


22. B. Bryant. J. Hopkins, S. Arceo, S. Leitman. Evaluation of low red blood cell mean corpuscular volume in an apheresis donor population. Transfusion 2009, in press

23. Nadarajan V, Sthaneshwar P, Jayaranee S. RBC-Y/MCV as a discriminant function for differentiating carriers of thalassaemia and HbE from iron deficiency. International Journal of Laboratory Hematology. 2009, online early, doi:10.1111/j.1751-553X.2009.01174.x

24. Rahim F, Keikhaei B. Better differential diagnosis of iron deficiency anemia from beta-thalassemia trait. Turk J Hematol 2009; 26:138-45

25. Piroonratana T, Wongseree W, Assawamakin A, Paulkhaolarn N, Kanjanakorn C, Sirikong M, et al. Classification of haemoglobin typing chromatograms by neural networks and decision trees for thalassaemia screening. Chemometrics and Intelligent Laboratory Systems. 2009, in press

26. M. Santiago. Thalassemia trait: What every NP should know. The Nurse Practitioner 2009; 34:14-21 27. Ferrara M, Capozzi L, Russo R, Bertocco F, Ferrara D. Reliability of red blood cell indices and formulas to discriminate between beta

thalassemia trait and iron deficiency in children. Hematology 2010; 15:112-5. 28. Keikhaei B. A new valid formula in differentiating iron deficiency Anemia from ß–thalassemia trait. Pak J Med Sci 2010;26(2):368-

373. 29. Urrechaga E, Borque L, Escanero JF. The role of automated measurement of red cell subpopulations on the Sysmex XE 5000 analyzer

in the differential diagnosis of microcytic anemia. Int J Lab Hematol 2010 in press 30. Can M, Kelek S, Hakimoglu Y, Acikgoz S, Mungan G, Begendik F. Evaluation of Indices in Differentiation of Iron Deficiency Anemia

and Β-thalassemic Trait According to Age and Hemoglobin Concentration. The Journal of Zonguldak Karaelmas University Faculty of Medicine 2008; 5: 26-29

31. Shen C, Jiang YM, Shi H, Liu JH, Zhou WJ, Dai QK, Yang H. Evaluation of Indices in Differentiation between Iron Deficiency Anemia and beta-Thalassemia Trait for Chinese Children. J Pediatr Hematol Oncol. 2010, in press

32. Nesa A. RDWI is Better Discriminant than RDW in Differentiation of Iron Deficiency Anaemia and Beta Thalassaemia Trait. Bangladesh J Child Health 2009;33 (3): 100-103

33. Narchi H, Basak R. Comparison of erythrocyte indices to differentiate between iron deficiency and alpha-thalassaemias in children with microcytosis and/or hypochromia. EMHJ 2010; 16:966-971

34. Ntaios G, Gurer O, Faouzi M, Aubert C, Michel P. Red cell distribution width does not predict stroke severity or functional outcome. International Journal of Stroke, 2010, in press

35. Van Vraken M. Evaluation of microcytosis. Am Fam Physician 2010;82(9):1117-1122 36. Higgins J, Mahadevan L. Physiological and pathological population dynamics of circulating human red blood cells. Proceedings of

the National Academy of Sciences 2010, online early view 37. Ezer A, et al. Incidence of congenital hemolytic anemias in young cholelithiasis patients. World J Gastroenterol 2010 November 21;

16(43): 5457-5461 38. Niazi M, Tahir M, Raziq F, Hameed A. Usefulness of red cell indices in differentiating microcytic hypochromic anemias. Gomal

Journal of Medical Sciences 2010; 8:125-129 39. Weatherall D. Systems Biology and Red Cells. New England Journal of Medicine 2011; 364:376-377 40. Urrechaga E, Borque L, Escanero JF. The Role of Automated Measurement of RBC Subpopulations in Differential Diagnosis of

Microcytic Anemia and {beta}-Thalassemia Screening. Αm J Clin Pathol. 2011; 135(3):374-9 41. Hoffman J. Extended erythrocyte and reticulocyte parameters in anemia diagnosis. Transfuze a Hematologie dnes 2010; 16:7-9 42. Ou Z, Li Q, Liu W, Sun X. Elevated Hemoglobin A2 as a Marker for β-Thalassemia Trait in Pregnant Women. Tohoku J Exp Med.

2011;223(3):223-6. 43. Janel A, et al. Proposal of a score combining red blood cell indices for early differentiation of beta-thalassemia minor from iron

deficiency anemia. Hematology 2011, in press 44. Setsirichok D, et al. Classification of complete blood count and haemoglobin typing data by a C4.5 decision tree, a naïve Bayes

classifier and a multilayer perceptron for thalassaemia screening. Biomedical Signal Processing and Control 2011, in press 45. Urrechaga E, Borque L, Escanero JF. Erythrocyte and reticulocyte parameters in iron deficiency and thalassemia. J Clin Labor

Analysis 2011; 25:223-8 46. Tonbul A, et al. Red Cell Distribution Width (RDW) in the newborn: normative data. Journal of Clinical Laboratory Analysis 2011, in

press 47. Lazarte S, Leri De Nofal M, Rossi E, et al. Diagnostico differencial de anemia ferropenica y rasgo beta talasemico: valor predictive de

las pruebas de cribado. Archivos De Bioquimica, Quimica y Farmacia 2011; 21: 8-17. 48. Williams C. The use of the automated parameter RDW-SD as a discriminator of both alpha and beta thalassaemia trait from iron

deficiency. Australian Journal of Medical Science 2011; 32 (3):88-95. 49. Worwood M. Estimation of body iron stores. In: Iron physiology and pathophysiology in humans. Nutrition and Health 2012, Part 5,

499-528. DOI: 10.1007/978-1-60327-485-2_25 50. Y. Yousafzai, S. Khan, F. Raziq. β-thalassaemia trait: Haematological parameters. J Ayub Med Coll Abbottabad 2010;22(4) 51. Wongprachum K, Sanchaisuriya K, Sanchaisuriya P, et al. Proxy indicators for identifying iron deficiency among anemic vegetarians

in prevalent area for thalassemia and hemoglobinopathies. Acta Haematologica 2012, in press. DOI: 10.1159/000337032 52. Htet M, Dillon D, Akib A, et al. Microcytic anaemia predominates in adolescent school girls in the delta region of Myanmar. Asia

Pac J Clin Nutr. 2012;21(3):411-5. 53. B. Nalbantoglu, S. Guzel, V. Buyucalcin et al. Indices Used in Differentiation of Thalassemia Trait from Iron Deficiency Anemia in

Pediatric Population: Are They Reliable? Pediatric Hemotology-Oncology 2012; 29:472-478 54. Srivanichakorn S, Sukpordee N, Yana T, et al. Health status of diabetes type 2 patientsin Thailand contradicts their perception and

admitted compliance. Primary care diabetes 2011; 5:195-201 55. Matos, J.F., Dusse, L.M.S., Stubbert, R.V.B., et al. Comparison of discriminative indices for iron deficiency anemia and β thalassemia

trait in a Brazilian population. Hematology 2013; 18:169-74 56. Sahli CA, Bibi A, Ouali F, et al. Red cell indices: differentiation between β -thalassemia trait and iron deficiency anemia and

application to sickle-cell disease and sickle-cell thalassemia. Clin Chem Lab Med 2013, in press. 2013; 51:1595-1603 57. E. Erdem, D. Erdem, M. Dilek, et al. Red Cell Distribution Width and Mean Platelet Volume in Amyloidosis. Clinical and applied

thrombosis/hemostasis 2012, in press 58. Higgins JM. Red blood cell dynamics for diagnosis. US Patent 20,130,236,566, 2013

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shen%20C%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jiang%20YM%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shi%20H%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Liu%20JH%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Zhou%20WJ%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dai%20QK%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yang%20H%22%5BAuthor%5D


101


59. Wang YP, Chang J, Wu YC, et al. Oral manifestations and blood profile in patients with thalassemia trait. Journal of the Formosan Medical Association 2014; 113:83-87

60. Miri-Moghaddam E, Sargolzaie N. Cut off Determination of Discrimination Indices in Differential Diagnosis between Iron Deficiency Anemia and β- Thalassemia Minor. International Journal of Hematology- Oncology and Stem Cell Research 2014; 8:27-32

61. Vehapoglu A, Ozgurhan G, Demir A, et al. Hematological Indices for Differential Diagnosis of Beta Thalassemia Trait and Iron Deficiency Anemia. Anemia 2014; 576738

62. Sirachainan, N., Iamsirirak, P., Charoenkwan, P., Kadegasem, P., Wongwerawattanakoon, P., Sasanakul, W., Chansatitporn, N., Chuansumrit, A. New mathematical formula for differentiating thalassemia trait and iron deficiency anemia in thalassemia prevalent area: A study in healthy school-age children. Southeast Asian Journal of Tropical Medicine and Public Health 2014; 45: 174-182

63. Pornprasert S, Panya A, Punyamung M, et al. Red Cell Indices and Formulas Used in Differentiation of β-Thalassemia Trait from Iron Deficiency in Thai School Children. Hemoglobin 2014, in press

64. Abdulhusain Omran Mousa. Types of Anemias with Low MCV Using Mentzer Index and RBC Count among Patients Seen in Basrah Al-Sadir Teaching Hospital. Medical Journal of Babylon 2014; 11::292-6

65. Urrechaga E, Hoffmann J, Izquierdo S, et al. Differential diagnosis of microcytic anemia: the role of microcytic and hypochromic erythrocytes. International Journal of Laboratory Hematology 2014, online early

66. Y. Kim, H. Shim, K. Kim, et al. Profiling individual human red blood cells using common-path diffraction optical tomography. Scientific reports 2014; 4:6559

67. Lazarte S, Monaco M, Haro A, et al. Molecular Characterization and Phenotypical Study of β-Thalassemia in Tucumán, Argentina. Hemoglobin 2014, online early

68. DeLoughery TG. Microcytic anemia. N Engl J Med. 2014 Oct 2;371(14):1324-31 69. Huang T, Wu Y, Chen Y, et al. Discrimination Index of Microcytic Anemia in Young Soldiers: A Single Institutional Analysis.

PlosOne 2015; 10(2): e0114061. doi:10.1371/journal.pone.0114061 70. Kadgi N. Utility of automated RBC parameters in evaluation of anemia. International J. of Healthcare and Biomedical Research.

2015; 3:170-181 71. Hoffmann J, Urrechaga E, et al. Discriminant indices for distinguishing thalassemia and iron deficiency in patients with microcytic

anemia: a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/cclm-2015-0179, May 2015

72. Plengsuree S, et al. Red Cell Indices and Formulas Used in Differentiation of β-Thalassemia Trait from Iron Deficiency in Thai Adults. Hemoglobin 2015, online early

73. Getta H, et al. Hi & Ha, are new indices in differentiation between Iron deficiency anemia and beta-Thalassaemia trait /A Study in Sulaimani City-Kurdistan/Iraq. IOSR Journal of Dental and Medical Sciences 2015; 14: 67-72

74. Kamal A, et al. the impact of iron deficiency on hba2 level in beta thalassemia minor in sulaimani northeastern Iraq. International Journal of Applied Biology and Pharmaceutical Technology 2015; 6:59-62

75. Mukhopadhyay D, Saha K, Sengupta M, Mitra S, Datta C, Mitra PK. Role of discrimination indices in screening of betathalassemia trait in West Bengal, India: An institutional experience on 10,407 subjects. Saudi J Health Sci 2015;4:151-5


102


Άρθρα ανασκόπησης

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή Difficult situations in anticoagulation after stroke: between Scylla and Charybdis George Ntaios, Gregory Lip Current Opinion in Neurology 2016, online early Predicting functional outcome and symptomatic intracranial hemorrhage in patients with acute ischemic stroke: a glimpse into the crystal ball? G. Ntaios, V. Papavasileiou, P. Michel, T. Tatlisumak, D. Strbian Stroke 2015, online early IF: 5.729 Αναφορές: 3 (εκ των οποίων, η 1 αυτό-αναφορά)

1. M. Al-Khaled, B. Langner andT. Brüning. Predicting risk of symptomatic intracerebral hemorrhage and mortality after treatment with recombinant tissue-plasminogen activator using SEDAN score. Acta Neurologica Scandinavica 2015, online early

2. Papavasileiou V, et al. External validation of the ISAN score for predicting stroke-associated pneumonia in the Athens Stroke Registry. Journal of Stroke and Cerebrovascular Diseases 2015, online early

3. Bushi D, et al. Increased thrombin activity following reperfusion after ischemic stroke alters synaptic transmission in the hippocampus. Journal of Neurochemistry, 2015; online early

Μετά την εκλογή στη θέση Λέκτορα Adipokines as mediators of endothelial function and atherosclerosis G. Ntaios, N. Gatselis, K. Makaritsis, G. Dalekos Atherosclerosis 2013; 227:216-21 IF: 3.706 Αναφορές: 44 1. S. Wei, L. Zhang, X. Zhou, et al. Emerging roles of zinc finger proteins in regulating adipogenesis. Cellular and Molecular Life Sciences

2013, in press 2. Burgmaier M, Frick M, Liberman A, et al. Plaque vulnerability of coronary artery lesions is related to left ventricular dilatation as

determined by optical coherence tomography and cardiac magnetic resonance imaging in patients with type 2 diabetes. Cardiovascular Diabetology 2013, 12:102 doi:10.1186/1475-2840-12-102

3. Huke V, Rudloff S, Brugger M, et al. Prematurity Is Not Associated with Intra-Abdominal Adiposity in 5- to 7-Year-Old Children. The Journal of Pediatrics 2013 ; 163:1301-6

4. Mills K, Hamm L, Brent Alper A, et al. Circulating Adipocytokines and Chronic Kidney Disease. PLoS ONE 8(10): e76902. doi:10.1371/journal.pone.0076902

5. Reinstadler S, Klug G, Feistritzer H, et al. Relation of plasma adiponectin levels and aortic stiffness after acute ST-segment elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care 2014 ; 3 :10-7

6. Tang YC, Liu CW, Chang HH, et al. Endothelin-1 Stimulates Resistin Gene Expression. Endocrinology 2014, in press 7. Jamroz-Wiśniewska A, Gertler A, Solomon G, Wood ME, Whiteman M, et al. (2014) Leptin-Induced Endothelium-Dependent

Vasorelaxation of Peripheral Arteries in Lean and Obese Rats: Role of Nitric Oxide and Hydrogen Sulfide. PLoS ONE 9(1): e86744. doi:10.1371/journal.pone.0086744

8. Kostopoulos C, Spiroglou S, Varakis J, et al. Adiponectin/T-cadherin and apelin/APJ expression in human arteries and periadventitial fat: implication of local adipokine signaling in atherosclerosis? Cardiovascular pathology 2014, in press

9. Fonseca D, Antunes P, Cotrim M. Endothelium-dependent vasoactivity of the human internal mammary artery. Coronary Artery Disease 2014; 25 :266-74

10. Lee M, Chen YC, Ho GJ, et al. Serum Leptin Levels Positively Correlate With Peripheral Arterial Stiffness in Kidney Transplantation Patients. Transplantation proceedings 2014; 46:353-8

11. Berg G, Schreier L, Miksztowitz V. Circulating and adipose tissue matrix metalloproteinases in cardiometabolic risk environments: pathophysiological aspects. Hormone Molecular Biology and Clinical Investigation. Volume 17, Issue 2, Pages 79–87, ISSN (Online) 1868-1891, ISSN (Print) 1868-1883, DOI: 10.1515/hmbci-2013-0069, March 2014

12. Fullop P, Seres I, Lorincz H, et al. Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. Journal of Cellular and Molecular Medicine 2014 ; 18 :1313-20

13. Ozmak-Tizon L, Poussier M, Cottin Y, et al. Non-genomic actions of thyroid hormones: Molecular aspects. Archives of Cardiovascular Diseases 2014; online early

14. Guenther M, James R, Marks J, et al. Adiposity distribution influences circulating adiponectin levels. Translational Research 2014, online early

15. Pereira SS, Alvarez-Leite JI. Adipokines: biological functions and metabolically healthy obese profile. Journal of Receptor, Ligand and Channel Research. 2014; 7:15-25

16. Younk L, Lamos E, Davis S. The cardiovascular effects of insulin. Expert Opinion on Drug Safety 2014; 13:955-966 17. Lin N, Zhang Z, Zhang H, et al. Effects of hypoxia induced by CoCl2 on expression of adiponectin in 3T3-L1 adipocytes. Journal of

Shanghai Jiaotong University (Medical Science) 2014; 34:464-8 18. Chang Y, Kim B, Yun K, et al. Metabolically-Healthy Obesity and Coronary Artery Calcification. J Am Coll Cardiol. 2014;63(24):2679-

2686 19. Yoo H, Choi K, et al. Adipokines as a novel link between obesity and atherosclerosis. World J Diabetes 2014 June 15; 5(3): 357-363


103


20. Trifunovic D, Stankovic S, Marinkovic J, et al. Time-dependent changes of plasma adiponectin concentration in relation to coronary microcirculatory function in patients with acute myocardial infarction treated by primary percutaneous coronary intervention. Journal of Cardiology 2014, online early

21. Alix P, Guebre-Egziabher F, Soulage C. Leptin as an uremic toxin: Deleterious role of leptin in chronic kidney disease. Biochimie 2014, online early

22. Bellisario V, Berry A, Capoccia S, Raggi C, Panetta P, Branchi I, Piccaro G, Giorgio M, Pelicci P and Cirulli F(2014) Genderdependent resiliency to stressful and metabolic challenges following prenatal exposure to high-fat diet in the p66Shc-/- mouse. Front. Behav. Neurosci. 8:285. doi:10.3389/fnbeh.2014.00285

23. Fichna M, Fichna P, Gryczynska M, et al. Steroid replacement in primary adrenal failure does not appear to affect circulating adipokines. Endocrine 2015 ; 48 :677-85

24. K. Kohara, M. Ochi, Y. Okada, et al. Clinical characteristics of high plasma adiponectin and high plasma leptin as risk factors for arterial stiffness and related end-organ damage. Atherosclerosis 2014; 235:424-429

25. Qingwei Ji, Yingzhong Lin, Zhishan Liang, et al. Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris. Cardiovascular Diabetology 2014, 13:145 doi:10.1186/s12933-014-0145-4

26. R Jones, R Hardy, N Sattar, et al. Novel coronary heart disease risk factors at 60-64 years and life course socioeconomic position: The 1946 British birth cohort. Atherosclerosis 2014, online early

27. Muse E, Feldman D, Blaha M, et al. The Association of Resistin with Cardiovascular Disease in The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2015 ; 239 :101-8

28. Gao C, Yang B, Guo Q, et al. High Thyroid-Stimulating Hormone Level is Associated with the Risk of Developing Atherosclerosis in Subclinical Hypothyroidism. Horm Metab Res 2014; online early. DOI: 10.1055/s-0034-1394370

29. Jacobson S. Thesis : Severe sepsis : epidemiology and sex-related differences in inflammatory markers. Umeå: Umeå Universitet, 2014. 110 p. Umeå University medical dissertations, ISSN 0346-6612 ; 1680

30. Lima F, Braga V, Santos S, et al. Adipokines, diabetes and atherosclerosis : an inflammatory association. International Journal of Endocrinology 2015, online early

31. Liang B, Wang X, Guo X, et al. Adiponectin upregulates ABCA1 expression through liver X receptor alpha signaling pathway in RAW 264.7 macrophages. Int J Clin Exp Pathol 2015;8(1):450-457

32. Li S, Li W, Gao Q. Effects of strength training on aging vascular endothelial function and related mechanisms. Chinese Journal of Rehabilitation Medicine 2015; 30:147-51

33. Zhang O, Ji Q, et al. Circulating chemerin levels elevated in dilated cardiomyopathy patients with overt heart failure. Clinica Chimica Acta 2015, online early

34. Gu P, Cheng M, et al. Elevating circulation chemerin level is associated with endothelial dysfunction and early atherosclerotic changes in essential hypertensive patients. Journal of Hypertension 2015, online early

35. Crisafulli A, et al. Preconditioning cardioprotection and exercise performance: a radical point of view. Sports Science Health 2015, online early

36. Murray E, et al. Overweight across the life course and adipokines, inflammatory and endothelial markers at age 60–64 years: Evidence from the 1946 birth cohort. International Journal of Obesity 2015, online early

37. Wolski H, Krasnik W, et al. Analysis of -11391G>A and +45T>G polymorphisms of ADIPOQ gene in women with excessive weight gain during pregnancy. Ginekologia Polska 2015; 86:352 - 356

38. Kluzek S, et al. Is osteoarthritis a metabolic disorder? British Medical Bulletin 2015, 1-11, doi: 10.1093/bmb/ldv028 39. Lana Claudinez dos Santos. Combination of Azathioprine and Aminosalicylate Treatment Prevent Risk of Cardiovascular Disease in

Women with Ulcerative Colitis by Reducing Inflammation. Med Sci Monit, 2015; 21:2305-2315 40. Chan D, et al. Insulin resistance and vascular dysfunction in chronic kidney disease: mechanisms and therapeutic interventions.

Nephrol Dial Transplant 2015, online early 41. Kluzek S, et al. Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a

population-based cohort of middle-aged women. Ann Rheum Dis 2015, online early 42. Lu B, et al. Independent Association of Circulating Level of Chemerin With Functional and Early Morphological Vascular Changes in

Newly Diagnosed Type 2 Diabetic Patients. Medicine 2015, online early 43. Karakan et al. The relationship between left ventricular mass index and body composition in new-diagnosed hypertensive patients.

Clinical Hypertension (2015) 21:23 44. Kastorini et al. Metabolic syndrome, adherence to the Mediterranean diet and 10-year Cardiovascular Disease Incidence: the ATTICA

Study. Atherosclerosis 2015, online early

Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease N. Gatselis, G. Ntaios, K. Makaritsis, G. Dalekos Clinical and Experimental Medicine 2013, in press IF: 2.397 Αναφορές: 15 1. Sex Differences in Serum Leptin and Adiponectin levels in Apparently Healthy Iranian Adults. International Research Journal of

Applied and Basic Sciences. 2013; 4:3099-3103 2. K. Kishida, T. Funahashi, I. Shimomura. Adiponectin : basic and clinical aspects. Best Practice & Research Clinical Endocrinology &

Metabolism 2013, in press 3. Handa P, et al. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired

mitochondrial biogenesis. Hepatology 2013, in press 4. Xiao J, Wang J, Han T, Liong EC, Xing F, et al. (2013) Hepatic Lipid Metabolism and Herbal Impacts on Non-Alcoholic Fatty Liver

Disease. J Food Nutr Disor 2:4. doi:10.4172/2324-9323.1000122 5. Wang J, Guo X, Yu S, et al. Adiponectin polymorphisms and non-alcoholic fatty liver disease risk: A meta-analysis. Journal of Gastro-

enterology and hepatology 2014, in press 6. Meli R, Mattace Raso G and Calignano A (2014) Role of innate immune response in non-alcoholic fatty liver disease: metabolic

complications and therapeutic tools. Front. Immunol. 5:177. doi: 10.3389/fimmu.2014.00177


104


7. K. Kishida, T. Funahashi, I. Shimomura. Adiponectin as a routine clinical biomarker. Best Practice & Research Clinical Endocrinology & Metabolism. 2014 ; 28 :119-30

8. Liu J, Wang G, Jia Y, et al. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease. Diabetes/Metabolism Research and Reviews, online early

9. Ivanovic N, Minic R, Dimitrijevic L, et al. Lactobacillus rhamnosus LA68 and Lactobacillus plantarum WCFS1 differently influence metabolic and immunological parameters in high fat diet-induced hypercholesterolemia and hepatic steatosis. Food & Function 2014; online early. DOI: 10.1039/C4FO00843J

10. Sharma M, Mitnala S, et al. The riddle of Nonalcoholic fatty liver disease: Progression from NAFL to NASH. Journal of Clinical and experimental Hepatology 2015, online early

11. Hossain M, Mukheem A, Kamarul T. The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin. Life Sciences 2015, online early

12. Gupta V, et al. Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2015 ; 18884

13. Zhan YT et al. Glycosyltransferases and non-alcoholic fatty liver disease. World Journal of Gastroenterology 2015, online early 14. Solaleh Emamgholipour et al. The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with

nonalcoholic fatty liver disease and type 2 diabetes: a case–control study. Diabetology & Metabolic Syndrome 2015, 7:108 15. Chen-Ming Su. Adiponectin Induces OncostatinM Expression in Osteoblasts through the PI3K/Akt Signaling Pathway. Int. J. Mol. Sci.

2016, 17, 29; doi:10.3390/ijms17010029

Cardiovascular diseases in pregnancy Godosis D, Komaitis S, Tziomalos K, Baltatzi M, Ntaios G, Savopoulos C, Hatzitolios A. Am J Cardiovasc Dis 2012; 2:96-101 IF: - Αναφορές: 2

1. Bara P, Gjyli L, Gega M, et al. Aortic Pathologies and Pregnancy: A Special Focus on Connective Tissue Disorders. Cardiology and Angiology: An International Journal 2(3): XX-XX, 2014, Article no.CA.2014.3.004

2. Ramalingappa P, Aradhya HV, Hanumantharaya N, Bolarigowda P. Alpha methyldopa induced hepatotoxicity in pregnancy. Int J Reprod Contracept Obstet Gynecol. 2014; 3(3): 805-807

Stroke, obesity and gender: a review of the literature Katsiki N, Ntaios G, Vemmos K. Maturitas 2011; 69:239-43 IF: 2.844 Αναφορές: 25

1. S. Aydin, İ. Sahin, Y. Ozkan, et al. Examination of the tissue expression of rats with diet-induced obesity using radioimmunoassay and immunohistochemical methods. Molecular and cellular biochemistry 2012; 365:165-173. DOI: 10.1007/s11010-012-1256-4

2. Savopoulos CG, Apostolopoulou M, Miras A, Hatzitolios AI. Stroke, obesity and gender. Is there actually any relation regardless of age? Maturitas. 2011 Sep;70(1):92-3.

3. F. Accrocca. Tesi di dottorato: Caratterizzazione della placca carotidea instabile: indicazione al trattamento chirurgico o endovascolare. PADIS http://hdl.handle.net/10805/1103

4. H. Edgell, A.D. Robertson, R.L. Hughson. Hemodynamics and brain blood flow during posture change in younger women and post menopausal women compared to age-matched men. J Appl Physiol 2012 ; 112 :1482-93

5. Ding Q, White S, Ling C, et al. Resistin and cardiovascular disease. Trends in Cardiovascular Medicine 2012, in press. 6. D’Alessio P, Ostan R, Valentini L, et al. The ristomed study: Gender differences in response to dietary supplementation. Prime 2012;

2:30-37 7. Paternain, L, Batlle MA, De la Garza AL, et al. Transcriptomic and epigenetic changes in the hypothalamus are involved in an

increased susceptibility to a high-fat-sucrose diet in prenatally stressed female rats. Neuroendocrinology (DOI:10.1159/000341684) 8. M. Rastovic, et al. Obesity as a component of the global cardiometabolic disease risk. PONS 2012; 9:41-47 9. Brandon P. Lucke-Wold, Ryan C. Turner, A. Noelle Lucke-Wold, et al. Age and the Metabolic Syndrome as Risk Factors for Ischemic

Stroke: Improving Preclinical Models of Ischemic Stroke. Yale J Biol Med. 2012 December; 85(4): 523–539 10. Turner R, Lucke-Wold B, Lucke-Wold N, et al. Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying

Promising Directions. Int. J. Mol. Sci. 2013, 14, 1890-1917; doi:10.3390/ijms14011890 11. Fryer BJ. The relationship between task complexity and cerebral oxygenation in stroke patients. Thesis. Stellenbosch University. 2013 12. Obradovic M, Bjelogrlic P, Rizzo M, et al. Effects of obesity and estradiol on Na+/K+ATPase and their relevance to cardiovascular

disease. Journal of Endocrinology 2013, in press 13. R. Radice, L. Zanin, G. Marra. On the effect of obesity on employment in the presence of observed and unobserved confounding.

Statistica Neerlandica 2013 ; 67 :436-455 14. W. Morsy, H. Ali Elfeky, R. Ahmed, et al. Cerebrovascular Stroke Recurrence among Critically Ill Patients at a Selected University

Hospital in Egypt. Journal of Biology, Agriculture and Healthcare 2013; 3:22-34 15. Leahy S, Donoghue. O, O’Connell M, et al. Obesity and health outcomes in older Irish adults. In : The over 50s in a changing Ireland

2014. ISBN: 978-1-907894-07-7 16. Gavin JR. The role of phentermine/topiramate extended-release in the treatment of obesity and obesity-related adverse health

consequences. US Endocrinology 2013; 139-145 17. Yang Z, Chen Y, Zhang Y, et al. Sevoflurane postconditioning against cerebral ischemic neuronal injury is abolished in diet-induced

obesity: Role of brain mitochondrial KATP channels. Molecular Medicine Reports 2014; 9:843-850 18. Kernan W, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2014, in press 19. Luca Zanin. Exploring the Effect of Participation in Sports on the Risk of Overweight. Applied Research in Quality of Life 2014 ;

online early. 10.1007/s11482-014-9317-3 20. Fujioka K. Sustained-release Naltrexone/Bupropion— A Novel Pharmacologic Approach to Obesity and Food Craving. US

http://hdl.handle.net/10805/1103


105


Endocrinology, 2014;10(1):53–8 21. Barba R. Marco J, Ruiz J, et al. The Obesity Paradox in Stroke: Impact on Mortality and Short-term Readmission. Journal of Stroke and

Cerebrovascular Diseases 2015, online early 22. Amiano P, et al. Unprocessed red meat and processed meat consumption and risk of stroke in the Spanish cohort of the European

Prospective Investigation into Cancer and Nutrition (EPIC). European Journal of Clinical Nutrition 2015, online early 23. Ploner A, et al. Adiposity as a cause of cardiovascular disease: A Mendelian randomization study. International Journal of

Epidemiology 05/2015; 44(2). DOI:10.1093/ije/dyv094 24. Lehmann M, et al. Inflammatory and metabolic markers and short-time outcome in patients with acute ischemic stroke in relation to

TOAST subtypes. Metabolic Brain Disease 2015 ;30 :1417-28 25. Rapp S, et al. Living Long and Living Well: Results from the Women’s Health Initiative. J Gerontol A Biol Sci Med Sci 2015, online

early

Pharmaceutical modulation of the renin angiotensin aldosterone system for stroke prevention: a review of experimental and clinical evidence E. Moutzouri, G. Ntaios, M. Elisaf, H. Milionis CNS spectrums 2010, in press IF: 1.727 Αναφορές: 1 1. Prakash A, et al. Cerebroprotective effects of RAS inhibitors: Beyond their cardio-renal actions. Journal of Renin-

Angiotensin-Aldosterone System 05/2015; 16(3). DOI:10.1177/1470320315583582 Πριν την εκλογή στη θέση Λέκτορα The controversial role of B vitamins on cardiovascular risk: an update G. Ntaios, C.Savopoulos, D. Grekas, A. Hatzitolios Archives of Cardiovascular diseases, 2009; 102:847-54 IF: 1.662 Αναφορές: 28 (εκ των οποίων η 1 αυτοαναφορά) 1. G. Ntaios, C.Savopoulos, S. Chatzopoulos, D. Mikhailidis, A. Hatzitolios. Iatrogenic hyperhomocysteinemia in patients with

metabolic syndrome: a systematic review and metaanalysis. Atherosclerosis, 2010, in press 2. Jones JM. Folic Acid-Benefits, Risks, and Food Fortification. Cereal foods world 2010; 55:206-208 3. Fekete K, Berti C, Cetin I, Hermoso M, Koletzko B, Decsi T. Perinatal folate supply: relevance in health outcome parameters.

Maternal & Child Nutrition 2010: 6;23-28 4. Abraham J, Cho L. The homocysteine hypothesis: Still relevant to the prevention and treatment of cardiovascular disease? Cleveland

Clinic Journal of Medicine. 2010; 77:911-918 5. Chopra V, Eagle KA. Cardiac biomarkers in the diagnosis, prognosis and management of coronary artery disease: A primer for

internists. Indian J Med Sci 2011 6. Kardesoglu Ε, Uz Ο, Isilak Ζ, Cebeci Β. Homocysteine as a new risk factor for cardiovascular events in heart failure. International

Journal of Cardiology 2011; 146:126-127 7. Roten L, et al. A low COMT activity haplotype is associated with recurrent preeclampsia in a Norwegian population cohort

(HUNT). Molecular Human Reproduction 2011; 17:439-446 8. Van Schoor NM, Swart KM, Pluijm SM, et al. Cross-sectional and longitudinal association nbetween homocysteine, vitamin B12 and

physical performance in older persons. European Journal of Clinical Nutrition 2011, in press. DOI: 10.1038/ejcn.2011.151 9. Wang Z, Shou B, Nie Z, et al. Folate and risk of coronary heart disease: a meta-analysis of prospective studies. Nutrition, metabolism

and cardiovascular diseases 2011, in press 10. Huang YC, Lee MS, Wahlqvist ML. Prediction of all-cause mortality by B group vitamin status in the elderly. Clinical Nutrution

2011, in press 11. Park, J.Y., Nicolas, G., Freisling, H., et al. Comparison of standardised dietary folate intake across ten countries participating in the

European Prospective Investigation into Cancer and Nutrition. British Journal of Nutrition. 2012; 108:552-569 12. Park JY, Vollset SE, Melse-Boonstra A, et al. Dietary intake and biological measurement of folate: A qualitative review of validation

studies. Molecular Nutrition & Food Research 13. Wang, H.-L., Tan, S., Song, B., et al. Correlation of H-type hypertension and prognosis of ischemic stroke. National Medical Journal

of China 2012; 92: 1183-1186 14. V Spitzer, S Maggini. Phytosterols and Micronutrients for Heart Health. In: Bioactive Food as Dietary Interventions for Heart Health.

In: Bioactive food as dietary interventions for cardiovascular disease. Edited by R. Watson, V. Preedy. Academic Press, Elsevier 2013. ISBN: 978-0-12-396485-4

15. Zhou J, Zhang C. Current research on the relation between hyperhomocysteine and ischemic stroke. Chinese Journal of Neuromedicine 2012: 11: 6-28. DOI: 10.3760/cma.j.issn.1671-8925.2012.03.027

16. Bin Meng, Weina Gao, et al. Quercetin reduces serum homocysteine level in rats fed a methionine-enriched diet. Nutrition 2013, in press. doi:10.1016/j.nut.2012.10.012

17. Garg M, Wood L. Nutrition and physical activity in inflammatory diseases. 2013. ISBN: 978-1-84593-910-6 18. Blacher, J., Czernichow, S., Paillard, F., Ducimetiere, P., Hercberg, S., Galan, P. Cardiovascular effects of B-vitamins and/or N-3 fatty

acids: The Su.Fol.Om3 trial. International Journal of Cardiology 2013; 167:508-13 19. Dolman RC. The role of diet in cardiovascular disease in black South Africans: both sides of the story. 2013, in press 20. P. Suter. Vitamin nutriture in older adults. In: Geriatric Nutrition 2013.

http://doi.wanfangdata.com.cn/10.3760%2fcma.j.issn.1671-8925.2012.03.027


106


21. Morales-Vidal S, Biller J. Stroke due to systemic diseases. In: Neurological disorders dut to systemic diseases 2013:77-106. ISBN: 978-144433557-6. Elsevier

22. Sengwayo D, Moraba M, Motaung S. Association of homocysteinaemia with hyperglycaemia, dyslipidaemia, hypertension and obesity. Cardiovascular Journal of Africa 2013; 24:265-9

23. Keskek S, Cinar Y, Kirim S, et al. High renal resistive index in hypertensive patients is also associated with serum homocysteine level. Clinical and experimental nephrology 2014; online early

24. Nicolas G, Witthoft C, Vignat J, et al. Compilation of a standardized international folate database for EPIC. Food chemistry 2014, online early

25. Bays H, Jones P, Brown W, Jacobson T. National lipid association annual summary of clinical lipidology 2015. Journal of clinical lipidology 2014; 8:S1-36

26. Martí-Carvajal AJ, Solà I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD006612. DOI: 10.1002/14651858.CD006612.pub4.

27. Moraba MM, et al. Determinants of association of hyperhomocysteinaemia and metabolic disorders: a review: health. African Journal for Physical Health Education, Recreation and Dance 2015; 21:363-90

28. Naseri M, et al. Mild Hyperhomocystinemia In Children And Young Adults Were Placed On Dialysis: A Single Center Study. Journal of pediatric nephrology 2015; 3:155-64

Blood pressure treatment in acute ischemic stroke: a review of studies and recommendations G. Ntaios, P. Bath, P. Michel Current Opinion in Neurology 2009; 23:46-52 IF: 5.416 Αναφορές: 28 (εκ των οποίων οι 4 αυτοαναφορές)

1. Rosenberg N. Chen M, Prabhakaran S. New Devices for Treating Acute Ischemic Stroke. Recent Patents on CNS Drug Discovery 2010; 5:118-134

2. Mahagne MH. Prise en charge thérapeutique à la phase aiguë d’un accident ischémique constitué. Les cahiers de l'année gérontologique. 2010, in press

3. A. Tuttolomondo, R. Di Sciacca, D. Di Raimondo, C. Pedone, S. La Placa, A. Pinto, G. Licata. Effects of clinical and laboratory variables and of pretreatment with cardiovascular drugs in acute ischaemic stroke: A retrospective chart review from the GIFA study. Int J Cardiol. 2011 Sep 15;151(3):318-22)

4. E. Moutzouri, G. Ntaios, M. Elisaf, H. Milionis. Pharmaceutical modulation of the renin angiotensin aldosterone system for stroke prevention: a review of experimental and clinical evidence. CNS spectrum 2010, in press

5. Henninger N, Kumar R, Fischer M. Acute ischemic stroke therapy. Expert Review of Cardiovascular Therapy 2010; 8:1389-1398 6. Staszewski J, Gasecki D, Wojczal J. [Report from International Stroke Conference 2010, San Antonio, USA]. Pol Merkur Lekarski.

2010 Nov;29(173):336-8. 7. Kozak O, et al. High Risk of Recurrent Ischemic Events among Patients with Deferred Intracranial Angioplasty and Stent Placement

for Symptomatic Intracranial Atherosclerosis. Neurosurgery 2011, in press 8. Ntaios G, Lambrou D, Michel P. Blood pressure change and outcome in acute ischemic stroke: the impact of baseline values,

previous hypertensive disease and previous antihypertensive treatment. Journal of Hypertension 2011, in press 9. G. Ntaios, M. Faouzi, P. Michel. The short-term effect of thrombolysis decreases with increasing stroke severity. Journal of

Neurology 2011, in press 10. Liu X, Wang K, Lee K. Association of standardized estimated glomerular filtration rate with the prevalence of hypertension among

adults in the United States. Journal of Human Hypertension 2011; 25:469-475 11. Seung-Hun Oh. Blood pressure control in Neurocritical patients: focusing on the blood pressure control during acute phase of

stroke. J Neurocrit Care 2011; 4 Suppl 1:S6-S12 12. L McWilliam. Hypertensive Emergency. In: Emergency Management in Neurocritical Care, First Edition. Edited by Edward M.

Manno. 2012 John Wiley & Sons, Ltd. Published 2012 by John Wiley & Sons, Ltd, pages 1-11 13. Grise E, Adeoye O. Blood pressure control for acute ischemic and hemorrhagic stroke. Current Opinion in Critical Care 2012; 18:132-

138 14. Asaithambi G, Chaudhry S, Hassan A, et al. Adherence to Guidelines by Emergency Medical Services During Transport of Stroke

Patients Receiving Intravenous Thrombolytic Infusion. Journal of Stroke and cerebrovascular diseases. 2012, in press 15. Shuaib F, Durant R, Parmar G, et al. Awareness, treatment and control of hypertension, diabetes and hyperlipidemia and area-level

mortality regions in the reasons for geographic and racial differences in stroke (REGARDS) study. Journal of Health Care for the Poor and Underserved 2012; 23:903-92

16. G. Ntaios, D. Lambrou, P. Michel. Association between blood pressure changes in the acute phase of stroke and outcome with respect to stroke etiology. Neurology 2012; 79:1440-1448

17. Bruder N, Pellegrini L, Velly L. Pression arterielle dans l’ AVC ischemique et hemorragicue. MAPAR communications 2011; 681-688 18. Juraj Culman, Miriam Nguyen-Ngoc, Torben Glatz et al. Treatment of rats with pioglitazone in the reperfusion phase of focal

cerebral ischemia: A preclinical stroke trial. Experimental Neurology 2012, in press 19. P. Sanchetee, A. Mathur, S. Sanchetee. Advances in acute stroke management. Medicine update 2011; 221-228 20. S. Vidale. Letter by Simone Vidale Regarding Article,“Relation Between Change in Blood Pressure in Acute Stroke and Risk of Early

Adverse Events and Poor Outcome”. Stroke 2012;43:e176 21. Shammy M, Meisel K, Josephson SA. In-hospital management of stroke. Stroke management and recovery 2013; April: 66-80. Doi:

10.2217/ebo.12.433 22. Hayman M, Paleologos M, Kam P. Interventional neuroradiological procedures - A review for anaesthetists. Anaesthesia and

Intensive Care , 41 ( 2 ) pp. 184 – 201 23. Goodfellow S, Dawson J, Quinn T. Management of blood pressure in acute stroke. Expert review of neurotherapeutics 2013; 13:911-

923 24. Guo Z, Yang G, Zhou HW, et al. Xenon-enhanced CT assessment of cerebral blood flow in stroke-in-progress patients with unilateral

internal carotid artery or middle cerebral artery stenosis. Neuroscience bulletin 2013, in press

http://www.ingentaconnect.com/content/ben/prn;jsessionid=235cet65r65oh.victoria

http://www.internationaljournalofcardiology.com/article/S0167-5273(10)00480-8/abstract







http://www.scopus.com/source/sourceInfo.url?sourceId=15915&origin=recordpage

http://www.scopus.com/source/sourceInfo.url?sourceId=15915&origin=recordpage


107


25. Katz B, Flemming K. Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack. Neurosurgical focus 2014; 36:E10

26. Hao Z, Liu M, Wang D, et al. High Blood Pressure on Admission in Relation to Poor Outcome in Acute Ischemic Stroke with Intracranial Atherosclerotic Stenosis or Occlusion. Journal of Stroke and Cerebrovascular Diseases 2014, online early

27. Kakaletsis N, Ntaios G, Milionis H, et al. Prognostic value of 24-h ABPM in acute ischemic stroke for short, medium and long-term outcome: A systematic review and meta-analysis. Internationl Journal of Stroke 2015, online early

28. Weiss A, et al. Change in Systolic Blood Pressure During Stroke, Functional Status, and Long-Term Mortality in an Elderly Population. Am J Hypertens 2015, doi: 10.1093/ajh/hpv118

Amiodarone: pharmacological profile and animal-model experimental data on its vasodilating effect A. Hatzitolios, G. Ntaios, C. Savopoulos International angiology, 2009; 28:353-62 IF=1.462 Αναφορές: 1 1. C. Diazzi, G. Brigante, G. Rossi, V, Rochira. Propylthiouracil-induced Interstitial Pneumonia in a Caucasian Women with Amiodarone

Induced Thyrotoxicosis. Thyroid 2011, in press. doi:10.1089/thy.2011-0328.

The neuroprotective role of erythropoietin in the management of acute ischemic stroke: from bench to bedside G. Ntaios, C. Savopoulos, A. Chatzinikolaou, A. Hatzitolios Acta Neurologica Scandinavica 2008; 118:362-6 IF: 2.474 Αναφορές: 6 1. Sicard KM, Fischer M. Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009; 1433-42 2. Fodor D, Perju-Dumbrava L. The hematopoietic growth factors – a new perspective in the neuroprotective therapy of the ischemic

stroke. 2009; 8:172-174 3. Kaneda T, Tsuruoka S, Fujimura A. Statins inhibited erythropoietin-induced proliferation of rat vascular smooth muscle cells.

European Journal of Pharmacology 2010, in press 4. Tanaka T, Kai S, Koyama T, Daijo H, Adachi T, et al. General Anesthetics Inhibit Erythropoietin Induction under Hypoxic

Conditions in the Mouse Brain. PLoS ONE 2011;6: 12: e29378. doi:10.1371/journal.pone.0029378 5. Asadi B, Askari GR, Khorvash F, Bagherpur A, Mehrabi F, Karimi M, et al. Neuroprotective effects of erythropoietin in acute

ischemic stroke. Int J Prev Med 2013;Suppl 2: S306-12 6. Hassani V, Homaei M, Shahbazi A, et al. Human Erythropoietin Effect in Postoperative Visual Loss Following Spine Surgery: A

Case Report. Anesthesiology and Pain Medicine 2014;4(2): E7291

Vitamins and stroke: the homocysteine hypothesis still in doubt G. Ntaios, C. Savopoulos, A. Chatzinikolaou, G. Kaiafa, A. Hatzitolios The Neurologist 2008; 14:2-4 IF: 1.475

Αναφορές: 20 (εκ των οποίων οι 5 αυτοαναφορές) 1. G. Ntaios, A. Chatzinikolaou, C. Savopoulos, A. Hatzitolios Well done folate, the little boy was born healthy without spina bifida.

But will he suffer a stroke when elderly? European Journal of Internal Medicine, 2009; 20:2 2. G. Ntaios, C. Savopoulos, D. Karamitsos Effect of Folic Acid and B Vitamins on Cardiovascular disease in women. JAMA.

2008;300(12):1409 3. G. Ntaios, C. Savopoulos, D. Karamitsos, I. Economou, E. Destanis, I. Chryssogonidis, et al. The effect of folic acid supplementation

on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial. International Journal of Cardiology, Online early view

4. Biswas A, R. Ranjan, A. Meena, M. Akhter, B. Yadav, M. Munisamy, et al. Homocystine levels, polymorphisms and the risk of ischemic stroke in young Asian indians. Journal of Stroke and Cerebrovascular Diseases. 2009; 18:103-110

5. Gariballa S. Homocysteine and stroke. Current topics in nutraceutical research. 2008: 6:211-218 6. C. Sanchez-Moreno, A. Jimenez-Escrig, A. Martin. Stroke: roles of B-vitamins, homocysteine and antioxidants. Nutrition research

reviews. 2009; 22: 49-67 7. Tascilar N, Ekem S, Aciman E, Ankarali H, Mungan G, Ozen B, Unal A. Hyperhomocysteinemia as an independent risk factor for

cardioembolic stroke in the Turkish population. Tohoku J Exp Med. 2009; 218(4):293-300. 8. Lam T, Seto S, Au A, et al. Folic Acid Supplementation Modifies �-Adrenoceptor-Mediated in vitro Lipolysis of Obese/Diabetic

(+db/+db) Mice, Experimental Biology and Medicine, 2009, in press 9. G. Ntaios, C.Savopoulos, D. Grekas, A. Hatzitolios. The controversial role of B vitamins on cardiovascular risk: an update. Archives

of Cardiovascular diseases, 2009, in press 10. Zhang W, Dewey HM, Cadilhac DA, Donnan GA. Emerging risk factors for stroke. Medicine Today 2009; 10:35-41 11. Stroke & prevention - B vitamins. Arbor Clinical Nutrition Updates 2010 (Mar);318:1-5 12. H. Jin, X. Jinyu, W. Yongang. The relationship between homocysteine and common diseases in nervous system. Journal of

Neurology and Neurorehabilitation 2009; 6:157-160 13. El Oudi M, Aouni Z, Ouertani H, Mazigh C, Machghoul. Effect of lipopenic and hypotensive treatment on homocysteine levels in

type 2 diabetics. Vascular Health and Risk Management 2010:6 327–332 14. G. Ntaios, C.Savopoulos, S. Chatzopoulos, D. Mikhailidis, A. Hatzitolios. Iatrogenic hyperhomocysteinemia in patients with

metabolic syndrome: a systematic review and metaanalysis. Atherosclerosis, 2010, in press 15. Chen M, Wu B, Ye X, et al. Association between plasma homocysteine levels and obstructive sleep apnoea in patients with ischemic

stroke. Journal of clinical neurosciences 2011; 18:1454-1457. 16. Hsu F, Sides E, et al. Transcobalamin 2 variant associated with poststroke homocysteine modifies recurrent stroke risk. Neurology,


108


Oct 2011; 77: 1543 - 1550. 17. Zhang B, Qiu L, Fu M, et al. Interference in mevalonate pathway ameliorates homocysteine-induced endothelium-dysfunction.

European Journal of Pharmacology 2012, in press 18. Garg M, Wood L. Nutrition and physical activity in inflammatory diseases. 2013. ISBN: 978-1-84593-910-6 19. KL Keene, W Chen, F Chen, et al. Genetic associations with plasma B12, B6, and folate levels in an ischemic stroke population from

the Vitamin Intervention for Stroke Prevention (VISP) trial. Frontiers in Public Health 2014; online early 20. Bayir A, et al. Chapter 32 – The Effects of Vitamin B12 and Folic Acid Deficiencies on Stroke, and Vitamin B12 and Folic Acid

Supplements. In: Foods and Dietary Supplements in the Prevention and Treatment of Disease in Older Adults. 2015; 335-40. Academic press. doi:10.1016/B978-0-12-418680-4.00032-4


109


Μεταναλύσεις

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή Prognostic value of 24-h ABPM in acute ischemic stroke for short, medium and long-term outcome: A systematic review and meta-analysis N. Kakaletsis, G. Ntaios, H. Milionis, A. Haidich, K. Makaritsis, C. Savopoulos, E. Berge, A. Hatzitolios International Journal of Stroke, 2015, online early Μετά την εκλογή στη θέση Λέκτορα Intravenous insulin treatment in acute stroke: a systematic review and meta-analysis of randomized controlled trials G. Ntaios, V. Papavasileiou, A. Bargiota, K. Makaritsis, P. Michel International Journal of Stroke 2013, in press IF: 2.748 Αναφορές: 5

1. Zuloaga K, Krasnow S, Zhu X, et al. Mechanism of protection by soluble epoxide hydrolase inhibition in type 2 diabetic stroke. PlosOne; 2014: DOI:10.1371/journal.pone.0097529

2. Reeson P, Tennant K, Gerrow K, et al. Delayed Inhibition of VEGF Signaling after Stroke Attenuates Blood–Brain Barrier Breakdown and Improves Functional Recovery in a Comorbidity-Dependent Manner. Journal of Neuroscience 2015; 35:5128-43

3. Moretti A, et al. Pharmacological therapy of acute ischemic stroke: achievements and problems. Pharmacology and Therapeutics 2015; 153:79-89

4. Masrur S, et al. Association of Acute and Chronic Hyperglycemia With Acute Ischemic Stroke Outcomes Post‐Thrombolysis: Findings From Get With The Guidelines‐Stroke. J Am Heart Assoc. 2015; 4: e002193

5. Hewitt J. Treatment of hyperglycemia in patients with acute stroke. Revista Clínica Española 07/2015; DOI:10.1016/j.rce.2015.06.005

PFO closure vs. medical therapy in cryptogenic stroke: a systematic review and meta-analysis G. Ntaios, V. Papavasileiou, K. Makaritsis, P. Michel International Journal of cardiology 2013; 169:101-5

IF: 5.509 Αναφορές: 33 (εκ των οποίων η 1 αυτοαναφορά) 1. Freixa X, et al. Cardiac Procedures to Prevent Stroke: Patent Foramen Ovale Closure / Left Atrial Appendage Occlusion. Canadian

Journal of Cardiology 2013; online early 2. Soufras G, Kounis N. Patent foramen ovale, transient ischemic attack and Kounis syndrome. International Journal of Cardiology 2014,

in press 3. Nagaraja V, Eslick G. Stroke prevention by percutaneous closure of patent foramen ovale: A meta-analytic review.International

Journal of Cardiology 2014, in press 4. Putaala J, Tatlisumak T. Prime Time for Dissecting the Entity of Cryptogenic Stroke. Stroke 2014; 45:950-952. 5. Messe S, Schwarz R, Perloff J. Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults.

UptoDate 2014; Topic 1100 Version 13.0 6. Crosca S, Torrisi G, Calvagna G, et al. Transient ischemic attack due to an atrial septal defect. International Journal of Cardiology

2014 ; 173 :e5-6 7. Sveinsson O. Ischemic Stroke / cerebral infarction. Epidemiology, causes and symptoms. Laeknabladid/The Icelandic Medical

Journal 2014, volume 5. 8. Udell J, Opotowsky A, Khairy P, et al. Patent Foramen Ovale Closure versus Medical Therapy for Stroke Prevention: Meta Analysis of

Randomized Trials and Review of Heterogeneity in Meta Analyses. Canadian Journal of Cardiology 2014, in press 9. Meier B. Patent foramen ovale and closure technique with the Amplatzer Occluder. Scientifica 2014, online early 10. Hernández-Enríquez M, Freixa X. Current Indications for Percutaneous Closure of Patent Foramen Ovale. Revista Espanola de

Cardiologia 2014, online early 11. Spatola M, et al. Nouveautés en médecine 2013. Revue medical suisse 2014, online early 12. Roth C. Patent foramen ovale and cryptogenic stroke: Many unanswered questions. Cleveland Clinic Journal of Medicine 2014; 81:7

417-42 13. Wahl A, Meier B. Closure of patent foramen ovale for secondary prevention of cerebrovascular events. SAHeart 2014;11:18-27 14. Windecker S, Stortecky S, Meier B. Paradoxical embolism. Journal of American College of Cardiology 2014 ; 64 :403-15 15. De Ridder W, Verslegers L, Cras P, et al. Acute dysgrafie bij een voordien gezonde 33-jarige man: is er nog een indicatie voor de

percutane sluiting van een patent foramen ovale? Tijdschr. voor Geneeskunde 2014 ; online early. doi: 10.2143/TVG.70.00.2000000 16. Bhan A, Clapp B. Review of data and discussion - Who should undergo patent foramen ovale closure in 2014? Interventional

Cardiology review 2014 ; 9 :115-120 17. Blue Cross and Blue Shield of Alabama. Transcatheter Closure Devices for Septal Defects. Medical Policy 218. October 2014 18. Liang Tian M. The influence of CYP2C19 gene polymorphism on efficacy of combinational antiplatelet therapy for cerebral small

vessel disease. Chinese Journal of New Drugs 2014; 23:2180-4 19. Pugliatti P, Recupero A, Zito C, et al. The chance finding of an atrial septal defect in a cancer patient. International Journal of

Cardiology 2014; 177:e68-e69 20. Jeger R, Toggweiler S. Interventional treatment for structural heart disease: who is deciding, and can we afford it? Swiss Medical

Weekly 2014; 144:w14046 21. Rhodes J, Kasner S. The Gore REDUCE Clinical Study. In : Z. Amin, et al. (eds) Patent Foramen Ovale 2015; 181-4. DOI : 10.1007/978-


110


1-4471-4987-3_23 22. Yang Y, Zheng H, Jiang S, et al. Assessment of the clinical effects and safety of transcatheter patent foramen ovale occlusion. Journal

of Cardio vascular Surgery (electronic edition) 2014 ; 3 :177-180 23. Tsetsou S, Rossetti A, Michel P, et al. News in Neurology 2014. Revue Medicale Suisse 2015; 11:456-7 24. Almehmadi F, Mehdar A, Sridhar K, et al. ST-elevation myocardial infarction secondary to paradoxical coronary emboli in a patient

with massive pulmonary embolism and essential thrombocytosis: A case report. Int J Case Rep Images 2015, online early 25. Stortecky S, Windecker S. Percutaneous Closure Of Patent Foramen Ovale – Data From Randomized Clinical Trials And Meta-

Analyses. Interventional Cardiology Review, 2015;10(1):45–8 26. Wessler B, Kent D. Prevention of Recurrent Stroke in Patients with Patent Foramen Ovale. Neurologic Clinics 2015; online early 27. Roth C, Alli O. Role of Occlusive Devices to Prevent Thromboembolism Among Persons With a Patent Foramen Ovale and Prior

Stroke. Current Treatment Options in Neurology 2015; 17:13 28. Eeckhout E, Martin S, Delabays A, et al. Very long-term follow-up after percutaneous closure of patent foramen ovale.

Eurointervention 2015; 10:1474-9 29. Mohammad Khalid Mojadidi, et al. Patent foramen ovale: Unanswered questions. European Journal of Internal Medicine 2015; online

early 30. Irbaz bin Riaz, et al. Disorganized Systematic reviews and Meta-Analyses: Time to systematize the conduct and publication of these

study overviews? The American Journal of Medicine 2015, online early 31. Γ. Ντάιος. Εμβολικά εγκεφαλικά απροσδιόριστης προέλευσης. Μια νέα κατηγορία ασθενών με ισχαιμικό εγκεφαλικό επεισόδιο 32. Yaghi S, et al. Clinical Reasoning: A 50-year-old man with “elephantiasis” and headache. Neurology 2015; 85:e152-5 33. Tobe et al. Transcranial Doppler is complementary to echocardiography for detection and risk stratification of patent foramen ovale.

Canadian Journal of Cardiology 2015, online early

Non-vitamin-K-antagonists oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials G. Ntaios, V. Papavasileiou, H.C. Diener, K. Makaritsis, P. Michel Stroke 2012; 43:3298-304 IF: 5.729 Αναφορές: 58 (εκ των οποίων οι 6 αυτοαναφορές) 1. Di Minno M, et al. Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial

fibrillation patients. Expert Opin. Emerging Drugs (2013) 18(1):9-23 2. JL Mas. Actualités sur la prévention secondaire après un AIT ou un infarctus cerebral. Pratique Neurologique - FMC. 2013; 4:97-101 3. K. Gröschel, J. Röther, U. Laufs, R. Wachter. Herz oder Hirn? Herz-Cardiovascular diseases 2013, in press 4. Diener HC, Weimar C. The new S3-guidelines for the secondary prevention of stroke by the German Society of Neurology and the

German Stroke Society. Psychopharmacotherapie 2013 ; 20:58-65 5. Purrucker, J.C., Veltkamp, R. Anticoagulation in neurological disease - Significance and indication of new substances. Klinikartz 2013;

42(suppl 1): 26-32 6. Bas DF, Topcuoglu MA, Arsava EM. Atrial fibrillation and stroke in the perspective of new oral anticoagulants. Turkish Journal of

Cerebrovascular Diseases 2013, in press. doi: 10.5505/tbdhd.2013.33042 7. HC. Diener. Pro: “The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial

fibrillation.” Thromb Haemost 2013, in press 8. C. Stöllberger, J. Finsterer. Contra: “New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial

fibrillation”. Thromb Haemost 2013, in press 9. Diener HC, Easton JD, Hankey GJ, et al. Novel oral anticoagulants in secondary prevention of stroke. Best Practice and Research

Clinical Haematology 2013, in press 10. Hankey G. Secondary stroke prevention. Lancet Neurology 2013, online early 11. Guang Jian Liu, Yun Fu Wang, Ping You Chen et al. The efficacy and safety of novel oral anticoagulants for the preventive treatment

in atrial fibrillation patients: a systematic review and meta-analysis.Drug Deliver 2014, online early 12. Diener HC. To Monitor or to Not Monitor for Paroxysmal Atrial Fibrillation After Transient Ischemic attack or stroke: this is the

question. Stroke 2014; 45:355-6 13. Arboix A, et al. Advancements in understanding the mechanisms of symptomatic lacunar ischemic stroke: translation of knowledge

to prevention strategies. Expert Review of Neurotherapeutics 2014; 14:261-276 14. Spina R, Subbiah R, Markus R, et al. Percutaneous Left Atrial Appendage Occlusion with a Watchman Device Following Recurrent

Stroke on Warfarin and Rivaroxaban in Patient with Paroxysmal Atrial Fibrillation. Heart, lung and circulation 2014; 23:171-3 15. Ntaios G, et al. Association of ischemic stroke subtype with long-term cardiovascular events. European Journal of Neurology 2014, in

press 16. Undas A, et al. Practical therapeutic aspects of new oral anticoagulants use in atrial Fibrillation. Polish archives of Internal medicine

2014, in press 17. Hart R, Eikelboom J. Stroke prevention in atrial fibrillation: commentary regarding the AAN’s evidence-based guideline update.

Neurology Clinical Practice 2014 , online early, DOI 10.1212/CPJ.0000000000000003 18. Collet J. Complications hιmorragiques:conduite ΰ tenir. Cadiologiques 2014; 298:24-30 19. Manning W, Singer D, Lip G. Antithrombotic therapy to prevent embolization in atrial fibrillation. UpToDate 2014; Topic: 1031,

Version: 55.0 20. Reiffel J. The new novel oral anticoagulants (NOACs) in patients with atrial fibrillation: Dogma, dilemmas, and decisions on dosing.

Journal of Atrial Fibrillation 2014; 6:6-9

21. Young Dae Kim. Atrial fibrillation with various aspects for stroke. 2014년 대한뇌졸중학회 춘계학술대회; 19 22. Hankey G, Norrving B, Hacke W, Steiner T. Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke

2014, in press 23. Bang O, Hong K, Heo J, et al. New Oral Anticoagulants May Be Particularly Useful for Asian Stroke Patients. Journal of Stroke

2014;16(2):73-80

http://www.sciencedirect.com/science/journal/18787762


111


24. Spatola M, et al. Nouveautés en médecine 2013. Revue medical suisse 2014, online early 25. Kakkos S, Kirkilesis G, Tsolakis I. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and

Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials. European Journal of Vascular and Endovascular Surgery 2014, online early

26. Ntaios G, Melikoki V, Perifanos G, et al. Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-sectional national survey in Greece. Journal of Stroke and Cerebrovascular Diseases 2014, online early

27. Levy J. Pharmacology and Safety of New Oral Anticoagulants : The Challenge of Bleeding Persists. Clinics in Laboratory Medicine 2014, online early

28. Halperin J, Dorian P. Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation. Curr Cardiol Rev. 2014;10(4):297-302

29. Diener HC, Stanford S, Abdul-Rahim A, et al. Anti-thrombotic therapy in patients with atrial fibrillation and intracranial haemorrhage. Expert review on neurotherapeutics 2014;14:1019-28

30. Liu, G.J., Wang, Y.F., Chen, P.Y., et al. The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: A systematic review and meta-analysis. Drug delivery 2014 ; 21 :436-52

31. Wilke T, Groth A, Pfannkuche M, et al. Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. Journal of Thrombosis and Thrombolysis 2014 ; online early

32. Andrew N, Hankey G, Cadilhac D. Evidence-to-practice gaps in post-stroke management: a focus on care in a stroke unit and anticoagulation to prevent death, disability and recurrent stroke. Future Neurology 2014 ; 9 :449-459

33. P. Bahrmann, M. Wehling, D. Ropers, J. Flohr, A. Leischker, J. Röther. Optimal Stroke Prevention in the Geriatric Patient with Atrial Fibrillation: Position Paper of an Interdisciplinary Expert Panel. Drug Res (Stuttg) 2014, online early. DOI: 10.1055/s-0034-1389984

34. Palm F, Kraus M, Safer A, et al. Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt). BMC Neurology 2014, 14:199

35. Liang Tian M. The influence of CYP2C19 gene polymorphism on efficacy of combinational antiplatelet therapy for cerebral small vessel disease. Chinese Journal of New Drugs 2014; 23:2180-4

36. Zakhary D, Germano J, Josephson M. Management of Arrhythmia: Medications, Electrophysiology Studies and Ablation. In : Hypertrophic cardiomyopathy 2015; 193-205. Print ISBN : 978-1-4471-4955-2

37. G. Ntaios. Restarting oral anticoagulants after intracerebral hemorrhage. Pros. Internal and emergency Medicine 2014, in press 38. Zeng WT, Sun XT, Tang K, et al. Risk of Thromboembolic Events in Atrial Fibrillation With Chronic Kidney Disease. Stroke 2015 ;

46 :157-163 39. Tsetsou S, Rossetti A, Michel P, et al. News in Neurology 2014. Revue Medicale Suisse 2015; 11:456-7 40. Nomura E, Ohshita T, Imamura E, et al. Early Administration of Non-Vitamin K Antagonist Oral Anticoagulants for Acute Ischemic

Stroke Patients with Atrial Fibrillation in Comparison With Warfarin Mostly Combined With Heparin. Circulation Journal 2015; 79:862-6.

41. Kim Y, Lee K, Nam H, et al. Factors Associated with Ischemic Stroke on Therapeutic Anticoagulation in Patients with Nonvalvular Atrial Fibrillation. Yonsei Med J. 2015 Mar;56(2):410-417

42. Sposato L, Cipriano L, Saposnik G, et al. Diagnosis of atrial fi brillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurology 2015; online early

43. Abdul-Rahim A, Lees K. Screening for atrial fi brillation after stroke or TIA. Lancet Neurology 2015, online early 44. Cope S, Clemens A, Hammes F, et al. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral

anticoagulants in atrial fibrillation stroke prevention trials. Value in Health 2015; 18:234-249 45. Ντάιος Γ. Δευτερογενής πρόληψη σε ασθενείς με ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο. Ελληνική Ιατρική Επιθεώρηση 2014:

103:139-44 46. Didem Oguz, Aysen Kutan Fenercioglu. Yeni Nesil Oral Antikoagülanların Birinci Basamakta Kullanımı. Turkish Family physician

2015; 6: 33-37 47. Arnao V, Agnelli G, Paciaroni M. Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in

patients with atrial fibrillation. Internal and Emergency Medicine 2015; 10:555-560 48. Jung KH, et al. Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient

Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. J Stroke 2015; 17:210-5 49. Potpara T, Lip G. Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk. Progress in

Cardiovascular Diseases 2015, online early 50. Arbit, B. and Hsu, J. C. (2015), Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated

Intracranial Hemorrhage: A Focused Review. Clin Cardiol. doi: 10.1002/clc.22434 51. Nomura E. Early Administration of OAC (Oral Anticoagulant) for Acute Ischemic Stroke Patients with Atrial Fibrillation. Austin J

Clin Neurol 2015;2(1): 1017 52. G. Ntaios, G. Lip. Difficult situations in anticoagulation after stroke: between Scylla and Charybdis. Curent Opinion in Neurology

2016, online early 53. Xiong Q, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart

failure: a systemic review and meta-analysis of randomized trials. European Journal of Heart Failure 2015, online early 54. Seiffge D, et al. Recanalization Therapies in Acute Ischemic Stroke Patients: Impact of Prior Treatment With Novel Oral

Anticoagulants on Bleeding Complications and Outcome. Circulation 2015;132:1261-1269 55. Γ. Ντάιος. Εμβολικά εγκεφαλικά απροσδιόριστης προέλευσης. Μια νέα κατηγορία ασθενών με ισχαιμικό εγκεφαλικό επεισόδιο 56. Steffel J, et al. Risk-adapted anticoagulation in atrial fibrillation in Germany, Austria and Switzerland -an analysis from the PREFER-

in-AF study. Deutsche Medizinische Wochenschrift 2015;140:e247 - e255 57. Kim J, et al. Personalized medicine and stroke prevention: where are we? Vasc Health Risk Manag. 2015; 11: 601–611 58. Tommaso Sacquegna, et al. Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation. Italian Journal of

Medicine 2015; volume 9:314-322

Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis


112


G. Ntaios, C. Savopoulos, S. Chatzopoulos, D. Mikhailidis, A. Hatzitolios

Atherosclerosis 2010; 214(1):11-9 IF : 3.706 Αναφορές: 18

1. Martin-Merino E, Ruigomez A, Johansson S, Garcia-Rodriguez LA. Hospitalised ischemic cerebrovascular accident and risk factors in a primary care database. Pharmacoepidemiology and D ug Safety 2011, in press. DOI: 10.1002/pds.2201

2. Chauhan G, Kaur I, Tabassum R, et al. Common variants of homocysteine metabolism pathway genes and risk of type 2 diabetes and related traits in Indians. Experimental Diabetes Research 2012, in press

3. Gazzaruso C, Coppola A, Montalcini T, et al. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine 2011, in press. DOI: 10.1007/s12020-011-9544-4

4. Hristova M. Metabolic Syndrome and Neurotrophins: Effects of Metformin and Non-Steroidal Antiinflammatory Drug Treatment. The Eurasian Journal of Medicine 2011; 43:141-145

5. McCullough P, Ahmed A, Zughaib M, Glanz E, Loreto M. Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events. Rev Cardiovasc Med. 2011;12(4):173-185 doi: 10.3909/ricm0619

6. Tabassum R, Jaiswal A, Chauhan G, et al. Genetic Variant of AMD1Is Associated with Obesity in Urban Indian Children. PLoS ONE 2012; 7(4): e33162.

7. Kang JY, Park IK, Lee JY, et al. Use of Serum Homocysteine to Predict Cardiovascular Disease in Korean Men with or without Metabolic Syndrome. J Korean Med Sci 2012; 27: 500-505

8. Ankur R, Pooja D, Seema R, et al. Hyperhomocysteinemia and cardiovascular disease: A transitory glance. International journal of drug development and research 2012; 4:70-75

9. Svingen GF, Ueland PM, Pedersen EK, et al. Plasma Dimethylglycine and Risk of Incident Acute Myocardial Infarction in Patients With Stable Angina Pectoris. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, in press.

10. Herman W.A., Krzoska A., Łącka K., Bugaj R., Dorszewska J. Evaluation of the relationships between plasma homocysteine level and selected low-grade inflammation indices according to the prevalence of metabolic syndrome in men. Pol. Merk. Lek., 2013; 34:320-24

11. A. Akilzhanova, Z. Nurkina, K. Momynaliev, et al. Genetic Profile and Determinants of Homocysteine Levels in Kazakhstan Patients with Breast Cancer. Anticancer research 2013; 33:4049-60

12. Keskek S, Kirim S, Capar H, et al. Frequency of hyperhomocysteinemia in patients with metabolic syndrome. Ic Hastaliklari Dergisi 2013; 20:129-34

13. KatsikiN, MikhailidisDP, NairDR , The effects of antiepileptic drugs on vascular risk factors: a narrative review, SEIZURE: European Journal of Epilepsy 2014; 23:677-84

14. Szoke D, Dolci A, Russo U, et al. Determination of plasma homocysteine: Recommendations for test requesting. Biochimica Clinica 2014; 38:234-7

15. Katsiki N, Athyros V, Karagiannis A, et al. Characteristics other than the diagnostic criteria associated with metabolic syndrome: An overview. Current Vascular Pharmacology 2014; 12:627-41

16. Keskek S, Cinar Y, Kirim S, et al. High renal resistive index in hypertensive patients is also associated with serum homocysteine level. Clinical and experimental nephrology 2014; online early

17. Bonetti F, Brombo G, et al. Cognitive Status According to Homocysteine and B-Group Vitamins in Elderly Adults. Journal of the American Geriatrics Society 2015, online early

18. Zoet G, et al. Determinants of future cardiovascular health in women with a history of preeclampsia. Maturitas 82; 2:153-61 19. Li et al. (2015) Study of Intermolecular Interaction of Hydroxypropyl-β-cyclodextrin Complexes through Phase Diagrams of the

Fusion Entropy: Contrast between Nifedipine and Nicardipine Hydrochloride. J Phys Chem Biophys 5: 187.


113


Ενδιαφέρουσες περιπτώσεις

Πριν την εκλογή στη θέση Λέκτορα Hypokalemia induced myopathy as first manifestation of primary hyperaldosteronism - an elderly patient with unilateral adrenal hyperplasia: a case report P. Kotsaftis, C. Savopoulos, D. Agapakis, G. Ntaios, V. Tzioufa, V. Papadopoulos, E. Fahantidis, A. Hatzitolios Cases Journal 2009; 2:6813 IF=- Αναφορές: 6

1. Chawla J. Stepwise approach to myopathy in systemic disease. Frontiers in Nurology 2011, in press. DOI: 10.3389/fneur.2011.00049 2. J. Grasko. Delayed diagnosis of primary hyperaldosteronism. BMJ 2010;340:c2461 3. Karunaratna W, et al. Hypokalaemia-induced rhabdomyolysis as the presenting feature of primary hyperaldosteronism. Galle

Medical Journal 2013; 18:28-30 4. Ferreira-Hermosillo, A., Hernández-Martínez, A.F., Hernández-García, I., Molina-Ayala, M. Primary aldosteronism (HAP) by

unilateral adrenal hyperplasia (HSU). Report of two cases. Gaceta Medica de Mexico 2013; 149:668-672 5. Bo Yang, Yuan Yang, Wenling Tu, et al. A rare case of unilateral adrenal hyperplasia accompanied by hypokalaemic periodic

paralysis caused by a novel dominant mutation in CACNA1S: features and prognosis after adrenalectomy. BMC Urology 2014, 14:96

6. Yeter H. Endocrine myopathies: clinical review. Endocrinol Metab Synd 2015, 4:2

Differential diagnosis and treatment of a primary cutaneous anaplastic large cell lymphoma: Not always an easy task M. Diamantidis, A. Papadopoulos, G. Kaiafa, G. Ntaios, G. Karayannopoulou, I. Kostopoulos, F. Girtovitis, Z. Saouli, Z. Kontoninas, I. Raptis, C. Savopoulos, A. Hatzitolios International Journal of Hematology, 2009 90:226-9. IF: 1.681 Αναφορές: 15

1. Papalas JA, Van Mater D, Wang E. Pyogenic Variant of Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Lymphoproliferative Disorder with a Predilection for the Immunocompromized and the Young. Am J Dermatopathol. 2010 in press

2. Min JA, et al. Lymphomatoid Papulosis Followed by Anaplastic Large Cell Lymphoma in a Pediatric Patient. Annals of Dermatology 2010; 22: 447-451

3. Perry E, et al. Primary cutaneous anaplastic large-cell lymphoma. American Journal of Clinical Oncology 2011, in press 4. Q. Liao, X. Chen, W. Wang, T. Lin, Y. Liao. Primary cutaneous CD30 positive lymphoproliferative disorders: a clinicopathologic

analysis. Chinese Journal of Dermatology 2011; 44(3) 5. Diamantidis M, Myrou A. Perils and pitfalls regarding differential diagnosis and treatment of primary cutaneous anaplastic large-

cell lymphoma. The Scientific World Journal 2011; 11:1048-1055 6. Kempf W, et al. European Organization for Research and Treatment of Cancer (EORTC), International Society of Cutaneous

Lymphoma (ISCL) and United States Cutaneous Lymphoma Consortium (USCLC) consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011, in press

7. Mehdi I, et al. Anaplastic large cell lymphoma of scrotal skin. Journal of Pakistan Medical Association. 2011; 61:1140-3 8. Mutsaers ER, Willemze R, Van Rossum MM. A spontaneously disappearing T-cell lymphoma. 2011; 144:2065-2068 9. Rodriguez V, Perolada HM, Ibanez I, et al. Linfoma T anaplásico de células grandes de pabellón auricular en la infancia [Anaplastic

large T-cell lymphoma of the external ear in childhood]. Acta Otorrinolaringologica Espanola 2013; 64:230-32, in press. doi:10.1016/j.otorri.2012.01.004

10. M. Kumaran, M. Jithendriya, P. Nagaraj, R Tirumalae, E Jayaseelan. Anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphoma- Is it a new variant? Indian Journal of Dermatology, Venerealogy and Leprology 2012; 78:354-357

11. Pulitzer MP, Nolan KA, Oshman RG, et al. CD30+ lymphomatoid drug reactions. American Journal of Dermatopathology 2013; 35:343-350

12. De Oliveira L, Nobrega M, Monteiro M, de Almeida W. Primary cutaneous anaplastic large-cell lymphoma - case report. An Bras Dermatol 2013 ; 88, suppl 1.

13. Feryal Karaca, Fatma Sert, Elif Calıs, Emine Bagır, Erkut Erku. Literature evaluation of a case with endometrial cancer and primary cutaneous anaplastic large cell lymphoma. El Mednifico Journal v. 2, n. 4, jan. 2015. ISSN 2307-7301

14. Choi J, et al. Lymphomatoid papulosis following anaplastic large cell lymphoma in a child. Korean Journal of Dermatology 2015; 53:638 – 642

15. Sameh A, et al. Neutrophil rich CD30 Positive Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature. Aktuelle Dermatologie 2015; 41:471 - 477

Solitary large hepatic metastasis in an elderly patient with anaplastic thyroid carcinoma: a case report Adamidou, P. Kotsaftis, A. Zantidis, M. Vlachou, A. Haritandi, I. Xanthakis, G. Ntaios Cases Journal 2009; 2:41 IF: - Αναφορές: 2 1. Costaldi, M. E. and Zhou, Z. (2013), Case report: Different metastatic components from anaplastic thyroid carcinoma in mediastinal

and neck lymph nodes simultaneously diagnosed by FNA. Diagn. Cytopathol.. doi: 10.1002/dc.23016 2. Meng F, Dai L. Clinical characteristics and prognosis of elderly patients with thyroid carcinoma: 175 Cases report. Journal of Dalian


114


Medical University 2013; 35:596 - 599

Veno-occlusive disease of the liver during induction therapy for acute lymphoblastic leukemia Papadopoulos, G. Ntaios, G. Kaiafa, F. Girtovitis, Z. Saouli, Z. Kontoninas, M. Diamantidis, C. Savopoulos, A. Hatzitolios International Journal of Hematology 2008; 88:441–442 IF: 1.681 Αναφορές: 5 1. Cecinati V, Giordano P, Leonardis FD, Grassi M, Arcamone G, Mattia DD, Santoro N. Hepatic Veno-Occlusive Disease during

chemotherapy for nephroblastoma: successful and safe treatment with defibrotide. Report of a clinical case. Immunopharmacology and Immunotoxicology, 2009, in press

2. Singh M, Pockros M. Hematological and oncological diseases and the liver. Clinics in Liver Disease 2011; 15:1:69-87 3. Sahoo RK, Sharma A. Sinusoidal obstruction syndrome during induction therapy for acute lymphoblastic leukemia managed with

N-acetyl Cysteine. Pediatr Blood Cancer 2011; 57: 700 4. S Yamamoto, K Akiyama, N Oyama, et al. Fatal hepatic sinusoidal obstruction syndrome in a child with primary CNS lymphoma

during induction therapy. International Journal of Hematology 2012, in press. 5. Edgar J, Molyneux R, Colegate S. Pyrrolizidine Alkaloids: Potential Role in the Etiology of Cancers, Pulmonary Hypertension,

Congenital Anomalies and Liver Disease. Chem. Res. Toxicol 2015, in press. DOI: 10.1021/tx500403t

Coexistence of B-cell non-Hodgkin lymphoma and cutaneous T-cell lymphoma in a patient with chronic hepatitis C and cryoglobulinemia F. Girtovitis, A. Papadopoulos, G. Ntaios, V. Kaloutsi, V. Kotoula, G. Kaiafa Internal Medicine Journal, in press IF: 2.027 Αναφορές: 1

1. Paramesh A, Cannon R, Buell JF. Malignancies in pediatric solid organ transplant recipients: epidemiology, risk factors, and prophylactic approaches. Curr Opin Organ Transplant. 2010

Ticlopidine-induced myelosuppression spontaneously remitted after five years: a possible causative link with amlodipine co-administration F. Girtovitis, G. Ntaios, M. Baltatzi, G. Kaiafa, G. Ioannidis, A. Chatzinikolaou, A. Hatzitolios, A. Papadopoulos Internal Medicine Journal, in press IF: 1.823

Fatal pulmonary and cerebral aspergillosis after a short course of corticosteroids for idiopathic thrombocytopenic purpura Papadopoulos, G. Ntaios, G. Kaiafa, F. Girtovitis, G. Charisopoulos, I. Chryssogonidis Annals of Hematology 2008; 87:685-6 IF: 2.866

Αναφορές: 3 1. Smith J, Leather H. Adult idiopathic thrombocytopenic purpura. A review of the disease. Pharmacy Practice News. July 2008 2. Costa J, Farre M. Chapter 39: Corticotrophins, corticosteroids, and prostaglandins. In “Side Effects of Drugs Annual” 2011; 33:841-

850 3. Moulis G, Palmaro A, Sailler L, Lapeyre-Mestre M (2015) Corticosteroid Risk Function of Severe Infection in Primary Immune

Thrombocytopenia Adults. A Nationwide Nested Case-Control Study. PLoS ONE 10(11): e0142217

Haemarthrosis after superwarfarin poisoning P. Kotsaftis, F. Girtovitis, A. Boutou, G. Ntaios, P. Makris European Journal of Hematology 2007; 79:255-257 IF: 2.548

Αναφορές: 11 1. Zolcinski M, Padjas A, Musial J. Intoxication with three different superwarfarin compounds in an adult woman. Thromb Haemost.

2008; 100:156-7 2. Ishizuka M, Tanikawa T, Tanaka KD, Heewon M, Okajima F, Sakamoto KQ, Fujita S. Pesticide resistance in wild mammals--

mechanisms of anticoagulant resistance in wild rodents.. J Toxicol Sci.2008; 33:283-91. 3. Gunja N, Coggins A, Bidny S. Management of intentional superwarfarin poisoning with long-term vitamin K and brodifacoum

levels. Clinical toxicology 2011; 49: 385-390. 4. Kamijo, Y., Sato, C., Yoshimura, K., Soma, K. Notable pink excreta and severe myocardial suppression in superwarfarin

(difethialone) intoxication. Internal Medicine 2011; 50:2819-2822. 5. SE Aghahowa. Zinc phosphide toxicities among patients of the University of Benin Teaching Hospital, Benin city, Nigeria: A 10 year

experience. Annals of tropical medicine and public health 2012; 5:24-28 6. Saxena K. Laboratory Evaluation of Difethialone for Bait Shyness in Indian Desert Gerbil, Meriones hurrianae Jerdon. Int J Curr

Microbiol App Sci (2014) 3(1): 140-144 7. Xiang L, Min Z, Alan Z, Yaohui W. Retrospective study of twenty-four patients with prolonged coagulopathy due to long-acting

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Cecinati%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Giordano%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Leonardis%20FD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Grassi%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Arcamone%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mattia%20DD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Santoro%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus


115


anti-vitamin K rodenticide poisoning. American Journal of the Medical Sciences 2014; 347:299-304 8. Davis Christine B., Nowak Richard M., Anticoagulant-induced Hemarthrosis Presenting as Anterior Shoulder Dislocation, American

Journal of Emergency Medicine (2014), doi:10.1016/j.ajem.2014.05.042 9. Takada, H., Toru, H., Bunya, N. et al. Acquired absolute vitamin K deficiency in a patient undergoing warfarin therapy. American

Journal of Emergency Medicine 2014; 32:688.e1-688.e2 10. Galofre-Ruiz, M.D., Padilla-Castañeda, É.I.. Rodenticide poisoning cases reported to the Toxicology Research, Management and

Information Center, National University of Colombia. Revista Facultad de Medicina 2014; 62:27 – 32 11. King N, et al. Long-Acting Anticoagulant Rodenticide (Superwarfarin) Poisoning: A Review of Its Historical Development,

Epidemiology, and Clinical Management. Transfusion Medicine Reviews 2015; 29:250 - 258.

Hypertrophic pulmonary osteoarthropathy secondary to bronchial adenocarcinoma and coexisting pulmonary tuberculosis: a case report G. Ntaios, A. Adamidou, D. Karamitsos Cases Journal 2008; 1:221 IF: -

Αναφορές: 7 1. Poantă L, Parasca I, Fazakas E, Porojan M, Pais R, Boian L. Paraneoplastic hypertrophic osteoarthropathy: evaluation at 25 years

after pneumectomy. Pol Arch Med Wewn. 2009;119(9):603-6. 2. Nguyen S, Hojjati M. Review of current therapies for pulmonary osteoarthropathy. Clinical Rheumatology 2010, in press. DOI

10.1007/s10067-010-1563-7 3. Lian L, Zhong D, Wu S. A case report of pulmonary hypertrophic osteoarthropathy secondary to pulmonary carcinoma. Chin J Lung

Cancer 2010; 13:917-919 4. E. Grandy, G. Grandy. Hypertrophic osteoarthropathy as the cause of situs inversus totalis: A case report. Open Journal of Internal

Medicine, 2012, 2, 198-201 5. I. Aissa, A. Messadi, S. Boudaya, et al. Hypertrophic osteoarthropathy associated with pulmonary tuberculosis. Review de

Pneumologie Clinicque 2011; 67:101-104 6. Nguyen S, Hojjati M. Hypertrophic pulmonary osteoarthropathy as the presenting symptom of non-small cell lung cancer: a case

report. Journal of Cancer Research and Experimental Oncology 2014;6:1-5 7. Huri Tilla İlçe. Akciğer Kanserine Bağlı Hipertrofik Pulmoner Osteoartropatide Sintigrafik Görünüm. Sakarya Med J 2015, 5(4):224-

227

Parathyroid crisis as first manifestation of primary hyperparathyroidism G. Ntaios, C. Savopoulos, A. Chatzinikolaou, G. Kaiafa, A. Hatzitolios, D. Karamitsos. European Journal of Internal Medicine 2007; 18:551-552 IF: 2.049

Αναφορές: 7 1. Van den Hauwe K, Oeyen SG, Schrijvers BF, Decruyenaere JM, Buylaert WA. A 50-year-old man with severe hypercalcemia: a case

report. Acta Clin Belg. 2009; 64:442-6. 2. Tahim A. A parathyroid adenoma – benign disease presenting with hyperparathyroid crisis. Case reports in Medicine 2010; in press 3. Serra Soler G, et al. Parathyroid crisis due to a cystic parathyroid adenoma. Endocrinol Nutr. 2011 Mar;58(3):148-150. 4. Angela Gurrado, Giuseppe Piccinni, Germana Lissidini et al. Hypercalcaemic crisis due to primary hyperparathyroidism - a

systematic literature review and case report. Endokrynol Pol 2012; 63 (6): 494–502 5. Ma SK, Oh TR, Choi YD, Kim SW. Parathyroid crisis caused by a large parathyroid adenoma. Internal Medicine 2014; 53:165-6 6. Chacon A, et al. Acute kidney failure secondary to very severe hypercalcaemia from primary hyperparathyroidism. Nefrologia 2015;

35:224-6 7. Gao B, et al. Surgical diagnosis and treatment of primary hyperparathyroidism: Analysis of 19 cases. International Journal of Clinical

and Experimental Medicine 2015; 8: 9512-8

Atypical petechial rash at the lower extremities due to Parvovirus B19 infection G. Ntaios, A. Chatzihidiroglou, A. Chatzinikolaou, F. Iliadis, A. Adamidou, D. Karamitsos International Journal of Dermatology 2008; 47:760-762 IF: 1.342

http://www.ncbi.nlm.nih.gov/pubmed/19999395?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

http://www.ncbi.nlm.nih.gov/pubmed/19999395?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1


116


Debates

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή Restarting oral anticoagulants after intracerebral hemorrhage: Pros G. Ntaios Internal and Emergency Medicine 2015 Feb;10(1):3-4 IF: 2.41 Αναφορές: 4 (εκ των οποίων, οι 2αυτοαναφορές) 1. Balestrino M, Bruno C, Finocchi C, Gandolfo C. Resuming anticoagulation after brain haemorrhage while on warfarin treatment:

INR at the time of bleeding should be taken into consideration. Internal and Emergency Medicine 2015, online early 2. G. Ntaios, S. Sacco. Resuming anticoagulation after brain hemorrhage while on warfarin treatment: INR at the tie of bleeding should

be taken into consideration: authors’ reply. Internal and Emergency Medicine 2015, online early 3. G. Ntaios, G. Lip. Difficult situations in anticoagulation after stroke: between Scylla and Charybdis. Curent Opinion in Neurology

2016, online early 4. Epple et al. Update on Therapy of Intracerebral Hemorrhage. Aktuelle Neurologie 2015;42:581 - 595


117


Προσκεκλημένα Editorials

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή The European Stroke Organization (ESO) Guidelines T. Steiner, RA. Salman, G. Ntaios International Journal of Stroke 2014; 9:838-9 Αναφορές: 3 1. Parry-Jones A, et al. Reversal Strategies for Vitamin K Antagonists in Acute Intracerebral Hemorrhage. ANN NEUROL 2015;78:54–62 2. Toyoda K. Blood pressure management in acute stroke. Respiration and Circulation 2015 ; 63 :682-8 3. Mendelow A. Surgical Craniotomy for Intracerebral Haemorrhage. Frontiers of Neurology and Neuroscience 2015 ; 37 :148-54

Μετά την εκλογή στη θέση Λέκτορα Blood pressure variability in subacute ischemic stroke: a neglected potential therapeutic target G. Tsivgoulis, G. Ntaios Neurology 2012; 79:2014-5 IF: 8.249 Αναφορές: 5 1. Zis P, Vemmos K, SPengos K, et al. Ambulatory blood pressure monitoring in acute stroke: pathophysiology of the time rate of blood

pressure variation and association with the 1-year outcome. Blood pressure monitoring 2013, in press 2. Jiang Wenjun Relationship of blood pressure and its prognosis in patients with acute cerebral infarction. Journal of Clinical Medicine

in Practice 2012, 16 (23) 3. Buratti L, Cagnetti C, Balucani C, et al. Blood pressure variability and stroke outcome in patients with internal carotid artery

occlusion. Journal of the Neurological Sciences, 2014, in press 4. Rickards CA and Tzeng Y-C (2014) Arterial pressure and cerebral blood flow variability: friend or foe? A review. Front. Physiol. 5:120.

doi: 10.3389/fphys.2014.00120 - See more at: http://journal.frontiersin.org/Journal/10.3389/fphys.2014.00120 5. Kakaletsis N, Ntaios G, Milionis H, et al. Prognostic value of 24-h ABPM in acute ischemic stroke for short, medium and long-term

outcome: A systematic review and meta-analysis. Internationl Journal of Stroke 2015, online early

Πριν την εκλογή στη θέση Λέκτορα Well done folate, the little boy was born healthy without spina bifida. But will he suffer a stroke when elderly? G. Ntaios, A. Chatzinikolaou, C. Savopoulos, A. Hatzitolios European Journal of Internal Medicine, 2009; 20:2 IF: 2.049 Αναφορές: 2 (εκ των οποίων οι 2 αυτοαναφορές) 1. G. Ntaios, C. Savopoulos, D. Karamitsos, I. Economou, E. Destanis, I. Chryssogonidis, et al. The effect of folic acid supplementation


2. G. Ntaios, C.Savopoulos, D. Grekas, A. Hatzitolios. The controversial role of B vitamins on cardiovascular risk: an update. Archives of Cardiovascular diseases, 2009, in press

http://journal.frontiersin.org/Journal/10.3389/fphys.2014.00120


118


Απαντήσεις σε Επιστολές

Μετά την εκλογή στη θέση Λέκτορα Resuming anticoagulation after brain hemorrhage while on warfarin treatment: INR at the tie of bleeding should be taken into consideration: authors’ reply

G. Ntaios, S. Sacco

Internal and Emergency Medicine 2015, online early IF: 2.41 Response to Letter Regarding Article "Embolic stroke of undetermined source in the Athens Stroke registry: a descriptive analysis.” G. Ntaios, K. Vemmos Stroke 2015, online early IF: 5.729 Response to Letter by Doehner et al. regarding article, "The association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox" G. Ntaios, K. Vemmos Stroke, in press IF: 5.729 Response to Letter by Kalita et al. regarding article, "The association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox" G. Ntaios, K. Vemmos Stroke, in press IF: 5.729 Response to Letter by Fuentes et al Regarding Article, "J-Shaped Association Between Serum Glucose and Functional Outcome in Acute Ischemic Stroke" Ntaios G, Egli M, Michel P. Stroke, in press IF: 5.729 Πριν την εκλογή στη θέση Λέκτορα Re: Discrimination indices as screening tests for β-thalassemic trait G. Ntaios, A. Chatzinikolaou Annals of Hematology 2007; 87:329-30 IF: 2.866 Αναφορές: 9 (εκ των οποίων οι 6 αυτοαναφορές) 1. G. Ntaios, A. Chatzinikolaou. Inadequate awareness of the role of erythrocytic parameters in the detection of beta-thalassemia

minor. Journal of Postgraduate Medicine 2008; 54:61 2. G. Ntaios, A. Chatzinikolaou. Red cell distribution width in iron deficiency anemia and beta-thalassemia minor. American Journal

of Clinical Pathology 2008; 130:313-314 3. G. Ntaios, A. Chatzinikolaou. Incorporation of erythrocytic and reticulocytic parameters in a common formula: will it provide a


4. G. Ntaios, A. Chatzinikolaou. M/H ratio for the differential diagnosis of microcytic anemia. International Journal of Laboratory Hematology, 2009; 31:248-249

5. E Urrechaga. M/H ratio for the differential diagnosis of microcytic anemia-reply. International Journal of Laboratory Hematology, 2009; 31:250-251



8. Ou Z, Li Q, Liu W, Sun X. Elevated Hemoglobin A2 as a Marker for β-Thalassemia Trait in Pregnant Women. Tohoku J Exp Med. 2011;223(3):223-6.

9. Urrechaga E, Borque L, Escanero JF. Erythrocyte and reticulocyte parameters in iron deficiency and thalassemia. J Clin Labor Analysis 2011; 25:223-8

10. B. Nalbantoglu, S. Guzel, V. Buyucalcin et al. Indices Used in Differentiation of Thalassemia Trait from Iron Deficiency Anemia in Pediatric Population: Are They Reliable? Pediatric Hemotology-Oncology 2012; 29:472-478


119



120


Επιστολές

Πριν την εκλογή στη θέση Λέκτορα Novel extended reference range for serum κ/λ free light chain ratio in diagnosing monoclonal gammopathies in renal insufficient patients M. Diamantidis, E. Ioannidou-Papagiannaki, G. Ntaios

Clinical Biochemistry 2009; 42(10-11):1202-3 IF: 2.450

Αναφορές: 5 1. Maurer M, et al. Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent

Cohorts of Patients With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2011, in press 2. Woo Park J, Kim YK, Hui Bae E et al. Combined analysis using extended renal reference range of serum free light chain ratio and

serum protein electrophoresis improves the diagnostic accuracy of multiple myeloma in renal insufficienc. Clinical Biochemistry 2012; 45:740-44

3. Bibas M, Trotta MP, Cozzi-Lepri A, et al. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin’s lymphoma and its correlation with antiretroviral therapy. American Journal of Hematology 2012, in press

4. K. Charafeddine, M. Jabbour, R. Kadi, R. Daher. Extended Use of Serum Free Light Chain as a Biomarker in Lymphoproliferative Disorders: a Comprehensive Review. Am J Clin Pathol. 2012; 137:890-897

5. Liang YF, Chen WM, Wang QT, et al. Establishment and Validation of Serum Free Light Chain Reference Intervals in an Ethnic Chinese Population. Clin Lab 2014, in press

Red blood cell flags for the differential diagnosis between thalassemia trait and iron deficiency anemia G. Ntaios Hematology 2009; 14:304 IF: 1.393 Αναφορές: 3 1. Shen C, Jiang YM, Shi H, Liu JH, Zhou WJ, Dai QK, Yang H. Evaluation of Indices in Differentiation Between Iron Deficiency

Anemia and beta-Thalassemia Trait for Chinese Children. J Pediatr Hematol Oncol. 2010, in press 2. Ou Z, Li Q, Liu W, Sun X. Elevated Hemoglobin A2 as a Marker for β-Thalassemia Trait in Pregnant Women. Tohoku J Exp Med.

2011;223(3):223-6. 3. Urrechaga E, Borque L, Escanero JF. Erythrocyte and reticulocyte parameters in iron deficiency and thalassemia. J Clin Labor

Analysis 2011; 25:223-8

Improper use of tumour markers as cancer screening tests among Greek physicians G. Ntaios, A. Hatzitolios, C. Savopoulos European Journal of Internal Medicine, 2009;20:e128 ΙF: 2.049 Αναφορές: 1

1. Kaiafa G, Saouli Z, Diamantidis M, et al. Copper levels in patients with hematological malignancies. European Journal of Internal Medicine 2012, in press

Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease G. Ntaios, C. Savopoulos, A. Hatzitolios JAMA 2008; 300:2852-2853 ΙF: 29.978

Αναφορές: 3 (εκ των οποίων οι 2 αυτοαναφορές) 1. G. Ntaios, C. Savopoulos, D. Karamitsos, I. Economou, E. Destanis, I. Chryssogonidis, et al. The effect of folic acid supplementation


2. G. Ntaios, C.Savopoulos, S. Chatzopoulos, D. Mikhailidis, A. Hatzitolios. Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis. Atherosclerosis, 2010, in press

3. Chopra V, Eagle KA. Cardiac biomarkers in the diagnosis, prognosis and management of coronary artery disease: A primer for internists. Indian J Med Sci 2011

Telmisartan and carotid intima-media thickness regression: a class effect of angiotensin-receptor blockers? G. Ntaios, C. Savopoulos, A. Hatzitolios Hypertension Research, 2008; 31:2187 IF: 2.791

Aναφορές: 4 (εκ των οποίων οι 2 αυτοαναφορές) 1. G. Ntaios, C. Savopoulos, D. Karamitsos, I. Economou, E. Destanis, I. Chryssogonidis, et al. The effect of folic acid supplementation


2. Saeed N, Graf IM. From Radio Frequency Data to Vascular Diagnosis. Ultrasound 2009 17; 3:131-136









121


3. E. Moutzouri, G. Ntaios, M. Elisaf, H. Milionis. Pharmaceutical modulation of the renin angiotensin aldosterone system for stroke prevention: a review of experimental and clinical evidence. CNS spectrum 2010, in press

4. Takagi H, YamamotoH, Iwata K, et al. Effects of telmisartan on proteinuria or albuminuria: A meta-analysis of randomized trials. Int J Cardiology 2013 ; 167 :1443-9

Separating Thalassemia Trait and Iron Deficiency by Simple Inspection G. Ntaios American Journal of Clinical Pathology, 2009; 131:445 IF: 2.881 Aναφορές: 2 1. Gibbs G. Separating Thalassemia Trait and Iron Deficiency by Even Simpler Inspection. Am J Clin Pathol 2009;132:643-644 2. Elsayed L, et al. Nursing Guidelines for Children Suffering from Beta Thalassemia. - International Journal of Nursing Science 2015,

online early

Letter by Ntaios et al Regarding Article, ‘Impact of Statin Therapy on Left Ventricular Function and Carotid Arterial Stiffness in Patients With Hypercholesterolemia’ G. Ntaios, C. Savopoulos, A. Hatzitolios Circulation Journal 2008; 72:2101 IF: 3.578

Αναφορές: 1 (εκ των οποίων η 1 αυτοαναφορά) 1. G. Ntaios, C. Savopoulos, D. Karamitsos, I. Economou, E. Destanis, I. Chryssogonidis, et al. The effect of folic acid supplementation


Effect of Folic Acid and B Vitamins on Cardiovascular disease in women G. Ntaios, C. Savopoulos, D. Karamitsos JAMA 2008; 300:1409 IF: 29.978 Αναφορές: 2 (εκ των οποίων οι 2 αυτοαναφορές) 1. G. Ntaios, C. Savopoulos, D. Karamitsos, I. Economou, E. Destanis, I. Chryssogonidis, et al. The effect of folic acid supplementation


2. G Ntaios, C.Savopoulos, D. Grekas, A. Hatzitolios. The controversial role of B vitamins on cardiovascular risk: an update. Archives of Cardiovascular diseases, 2009, in press

M/H ratio for the differential diagnosis of microcytic anemia G. Ntaios, A. Chatzinikolaou International Journal of Laboratory Hematology, 2009; 31:248-249 IF: 1.293 Αναφορές: 3 1. Shen C, Jiang YM, Shi H, Liu JH, Zhou WJ, Dai QK, Yang H. Evaluation of Indices in Differentiation Between Iron Deficiency



Analysis 2011; 25:223-8

Evaluation of mean platelet volume in the differential diagnosis of thrombocytopenia G. Ntaios, A. Papadopoulos, A. Chatzinikolaou, F. Girtovitis, G. Kaiafa, C. Savopoulos, A. Hatzitolios International Journal of Laboratory Hematology, Online early view IF: 1.293 Αναφορές: 5 (εκ των οποίων η 1 αυτοαναφορά) 1. G. Ntaios, O. Gurer, M. Faouzi, C. Aubert, P. Michel. Mean platelet volume in the early phase of acute ischemic stroke is not

associated with severity or functional outcome. Cerebrovascular Diseases, 2010, in press 2. Ten Berg M, et al. Discriminative value of platelet size indices for the identification of the mechanism of chemotherapy-induced

thrombocytopenia. Biomarkers 2010, in press 3. Cil H, Islamoglu Y, Tekbas E, et al. Platelet count and mean platelet volume in patients with in-hospital deep venous thrombosis.

Clinical And Applied Thrombosis/Hemostasis 2012; 18:650-653. 4. Latger-Cannard V, Hoarau, M, Salgnac V, et al. Mean platelet volume: comparison of three analysers towards standardization of

platelet morphological phenotype. International Journal of Laboratory Hematology. 2012, in press. doi: 10.1111/j.1751-553X.2011.01396.x

5. S Salignac, V Latger-Cannard, N Schlegel, TP Lecompte. Platelet counting. In: Paul Monagle (ed), Hemostasis: Methods and protocols, Methods in Molecular Biology, vol 992, DOI: 10.1007/978-1-62703-339-8_15, Springer Science+Bussiness Media New York 2013.

Are UK South Asians still a low-risk population for gastrointestinal cancer?









122


G. Ntaios, A. Chatzinikolaou Indian Journal of Gastroenterology 2008; 27:175 IF: - The spleen in beta thalassemia minor: splenomegaly or just “scanomegaly”? G. Ntaios, A. Chatzinikolaou British Journal of Haematology 2008; 143:143 IF: 4.942 Αναφορές: 1 1. Shen C, Jiang YM, Shi H, Liu JH, Zhou WJ, Dai QK, Yang H. Evaluation of Indices in Differentiation Between Iron Deficiency

Anemia and beta-Thalassemia Trait for Chinese Children. J Pediatr Hematol Oncol. 2010, in press

Incorporation of erythrocytic and reticulocytic parameters in a common formula: will it provide a more accurate differentiation between iron deficiency anemia and β-thalassemic trait? G. Ntaios, A. Chatzinikolaou International Journal of Laboratory Hematology, in press IF: 1.293

Αναφορές: 5 (εκ των οποίων η 1 αυτοαναφορά) 1. G. Ntaios, A. Chatzinikolaou M/H ratio for the differential diagnosis of microcytic anemia. International Journal of Laboratory

Hematology, 2009; 31:248-249 2. Shen C, Jiang YM, Shi H, Liu JH, Zhou WJ, Dai QK, Yang H. Evaluation of Indices in Differentiation Between Iron Deficiency



Analysis 2011; 25:223-8 5. B. Nalbantoglu, S. Guzel, V. Buyucalcin et al. Indices Used in Differentiation of Thalassemia Trait from Iron Deficiency Anemia in

Pediatric Population: Are They Reliable? Pediatric Hemotology-Oncology 2012; 29:472-478

Is there a beneficial effect of folic acid on carotid intima-media thickness? G. Ntaios, C. Savopoulos, A. Hatzitolios, A. Chatzinikolaou, D. Karamitsos International Journal of Cardiology, Online early view IF: 5.509 Αναφορές: 3 (εκ των οποίων οι 2 αυτοαναφορές) 1. G. Ntaios, C. Savopoulos, D. Karamitsos, I. Economou, E. Destanis, I. Chryssogonidis, et al. The effect of folic acid supplementation


2. G. Ntaios, C.Savopoulos, D. Grekas, A. Hatzitolios. The controversial role of B vitamins on cardiovascular risk: an update. Archives of Cardiovascular diseases, 2009, in press

3. Chopra V, Eagle KA. Cardiac biomarkers in the diagnosis, prognosis and management of coronary artery disease: A primer for internists. Indian J Med Sci 2011

Is there a geographic variation in the seasonal distribution of acute myocardial infarction and sudden cardiac death? C. Savopoulos, G. Ntaios, A. Hatzitolios International Journal of Cardiology, Online early view IF: 5.509 Αναφορές: 4 1. Kriszbacher, J. Bódis J, A. Koppan, I. Boncz , M. Koppán. The effect of climate on heart attack mortality. International Journal of

Cardiology 2008, Online early view 2. Hopstock LA, et al. Seasonal variation in incidence of acute myocardial infarction in a sub-Arctic population: the Tromso Study

1974-2004. European Journal of Cardiovascular Prevention 2010, in press 3. Ravljen M, Bilban M, et al. Influence of Daily Individual Meteorological Parameters on the Incidence of Acute Coronary Syndrome.

2014; 11:11616-11626 4. Shigematsu K, Watanabe Y, Nakano H, et al. Higher risk of ischemic stroke to hemorrhagic stroke in summer. Acta Neurologica

Scandinavica 2015, online early.

Red cell distribution width in iron deficiency anemia and beta-thalassemia minor G. Ntaios, A. Chatzinikolaou American Journal of Clinical Pathology 2008; 130:313 IF: 2.881 Αναφορές: 6 (εκ των οποίων οι 3 αυτοαναφορές) 1. G. Ntaios. Separating Thalassemia Trait and Iron Deficiency by Simple Inspection – Reply. American Journal of Clinical Pathology,

2009; 131:445 2. Burdick. Separating Thalassemia Trait and Iron Deficiency by Simple Inspection. American Journal of Clinical Pathology, 2009;

131:444 3. Ntaios G. Red blood cell flags for the differential diagnosis between thalassemia trait and iron deficiency anemia. Hematology, 2009,
















123


in press 4. Shen C, Jiang YM, Shi H, Liu JH, Zhou WJ, Dai QK, Yang H. Evaluation of Indices in Differentiation Between Iron Deficiency

Anemia and beta-Thalassemia Trait for Chinese Children. J Pediatr Hematol Oncol. 2010, in press 5. Ntaios G, Gurer O, Faouzi M, Aubert C, Michel P. Red cell distribution width does not predict stroke severity or functional

outcome. International Journal of Stroke, 2010, in press. 6. Ou Z, Li Q, Liu W, Sun X. Elevated Hemoglobin A2 as a Marker for β-Thalassemia Trait in Pregnant Women. Tohoku J Exp Med.

2011;223(3):223-6.

Appropriateness of the use of serum ferritin or serum transferrin saturation as a diagnostic tool for the evaluation of anaemia G. Ntaios, A. Chatzinikolaou Southern Medical Journal 2008; 101:853-854 IF: 0.915 Both spontaneous pneumothorax and spontaneous pneumomediastinum may constitute a complication in underweight patients A. Hatzitolios, G. Ntaios, M. Sion Chest 2008; 134:216-7 IF: 5.854

Αναφορές: 2 1. Linder A, Welcker K, Ertner C, Schwarze, Jend H. Mediastinalemphysem. Der Pneumologe 2009; 6:165-171 2. Flores-Franco, R.A., Limas-Frescas, N.E. The overused airway: Lessons from a young trumpet player. Medical Problems of

Performing Artists 2010; 25:35-38

Inadequate awareness of the role of erythrocytic parameters in the detection of beta-thalassemia minor G. Ntaios, A. Chatzinikolaou Journal of Postgraduate Medicine 2008; 54:61 IF: - Αναφορές: 5 1. Shen C, Jiang YM, Shi H, Liu JH, Zhou WJ, Dai QK, Yang H. Evaluation of Indices in Differentiation Between Iron Deficiency



Analysis 2011; 25:223-8 4. Wongprachum K, Sanchaisuriya K, Sanchaisuriya P, et al. Proxy indicators for identifying iron deficiency among anemic vegetarians

in prevalent area for thalassemia and hemoglobinopathies. Acta Haematologica 2012, in press. DOI: 10.1159/000337032 5. Srivanichakorn S, Sukpordee N, Yana T, et al. Health status of diabetes type 2 patientsin Thailand contradicts their perception and

admitted compliance. Primary care diabetes 2011; 5:195-201

Recurrent peripheral facial paresis may constitute the sole clinical manifestation in Neuro-Behcet Disease A. Hatzitolios, C. Savopoulos, G. Ntaios, E. Tsirogianni, M. Baltatzi, M. Apostolopoulou, E. Dimitrakoudi The Neurologist 2008; 14:77 IF: 1.475 Αναφορές: 6 1. Siva A, Saip S. The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis. Journal of

Neurology 2009; 256: 513-529 2. Oosterveer, D.M., Bénit, C.P., De Schryver, E. Differential diagnosis of recurrent or bilateral peripheral facial palsy. Journal of

Laryngology and Otology 2012; 126: 833-836 3. Saip S, Akman-Demir G, Siva A. Neuro-Behcet syndrome. Handbook of Clinical Neurology 2014; 121:1703-23 4. Morales-Angulo C, Vergara Pastrana S, et al. Otorhinolaryngological manifestations in patients with Behçet disease. Acta

Otorrinolaringologica Espanola. 2014; 65:15-21 5. Gill, J., Bhardwaj, B. Neurobehcet syndrome: Ear canal ulcer with ipsilateral facial nerve palsy: A rare presentation. Indian Journal of

Otology 2014; 20:143-145

6. Yilmaz U, Cubukcu D, Yilmaz T, et al. Peripheral facial palsy in children. Journal of child neurology 2014; 29:1473-1478 Spontaneous pneumomediastinum may be associated with both anorexia nervosa and obesity A. Hatzitolios, G. Ntaios

Lung 2007; 185:373 IF: 2.062 Αναφορές: 3 (εκ των οποίων η 1 αυτοαναφορά) 1. Hatzitolios A, G. Ntaios, M. Sion Both spontaneous pneumothorax and spontaneous pneumomediastinum may constitute a

complication in underweight patients. Chest 2008; 134:216-7 2. M. Sayhan, M. Orak, M. Ustundag. Posttussive Pneumomediastinum. Lung, in press 3. M Brand, D B Bizos, L Burnell. A review of non-obstetric spontaneous pneumomediastinum and subcutaneous emphysema. South

African Journal of Surgery 2011; 49:135-136








http://www.scopus.com/search/submit/author.url?author=Flores-Franco%2c+R.A.&origin=resultslist&authorId=12788406000&src=s

http://www.scopus.com/search/submit/author.url?author=Limas-Frescas%2c+N.E.&origin=resultslist&authorId=35784427000&src=s

http://www.scopus.com/source/sourceInfo.url?sourceId=17874&origin=resultslist

http://www.scopus.com/source/sourceInfo.url?sourceId=17874&origin=resultslist









124


Beta-thalassemic trait cannot be safely differentiated from iron deficiency anemia G. Ntaios, A. Chatzinikolaou European Journal of Hematology 2007; 79:554 IF: 2.548 Αναφορές: 10 (εκ των οποίων οι 6 αυτοαναφορές) 1. G. Ntaios, A. Chatzinikolaou. Inadequate awareness of the role of erythrocytic parameters in the detection of beta-thalassemia

minor. Journal of Postgraduate Medicine 2008; 54:61 2. G. Ntaios, A. Chatzinikolaou. Red cell distribution width in iron deficiency anemia and beta-thalassemia minor. American Journal

of Clinical Pathology 2008; 130:313-314 3. G. Ntaios, A. Chatzinikolaou. Incorporation of erythrocytic and reticulocytic parameters in a common formula: will it provide a


4. G. Ntaios, A. Chatzinikolaou. M/H ratio for the differential diagnosis of microcytic anemia. International Journal of Laboratory Hematology, 2009; 31:248-249


6. B. Bryant. J. Hopkins, S. Arceo, S. Leitman. Evaluation of low red blood cell mean corpuscular volume in an apheresis donor population. 2009, in press


8. Ou Z, Li Q, Liu W, Sun X. Elevated Hemoglobin A2 as a Marker for β-Thalassemia Trait in Pregnant Women. Tohoku J Exp Med. 2011;223(3):223-6.

9. Urrechaga E, Borque L, Escanero JF. Erythrocyte and reticulocyte parameters in iron deficiency and thalassemia. J Clin Labor Analysis 2011; 25:223-8

10. Narjes Sargolzaie1, and Ebrahim Miri-Moghaddam. A Local Equation for Differential Diagnosis of β-Thalassemia Trait and Iron Deficiency Anemia by Logistic Regression Analysis in Southeast Iran. Hemoglobin 2014, online early


125


ΠΛΗΡΕΙΣ ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΑΓΓΛΟΦΩΝΑ ΕΛΛΗΝΙΚΑ ΠΕΡΙΟΔΙΚΑ

Πριν την εκλογή στη θέση Λέκτορα Stroke and conditions that mimic it: a protocol secures a safe, early recognition A Hatzitolios, C. Savopoulos, G. Ntaios, F. Papadidaskalou, E. Dimitrakoudi, M. Kosmidou, M. Baltatzi, D. Karamitsos Hippokratia 2008; 12:98-102 IF: 0.589 Αναφορές: 11 1. M. Mandala, A. Rufa, A. Gerase, S. Bracco, P. Galluzzi, C. Venturi, D. Nuti. Lateral Medullary Ischemia Presenting with Persistent

Hiccups and Vertigo. International Journal of Neuroscience 2010; 120:226-230 2. Souza CN , Breda LCD , Aguiar CF , Custódio FB, Machado JR, Abate DT RS, Llaguno MM , Reis MA, Faleiros ACG. Clinical

analysis and quantification of heart and kidney fibrosis in hypertensive patients with or without stroke. Rev Bras Hipertens 2010: 17(2):87-91

3. Meng R. Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke. Clinical Neurology and Neurosurgery 2011, in press

4. Tsai SH, Lin YY, Hsu CW, et al. Hypoglycemia revisited in acute care setting. Yonsei Med J 2011; 52:898-908 5. C. Tziotzios, J. Dawson and M. Walters. Stroke mimics. In: Stroke practice: From diagnosis to evidence-based management. Oxford

Radcliffe Publishing. 2011 ISBN-10: 1846194733 6. Rasalkar D, Chu W. Imaging in children presenting with acute neurological deficit: stroke. Postgrad Med J 2012, in press.

doi:10.1136/postgradmedj-2011-130087 7. Papavasileiou V, et al. Aseptic meningoencehalitis mimicking transient ischemic attacks. Infection 2013, in press 8. Xiang Liu, Jeevak Almast, Sven Ekholm, et al. Lesions masquerading as acute stroke. Journal of Magnetic Resonance Imaging 2013;

37:15-34. 9. Tuntiyatorn, L. , Saksornchai, P, Tunlayadechanont, S. Identification of stroke mimics among clinically diagnosed acute strokes.

Journal of the Medical Association of Thailand 2013; 96:1191-8 10. Jiang H-l, Chan CP-y, Leung Y-k, Li Y-m, Graham CA, et al. (2014) Evaluation of the Recognition of Stroke in the Emergency Room

(ROSIER) Scale in Chinese Patients in Hong Kong. PLoS ONE 9(10): e109762 11. Malekzadeh J, et al. The effect of Cincinnati Prehospital Stroke Scale on telephone triage of stroke patients: evidence-based practice

in emergency medical services. International Journal of Evidence-Based Healthcare 2015; 13:87-92

http://informahealthcare.com/loi/nes

mailto:[email protected]


126


ΠΛΗΡΕΙΣ ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΕΛΛΗΝΙΚΑ ΠΕΡΙΟΔΙΚΑ

Μετά την εκλογή στη θέση Επίκουρου Καθηγητή Συμφωνία (Consensus) ειδικών για την ορθολογική χορήγηση των αναστολέων της PCSK9

Β. Άθυρος, Θ. Αλεξανδρίδης, Δ. Αλεξόπουλος, Α. Αχείμαστος, Π. Βάρδας, Δ. Βλαχάκος, Χ. Βλαχόπουλος, Ε. Γανωτάκης, Ι. Γουδέβενος, Ευ. Δρογκάρη, Μ. Ελισάφ, Ι. Ιωαννίδης, Γ. Κολοβού, Β. Κώτσης, Ι. Λεκάκης, Ευ. Λυμπερόπουλος, Α. Μελιδώνης, Α. Μπαργιώτα, Ε. Μπιλιανού, Β. Νικολάου, Γ. Ντάιος, Ν. Παπάνας, Στ. Παππάς, Χ. Πίτσαβος, Λ. Ραλλίδης, Δ. Ρίχτερ, Ι. Σκούμας, Ν. Τεντολούρης, Δ. Τζιακάς, Κ. Τζιόμαλος, Δ. Τούσουλης, Α. Τσελέπης, Κ. Τσιούφης, Χ. Χρυσοχόου Ελληνική Επιθεώρηση Αθηροσκλήρωσης 6(Συμπλήρωμα):3–8 IF: 0 Εμβολικά εγκεφαλικά απροσδιόριστης προέλευσης. Μια νέα κατηγορία ασθενών με ισχαιμικό εγκεφαλικό επεισόδιο

Γ. Ντάιος

Heart Vessels & Brain 2015, online early

Δευτερογενής πρόληψη σε ασθενείς με ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο Γ. Ντάιος Ελληνική Ιατρική Επιθεώρηση 2014: 103:139-44 Διεθνές Συνέδριο Εγκεφαλικών, San Diego (ΗΠΑ), 12-14 Φεβρουαρίου 2014 Β. Παπαβασιλείου, Γ. Ντάιος, Κ. Βέμμος Heart Vessels and Brain: thrombosis and antithrombosis 2012; 1:74-77 Μετά την εκλογή στη θέση Λέκτορα Υπάρχει όφελος από τη θρομβόλυση σε μεγαλύτερο χρονικό παράθυρο σε ασθενείς με οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο; Κριτική θεώρηση της μελέτης IST-3 (The Third International Stroke Study) Β. Παπαβασιλείου, Γ. Ντάιος, Κ. Μακαρίτσης, Κ. Βέμμος, Χ. Μηλιώνης Ελληνική Επιθεώρηση Αθηροσκλήρωσης 2013 Η χρήση υπολογιστικών μοντέλων (scores) στην πρόληψη, αντιμετώπιση και πρόγνωση των ισχαιμικών αγγειακών εγκεφαλικών επεισοδίων Β. Παπαβασιλείου, Χ. Μηλιώνης, Κ. Μακαρίτσης, Κ. Βέμμος, Γ. Ντάιος Ελληνική Επιθεώρηση Αθηροσκλήρωση 2013, 4(1):19–30 Συμπτωματική καρωτιδική νόσος: Ενδαρτηρεκτομή ή αγγειοπλαστική; Γ. Ντάιος, Κ. Μακαρίτσης Heart Vessels and Brain: thrombosis and antithrombosis 2012; 1:74-77 Πριν την εκλογή στη θέση Λέκτορα To όφελος της αυξημένης πρόσληψης φυτικών ινών στη Χρόνια Δυσκοιλιότητα, στο Σύνδρομο Ευερέθιστου Εντέρου και στην εμφάνιση Ορθοκολικών πολυπόδων και Καρκίνου: Πραγματικότητα ή Μύθος; Κ. Αργυρίου, Γ. Ντάιος, Α. Χατζητόλιος Αρχεία Ελληνικής Ιατρικής 2010; 27:907-917 Αναφορές: 1 1. Gelinas P. Preventing constipation: a review of the laxative potential of food ingredients. International Journal of Food

Science & Technology 2012, in press Arterial Hypertension in diabetic mellitus and diabetic nephropathy

C. Savopoulos, G. Ntaios, A. Hatzitolios Ελληνικά Διαβητολογικά Χρονικά, 2009; 22(3): 218-219 Ο ρόλος της ερυθροποιητίνης στην οξεία αντιμετώπιση των ισχαιμικών αγγειακών εγκεφαλικώνεπεισοδίων και στην εξέλιξη της Χρόνιας Νεφρικής Ανεπάρκειας Χ. Σαββόπουλος, Γ. Ντάιος, Α. Χατζητόλιος, Εισήγηση στο 10ο Κύκλο των ‘Αλκυονίδων ημερών νεφρολογίας’ με θέμα: «Η Επίδραση των Ορμονών στη Νεφρική και


127


Καρδιαγγειακή Βλάβη» Παράγοντες καρδιαγγειακού κινδύνου σε ηλικιωμένους και υπέργηρους ασθενείς με ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο Π. Κοτσάφτης, Γ. Ντάιος, Α. Χατζητόλιος, Χ. Σαββόπουλος, Ρ. Κηπάρογλου, Δ. Αγαπάκης, Μ. Μπαλτατζή, Δ. Καραμήτσος Διαβητολογικά Χρονικά 2009, in press

Υποτροπή συνδρόμου Guillain Barre μετά από αντιγριπικό εμβολιασμό Α. Αδαμίδου, Γ. Ντάιος, Α. Καρλοβασίτου, Ι. Μαυρομάτης, Μ. Αλεβίζος, Δ. Καραμήτσος Ελληνική Ιατρική 2005; 71:292-295 Παραθυρεοειδική κρίση ως πρώτη εκδήλωση πρωτοπαθούς υπερπαραθυρεοειδισμού Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Α. Χατζηνικολάου, Γ. Καϊάφα, Ι. Οικονόμου, Ι. Σουλτάτη, Δ. Καραμήτσος Ελληνική Ιατρική 2007; 73:142-145 Άτυπο πορφυρικό εξάνθημα κάτω άκρων μετά από λοίμωξη με PARVO B-19 Α. Αδαμίδου, Α. Χατζηχηδήρογλου, Γ. Ντάιος, Φ. Ηλιάδης, Α. Χατζηνικολάου, Δ. Καραμήτσος Ελληνική Ιατρική 2007; 73:243-246


128


ΑΝΑΚΟΙΝΩΣΕΙΣ ΣΕ ΞΕΝΑ ΣΥΝΕΔΡΙΑ


Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation

G. Ntaios, G. Lip, D. Lambrou, V. Papavasileiou, E. Manios, H. Milionis, K. Spengos, K. Makaritsis, K. Vemmos


Comorbidity analysis and long-term mortality in acute ischemic stroke: data from the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P.


Predictive value of the ASTRAL score, the Charlson and the Elixhauser indexes in acute ischemic stroke Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P.


Comorbidity analysis and 3-months functional outcome in acute ischemic stroke: data from the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) Kakaletsis N., Papavasileiou V., Lambrou D., Ntaios G., Michel P.


Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis George Ntaios, Vasileios Papavasileiou, Haralampos Milionis, Konstantinos Makaritsis, Anastasia Vemmou, Eleni Koroboki, Efstathios Manios, Konstantinos Spengos, Patrik Michel, Konstantinos Vemmos


Temperature change, short and long-term mortality in acute ischemic stroke Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P. Poster Presentation at the 1st European Stroke Organisation Conference, 17-19/04/2015, Glasgow

Statin treatment is associated with improved prognosis in patients with af-related stroke

G. Ntaios, V. Papavasileiou, K. Makaritsis, A. Karagiannaki, H. Milionis, E. Manios, P. Michel, G.Y.H. Lip, K. Vemmos Poster Presentation at the 1st European Stroke Organisation Conference, 17-19/04/2015, Glasgow

Temperature change, short and long-term handicap in acute ischemic stroke Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P. Poster Presentation at the 1st European Stroke Organisation Conference, 17-19/04/2015, Glasgow

Prognostic value of 24-h ABPM in acute ischemic stroke: A systematic review and meta-analysis

N Kakaletsis, G Ntaios, H Milionis, A B Haidich, K Makaritsis, C Savopoulos, E Berge, A I Hatzitolios

Poster Presentation at the 1st European Stroke Organisation Conference, 17-19/04/2015, Glasgow

Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-sectional national survey in Greece G. Ntaios, V. Melikoki,, G. Perifanos, K. Perlepe, F. Gioulekas, A. Karagiannaki, I. Tsantzali, C. Lazarou, N. Beradze, E. Poulianiti, M. Poulikakou, F. Palantzas, S. Kaditi, F. Perlepe, G. Sidiropoulos, K. Papageorgiou, V. Papavasileiou, K. Vemmos, K. Makaritsis, G.N. Dalekos Poster Presentation at the 1st European Stroke Organisation Conference, 17-19/04/2015, Glasgow A Clinical Score to Predict Major Arterial Occlusions Eligible for Endovascular Recanalization in Acute Stroke based on the ASTRAL registry Peter Vanacker, Mirjam Heldner, Michael Amiguet, Mohamed Faouzi, Patrick Cras, George Ntaios, Marcel Arnold, Heinrich P Mattle, Urs Fischer, and Patrick Michel Poster presentation at the International Stroke Conference, Nashville, USA, 11/02/2015 Delays in pre-hospital and in-hospital acute ischemic stroke management Nikolaos Kakaletsis, Haralampos Milionis, George Ntaios, Ioanna A. Panagopoulou, Anastasia Karagiannaki, Konstantinos Makaritsis, Thomas Tegos, Konstantinos Tziomalos, Christos Savopoulos, Apostolos I. Hatzitolios Poster presentation at European Stroke Organisation Conference 2015


129


Blood pressure variability in acute ischemic stroke patients: : preliminary results of the PREVISE study N. Kakaletsis, G. Ntaios, H. Milionis, I. Chouvarda, A. Chytas, K. Tziomalos, D. Filos, C. Savopoulos, A.I. Hatzitolios Poster at the World Stroke Congress, Istanbul, 2014 The impact of b-blockers on blood pressure variability in acute ischemic stroke: preliminary results of the PREVISE study N. Kakaletsis, H. Milionis, G. Ntaios, I. Chouvarda, A. Chytas, K. Tziomalos, D. Filos, C. Savopoulos, A.I. Hatzitolios Poster at the World Stroke Congress, Istanbul, 2014 Association of ischemic stroke subtype with long-term cardiovascular events G. Ntaios, V. Papavasileiou, K. Makaritsis, H. Milionis, M. Patrik, K. Vemmos Oral presentation at the European Stroke Conference, Nice, France, 08/05/2014 Circadian blood pressure and heart rate patterns in acute ischaemic stroke and their relationship with short term mortality: preliminary results N. Kakaletsis, G. Ntaios, H. Milionis, C. Savopoulos, K. Makaritsis, K. Tziomalos, G.N. Dalekos, M. Elisaf, A.I. Hatzitolios E-poster at the European Stroke Conference, Nice, France, 08/05/2014 Poster at the World Stroke Congress, Istanbul, 2014

Anaemia on admission predicts short and long-term outcome in patients with acute ischaemic stroke H. Milionis, V. Papavasileiou, A. Eskandari, S. D’Ambrogio-Remillard, G. Ntaios, P. Michel E-poster at the European Stroke Conference, Nice, France, 08/05/2014 Acute imaging does not improve ASTRAL score’s accuracy despite having a prognostic value G. Ntaios, V. Papavasileiou, M. Faouzi, P. Vanacker, M. Wintermark, P. Michel E-poster at the European Stroke Conference, Nice, France, 08/05/2014 ASTRAL-R score Predicts absence of Recanalization after Intravenous Thrombolysis in Acute Ischemic Stroke Peter Vanacker, Dimitris Lambrou, Mirjam Heldner, David Seiffge, Hubertus Mueller, Ashraf Eskandari, George Ntaios,

Pascal J Mosimann, Roman Sztajzel, Vitor Mendes Pereira, Patrick Cras, Stefan Engelter, Philippe Lyrer, Urs Fischer, Marcel Arnold, and Patrik Michel Προφορική ανακοίνωση στο International Stroke Conference 2014, Stroke. 2014; 45:ATP50 Μετά την εκλογή στη θέση Λέκτορα Improving the Prediction of Spontaneous and IV Thrombolysis induced Recanalisation in Ischemic Stroke patients P. Vanacker, D. Lambrou, A. Eskandari, M. Cordier, G. Ntaios, P. Maeder, R. Meuli, P. Michel Ανηρτημένη ανακοίνωση στο 2nd Congress of Swiss Federation of Clinical Neuro-societies, 5-7/06/2013, Montreux, Switzerland Predictors of successful recanalization in acute large vessel occlusion ischemic stroke P. Vanacker, D. Lambrou, A. Eskandari, M. Cordier, P. Maeder, R. Meuli, G. Ntaios, P. Michel Ανηρτημένη ανακοίνωση στο 2nd Congress of Swiss Federation of Clinical Neuro-societies, 5-7/06/2013, Montreux, Switzerland Early major worsening in ischemic stroke: predictors and outcome G. Ntaios, D. Lambrou, D. Cuendet, P. Michel Swiss Stroke Trialists, Zurich, 9-10/02/2012 European Stroke Conference, London, UK, 28-31/06/2013 The ASTRAL score predicts 5-year dependence and mortality in acute ischemic stroke V. Papavasileiou, H. Milionis, P. Michel, K. Makaritsis, A. Vemmou, E. Koroboki, E. Manios, K. Vemmos, G. Ntaios European Stroke Conference, London, UK, 28-31/06/2013 Non-vitamin-K-antagonists oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials G. Ntaios, V. Papavasileiou, H.C. Diener, K. Makaritsis, P. Michel 17ο Swiss Trialists Stroke Meeting, St. Gallen, 31/01/2013 Independent Predictors of Recanalisation in Acute Ischemic Stroke P. Vanacker, D. Lambrou, A. Eskandari, G. Ntaios, P. Maeder, P. Michel 17ο Swiss Trialists Stroke Meeting, St. Gallen, 31/01/2013


130


European Stroke Conference, London, UK, 28-31/06/2013 Extension of the ASTRAL score to predict 12-months functional outcome after ischemic stroke: Results from the Chinese National Stroke Registry Gaifen Liu, Huaguang Zheng, Yilong Wang, Patrik Michel, D.Z. Wang, Jiming Fang, Vasileios Papavasileiou, Liping Liu, Kehui Dong, Chunxue Wang, Xingquan Zhao, George Ntaios,Yongjun Wang 2nd International Conference on Neurology and Epidemiology, 8-10/11/2012, Nice, France CHADS2, CHA2DS2-VASc and long-term stroke outcome in patients without atrial fibrillation G. Ntaios, G.Y.H. Lip, K. Makaritsis, V. Papavasileiou, H. Milionis, A. Vemmou, E. Koroboki, P. Savvari, E. Manios, H. Milionis, K. Vemmos European Stroke Conference, Λισαβώνα, 24/05/2012 Low ankle-brachial index predicts 5-year mortality but not recurrent stroke in patients with acute first-ever ischemic stroke H. Milionis, A. Vemmou, G. Ntaios, K. Makaritsis, E. Koroboki, V. Papavasileiou, P. Savvari, K. Spengos, K. Vemmos E-poster στο European Stroke Conference, Λισαβώνα, 24/05/2012 Inhospital mortality and associated factors – final results of the Hellenic Stroke Registry K. Spengos, C. Milionis, K. Makaritsis, S. Markoula, G. Ntaios, et el. for the Hellenic Stroke Registry Trialists European Stroke Conference, Λισαβώνα, 24/05/2012 Derivation and Double External Validation of an Integer-based Prognostic Score (ASTRAL Score) to Predict Functional Outcome in Acute Ischemic Stroke: a Collaborative Analysis from the ASTRAL, Athens and Vienna Stroke Registries G Ntaios, M Faouzi, J Ferrari, W Lang, K Vemmos, P Michel International Stroke Conference, New Orleans, USA 2012 Swiss Stroke Trialists, Zurich, 9-10/02/2012 Major Neurological Improvement is Predicted by Recanalisation and Absence of Acute Tissue Damage: An Analysis of 2'006 Consecutive Acute Ischemic Strokes David Cuendet, George Ntaios, Dimitris Lambrou, Patrik Michel International Stroke Conference, New Orleans, USA 2012 Risk factors for ischaemic stroke among hypertensive patients K. Tziomalos, M. Baltatzi, M. Apostolopoulou, E. Efthymiou, K. Psianou, D. Magkou, N. Katsiki, G. Ntaios, C. Savopoulos, A. Hatzitolios European Stroke Congress, 26/05/2011, Αμβούργο Isolated cerebellar infarct: imaging findings, etiopathogenesis and clinical outcome A. Vemmou, E. Koroboki, G. Ntaios, P. Savvari, A. Skafida, K. Spengos, K.N. Vemmos, European Stroke Congress, 26/05/2011, Αμβούργο Stroke in the anterior circulation: two-center comparison of combined (intravenous, intra-arterial and / or mechanical thrombectomy) with intravenous thrombolysis R.F. Sztajzel, G. Ntaios, I. Kuzmanovic, I. Momjian-Mayor, C. Bonvin, A. Viaccoz, V. Mendez-Pereira, A.P. Narata, K. Lovblad, P. Michel European Stroke Congress, 26/05/2011, Αμβούργο Association between blood pressure changes in the acute phase of stroke and outcome with respect to stroke etiology G. Ntaios, D. Lambrou, P. Michel European Stroke Congress, 26/05/2011, Αμβούργο A safe and efficacious intravenous insulin protocol for strict glycemic control in acute ischaemic stroke G. Ntaios, M. Egli, A. Arsovka, D. Joye, Y. Bettex, E. Lauber, A. Eskandari, S. D’Ambrogio, B. Richoz, J. Ruiz, P. Michel, European Stroke Congress, 26/05/2011, Αμβούργο Long-term mortality and stroke recurrence in patients with ischaemic stroke and atrial fibrillation are associated with the type of atrial fibrillation G. Ntaios, A. Vemmou, E. Koroboki, P. Savvari, M. Saliaris, K. Spengos, K. Vemmos Προφορική ανακοίνωση, European Stroke Congress, 26/05/2011, Αμβούργο Προφορική ανακοίνωση, European Congress of Internal Medicine, 7/10/2011, Αθήνα Mise en place d’un protocole d’insulinothιrapie intraveineuse sϋr et efficace hors des soins intensifs


131


M. Egli, G. Ntaios, D. Joye, J. Ruiz, P. Michel Congress de la Societe Francophone du Diabete, Geneva, 2011 The short-term effect of thrombolysis decreases with increasing stroke severity Ntaios G, Faouzi M, Michel P. International Stroke Congress, Los Angeles, 7-9/02/2011 Evaluation of a fixed enalapril/nitrendipine combination and concomitant atorvastatin treatment in the management of obese hypertensive patients with or without cardiovascular disease and/or diabetes Katsiki N, Baltatzi M, Savopoulos C, Agapakis D, Ntaios G, Karlafti H, Tziomalos K, Hatzitolios AI. 1st International Diabetes and Obesity Forum, Athens, 21–23/10/2010 Amiodarone: pharmacological profile and animal-model experimental data on its vasodilating effect A. Hatzitolios, G. Ntaios, C. Savopoulos 16th World Congress on Basic and Clinical Pharmacology, Copenhagen, Denmark, 17-23/07/2010 Two unusual cases of primary hyperaldosteronism C. Savopoulos, P. Kotsaftis, G. Ntaios, N. Katsiki, A. Adamidou, A. Hatzitolios 20th European Meeting on Hypertension, Oslo, Norway, 18-21/06/2010 Predictors of severity and early course in acute ischemic stroke G. Ntaios, M. Faouzi, C. Aubert, P. Maeder, P. Michel European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Anticoagulation management in patients with atrial fibrillation K. Tziomalos, K. Psianou, A. Konstantakou, I. Raptis, A. Hatzopoulos, I. Iordanidou, M. Apostolopoulou, A. Nikopoulou, G. Ntaios, A. Adamidou, C. Savopoulos, A.Hatzitolios European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Statin treatment and reaching low density lipoprotein cholesterol targets in elderly patients with ischemic stroke K. Tziomalos, N. Papastergiou, K. Psianou, I. Raptis, E. Siehou, I. Merakis, A. Pavlidis, S. Fotiadis, G. Ntaios, A. Adamidou, C. Savopoulos, A. Hatzitolios European Stroke Congress, Βαρκελώνη, 25-28/05/2010 J-shaped association between serum glucose and functional outcome in patients with acute ischemic stroke G. Ntaios, M. Egli, M. Faouzi, P. Michel European Stroke Congress, Βαρκελώνη, 25-28/05/2010 The effect of obesity on long-term mortality after acute first-ever stroke: the obesity stroke paradox G. Ntaios, P. Savvari, S. Skalidi, A. Vemmou, A. Skafida, K. Spengos, K. Vemmos European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Prevalence of atrial fibrillation in a Greek rural Population Ntaios G, Synetou M, Saliaris M, Xynos K, Pappa D, Savvari P, Spengos K, Vemmos K European Stroke Congress, Βαρκελώνη, 25-28/05/2010 Πριν την εκλογή στη θέση Λέκτορα The Acute STroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging P. Michel, C. Odier, M. Rutgers, M. Reichhart, P. Maeder, Re. Meuli, M. Wintemark, A. Maghraoui, M. Faouzi, A. Croquelois, G. Ntaios

ZAS meeting, Lausanne, Switzerland, 4/02/2010 European Stroke Congress, Βαρκελώνη, 25-28/05/2010 International Stroke Conference, San Antonio, USA, 23-26/02/2010

Is COPD a risk factor for sepsis? D. Agapakis, E. Massa, G. Ntaios, M. Papagianni, A. Zantidis, C. Savopoulos, A. Satsoglou, A. Hatzitolios Sepsis 2009, International Symposium, Amsterdam, 11-14/11/ 2009


132


Correlation of the QT dispersion and sepsis D. Agapakis, E. Massa, G. Ntaios, M. Papagianni, P. Kotsaftis, C. Savopoulos, A. Satsoglou, A. Hatzitolios Sepsis 2009, International Symposium, Amsterdam, 11-14/11/ 2009 Veno-occlusive disease of the liver during induction therapy for acute lymphoblastic leukemia A. Papadopoulos, G. Ntaios, G. Kaiafa, F. Girtovitis, Z. Saouli, Z. Kontoninas, M. Diamantidis, C. Savopoulos, A. Hatzitolios 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 2008 Influence of infections on lipids parameters D. Agapakis, C. Savopoulos, A. Hatzitolios, G. Ntaios, A. Zantidis, E. Massa, V. Tatola, D. Karamitsos 77th Congress of the European Atherosclerosis Society, April 26-29, 2008, Istanbul, Turkey Heparin affecting lipid metabolism D. Agapakis, C. Savopoulos, A. Hatzitolios, A. Xanthis, G. Ntaios, D. Karamitsos 7th International Congress on Coronary Artery Disease – From Prevention to Intervention, Venice, Italy, 7-10/10/07

Cardiovascular risk factors in elderly and over-aged ischemic stroke patients. The role of diabetes mellitus P. Kotsaftis, G. Ntaios, A. Hatzitolios, C. Savopoulos, D. Agapakis 77th Congress of the European Atherosclerosis Society, 26-29/04/08, Istanbul, Turkey Soluble receptor of advanced glycation end products is related to coronary atheromatosis estimated by quantitative coronary angiography in diabetic men A. Xanthis, A. Hatzitolios, G. Koliakos, S. Hatzimiltiadis, S. Fidani, G.Ntaios, G. Giannakoulas 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07 Levels of serum β2 microglobulin and lactate dehydrogenase in myeloproliferative disorders Z. Kontoninas, Z. Saouli, A. Papadopoulos, G. Kaiafa, V. Tsavdaridou, F. Girtovitis, G. Charisopoulos, G. Ntaios

6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07

Hyponatremia caused by syndrome of inappropriate antidiuretic hormone secretion D. Agapakis, K. Tzavella, G. Ntaios, Ch. Margaritidis, E. Massa, Ch. Savopoulos, A. Hatzitolios, D. Karamitsos. 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07

Homocysteine levels in patients with Myeloproliferative and cerebrovascular disease G. Ntaios, C. Savopoulos, Z. Saouli, G. Kaiafa, A. Papadopoulos, A. Hatzitolios, Z. Kontoninas, D. Agapakis, A. Chatzinikolaou, C. Margaritidis 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07 Cardiac valvular lesions in patients with Myeloproliferative diseases A. Papadopoulos, Ch. Pliakos, Z. Kontoninas, Z. Saouli, G. Kaiafa, F. Girtovitis, G. Charisopoulos, V. Tsavdaridou, G. Ntaios 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07 Copper and iron status in myelodysplastic syndromes Z. Saouli, G. Kaiafa, Z. Kontoninas, H. Tsoukali, N. Raikos, F. Girtovitis, G. Charisopoulos, G. Ntaios, A. Papadopoulos 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/07 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 8-11/12/07

Copper Levels in Patients with Hematological Malignancies Z. Saouli, M. Diamantidis, A. Papadopoulos, G. Kaiafa, F. Girtovitis, Z. Kontoninas, G. Ntaios, C. Andreadis, C. Savopoulos, A. Hatzitolios 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 2008 Factor V Deficiency in a Patient with Polycythemia Vera and Huntington’s Chorea F. Girtovitis, M. Diamantidis, G. Kaiafa, N. Constantinou, D. Lazaridou, Z. Saouli, G. Ntaios, Z. Kontoninas, C. Andreadis, A. Papadopoulos 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 2008 Correlation of red blood cells and platelets parameters


133


Z. Saouli, G. Kaiafa, F. Girtovitis, Z. Kontoninas, G. Ntaios, G. Charisopoulos, V. Tsavdaridou, C. Aggouridaki, A. Papadopoulos 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 8-11/12/07 Macrocytosis in COPD and course of the disease Z. Kontoninas, F. Girtovitis, G. Kaiafa, G. Ntaios, Z. Saouli, A. Hatzitolios, G. Charisopoulos, C. Savopoulos, A. Papadopoulos 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 8-11/12/07 Discrimination indices as screening tests for β- thalassemic trait G. Ntaios, A. Chatzinikolaou, Z. Saouli, F. Girtovitis, M. Tsapanidou, G. Kaiafa, Z. Kontoninas, A. Nikolaidou, C. Savopoulos, I. Pidonia, S. Alexiou-Daniel 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, USA, 8-11/12/07 Serum cholesterol levels and sepsis G. Ntaios, D. Agapakis, C. Savopoulos, E. Massa, A. Chatzinikolaou, G. Kaiafa, A. Hatzitolios 76th Congress of the European Atherosclerosis Society, Helsinki, Finland, 10-13/06/07 Predictive value of lactate dehydrogenase in myelodysplastic syndromes A. Papadopoulos, F. Girtovitis, Z. Saouli, G. Kaiafa, Z, Kontoninas, G. Charisopoulos, G. Ntaios, D. Sioutis 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/2007 Guillain Barre syndrome after influenza immunization G. Ntaios, A. Adamidou, A. Chatzinikolaou, D. Agapakis, Z. Saouli, A. Karlovasitou, D. Karamitsos

6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/2007 Parathyroid crisis as first manifestation of primary hyperparathyroidism G. Ntaios, C. Savopoulos, A. Chatzinikolaou, G. Kaiafa, A. Hatzitolios, D. Karamitsos. 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/2007 Causes of microcytosis in the general Greek population G. Ntaios, Z. Saouli, C. Savopoulos, A. Chatzinikolaou, G. Kaiafa, Z. Kontoninas, D. Agapakis 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/2007 Atypical petechial rash at the lower extremities due to Parvovirus B19 infection G. Ntaios, A. Chatzihidiroglou, A. Chatzinikolaou, F. Iliadis, A. Adamidou, D. Karamitsos 6th Congress of the European Federation of Internal Medicine, Lisbon, Portugal, 23-26/05/2007 Cholesterol-to-HDL ratio in patients with chronic obstructive pulmonary disease D. Agapakis, G. Ntaios, C. Savopoulos, E. Massa, A. Chatzinikolaou, G. Kaiafa, A. Hatzitolios 76th Congress of the European Atherosclerosis Society, Finland, 2007 Apolipoprotein A-1, apolipoprotein B and lipoprotein (a) levels at patients with ischemic stroke D. Agapakis, G. Ntaios, E. Massa, C. Savopoulos, G. Kaiafa, A. Hatzitolios XIV International Symposium on Atherosclerosis, Rome, Italy, 18-22/06/2006 Hyperhomocysteinemia as a risk factor for stroke D. Agapakis, G. Ntaios, E. Massa, C. Savopoulos, G. Kaiafa, A. Hatzitolios XIV International Symposium on Atherosclerosis, Rome, Italy, 18-22/06/2006


134


ΑΝΑΚΟΙΝΩΣΕΙΣ ΣΕ ΕΛΛΗΝΙΚΑ ΣΥΝΕΔΡΙΑ


Embolic strokes of undetermined source (ESUS) in the Athens Stroke Registry: a descriptive analysis G. Ntaios, V. Papavasileiou, H. Milionis, K. Makaritsis, E. Manios, K. Spengos, P. Michel, K. Vemmos


Comorbidity analysis and 3-months functional outcome in acute ischemic stroke: data from the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) Kakaletsis N., Papavasileiou V., Lambrou D., Ntaios G., Michel P. Ανηρτημένη ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015


Predictive value of the ASTRAL score, the Charlson and the Elixhauser indexes in acute ischemic stroke Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P. Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015


Association of circadian blood pressure and heart rate patterns with severity of acute ischemic stroke: preliminary results

N. Kakaletsis, H. Milionis, G. Ntaios, C. Savopoulos, K. Makaritsis, K. Tziomalos, G.N. Dalekos, M. Elisaf, A.I. Hatzitolios


Temperature change, short and long-term handicap in acute ischemic stroke Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P. Ανηρτημένη ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015


Temperature change, short and long-term mortality in acute ischemic stroke Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P. Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015


Comorbidity analysis and long-term mortality in acute ischemic stroke: data from the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) Kakaletsis N., Papavasileiou V., Lambrou D., Eskandari A., Ntaios G., Michel P. Ανηρτημένη ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015


Statin treatment is associated with improved prognosis in patients with af-related stroke

G. Ntaios, V. Papavasileiou, K. Makaritsis, A. Karagiannaki, H. Milionis, E. Manios, P. Michel, G.Y.H. Lip, K. Vemmos


Βaseline characteristics and outcomes of patients with acute ischemic stroke treated with intravenous thrombolysis in the department of medicine of the University of Thessaly

G. Ntaios, A. Karagiannaki, K. Makaritsis, G. N. Dalekos, on behalf of the medical personnel of the Department of Medicine of the University of Thessaly

Προφορική ανακοίνωση στο 7o Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας 19-21/03/2015, Λάρισα Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-sectional national survey in Greece G. Ntaios, V. Melikoki,, G. Perifanos, K. Perlepe, F. Gioulekas, A. Karagiannaki, I. Tsantzali, C. Lazarou, N. Beradze, E.


135


Poulianiti, M. Poulikakou, F. Palantzas, S. Kaditi, F. Perlepe, G. Sidiropoulos, K. Papageorgiou, V. Papavasileiou, K. Vemmos, K. Makaritsis, G.N. Dalekos Ανηρτημένη ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015


Circadian blood pressure and heart rate patterns in acute ischemic stroke and their relationship with short term mortality: preliminary results N. Kakaletsis, G. Ntaios, H. Milionis, C. Savopoulos, K. Makaritsis, K. Tziomalos, G.N. Dalekos, M. Elisaf, A.I. Hatzitolios Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015 Blood pressure variability in acute ischemic stroke patients: : preliminary results of the PREVISE study N. Kakaletsis, G. Ntaios, H. Milionis, I. Chouvarda, A. Chytas, K. Tziomalos, D. Filos, C. Savopoulos, A.I. Hatzitolios Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015 Προγνωστική ισχύς της 24ωρης καταγραφής της αρτηριακής πίεσης στο οξύ ισχαιμικό ΑΕΕ: μετα-ανάλυση Κακαλέτσης Ν., Ντάιος Γ., Μηλιώνης Χ., Χάιδιτς Α.-Μ., Μακαρίτσης Κ., Σαββόπουλος Χ., Berge E., Χατζητόλιος Ι. Α. Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015

Προφορική ανακοίνωση στο 7o Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας 19-21/03/2015, Λάρισα Ιστορική μελέτη για την ανακάλυψη της ασπιρίνης και της βαρφαρίνης Γιαννοτάκη Κ., Καδδίτη Σ., Φιλιππίδου Α., Ντάιος Γ. Ανηρτημένη ανακοίνωση στο 20ο Επιστημονικό Συνέδριο Φοιτητών Ιατρικής Ελλάδας, 9-11/05/2014 Circadian bllod pressure and heart rate patterns in acute ischemic stroke and their relationship with short term mortality: preliminary results N. Kakaletsis, G. Ntaios, H. Milionis, C. Savopoulos, K. Makaritsis, K. Tziomalos, G.N. Dalekos, M. Elisaf, A.I. Hatzitolios Προφορική ανακοίνωση στο 6ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 27/03/2014 Προφορική ανακοίνωση στο 1ο Πανελλήνιο Συνέδριο Συνεχιζόμενης Εκπαίδευσης στην Εσωτερική Παθολογία, Θεσσαλονίκη, 28/02/2015 Patient with sudden-onset left hemiplegia, atrial fibrillation on acenocumarol and INR:4.1: a case report Ε. Manoulakas, C. Lazarou, Th. Palantzas, K. Οikonomou, D. Kolovos, A. Bakalis, P. Thoda, Μ. Vlychou, M. Sgantzos, V. Papavasileiou, G. Papadamou, Κ. Μakaritsis, G. Ntaios, G.Ν. Dalekos Προφορική ανακοίνωση στο 6ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 27/03/2014 Acute stroke multimodal imaging does not improve ASTRAL score’s accuracy despite having an independent prognostic value G. Ntaios, V. Papavasileiou, M. Faouzi, P. Vanacker, M. Wintermark, P. Michel Προφορική ανακοίνωση στο 6ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 27/03/2014 Ischemic stroke is associated with icreased cardiovascular risk irrespective of the TOAST type G. Ntaios, V. Papavasileiou, K. Makaritsis, H. Milionis, P. Michel, K. Vemmos Προφορική ανακοίνωση στο 6ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 27/03/2014 Larissa Stroke Outcome (LASTRO) registry: Design and methodology V. Melikoki, I. Tsantzali, K. Perlepe, G. Perifanos, T. Palantzas, N, Beradze, E. Poulianiti, M. Poulikakou, K. Papageorgiou, M. Sgantzos, E. Papadopoulos, V. Papavasileiou, K. Makaritsis, G. Ntaios, G.Ν. Dalekos Προφορική ανακοίνωση στο 6ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 27/03/2014 Anemia on admission predicts short and long term outcome in patients with acute ischemic stroke H. Milionis, V. Papavasileiou, A. Eskandari, S. D’Ambrogio-Remillard, G. Ntaios, P. Michel Προφορική ανακοίνωση στο 6ο Διεθνές Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 27/03/2014 Larissa Stroke Outcome (LASTRO) registry: baseline characteristics of patients registered during the first five months K. Perlepe, V. Melikoki, E. Poulianiti, M. Poulikakou, I. Tsantzali, G. Perifanos, T. Palantzas, N. Beradze, C. Lazarou, K. Papageorgiou, M. Sgantzos, E. Papadopoulos, V. Papavasileiou, K. Makaritsis, G. Ntaios, G.N. Dalekos Ανηρτημένη ανακοίνωση στο 6ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 28/03/2014


136


Estimation of the number of acute stroke patients who are eligible for intravenous thrombolysis on annual basis in department of medicine in Larissa University hospital C. Lazarou, T. Palantzas, I. Tsantzali, V. Melikoki, K. Perlepe, N. Beradze, E. Poulianiti, M. Poulikakou, G. Perifanos, K. Papageorgiou, M. Sgantzos, E. Papadopoulos, V. Papavasileiou, K. Makaritsis, G. Ntaios, G.N. Dalekos Ανηρτημένη ανακοίνωση στο 6ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 28/03/2014

Μετά την εκλογή στη θέση Λέκτορα Τα CHADS2 και CHA2DS2-VASC scores στην πρόβλεψη της μακρορόθεσμης έκβασης του ισχαιμικού αγγειακού εγκεφαλικού επεισοδίου σε ασθενείς χωρίς κολπική μαρμαρυγή Γ. Ντάιος, Β. Παπαβασιλείου, Χ. Μηλιώνης, G.Y.H. Lip, Α. Βέμμου, Ε. Κορομπόκη, Π. Σάββαρη, Ε. Μανιός, Κ. Βέμμος, Κ. Μακαρίτσης

Προφορική ανακοίνωση στο 5ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 28/03/2013 Τα νέα από-του-στόματος αντιπηκτικά σε ασθενείς με κολπική μαρμαρυγή και προηγούμενο ΑΕΕ: Συστηματική ανασκόπηση και μετα-ανάλυση των τυχαιοποιημένων μελετών Β. Παπαβασιλείου, Κ. Μακαρίτσης, Χ. Μηλιώνης, HC. Diener, P. Michel, Γ. Ντάιος Προφορική ανακοίνωση στο 5ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 28/03/2013 An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score G Ntaios, M Faouzi, J Ferrari, W Lang, K Vemmos, P Michel Προφορική ανακοίνωση στο 4ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 29/03/2012 Παράγοντες κινδύνου για ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο σε υπερτασικούς ασθενείς K. Tziomalos, M. Baltatzi, M. Apostolopoulou, E. Efthymiou, K. Psianou, D. Magkou, N. Katsiki, G. Ntaios, C. Savopoulos, A. Hatzitolios 4ο Συμπόσιο Ομάδων Εργασίας της Ελληνικής Εταιρίας Αθηροσκλήρωσης, 03/12/2011, Αθήνα Ενδοφλέβια θρομβόλυση υπό την καθοδήγηση perfusion-CT σε ασθενείς με ΑΕΕ αγνώστου ενάρξεως: μια διπλή-τυφλή, τυχαιοποιημένη πιλοτική μελέτη Michel P, Ntaios G, Reichhart M, Schindler C, Bogousslavsky J, Maeder P, Meuli R, Wintermark M Προφορική ανακοίνωση στο 3ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 10/03/2011 Πριν την εκλογή στη θέση Λέκτορα Αποτελεσματικότητα και ασφάλεια συνδυασμένης αντιυπερτασικής και υπολιπιδαιμικής αγωγής σε ασθενείς με σακχαρώδη διαβήτη ή/και καρδιαγγειακή νόσο Ν. Κατσίκη, Μ. Μπαλτατζή, Χ. Σαββόπουλος, Γ. Ντάιος, Δ. Αγαπάκης, Σ. Φωτιάδης, Χ. Δημητρούλα, Α. Νικοπούλου, Α. Χατζητόλιος Ανακοινώθηκε στο 6ο Ετήσιο Συνέδριο Αθηροσκλήρωσης της Εταιρείας Αθηροσκλήρωσης Βορείου Ελλάδος, Θεσσαλονίκη, 11-13/03/2010 Η επίδραση της παχυσαρκίας στην μακροπρόθεσμη έκβαση των ασθενών με οξύ αγγειακό εγκεφαλικό επεισόδιο: «το παράδοξο της παχυσαρκίας» Κ. Βέμμος, Γ. Ντάιος, Α. Σκαφίδα, Γ. Τσαγκάλης, Α. Βέμμου

Ανακοινώθηκε στο 2ο Συνέδριο Παθολογίας Κεντρικής Ελλάδος, Λάρισα, 18-20 Μαρτίου 2010

The Acute STroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging P. Michel, C. Odier, M. Rutgers, M. Reichhart, P. Maeder, Re. Meuli, M. Wintemark, A. Maghraoui, M. Faouzi, A. Croquelois, G. Ntaios Ανακοινώθηκε στο 2ο Συνέδριο Παθολογίας Κεντρικής Ελλάδος, Λάρισα, 18-20 Μαρτίου 2010 Ποσοστά χορήγησης της ενδεδειγμένης αντιπηκτικής αγωγής σε ασθενείς με χρόνια κολπική μαρμαρυγή


137


Κ. Τζιόμαλος, Κ. Ψιάνου, Α. Κωνσταντάκου, Ι. Ράπτης, Α. Χατζόπουλος, Ι. Ιορδανίδου, Α. Νικοπούλου, Γ. Ντάιος, Α. Αδαμίδου, Χ. Σαββόπουλος, Α. Ι. Χατζητόλιος Ανακοινώθηκε στο 2ο Συνέδριο Παθολογίας Κεντρικής Ελλάδος, Λάρισα, 18-20 Μαρτίου 2010 Hypertension is an indepedent predictor of mean platelet volume in patients with acute ischemic stroke G. Ntaios, O. Gurer, M. Faouzi, C. Aubert, P. Michel Ανακοινώθηκε στο 2ο Συνέδριο Παθολογίας Κεντρικής Ελλάδος, Λάρισα, 18-20 Μαρτίου 2010 Το εύρος κατανομής των ερυθρών αιμοσφαιρίων δεν σχετίζεται με τη βαρύτητα ή την λειτουργική έκβαση των ασθενών με οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο G. Ntaios, O. Gurer, M. Faouzi, C. Aubert, P. Michel Ανακοινώθηκε στο 2ο Συνέδριο Παθολογίας Κεντρικής Ελλάδος, Λάρισα, 18-20 Μαρτίου 2010 Mean platelet volume in the early phase of acute ischemic stroke is not associated with severity or functional outcome G. Ntaios, O. Gurer, M. Faouzi, C. Aubert, P. Michel Ανακοινώθηκε στο 2ο Συνέδριο Παθολογίας Κεντρικής Ελλάδος, Λάρισα, 18-20 Μαρτίου 2010 Ποσοστά χορήγησης στατίνης σε ασθενείς με ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο Κ. Τζιόμαλος, Κ. Ψιάνου, Ν. Παπαστεργίου, Ι. Ράπτης, Η. Μεράκης, Ε. Σιέχου, Α. Παυλίδης, Γ. Ντάιος, Α. Αδαμίδου, Χ. Σαββόπουλος, Α.Ι. Χατζητόλιος Ανακοινώθηκε στο 4ο Πανελλήνιο Συνέδριο Αγγειακών Εγκεφαλικών Νόσων, 2009

Η επίδραση των λοιμώξεων στις λιπιδαιμικες παραμέτρους Δ. Αγαπάκης, Χ. Σαββόπουλος, Ε. Μάσσα, Γ. Ντάιος, Α. Θεοδωρίδης, Φ. Ηλιάδης 10ο Συνέδριο Ελληνικής Εταιρείας Λιπιδιολογίας και Αθηροσκλήρωσης Implementation of strategy for the management of overt dyslipidemia. The IMPROVE study A. Hatzitolios, V. G. Athyros, A. Karagiannis, C. Savopoulos, C. Charalambous, G. Kyriakidis, Th. Milidis, C. Papathanakis, A. Bitli, I. Vogiatsis, G. Makridis, G. Ntaios, N. Katsiki, A. Symeonidis, D. P. Mikhailidis 3ο Πανελλήνιο Συνέδριο Αθηροσκλήρωσης, Αθήνα, 3-6 Δεκεμβρίου 2008 Θρομβοκυττάρωση και υπερκαλιαιμία Ζ. Σαούλη, Φ. Γκιρτοβίτης Χ. Μαργαριτίδης, Ζ. Κοντονίνας, Γ. Χαρισόπουλος, Γ. Ντάιος, Α. Παπαδόπουλος 33ο Πανελλήνιο Ιατρικό Συνέδριο, Αθήνα 2007 Παράγοντες καρδιαγγειακού κινδύνου σε ηλικιωμένους και υπέργηρους με ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο: η θέση του σακχαρώδη διαβήτη Π. Κοτσάφτης, Γ. Ντάιος, Α. Χατζητόλιος, Χ. Σαββόπουλος, Δ. Αγαπάκης, Δ. Καραμήτσος 21ο Συνέδριο της Διαβητολογικής Εταιρείας Βορείου Ελλάδος, Θεσσαλονίκη 2007 Eίδος αντιθρομβωτικής αγωγής που χορηγήθηκε σε ασθενείς με ισχαιμικό ΑΕΕ σε πανεπιστημιακή παθολογική κλινική Α.Π.Θ Α. Ξάνθης, Γ. Ντάιος, Α.Ι. Χατζητόλιος, Χ. Σαββόπουλος, Δ. Αγαπάκης, Ε. Μπουλτούκας 33ο Πανελλήνιο Ιατρικό Συνέδριο, Αθήνα 2007 Δευτεροπαθής υπερτροφική oστεοαρθροπάθεια σε έδαφος αδενοκαρκινώματος πνεύμονος και ενεργού φυματίωσης Γ. Ντάιος, Α. Αδαμίδου, Α. Χατζηνικολάου, Μ. Αλεβίζος, Δ. Καραμήτσος Προφορική ανακοίνωση στο 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Συχνότητα συνταγογράφησης αντλίας πρωτονίων έναντι Η2 ανταγωνιστών Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Α. Χατζητόλιος, Χ. Σαββόπουλος 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Συσχέτιση αιμορραγίας πεπτικού έλκους και ομάδας αίματος. Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Α. Ξάνθης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Χ. Σαββόπουλος, Α. Χατζητόλιος 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Συσχετισμός επιπέδων φερριτίνης με το υποκείμενο νόσημα.


138


Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Χ. Σαββόπουλος, Α. Χατζητόλιος 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Διερεύνηση αιτιών ικτέρου σε ασθενείς παθολογικής κλινικής Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Χ. Σαββόπουλος, Α. Χατζητόλιος 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07 Διαφοροδιάγνωση μεταξύ σιδηροπενικής αναιμίας και ετερόζυγης β-μεσογειακής αναιμίας με τη βοήθεια ερυθροκυτταρικών δεικτών Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηινικολάου, Δ. Αγαπάκης, Μ. Τσαπανίδου, Χ. Σαββόπουλος, Ι. Πηδόνια, Σ. Αλεξίου 22ο Βορειοελλαδικό Ιατρικό Συνέδριο της Ιατρικής Εταιρείας Θεσσαλονίκης, Θεσσαλονίκη, 19-21/04/07

Ρύθμιση της Αρτηριακής Πίεσης και Βλάβη σε Όργανα Στόχους σε θεραπευόμενους υπερτασικούς ασθενείς, πάσχοντες και μη από μεταβολικό σύνδρομο Μ. Μπαλτατζή, Α. Χατζητόλιος, Χ. Σαββόπουλος, Χ. Δημητρούλα, Ν. Κατσίκη, Γ. Ντάιος, Π. Κοτσάφτης, Μ. Αποστολοπούλου 3ο Ετήσιο Συνέδριο Αθηροσκλήρωσης, Θεσσαλονίκη 2007 Κακοήθης υπέρταση νεφραγγειακής αιτιολογίας σε μονόνεφρο νεφρό Α. Μύρου, Χ. Σαββόπουλος, Α. Χατζητόλιος, Μ. Μπαλτατζή, Γ. Ντάιος, Φ. Ηλιάδης, Χ. Δημητρούλα, Κ. Γιαβρόγλου 10ο Πανελλήνιο Συνέδριο Αρτηριακής Υπέρτασης, Θεσσαλονίκη, 1-3 /02/07

Διερεύνηση αιτιών υπονατριαιμίας σε παθολογική κλινική Δ. Αγαπάκης, Κ. Τζαβέλλα, Χ. Μαργαριτίδης, Γ. Ντάιος, Α. Ξάνθης, Α. Χατζηχηδήρογλου, Δ. Καραμήτσος Ιατρικό Συνέδριο Ενόπλων Δυνάμεων, Θεσσαλονίκη, 23-26/11/2006 Θρομβοεμβολικές επιπλοκές και καρκίνος Φ. Γκιρτοβίτης, Κ. Τζαβέλλα, Γ. Ντάιος, Γ. Χαρισόπουλος, Π. Κοτσάφτης, Α. Μύρου, Π. Μακρής, Σ. Παπαμίχος, Π.Ε. Μακρής 17ο Πανελλήνιο Αιματολογικό Συνέδριο, Αθήνα, 22-26/11/2006 Η σημασία της γαλακτικής αφυδρογονάσης σε ασθενείς με μυελοδυσπλαστικά σύνδρομα Φ. Γκιρτοβίτης, Γ. Χαρισόπουλος, Ζ. Σαούλη, Γ. Καϊάφα, Α. Παπαδόπουλος, Γ. Ντάιος, Α. Ζαντίδης 17ο Πανελλήνιο Αιματολογικό Συνέδριο, Αθήνα, 22-26/11/2006 Υποτροπή συνδρόμου Guillain-Barre μετά από αντιγριπικό εμβολιασμό Γ. Ντάιος , Α. Αδαμίδου, Α. Χατζηνικολάου, A. Καρλοβασίτου, Ι. Μαυρομάτης, Μ. Αλεβίζος, Δ. Καραμήτσος 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10-3/11/06 Συχνότητα νοσημάτων σε ασθενείς παθολογικής κλινικής τριτοβάθμιου νοσοκομείου Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Μ. Μπαλτατζή, Φ. Ηλιάδης, Α. Χατζηνικολάου, Γ. Καϊάφα, Δ. Καραμήτσος. 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Οξεία Πυελονεφρίτιδα: κλινικό-επιδημιολογικά στοιχεία Γ. Ντάιος, Χ. Σαββόπουλος, Δ. Αγαπάκης, Α. Χατζητόλιος, Ι. Οικονόμου, Ε. Δεστάνης, Α. Χατζηνικολάου, Γ. Καϊάφα. 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Λιπιδαιμικό προφίλ ηλικιωμένων ασθενών παθολογικής κλινικής τριτοβάθμιου νοσοκομείου Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Μ. Μπαλτατζή, Φ. Ηλιάδης, Δ. Αγαπάκης, Α. Χατζηνικολάου, Γ. Καϊάφα 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Παραθυρεοειδική κρίση ως πρώτη εκδήλωση πρωτοπαθούς υπερπαραθυρεοειδισμού Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Α. Χατζηνικολάου, Γ. Καϊάφα, Δ. Αγαπάκης, Ι. Σουλτάτη, Δ. Καραμήτσος 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006

Διερεύνηση αιτιών σιδηροπενικής αναιμίας σε ασθενείς παθολογικής κλινικής


139


Γ. Ντάιος, Γ. Καϊάφα, Ζ. Σαούλη, Χ. Σαββόπουλος, Α. Χατζητόλιος, Α. Χατζηνικολάου, Ε. Τσιαούση, Α. Παπαδόπουλος 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006

Διερεύνηση τριψήφιας ΤΚΕ σε ασθενείς παθολογικής πανεπιστημιακής κλινικής του ΑΠΘ Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζηνικολάου, Ζ. Σαούλη, Δ. Αγαπάκης, Γ. Καϊάφα, Δ. Καραμήτσος 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Διερεύνηση αιτιών υποχρωμίας/μικροκυττάρωσης σε ασθενείς παθολογικής κλινικής Γ. Ντάιος, Γ. Καϊάφα, Ζ. Σαούλη, Χ. Σαββόπουλος, Α. Χατζητόλιος, Α. Χατζηνικολάου, Ε. Τσιαούση, Α. Παπαδόπουλος 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006

Ανάλυση περιστατικών εκούσιας φαρμακευτικής δηλητηρίασης Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Δ. Αγαπάκης, Α. Χατζηνικολάου, Σ. Μαγειρία, Α. Χατζηχηδήρογλου, Γ. Καϊάφα 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Σπάνια εκδήλωση λοίμωξης από Parvo B19 με πορφυρικό εξάνθημα G. Ntaios, A. Chatzihidiroglou, A. Chatzinikolaou, F. Iliadis, A. Adamidou, D. Karamitsos 12ο Πανελλήνιο Συνέδριο Εσωτερικής Παθολογίας, Αθήνα, 30/10- 3/11/ 2006 Υπομαγνησιαιμία σε οξύ ΑΕΕ Δ. Αγαπάκης, Χ. Σαββόπουλος, Ε. Μάσσα, Γ. Ντάιος, Α. Ξάνθης, Α. Χατζητόλιος 7ο Παμπελοποννησιακό Ιατρικό Συνέδριο, Πάτρα 2006 Διαταραχές λιπιδίων και χρόνια αποφρακτική πνευμονοπάθεια Δ. Αγαπάκης, Χ. Σαββόπουλος, Ε. Μάσσα, Γ. Ντάιος, Φ. Ηλιάδης, Γ. Καϊάφα 10ο Συνέδριο της Ελληνικής Εταιρίας Λιπιδιολογίας και Αθηροσκλήρωσης, Αθήνα, 26-27/05/06 Σπάνια εκδήλωση θρομβοπενίας σε νεαρό ενήλικα με HIV λοίμωξη Ι. Χατζηζήσης, Ζ. Σαούλη, Γ. Χαρισόπουλος, Γ. Ντάιος, Γ. Καϊάφα, Α. Παπαδόπουλος 21ο Βορειοελλαδικό Ιατρικό Συνέδριο ,2006 Εν τω βάθει φλεβική θρόμβωση ως πρώτη εκδήλωση καρκίνου παχέος εντέρου Κ. Τζαβέλλα, Γ. Ντάιος, Δ. Αγαπάκης, Φ. Γκιρτοβίτης, Α. Χατζημπαλόγλου, Κ. Γιαβρόγλου, Ε. Δεστάνης, Δ. Κολιούσκας, Π. Μακρής Ελληνικές Ημέρες Θρόμβωσης – Καρκίνος και Θρόμβωση, Θεσσαλονίκη, 10-11/02/2006 Νεοπλασματικοί ασθενείς στην αιμοκάθαρση Μ. Μαλλιάρα, Ι. Παπαδόπουλος, Π. Σπανού, Γ. Ντάιος, Α. Σαργιαννίδου, Ο. Λιάμος, Ι. Φωτιάδης 11ο Παγκρήτιο Ιατρικό Συνέδριο, Χανιά, 1-3/11/02 Προβλήματα των διαβητικών ασθενών στην αιμοκάθαρση Μ. Μαλλιάρα, Γ. Ντάιος, Π. Σπανού, Α. Σαργιαννίδου, Ο. Λιάμος, Ι. Φωτιάδης 11ο Παγκρήτιο Ιατρικό Συνέδριο, Χανιά, 1-3/11/02


140


ΠΕΡΙΛΗΨΕΙΣ ΕΡΓΑΣΙΩΝ ΔΗΜΟΣΙΕΥΜΕΝΕΣ ΣΕ ΕΛΛΗΝΙΚΑ ΠΕΡΙΟΔΙΚΑ

Ο ρόλος της ερυθροποιητίνης στην οξεία αντιμετώπιση των ισχαιμικών αγγειακών εγκεφαλικών επεισοδίων και στην εξέλιξη της Χρόνιας Νεφρικής Ανεπάρκειας Χ. Σαββόπουλος, Γ. Ντάιος, Α. Χατζητόλιος, Τόμος Περιλήψεων του 10ου Κύκλου των ‘Αλκυονίδων ημερών νεφρολογίας’ με θέμα: «Η Επίδραση των Ορμονών στη Νεφρική και Καρδιαγγειακή Βλάβη» Παράγοντες καρδιαγγειακού κινδύνου σε ηλικιωμένους και υπέργηρους με ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο: η θέση του σακχαρώδη διαβήτη Π. Κοτσάφτης, Γ. Ντάιος, Α. Χατζητόλιος, Χ. Σαββόπουλος, Δ. Αγαπάκης, Δ. Καραμήτσος Διαβητολογικά Χρονικά 2007; 20:144 Δευτεροπαθής υπερτροφική σστεοαρθροπάθεια σε έδαφος αδενοκαρκινώματος πνεύμονος και ενεργού φυματίωσης Γ. Ντάιος, Α. Αδαμίδου, Α. Χατζηνικολάου, Μ. Αλεβίζος, Δ. Καραμήτσος Ελληνική Ιατρική» 73 (Supl):72, 2007 Συχνότητα συνταγογράφησης αντλίας πρωτονίων έναντι Η2 ανταγωνιστών Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Α. Χατζητόλιος, Χ. Σαββόπουλος Ελληνική Ιατρική» (Supl):76, 2007 Συσχέτιση αιμορραγίας πεπτικού έλκους και ομάδας αίματος Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Α. Ξάνθης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Χ. Σαββόπουλος, Α. Χατζητόλιος Ελληνική Ιατρική (Supl):76, 2007 Συσχετισμός επιπέδων φερριτίνης με το υποκείμενο νόσημα Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Χ. Σαββόπουλος, Α. Χατζητόλιος Ελληνική Ιατρική» (Supl):74, 2007 Διερεύνηση αιτιών ικτέρου σε ασθενείς παθολογικής κλινικής Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Π. Κοτσάφτης, Ζ. Κοντονίνας, Γ. Καϊάφα, Χ. Σαββόπουλος, Α. Χατζητόλιος Ελληνική Ιατρική (Supl):74, 2007 Διαφοροδιάγνωση μεταξύ σιδηροπενικής αναιμίας και ετερόζυγης β-μεσογειακής αναιμίας με τη βοήθεια ερυθροκυτταρικών δεικτών Γ. Ντάιος, Ζ. Σαούλη, Α. Χατζηνικολάου, Δ. Αγαπάκης, Μ. Τσαπανίδου, Χ. Σαββόπουλος, Ι. Πηδόνια, Σ. Αλεξίου Ελληνική Ιατρική (Supl):75, 2007

Θρομβοεμβολικές επιπλοκές και καρκίνος Φ. Γκιρτοβίτης, Κ. Τζαβέλλα, Γ. Ντάιος, Γ. Χαρισόπουλος, Π. Κοτσάφτης, Α. Μύρου, Π. Μακρής, Σ. Παπαμίχος, Π.Ε. Μακρής Αίμα-Haema, 2006;9 Suppl(1): 126 Η σημασία της γαλακτικής αφυδρογονάσης σε ασθενείς με μυελοδυσπλαστικά σύνδρομα Φ. Γκιρτοβίτης, Γ. Χαρισόπουλος, Ζ. Σαούλη, Γ. Καϊάφα, Α. Παπαδόπουλος, Γ. Ντάιος, Α. Ζαντίδης Ιατρικό Βήμα Suppl : σελ. 93, 2006 Υποτροπή συνδρόμου Guillain-Barre μετά από αντιγριπικό εμβολιασμό Γ. Ντάιος, Α. Αδαμίδου, Α. Χατζηνικολάου, A. Καρλοβασίτου, Ι. Μαυρομάτης, Μ. Αλεβίζος, Δ. Καραμήτσος Ιατρικό Βήμα Suppl : σελ. 93, 2006 Συχνότητα νοσημάτων σε ασθενείς παθολογικής κλινικής τριτοβάθμιου νοσοκομείου Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Μ. Μπαλτατζή, Φ. Ηλιάδης, Α. Χατζηνικολάου, Γ. Καϊάφα, Δ. Καραμήτσος. Ιατρικό Βήμα Suppl : σελ. 73, 2006 Οξεία Πυελονεφρίτιδα: κλινικό-επιδημιολογικά στοιχεία


141


Γ. Ντάιος, Χ. Σαββόπουλος, Δ. Αγαπάκης, Α. Χατζητόλιος, Ι. Οικονόμου, Ε. Δεστάνης, Α. Χατζηνικολάου, Γ. Καϊάφα. Ιατρικό Βήμα Suppl : σελ. 80, 2006 Λιπιδαιμικό προφίλ ηλικιωμένων ασθενών παθολογικής κλινικής τριτοβάθμιου νοσοκομείου Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Μ. Μπαλτατζή, Φ. Ηλιάδης, Δ. Αγαπάκης, Α. Χατζηνικολάου, Γ. Καϊάφα Ιατρικό Βήμα Suppl : σελ. 7, 2006 Παραθυρεοειδική κρίση ως πρώτη εκδήλωση πρωτοπαθούς υπερπαραθυρεοειδισμού Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Α. Χατζηνικολάου, Γ. Καϊάφα, Δ. Αγαπάκης, Ι. Σουλτάτη, Δ. Καραμήτσος Ιατρικό Βήμα Suppl : σελ.57, 2006 Διερεύνηση αιτιών σιδηροπενικής αναιμίας σε ασθενείς παθολογικής κλινικής Γ. Ντάιος, Γ. Καϊάφα, Ζ. Σαούλη, Χ. Σαββόπουλος, Α. Χατζητόλιος, Α. Χατζηνικολάου, Ε. Τσιαούση, Α. Παπαδόπουλος Ιατρικό Βήμα Suppl : σελ. 101, 2006 Διερεύνηση τριψήφιας ΤΚΕ σε ασθενείς παθολογικής πανεπιστημιακής κλινικής του ΑΠΘ Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζηνικολάου, Ζ. Σαούλη, Δ. Αγαπάκης, Γ. Καϊάφα, Δ. Καραμήτσος Ιατρικό Βήμα Suppl : σελ.63, 2006 Διερεύνηση αιτιών υποχρωμίας/μικροκυττάρωσης σε ασθενείς παθολογικής κλινικής Γ. Ντάιος, Γ. Καϊάφα, Ζ. Σαούλη, Χ. Σαββόπουλος, Α. Χατζητόλιος, Α. Χατζηνικολάου, Ε. Τσιαούση, Α. Παπαδόπουλος Ιατρικό Βήμα Suppl : σελ.62, 2006

Ανάλυση περιστατικών εκούσιας φαρμακευτικής δηλητηρίασης Γ. Ντάιος, Χ. Σαββόπουλος, Α. Χατζητόλιος, Δ. Αγαπάκης, Α. Χατζηνικολάου, Σ. Μαγειρία, Α. Χατζηχηδήρογλου, Γ. Καϊάφα Ιατρικό Βήμα Suppl : σελ. 62, 2006 Σπάνια εκδήλωση λοίμωξης από Parvo B19 με πορφυρικό εξάνθημα G. Ntaios, A. Chatzihidiroglou, A. Chatzinikolaou, F. Iliadis, A. Adamidou, D. Karamitsos Ιατρικό Βήμα Suppl : σελ. 15, 2006 Σπάνια εκδήλωση θρομβοπενίας σε νεαρό ενήλικα με HIV λοίμωξη Ι. Χατζηζήσης, Ζ. Σαούλη, Γ. Χαρισόπουλος, Γ. Ντάιος, Γ. Καϊάφα, Α. Παπαδόπουλος Ελληνική Ιατρική» 72 (supl 1):161, 2006


142

ΑΞΙΟΛΟΓΗΤΗΣ 23 Φεβρουαρίου 2016

ΑΞΙΟΛΟΓΗΤΗΣ


143


ΑΡΘΡΩΝ ΣΕ ΔΙΕΘΝΗ ΙΑΤΡΙΚΑ ΠΕΡΙΟΔΙΚΑ

Annals of Hematology - Discrimination indices as screening tests for β-thalassemia trait, MS AOH-07-0211, 02/06/2007 Platelets - Fulminant thrombocytopenia and haemolytic anaemia associated with ciprofloxacin, CPLA-2007-0114, 2910/2007 - Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome,

CPLA-2008-0015, 31/01/2008 - Increased mean platelet volume in patients with slow coronary flow, CPLA-2008-0098, 10/07/2008 - Anti-psychotic Drug Usage is an Independent Predictor for the Increased Mean Platelet Volume in Schizophrenia

Patients, CPLA-2010-0220, 02/01/2011 - Mean platelet volume as a risk stratification tool in the emergency department for evaluating patients with

ischemic satroke and TIA, CPLA-2011-0017, 9/02/2011 Lung - Peripheral neuropathy in chronic obstructive pulmonary disease, Lung322, 02/12/2007 - Interleukin 7 receptor α polymorphisms in chronic obstructive pulmonary disease, Lung691, 05/04/2009 - Expression of CD147 in advanced non-small cell lung cancer: correlation with cisplatin-based chemotherapy

resistance , Lung1150, 03/07/2010 - Pulmonary embolism, myocardial infarction and ischemic stroke in lung cancer patients: results from a

longitudinal study. Lung2422, 19/05/2013 Antioxidants & Redox signaling - Cardiovascular significance of Homocysteine: from molecular mechanisms to clinical implications, ARS-2008-

2072, 18/03/2008 - ATF4 modulates glutathione synthesis, reactive oxygen species production and homocysteine metabolism via the

transsulfuration pathway in a cell specific manner, ARS-2009-2660, 31/05/2009 Gynecological Endocrinology - Evaluation of Endocrine Profile, Hypothalamic–Pituitary–Ovarian Axis and Reproduction in Female Patients with

Homozygous Beta- Thalassemia Major, DGYE-2008-0004, 11/04/2008 International Journal of Laboratory Hematology - Interpretation of hemoglobin A2 quantification in the presence of hemoglobin S using automated, high

throughput methods, IJLH-05-08-0126, 29/06/2008 - Frequency and type of newly diagnosed hemoglobin variants in Northern Italy, IJLH-02-09-0028, 23/02/2009 - Impact of methylenetetrahydrofolate reductase (MTHFR) gene polymorphism on methotrexate therapy in

childhood acute lymphoblastic leukemia, IJLH-03-09-0058, 12/05/2009 - Role of Mean Platelet Volume as Discriminating Guide for Bone Marrow Disease in Patients of

Thrombocytopenia, IJLH-09-09-0180, 17/06/2009 - Characteristic distribution of iron in the bone marrow after parenteral iron therapy, IJLH-12-09-0238, 08/01/2010 International Journal of Cardiology - Circulating Adiponectin is associated with various cardiovascular risk factors but not with Reynolds Risk Score in

women with no history of major cardiovascular events, IJC-D-08-01337, 30/06/2008 - Aortic atheromas and stroke, IJC-D-11-00198, 14/02/2010 - Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI. A single-center experience,

IJC-D-12-00356, 31/03/2012 - Association Between Stroke and Patients With Uterine fibroids: A longitudinal Study in Taiwan, IJC-D-12-04241,

14/01/2013 - Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation, IJC-D-13-

01828, 19/05/2013 - Medical Therapy versus Implantable Cardioverter-Defibrillator in Preventing Sudden Cardiac Death in Patients

with Left Ventricular Systolic Dysfunction and Heart Failure: A Meta-Analysis of >40,000 Patients. IJC-D-13-02542, 20/07/2013

- Alcohol intake and risk of stroke: a dose-response meta-analysis of prospective studies, IJC-D-13-03987, 01/01/2014

- The Association between Admission Systolic Blood Pressure in Patients with Acute Coronary Syndrome and Favorable Early and Late Outcomes, IJC-D-14-01260, 19/05/2014

- The Risk of Coronary Heart Disease in Patients with Kidney Stones: A Systematic Review and Meta-analysis. IJC-D-14-02442, 7/08/2014

- The association between multimorbidity and poor adherence with cardiovascular medications. IJC-D-14-03281, 30/08/2014

- Atherosclerosis: recent trials, new targets and future directions. IJC-D-15-00065, 13/02/2015 - Assessing the relationship between weight loss and causes of death in patients with cardiovascular disease: a

reanalysis of the SCOUT trial. IJCD1402849, 01/03/2015 - LASSBio-1425, an analog of thalidomide, decreases triglyceride and increases HDL cholesterol levels by inhibition


144


of TNF-α production. IJC-D-15-03946, 29/08/2015 Neuropsychiatric Disease and Treatment - Prophylaxis of Migraine: Patient Acceptability and Future Research, 3497, 11/09/2008 Vascular Health and Risk Management - Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction, 3148,

11/09/2008 - Natriuretic peptides (BNP and proBNP) measurement utility in heart failure, 5789, 16/06/2009 Clinical Interventions in Aging - Treatment of post-herpetic neuralgia: focus on Pregabalin, 3386, 18/09/2008 International Journal of COPD - Markers of early disease and prognosis in COPD, 3106, 13/11/2008 International Journal of Medicine and Medical Sciences - Variations in the presentation of aphasia in patients with closed head injuries, IJMMS 09-048, 30/01/2009 - Platelets: Indicator of inflammation in COPD, IJMMS 09-107, 10/04/2009 - Platelet counts and tumor progression in gastric cancer, IJMMS 09-135, 11/04/2009 - Study of endothelin-1 and vascular endothelial growth factor in patients with gastric cancer, IJMMS 09-155,

11/04/2009 - Recommended approach of the obese Greek military personnel, IJMMS 09-150, 15/04/2009 - Neuroimaging findings in breast cancer: a systematic review, IJMMS 09-274, 29/06/2009 - Detection the Chlamydia and Mycoplasma pneumonia,Helicobacter pylori DNAs in resected adenoid tissues,

IJMMS-09-318, 23/08/2009 - Low back pain radiating to the left buttock as a form of onset of multiple myeloma: a rare case report, IJMMS-09-

382, 14/11/2009 - The first pharmacist based warfarin monitoring service in Iran, IJMMS-09-412, 08/01/2010 Journal of Medicine and Medical Sciences - Mean Platelet Volume in Intensive Care Unit Patients: Is it a useful parameter in assessing prediction for

mortality?, JMMS-10-042, 8/02/2010 Archives of Medical Research - The Increased Soluble OX40L is Associated with Carotid Intima- Media Thickness and IL-10 in Patients with

Coronary Heart Disease, ARCMED-D-09-00031, 04/02/2009 Experimental Biology and Medicine - Folic acid supplementation modifies β-adrenoceptor-mediated in vitro lipolysis of the obese/diabetic (+db/+db)

mice, 0902-RM-44, 16/02/2009 Open Access Rheumatology Research and Reviews - Intra-articular corticosteroids in the treatment of Juvenile Idiopathic Arthritis: Safety, efficacy, and features

affecting outcome, 5103, 17/02/2009 Diabetes, Metabolic syndrome and obesity: Targets and Therapy - Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes, 3408, 17/02/2009 Cancer Therapy - Poorly differentiated thyroid carcinoma presenting as masive goitre, cauda anguina syndrome and

hyperthyroidism: literature review and prognostic factors, 23/03/2009 Expert opinion on biological therapy - Insights into defibrotide: an updated review, EOBT-2009-0039, 23/03/2009 Tohoku Journal of Experimental Medicine - Does homocysteine level affect the risk of atherothrombotic and cardioembolic stroke?, TJEM-20090147,

15/05/2009 - Haemoglobin A2 is also an effective screening tool for beta-thalassemia trait in pregnant women, TJEM-20100568,

22/12/2010 Journal of clinical laboratory analysis - Evaluation of discrimination indices in differentiation of iron deficiency anemia and β-thalassemic trait according

to age and hemoglobin concentration, JCLA-09-010, 12/06/2009 - Erythrocyte and reticulocyte parameters in iron deficiency and thalassemia, JCLA-10-227, 01/03/2011 - Red cell distribution width (RDW) in the newborn: normative data, JCLA-11-144, 8/08/2011 Therapeutics and Clinical Risk Management - Emerging treatments in the management of type 2 diabetes, 4975, 19/06/2009 Journal of Medical Case Reports - Hypertrophic osteoarthropathy as the cause of situs inversus totalis: a case report, MSID 7892, 24/07/2009 Acta Neurologica Scandinavica - Homocysteine in association with ischemic cerebrovascular disease, ANE-R-06-09-231, 15/7/2009 - Irregular breathing in stroke: Analysis of range and frequency of respiratory movements, ANE-O-12-09-500,

8/2/2010 - Hangover and the Risk of Stroke in Middle-aged Men, ANE-O-01-12-014, 21/02/2012


145


Journal of Cancer Research and Experimental Oncology - Metabolic and haematological effects of dietary supplementation with arginine on rats bearingascitic walker 256

tumor, JCREO-09-017, 21/08/2009 Journal of clinical medicine and reseasch - Alteration in chemical composition of red blood cells in iron deficiency anemia, JCMR-09-042, 08/10/2009 Anemia - Erythrocyte and reticulocyte indices on the LH 750 analyser (Beckman-Coulter) as potential markers of functional

iron deficiency, ANE/625919, 08/2/2010 Eastern Journal of Medicine - Is there an association of Giardiasis with beta-Thalassemia Minor?, 08/2/2010 Journal of Medical Genetics and Genomics - Co-inheritance ααα anti 3.7 triplication with Hemoglobin D/ β0 thalassemia: A Case Report from South West of

Iran, JMGG-09-021, 8/2/2010 Biomarkers - Discriminative value of platelet size indices for the identification of the mechanism of chemotherapy-induced

thrombocytopenia, TBMK-2010-0072, 24/04/2010 Journal of Pediatric Hematology and Oncology - Stroke in a Young Boy with <beta>-Thalassemia Intermedia Secondary to Moyamoya Syndrome, JPHO 10-170,

4/6/2010 - Evaluation of discrimination indices in differentiation between iron deficiency anemia and <beta>-thalassemia

trait in Chinese children, JPHO 10-90, 30/03/2010 - Indices used in differentiation of thalassemia trait from iron deficiency anemia: Are they reliable?, JPHO 12-26,

29/01/2012 - Prevalence of the beta-thalassemia trait and abnormal hemoglobins in the province of Adiyaman, Turkey, JPHO

12-192, 14/06/2012 Indian Journal of Medical Sciences - Cardiac Biomarkers in the Diagnosis, Prognosis and Management of Coronary Artery Disease: A Primer for

Internists, IJMS_590_10, 23/09/2010 Yonsei Medical Journal - Hypoglycemia revisited in the acute care settings, YMJ10342, 9/10/2010 - Effect of blood pressure variability on 3-month cognitive outcome in the subacute stage , of lacunar infarction,

YMJ12629, 08/02/2012 Journal of Public Health and Epidemiology - The Relation of Body Mass Index Distribution to Relative High Blood Pressure among Children and Adolescents

in Shandong, China, JPHE-010-056, 3/12/2010 Clinical Neurology and Neurosurgery - Antithrombin III associated with fibrinogen predict the risk of cerebral ischemic stroke, CNN-D-10-142,

30/06/2011 - Hospitalizations due to spontaneous intracerebral hemorrhage in the region of Nis (Serbia): 11-year time-series

analysis, CNN-D-10-577,2/01/2011 Acta Hematologica - Long-acting Vitamin K Rodenticide Poisoning With Prolonged Coagulopathy:A Case Series, MS 201103007,

24/03/2011 - Proxy indicators for identifying iron deficiency among anemic vegetarians in prevalent area for thalassemia and

hemoglobinopathies, Ms. No.: 201111010, 21/12/2011 European Journal of Neurology - Demographic, clinical and radiological predictors of early neurological deterioration in patients with acute

ischemic stroke, EJoN-11-0344, 27/04/2011 - Relationship of initial glucose level and all-cause death in patients with ischemic stroke: the roles of diabetes

mellitus and glycated hemoglobin level, EJoN-11-0539, 30/6/2011 - The relatively good outcome of cerebellum-brainstem ischemic strokes, EJoN-11-0776, 26/8/2011 - Intravenous thrombolysis in infratentorial vs. supratentorial ischemic strokes: clinical data and outcomes. EJoN-

12-0248, 23/2/2012 - DRAGON score replication and DRAGON-C. Prediction of stroke prognosis after IV thrombolysis. EJoN-12-1246,

22/12/2012 - Blood pressure influences long-term outcome in patients with acute ischemic stroke. A prospective study in a

Stroke Unit setting. EJoN13-0079, 03/02/2013 - Ischaemic stroke in patients with nonvalvular atrial fibrillation on therapeutic anticoagulation, EJoN-14-0038,

25/01/2014

- Transient and persistent symptoms in patients with lacunar infarcts: Results from a prospective cohort study, EJoN-014-0521, 14/06/2014

- Medical acute complications of intracerebral hemorrhage in young adults, EJoN-14-1000, 16/09/2014


146


- The relationship between the preadmission CHA2DS2-VASc score and proximal artery occlusion in patients with acute stroke and atrial fibrillation. EJoN-14-1227, 22/11/2014

Neurology India - Admission Hyperglycemia in Stroke patients and its Short-Term Outcome, Neurology India_406-11, 03/05/2011 - Outcomes of antiplatelets therapy for hemorrhage patients after thrombolysis: a prospective study based on

susceptibility-weighted imaging, Neurology India_688_11, 12/09/2011 Neurological Research - Serum C-Reactive Protein Reflect the Severity of Ischemic Stroke Associated with Stroke Subtype, NER2544,

1/07/2011 - Predictors of short-term improvement of ischemic stroke, NER3040, 02/10/2012 Journal of Hypertension - Prothrombotic status: Additional independent determinants for cerebral small vessel disease in the elderly

Japanese hypertensive patients. JH-11-00683, 30/08/2011 Thrombosis and Haemostasis - Prognostic value of Red Cell Distribution Width in patients with pulmonary embolism. TH-11-08-0575, 2/09/2011 - The safety and efficacy of new anticoagulants for the preventive treatment of atrial fibrillation patients: Systematic

review and Meta-analysis. TH-13-04-0344, 19/05/2013 - Red blood cell distribution width in patients with cryptogenic stroke, TH-14-01-0091, 14/02/2014 Clinical and Applied Thrombosis/Hemostasis - Mean platelet volume as an indicator of inhospital deep venous thrombosis, CATH-11-09-0204, 11/10/2011 - Impact of mean platelet volume on reperfusion in acute myocardial infarction treated with primary coronary

intervention, CATH-11-11-0234, 24/11/2011 - Relationship between mean platelet volume and mitral annular calcification, CATH-12-02-0033, 15/03/2012 - Decreased Mean Platelet Volume in Patients with Amylodiosis, CATH-12-10-0232, 24/10/2012 Cerebrovascular Diseases - Acute ischemic stroke and clinical deterioration in the setting of UCP2 polymorphisms: A proposed link. MS No.:

201107057, 11/10/2011 International Journal of Stroke - Effects of oral antidiabetic medications on reducing cerebrovascular accidents in patients with type 2 diabetes

mellitus:A Meta-Analysis of Randomized Controlled Trials, IJS-09-11-1471, 12/10/2011 - The obesity paradox in stroke: Lower mortality and lower risk of readmission for recurrent stroke in obese stroke

patients. IJS-04-12-1877, 12/05/2012 - The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial protocol; a randomized, blinded, efficacy trial of

standard versus intensive hyperglycemia treatment in acute stroke. IJS‐07‐12‐2053, 21/08/2012 - Chronic Kidney Disease as a Risk Factor for Carotid Atherosclerosis. IJS-12-14-3716, 3/02/2015 - Impact of obesity on the stroke recurrence and effectiveness of weight-loss interventions, IJS-10-15-4537,

26/10/2015 - Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. IJS‐11‐15‐

4562, 24/12/2015 Neurology - Central Adiposity and Mortality after First-Ever Acute Ischemic Stroke, NEUROLOGY/2011/419671, 14/10/2011 - Impact of Blood Pressure on 3-Month Functional Outcome in the Subacute Stage of Ischemic Stroke,

NEUROLOGY/2012/450452, 14/04/2012 - Visit-to-visit Blood Pressure Variability Predicts Cardiovascular Mortality after Lacunar Infarct,

NEUROLOGY/2013/524199, 01/06/2013 - The Obesity Paradox for Stroke Prognosis in the Chinese population. NEUROLOGY/2013/537381, 11/08/2013 - A Systematic Review of Non-Procedural Adverse Events after Patent Foramen Ovale Closure.

NEUROLOGY/2013/551903, 21/10/2013 - Obesity-Stroke Paradox and initial neurological severity. NEUROLOGY/2014/574541. 7/03/2014 - Comparative Effectiveness of IV Thrombolysis versus No Treatment for Mild Ischemic Stroke.

NEUROLOGY/2014/592840, 23/05/2014 - Hypothermia therapy for acute stroke: systematic review and meta-analysis of randomized controlled trials.

NEUROLOGY/2015/711804, 30/01/2016 Journal of Neurology - The relatively good outcome of cerebellum-brainstem ischemic strokes, JOON-D-11-01274, 27/12/2011 Journal of the American Aging Association - Fitness, fatness and survival in elderly populations, JAAS623, 23/01/2012 Hypertension research - Increased platelet volume in general population with prehypertension: a cross-sectional study of 80545

participants from China, HTR-2012-0017, 01/02/2012 Heart


147


- Stroke and coronary artery disease prediction from mean platelet volume in patients with diabetes mellitus, heartjnl-2012-301999, 28/03/2012

Annals, Academy of Medicine, Singapore - Predictive significance of platelet parameters in patients of ischaemic stroke: An Indian scenario, 12145,

11/05/2012 International journal of neuroscience - The effect of admission hyperglycemia in stroke patients treated with thrombolysis, GNES-2012-0100, 12/05/2012 Journal of Atherosclerosis and Thrombosis - Elevated mean platelet volume associated with silent cerebral infarction, JAT/2012/015636 Frontiers in Cardiovascular Drug Discovery (e-book) - Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation, 08/02/2013 Journal of Emergency Medicine, Trauma and Acute Care - Red Blood Cell distribution width and erythrocyte parameters in patients with brain injury after mild head

trauma, JEMTAC-D-13-00008 Atherosclerosis - Association between CHADS2 Score and Ankle-Brachial index < 0.9 in patients without atrial Fibrillation, ATH-

D-13-00311, 27/04/2013 - Metabolic Determinants of White Matter Hyperintensity Burden in Patients with Ischemic Stroke, ATH-D-14-

01023, 05/10/2014 Expert Opinion in Biological Therapy - Insights into defibrotide: an updated review, EOBT-2009-0039, 23/03/2009 Open Access Rheumatology Research and Reviews - Intra-Articular Corticosteroids in the Treatment of Juvenile Idiopathic Arthritis: Safety, Efficacy, and Features

Affecting Outcome, ID:5103, 17/02/2009 American Journal of Cardiovascular drugs

- The safety and efficacy of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis, CVDA-D-13-00057, 16/07/2013

Ελληνική Επιθεώρηση Αθηροσκλήρωσης - Η προγνωστική αξία του σφυροβραχιόνιου δείκτη σε ασθενείς με οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο,

HJA-13-09, 20/07/2013 - Η προηγηθείσα αγωγή με στατίνες βελτιώνει την λειτουργική έκβαση των ασθενών με οξύ ισχαιμικό αγγειακό

εγκεφαλικό επεισόδιο, HJA-14-10, 22/08/2014 - Συγκριτική αποτελεσματικότητα ασενοκουμαρόλης και χαμηλής δόσης νταμπιγκατράνης σε ασθενείς με

πρόσφατο ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο στην καθημερινή κλινική πράξη, HJA-15-06, 20/05/2015 - Transient hyperglycemia at admission and acute ischemic stroke severity and short-term outcome, HJA-16-01,

10/02/2016 BMC Medicine

- Formal and informal prediction of recurrent stroke and myocardial infarction after stroke: a systematic review and evaluation of clinical prediction models in a new cohort, 17/01/2014

Neurosurgery - Influence of Body Mass Index and Age on Functional Outcomes in Patients with Subarachnoid Hemorrhage NEU-

D-14-00183, 5/03/2014 Clinical Chemistry and Laboratory Medicine

- Diagnostic value of platelet indices and bone marrow megakaryocytic parameters in immune thrombocytopenic purpura, CCLM.2014.0428, 02/05/2014

Stroke Research and Treatment - The role of pre-stroke glycemic control on severity and outcome of acute ischemic stroke, 694569 26/06/2014 BMC Neurology

- Web-based Tool for Dynamic Functional Outcome after Acute Ischemic Stroke and Comparison with Existing Models, 1727353015134526, 5/08/2014

American Journal of Hypertensio - Elevated diastolic but not systolic blood pressure increases mortality risk in hypertensive but not normotensive

patients with acute ischemic stroke, AJH-D-14-00330, 22/08/2014 Journal of Neurological Sciences

- Predicting the Risk of Symptomatic Intracerebral Hemorrhage and Mortality in Acute Ischemic Stroke Patients Treated with rt-PA Using SEDAN Score in a Mono-center Study. JNS-D-15-00093, 10/02/2015

Medical Principles and Practice - Association of Red Cell Distribution Width with Blood Pressure Variability in Patients with Never Treated

Essential Hypertension. Ms. No.: 201502052, 25/03/2015 - Prognostic value of red blood cell distribution width in patients with left ventricular systolic dysfunction: insights

from the COMMIT-HF Registry, 18/02/2016 Annals of Medicine


148


- Undetermined stroke with an embolic pattern—a common phenotype with high early recurrence risk. SANN-2015-0048, 26/03/2015

Stroke - The Potential Impact of Abnormal Blood Platelet Count on Outcomes after Acute Ischemic Stroke,

STROKE/2015/010144, 4/06/2015 - Management of central post-stroke pain: a systematic review of randomized controlled trials,

STROKE/2015/010259, 22/06/2015 - EPAP for sleep apnea after stroke: a randomized, cross-over trial, STROKE/2015/011155, 22/08/2015 - Effect of Statin Use on Clinical Outcomes in Ischemic Stroke Patients with Atrial Fibrillation.

STROKE/2015/012272, 24/12/2015 Journal of Stroke and Cerebrovascular Diseases

- The pathophysiological mechanism is an independent predictor of long term outcome in stroke patients with large vessel atherosclerosis. JSCVD-D-15-00341

Journal of the American College of Cardiology - Impact of Asymptomatic Intra-cranial Lesions on Clinical Outcome in Patients with Coronary Artery Disease.

JACC010916-0081, 28/01/2016 Ελληνικά Διαβητολογικά Χρονικά

- Συσχετιση του παχους του εσω-μεσου χιτωνα των κοινων καρωτιδων και μηριαιων αρτηριων με το σταδιο της διαβητικης νεφροπαθειας, 10/02/2016


149


ΑΙΤΗΣΕΩΝ ΧΡΗΜΑΤΟΔΟΤΗΣΗΣ

ΕΡΓΑΣΙΩΝ ΣΕ ΔΙΕΘΝΗ ΣΥΝΕΔΡΙΑ

- European Stroke Organization Conference, Barcelona, Spain, 10-12/05/2016

- Πρόταση 144_27_1.5_1, Πρόγραμμα Επικαιροποίησης Γνώσεων Αποφοίτων ΑΕΙ, Υπουργείο Παιδείας, 7/07/2012

- Πρόγραμμα υποτροφιών Ι.Κ.Υ. με διαδικασία εξατομικευμένης αξιολόγησης - οριζόντια πράξη 2012-2013 (4 αιτήσεις: A/A:1706, 1937, 2190, 3203).

- Πρόταση 144_27_1.5_1, Πρόγραμμα Επικαιροποίησης Γνώσεων Αποφοίτων ΑΕΙ, Υπουργείο Παιδείας, 7/07/2012

- Πρόγραμμα υποτροφιών Ι.Κ.Υ. με διαδικασία εξατομικευμένης αξιολόγησης - οριζόντια πράξη 2012-2013 (4 αιτήσεις: A/A:1706, 1937, 2190, 3203).


150

ΣΥΝΕΧΙΖΟΜΕΝΗ ΙΑΤΡΙΚΗ ΕΚΠΑΙΔΕΥΣΗ 23 Φεβρουαρίου 2016

ΣΥΝΕΧΙΖΟΜΕΝΗ ΙΑΤΡΙΚΗ ΕΚΠΑΙΔΕΥΣΗ


151


Εσωτερικού Πριν την εκλογή στη θέση Λέκτορα

1. 3ο Πανελλήνιο Συνέδριο Αγγειακών Εγκεφαλικών Νόσων, Ελληνική Εταιρεία Αγγειακών Εγκεφαλικών Νόσων, Θεσσαλονίκη, 13-15/10/2004

2. Μετεκπαιδευτική ημερίδα, Ά Προπαιδευτικής Παθολογικής Κλινικής ΑΠΘ με θέμα: ‘Ινσουλινοθεραπεία στην πράξη’, Θεσσαλονίκη, 9/04/2005

3. Λοιμώξεις σε ανοσοκατασταλμένους ασθενείς, Ελληνική Αιματολογική Εταιρεία-Τμήμα Μεταμόσχευσης Αιμοποιητικών Κυττάρων, Θεσσαλονίκη, 15/06/2005

4. Ελληνικές Ημέρες Θρόμβωσης, Θεσσαλονίκη, 31/03 – 01/04/2005 5. 19ο Ετήσιο Συνέδριο Διαβητολογικής Εταιρείας Βόρειας Ελλάδας, Θεσσαλονίκη, 12 /11/2005 6. 16ο Πανελλήνιο Αιματολογικό Συνέδριο, Ελληνική Αιματολογική Εταιρεία, Θεσσαλονίκη, 16-19/11/2005 7. Εκπαιδευτική ημερίδα της Ά Προπαιδευτικής Παθολογικής Κλινικής ΑΠΘ με θέμα: ‘Αντιβιοτική θεραπεία’,

Θεσσαλονίκη, 21/01/2006 8. 4ο Πανελλήνιο Συμπόσιο Αρτηριακής Υπέρτασης «Υπέρταση-Από τη βασική έρευνα στην κλινική πράξη»,

Ελληνικής Αντιυπερτασικής Εταιρείας, Θεσσαλονίκη 2-4 /02/2006 9. Ελληνικές Ημέρες Θρόμβωσης – Καρκίνος και Θρόμβωση, Θεσσαλονίκη, 10-11 /02/2006 10. 2ο Ετήσιο Συνέδριο Αθηροσκλήρωσης «Από τον Ιπποκράτη μέχρι σήμερα», Εταιρεία Αθηροσκλήρωσης

Βορείου Ελλάδος, Θεσσαλονίκη, 23-25/02/2006. 11. Εκπαιδευτική διημερίδα με θέμα ‘Κίρρωση – μεταμόσχευση ήπατος’, Ελληνική Εταιρεία Μελέτης του

Ήπατος, Θεσσαλονίκη, 17-18/02/2006 12. 21ο Βορειοελλαδικό Ιατρικό Συνέδριο, Ιατρική Εταιρεία Θεσσαλονίκης, Θεσσαλονίκη, 30/03– 1/04/2006 13. Επιστημονική εκδήλωση με θέμα «Λοιμώξεις», Ιατρική Εταιρεία Θεσσαλονίκης, ΑΠΘ και Ελληνική Εταιρεία

Λοιμώξεων, Θεσσαλονίκη, 23 /09/2006 14. Εκπαιδευτική ημερίδα με θέμα ‘Νοσογόνος Παχυσαρκία’ , Επιστημονικό Συμβούλιο Γ.Ν.Θ. «Γ.

Γεννηματάς», 7/10/2006 15. Εκπαιδευτικό Σεμινάριο με θέμα ‘ Οι διαταραχές της οξεοβασικής ισορροπίας και των ηλεκτρολυτών’, Β΄

Προπαιδευτικής Παθολογικής Κλινικής Ιπποκράτειου Νοσοκομείου Θεσσαλονίκης και Β΄ Πανεπιστημιακή Παθολογική Κλινική του Πανεπιστημίου Ιωαννίνων, 7/10/2006

16. 1η Πανελλήνια Ημερίδα Ογκολογίας Πεπτικού με θέμα ‘Καρκίνος του στομάχου’, Ογκολογικό Τμήμα Ελληνικής Γαστρεντερολογικής Εταιρείας, Θεσσαλονίκη, 7 /10/2006

17. Επιστημονική εκδήλωση με θέμα: ‘Αντιβιοτικά και αντιμετώπιση των λοιμώξεων’, Ελληνική Εταιρεία Έρευνας, Μελέτης και Εκπαίδευσης στις Λοιμώξεις, Θεσσαλονίκη, 18/10/2006

18. 20ο Ετήσιο Συνέδριο Διαβητολογικής Εταιρείας Βόρειας Ελλάδας, Θεσσαλονίκη, 9-11 /11/2006 19. Διημερίδα με θέμα: ‘Δεοντολογικά, ηθικά και νομικά ζητήματα στην ιατρική πράξη’, Α΄ Δ.Υ.ΠΕ. Κεντρικής

Μακεδονίας, Θεσσαλονίκη, 10-11 /11/2006 20. 21o Ιατρικό Συνέδριο Ενόπλων Δυνάμεων, Θεσσαλονίκη, 23-26/11/2006 21. 5ο Ετήσιο Διεθνές Συνέδριο Καρδιολογίας, Ελληνικό Κολλέγιο Καρδιολογίας, Θεσσαλονίκη, 16-18/11/2006 22. 17ο Πανελλήνιο Αιματολογικό Συνέδριο, Ελληνική Αιματολογική Εταιρεία, Αθήνα, 22-26/11/2006 23. Επιστημονική Διακλινική Ημερίδα με θέμα: ‘Νεότερα δεδομένα στη θεραπευτική αντιμετώπιση του

καρκίνου του νεφρού’, Γ’ τμήμα Κλινικής Ογκολογίας – Χημειοθεραπείας του Θεαγένειου Αντικαρκινικού Νοσοκομείου και Α΄ Ουρολογική Κλινική του ΑΠΘ, Θεσσαλονίκη, 2/12/2006

24. Επιστημονική εκδήλωση της Ελληνικής Εταιρείας Έρευνας, Μελέτης και Εκπαίδευσης στις Λοιμώξεις με θέμα: ‘Γρίπη: Μία συνεχής Απειλή’, Θεσσαλονίκη, 2/12/2006

25. 11ο Διατομεακό Μεταπτυχιακό Σεμινάριο ‘Αναπνευστική Ανεπάρκεια: Διαγνωστική Προσέγγιση και Θεραπευτική Αντιμετώπιση’, Θεσσαλονίκη, 8-9/12/2006

26. Εκπαιδευτική ημερίδα με θέμα ‘Θεραπεία Σακχαρώδη Διαβήτη’, Α’ Προπαιδευτικής Παθολογικής Κλινικής ΑΠΘ, Θεσσαλονίκη, 16/12/2006

27. Πολυθεματική Επιστημονική Ημερίδα, Δ’ Παθολογική Κλινική ΑΠΘ, Θεσσαλονίκη, 16/12/2006 28. 7η Μετεκπαιδευτική Ημερίδα με θέμα ‘Νοσοκομειακές Λοιμώξεις’, Ιατρική Εταιρεία Θεσσαλονίκης και

Επιστημονικό Συμβουλίο Γ.Ν.Θ. ‘Γ. Γεννηματάς’, Θεσσαλονίκη, 13/01/2007 29. 6ο Σεμινάριο Επιστημονικών Εκδηλώσεων του Ελληνικού Κολλεγίου Νεφρολογίας και Υπέρτασης με θέμα

‘Ανοσοπαρέμβαση στη Μεταμόσχευση Νεφρού’ υπό την αιγίδα του Υπουργείου Υγείας & Κοινωνικής Αλληλεγγύης, Θεσσαλονίκη, 12-13/01/2007

30. Ημερίδα με θέμα ‘Γήρανση και Πνεύμονες’, Εταιρεία Μελέτης Πνευμονοπαθειών και Επαγγελματικών Παθήσεων Θώρακος και Γηριατρική Μονάδα Β΄ Παθολογικής Κλινικής ΑΠΘ, Θεσσαλονίκη, 20/01/2007

31. 1η Πανελλήνια Επιστημονική Ημερίδα Διασωστών ΕΚΑΒ με θέμα ‘Επείγουσα Προνοσοκομειακή Φροντίδα: ο ρόλος του διασώστη’, Θεσσαλονίκη, 20/01/2007

32. 10ο Πανελλήνιο Συνέδριο Αρτηριακής Υπέρτασης, Ελληνική Αντιυπερτασική Εταιρείας Θεσσαλονίκη, 1-3/02/2007


152


33. 10ο Σεμινάριο Παιδιατρικών Λοιμώξεων, Ελληνική Εταιρεία Λοιμώξεων, Θεσσαλονίκη, 24/02/2007 34. 1ο Εφαρμοσμένο Σεμινάριο Βασικής Διαχείρισης Αεραγωγού, Ελληνική Εταιρεία Διαχείρισης Αεραγωγού,

μετά το τέλος του οποίου απονεμήθηκε ‘Δίπλωμα Επάρκειας στη Διαχείριση του Αεραγωγού’, Θεσσαλονίκη, 11/03/2007

35. 3ο Ετήσιο Συνέδριο Αθηροσκλήρωσης, Εταιρεία Αθηροσκλήρωσης Βορείου Ελλάδος, Θεσσαλονίκη, 15-17/03/2007

36. Επιστημονική εκδήλωση του Ομίλου Μελέτης Ιατρικού Δικαίου και Βιοηθικής με θέμα “Ο άνθρωπος που υποφέρει: Ο πόνος στην Ιατρική, το δίκαιο και τη λογοτεχνία”, Δίκτυο ΑΠΘ ‘Σύγχρονη Ιατρική Πράξη, Βιοϊατρική και Δίκαιο’, Θεσσαλονίκη, 16/03/2007

37. Συμπόσιο Φυματίωσης, Εταιρεία Μελέτης Πνευμονοπαθειών και Επαγγελματικών Παθήσεων Θώρακος, Ελληνική Πνευμονολογική Εταιρεία και Ελληνική Ένωση κατά της Φυματίωσης και των Νόσων του Αναπνευστικού Συστήματος, Θεσσαλονίκη, 23-24 /03/2007

38. Επιστημονική Διημερίδα της Ομάδας Εργασίας Μελέτης του Διαβητικού Ποδιού, της Ελληνικής Διαβητολογικής Εταιρείας και της Διαβητολογικής Εταιρείας Βόρειας Ελλάδος, Θεσσαλονίκη, 30-31/03/2007

39. 7th Conference New trends in Cardiology, Α΄ Καρδιολογική Κλινική ΑΠΘ, Θεσσαλονίκη, 12-14/04/2007 40. 22ο Βορειοελλαδικό Ιατρικό Συνέδριο, Ιατρική Εταιρεία Θεσσαλονίκη, Θεσσαλονίκη, 19-21/04/2007 41. Σεμινάριο με θέμα: ‘Βασική Υποστήριξη της Ζωής στα παιδιά’, APLS-Επείγουσα Ιατρική για Παιδιά,

Θεσσαλονίκη, 29/04/2007 42. 8ο Σεμινάριο Επιστημονικών Εκδηλώσεων του Ελληνικού Κολλεγίου Νεφρολογίας και Υπέρτασης με θέμα

‘Γονότυπος MTHFR και ομοκυστεΐνη αίματος: Η μεγάλη τους βιολογική σημασία’ υπό την αιγίδα του Υπουργείου Υγείας & Κοινωνικής Αλληλεγγύης, Αθήνα, 11-12/05/2007

43. 4ο Επιστημονικό Συνέδριο της Ιατρικής Σχολής του Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης, Θεσσαλονίκη, 13-16/05/2007

44. 1st Postgraduate Workshop on Medical Prescribing, International Society of Quality of Life and Medical Practice, Thessaloniki, 17-18/05/ 2007

45. ‘Απόβλητα Νοσοκομείου ΑΧΕΠΑ και Νοσοκομειακές Λοιμώξεις’, Διεύθυνση Διοικητικής Υπηρεσίας, Νοσηλευτική Υπηρεσία και Επιτροπή Νοσοκομειακών Λοιμώξεων Νοσοκομείου ΑΧΕΠΑ, Νοσοκομείο ΑΧΕΠΑ, Θεσσαλονίκη, 7/06/2007

46. ‘Advanced Life Support (ALS) Provider Course’, European Resuscitation Council, Thessaloniki, 16-17/06/2007

47. 13η Διημερίδα Ελληνικής Εταιρείας Αθηροσκλήρωσης με θέμα ‘Πρόληψη και αντιμετώπιση της καρδιαγγειακής νόσου’, Θεσσαλονίκη, 28-29/09/2007

48. 21ο Ετήσιο Συνέδριο Διαβητολογικής Εταιρείας Βόρειας Ελλάδας, Θεσσαλονίκη, 8-10 /11/2007 49. 18ο Πανελλήνιο Αιματολογικό Συνέδριο, Θεσσαλονίκη, 14-17/11/2007 50. Ημερίδα με θέμα ‘Προσεγγίζοντας τη Δύσπνοια’, Παθολογικό Τομέα του ΓΝΘ ‘Γ. Γεννηματάς’,

Θεσσαλονίκη, 15/12/2007 51. Εκπαιδευτική Διημερίδα Παθολογίας, Α΄ Προπαιδευτική Παθολογική Κλινική, Θεσσαλονίκη, 15-16/02/2008 52. Ημερίδα με θέμα ‘Αιμόσταση – Διαταραχές και αντιμετώπιση’, Ελληνική Αιματολογική Εταιρεία,

Θεσσαλονίκη, 12 /04/2008 53. 15η Διημερίδα Ελληνικής Εταιρείας Αθηροσκλήρωσης, Θεσσαλονίκη, 25-26/09/2009 54. Εκπαιδευτική ημερίδα της Ιατρικής Εταιρείας Αθηνών με θέμα: «Συνδυάζοντας τη θεωρία με την κλινική

πράξη», Καστοριά, 23-25/10/2009 55. 4ο Πανελλήνιο Συνέδριο Αγγειακών Εγκεφαλικών Νόσων, Αλεξανδρούπολη, 29-31/10/2009 56. 23ο Διαβητολογικό Συνέδριο ΔΕΒΕ, Θεσσαλονίκη, 12-14/11/2009 57. 1ο Ετήσιο Συνέδριο με θέμα «Σύγχρονες Εξελίξεις της Λοιμωξιολογίας», Θεσσαλονίκη, 4-6/12/2009 58. «Κολπική Μαρμαρυγή και Αγγειακά Εγκεφαλικά Επεισόδια» υπό την αιγίδα της Hellenic Cardiovascular

Research Society και της Hellenic Cardiological Society, Αθήνα, 23-24/02/2010 Μετά την εκλογή στη θέση Λέκτορα

59. 15Ο Σεμινάριο του Ελληνικού Κολλεγίου Νεφρολογίας και Υπέρτασης με θέμα «Επείγουσες καταστάσεις στη Νεφρολογία», Ξάνθη, 18-20 Ιουνίου 2010

60. Heart Vessels and Stroke, Athens, 21-23/01/2011 61. 3ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 10-12/03/2011 62. Φθινοπωρινές ημέρες Παθολογίας, “Αγγειακά Εγκεφαλικά Επεισόδια: Και μετά τί;”, Λίμνη Πλαστήρα, 23-

24/09/2011 63. European Congress of Internal Medicine, Athens, 5-8/10/2011 64. 4ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 22-24/03/2012 65. Φθινοπωρινές ημέρες Παθολογίας: Παθήσεις αναπνευστικού. Καλαμπάκα 14-15/09/2012 66. 1η Πανθεσσαλική Εκπαιδευτική Συνάντηση, Λάρισα, 09/03/2013


153


67. 5ο Συνέδριο Παθολογίας Κεντρικής Ελλάδας, Λάρισα, 28-30/03/2013 68. Advances in diagnosis and management of intracranial vascular lesions, Larissa, 5/04/2013 69. 1ο Πανελλήνιο Συνέδριο Θρόμβωσης – Αντιθρομβωτικής Αγωγής, Αθήνα, 12/04/2013 70. 2ο Επιστημονικό Συμπόσιο ΕΠΒΕ με θέμα “Οδηγίες αντιμετώπισης καρδιαγγειακού κινδύνου στην καθ’

ημέρα πράξη», Αγριά Βόλου, 20-22/09/2013 71. Ημερίδα του ΙΜΕΘΑ αφιερωμένη στη σωστή χρήση των αντιαιμοπεταλιακών και αντιπηκτικών φαρμάκων

στην καθημερινή κλινική πράξη, Καβάλα, 28/09/2013 Μετά την εκλογή στη θέση Επίκουρου Καθηγητή

72. ALPIC, Μέτσοβο, 7-9/03/2014 73. 2η Πανθεσσαλική Εκπαιδευτική Διημερίδα, Λάρισα, 8-9/03/2014 74. Pulse & Cardioelectrics, Ηράκλειο Κρήτης

Εξωτερικού Πριν την εκλογή στη θέση Λέκτορα

1. 16th European Stroke Conference, Glascow, UK, 29/05–1/06/ 2007 2. ‘Patient – Crisis – Emergency Management’, Berlin School of Economics και το Διαβαλκανικό Ινστιτούτο Δημόσιας

Διοίκησης, Βερολίνο, 25-30/11/2007

3. 11th European Stroke Initiative (EUSI) Stroke Summer School, Barcelona, Spain, 25-29/06/2007 4. 12th EUSI-ESO Stroke Summer School, Lausanne, Switzerland, 22-28/06/2008 5. Σεμινάριο με θέμα ‘Cerebral metabolism in patients with cerebral lesions’, Centre Hospitalier Universitaire

Vaudois, Lausanne, Switzerland, 14/01/2009 6. Σεμινάριο με θέμα ‘Recuperation after acute cerebrovascular event – clinical pathophysiology’, Centre

Hospitalier Universitaire Vaudois, Lausanne, Switzerland, 21/01/2009 7. 13th Annual Meeting of the Swiss Stroke Trialists, Basel, Switzerland, 22/01/2009 8. Σεμινάριο με θέμα ‘Dysfunction of language as a diagnostic marker in neurodegenerative disorders’, Centre

Hospitalier Universitaire Vaudois, Lausanne/Switzerland, 25/02/2009 9. European Stroke Congress, Stockholm/Sweden, 25-29/05/2009

Μετά την εκλογή στη θέση Λέκτορα

10. European Stroke Congress, Barcelona, Spain 25-29/05/2010

11. Σεμινάριο με θέμα ‘Fibromuscular Dysplasia’, Centre Hospitalier Universitaire Vaudois, Lausanne/Switzerland, 8/09/2009

12. Ημερίδα με θέμα ‘Hospital management of stroke and TIAs: state of the art’. Centre Hospitalier Universitaire Vaudois, Lausanne/Switzerland, 9/09/2010

13. Future advances in the management of acute ischemic stroke, Budapest, Hungary 18-19/11/2010 14. International Stroke Conference, Los Angeles, USA 9-11/02/2011 15. European Stroke Congress, Hamburg, Germany 24-27/05/2011 16. European Stroke Congress, Lisbon, Portugal 25-28/05/2012 17. State of the Art: Stroke and Heart. CHUV Hospital, Lausanne, Switzerland, 06/09/2012 18. XII Congresso Nazionale Della Societa’ Italiana Per Lo Studio Dello Stroke. “Ictus: Quale futuro?” L” Aquila,

Italy, 27-29/09/2012 19. European Stroke Congress, London, UK 28-31/05/2013 20. 2nd ESO Stroke Science workshop, Garmisch, Germany, 21-22/11/2013 21. 2013 Joint meeting of the Belgian Neurological Society and the Belgian Stroke Council “Controversies in

Stroke”, Leuven, Belgium, 23/11/2013 22. Stroke Prevention in Atrial Fibrillation (SPAF) Academy, Mainz, Germany, 25-26/11/2013


23. European Stroke Conference, Nice, France, 06-09/05/2014 24. ESO Karolinska Stroke Update, Stockholm, Sweden, 16-18/11/2014


154


25. ESO GRADE workshop, Frankfurt, Germany, 12/01/2015 26. ESO Conference, Glasgow, 17-19/04/2015 27. GRADE methodology. 3rd ESO GRADE workshop, Garmisch-Partenkirchen, Germany


155

ΣΥΓΚΕΝΤΡΩΤΙΚΟΣ ΠΙΝΑΚΑΣ 23 Φεβρουαρίου 2016

ΣΥΓΚΕΝΤΡΩΤΙΚΟΣ ΠΙΝΑΚΑΣ

Πανεπιστημιακές σπουδές

- Πτυχίο Ιατρικής, Πανεπιστήμιο Καρόλου, Τσεχία 2000

- MSc (Ιατρική Ερευνητική Τεχνολογία), Ιατρική Σχολή ΑΠΘ, Θεσ/νίκη 2004

- Διδακτορική Διατριβή, Ιατρική Σχολή ΑΠΘ, Θεσ/νίκη 2008

- MSc (Stroke Medicine), Danube University, Krems, Αυστρία 2011

Ειδικότητα Παθολογίας, Α’ Προπαιδευτική Παθολογική ΑΠΘ, Θεσ/νίκη 2009

Μετεκπαίδευση στο εξωτερικό

- Stroke Unit, CHUV, Λωζάννη, Ελβετία ΙΑΝ-ΙΟΥN 2009 & ΙΟΥΛ-ΔΕΚ 2010

- Stroke Unit, St. George’s Hospital, Λονδίνο, Ηνωμένο Βασίλειο ΑΥΓ-ΟΚΤ 2011

Δημοσιεύσεις σε διεθνή περιοδικά 115

- Πρωτότυπες εργασίες/Άρθρα Ανασκόπησης/ Μεταναλύσεις/ Debates 60/12/5/1

- Ενδιαφέρουσες περιπτώσεις/ Επιστολές / Απάντησεις σε επιστολές/ 11/21/7

- Προσκεκλημένα Editorials 2

- Θέση μεταξύ των συγγραφέων: (πρώτος ή τελευταίος)/δεύτερος/τρίτος/άλλη 73/19/5/14

Συνολικός IF / Προσωπικός IF (all publications) 347.397 / 300.420 (87.0% του συνολικού)

Μέσος IF / Μέσος προσωπικός IF (all publications) 3.674 / 3.197

Συνολικός IF / Προσωπικός IF (original articles) 150.360 / 120.980 (82.2% του συνολικού)

Μέσος IF / Μέσος προσωπικός IF (original articles) 3.522 / 2.340

h-index 18

Βιβλιογραφικές αναφορές/ Ετεροαναφορές/αυτοαναφορές/ προσωπικές αναφορές

1271/1117/193/1050.5

Δημοσιεύσεις σε Eλληνικά αγγλόφωνα περιοδικά 1

Δημοσιεύσεις περιλήψεων σε ξένα περιοδικά (Supplements) 15

Ανακοινώσεις σε διεθνή/ Ελληνικά συνέδρια 74/77

Δημοσιεύσεις σε Ελληνικά περιοδικά 12

Αξιολογητής

- Εργασιών σε διεθνή περιοδικά (εργασίες/περιοδικά) 160/72

- Ερευνητικών Προτάσεων σε προσκλήσεις χρηματοδότησης 1

Συμμετοχή σε ιατρικά βιβλία (Ελληνικά / Διεθνή) 4/2

Μέλος Επιστημονικών εταιρειών 7

Ομιλίες-Εισηγήσεις-Συνεντεύξεις (Ελλάδα / Εξωτερικό) 54/15

* IF: Impact factor (Συντελεστής εμβέλειας). * Ο Προσωπικός IF υπολογίζεται στο 100% του αριθμού στις δημοσιεύσεις ως 1ος ή τελευταίος συγγραφέας, 50% σε δημοσιεύσεις ως 2ος, 33% σε δημοσιεύσεις ως 3ος και 25% σε δημοσιεύσεις ως συγγραφέας σε άλλη θέση. Ως μέσος IF υπολογίζεται ο IF/αριθμό των αντίστοιχων δημοσιεύσεων * Οι προσωπικές αναφορές υπολογίζονται στο 100% του αριθμού των αναφορών στις δημοσιεύσεις ως 1ος ή τελευταίος συγγραφές, 50% στις δημοσιεύσεις ως 2ος, 33% στις δημοσιεύσεις ως 3ος και 25% στις δημοσιεύσεις ως συγγραφέας σε άλλη θέση)

Larissa, 23/2/2016
